{"docstore/data": {"eff7e52a-08db-4ac3-b46e-6cc21f3adffd": {"__data__": {"id_": "eff7e52a-08db-4ac3-b46e-6cc21f3adffd", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Nov-2020  \nMcKesson Corp.   (MCK ) \nQ2 2021 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Nov-2020  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8b9e5ddb-7151-4cb2-836a-8f1bdc98fb5c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11998fa593cc95390e5a08ba0a82a28e03cc6a3a0c15811d2df8386212c1f8f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1da1dc66-7f50-43b3-91f0-293b59bf0317", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Nov-2020  \nMcKesson Corp.   (MCK ) \nQ2 2021 Earnings Call    ", "original_text": "(MCK ) \nQ2 2021 Earnings Call    "}, "hash": "26c94af681a878b622f6f8ed7d30ff55fb29efa5f37ecd42e0d26f48ae30f427", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Nov-2020  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1da1dc66-7f50-43b3-91f0-293b59bf0317": {"__data__": {"id_": "1da1dc66-7f50-43b3-91f0-293b59bf0317", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Nov-2020  \nMcKesson Corp.   (MCK ) \nQ2 2021 Earnings Call    ", "original_text": "(MCK ) \nQ2 2021 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8b9e5ddb-7151-4cb2-836a-8f1bdc98fb5c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11998fa593cc95390e5a08ba0a82a28e03cc6a3a0c15811d2df8386212c1f8f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eff7e52a-08db-4ac3-b46e-6cc21f3adffd", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Nov-2020  \nMcKesson Corp.   (MCK ) \nQ2 2021 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Nov-2020  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdc79c4c913235839802b027888f15a0eec2827c2fd83459c43a4015a91a2320", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5da07ecc-ff80-4239-aabc-a892eb1e1f53", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "917fe6ced7473f4698c3932856e26d27ac1a9cd13f8cb3d61899528a0e356d86", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5da07ecc-ff80-4239-aabc-a892eb1e1f53": {"__data__": {"id_": "5da07ecc-ff80-4239-aabc-a892eb1e1f53", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9364e07-dc15-47ba-96b5-75de90875e02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c17c28684202988209afc3f2fc4451d0d927792dc5284050b2890453d9c114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1da1dc66-7f50-43b3-91f0-293b59bf0317", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Nov-2020  \nMcKesson Corp.   (MCK ) \nQ2 2021 Earnings Call    ", "original_text": "(MCK ) \nQ2 2021 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd161097cdb1ae44418cef3d6f961db15fe03ec922b76976cf0a7af1e9f160b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b0f0910-2b13-4dbb-b754-de48679ad7f8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n"}, "hash": "cf1578104d3211aa11cabdf6b98baa24ef76bed566fd588b8b4c5aa7ac452fda", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b0f0910-2b13-4dbb-b754-de48679ad7f8": {"__data__": {"id_": "2b0f0910-2b13-4dbb-b754-de48679ad7f8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9364e07-dc15-47ba-96b5-75de90875e02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c17c28684202988209afc3f2fc4451d0d927792dc5284050b2890453d9c114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5da07ecc-ff80-4239-aabc-a892eb1e1f53", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98747909f7feeea0752842ce33042a6d035d47fb55eac7fd4c90cd8efa7c3cfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e42cb57f-4904-47c5-9d22-abab9171a7e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "e63f196895719e827fb5323f2bb19e0241035bca483cb75c711c3b19f7bc99a5", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e42cb57f-4904-47c5-9d22-abab9171a7e2": {"__data__": {"id_": "e42cb57f-4904-47c5-9d22-abab9171a7e2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9364e07-dc15-47ba-96b5-75de90875e02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c17c28684202988209afc3f2fc4451d0d927792dc5284050b2890453d9c114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b0f0910-2b13-4dbb-b754-de48679ad7f8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf0f5260780093edfc351363fd3b10c82c9bbcdd38a2efb6cc19343a4fa4d9da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e26c4f5-f14a-44d6-9b6c-b80aecbd24b4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n "}, "hash": "1411949b428eeaa206f4ac757fe21f28f4d6552ee1f79269996fd74569b4cbe1", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 283, "end_char_idx": 352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e26c4f5-f14a-44d6-9b6c-b80aecbd24b4": {"__data__": {"id_": "3e26c4f5-f14a-44d6-9b6c-b80aecbd24b4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9364e07-dc15-47ba-96b5-75de90875e02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c17c28684202988209afc3f2fc4451d0d927792dc5284050b2890453d9c114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e42cb57f-4904-47c5-9d22-abab9171a7e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f133b5a3474682912101ec934b5b6c17520d7028ec35236dd3f19d279735cfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8315f097-a3e9-4286-ae03-4ad1d4a71029", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "fa61e6b9d1d991f501a1cf2b638a973856ead912464081ae806e9b4d3ce06f54", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "start_char_idx": 352, "end_char_idx": 442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8315f097-a3e9-4286-ae03-4ad1d4a71029": {"__data__": {"id_": "8315f097-a3e9-4286-ae03-4ad1d4a71029", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9364e07-dc15-47ba-96b5-75de90875e02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c17c28684202988209afc3f2fc4451d0d927792dc5284050b2890453d9c114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e26c4f5-f14a-44d6-9b6c-b80aecbd24b4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cdaad2d8ccb54d854df8f59fbd2c47f8b50e26c992b17aa9e6c1958e0ea99f5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65d5b5b0-3eee-4144-9fc2-f8a843da5e7c", "node_type": "1", "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "efddbc0a958654b466d70ed4e06f58a3bd156182a653c9b29e07b778a2ba0b1b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 442, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65d5b5b0-3eee-4144-9fc2-f8a843da5e7c": {"__data__": {"id_": "65d5b5b0-3eee-4144-9fc2-f8a843da5e7c", "embedding": null, "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9364e07-dc15-47ba-96b5-75de90875e02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c17c28684202988209afc3f2fc4451d0d927792dc5284050b2890453d9c114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8315f097-a3e9-4286-ae03-4ad1d4a71029", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68aca5b23c7ceb53144e013bbfef456df4cc244942e8bc2011a0d36886fa77c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9ccbd9a-0451-4657-a0ca-cbdbeeb7f237", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "original_text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n"}, "hash": "7e1488089cc7f028b922eb470f8f934f2db330cc39d72a2c7bab3b58f1c9cc69", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 818, "end_char_idx": 1081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9ccbd9a-0451-4657-a0ca-cbdbeeb7f237": {"__data__": {"id_": "d9ccbd9a-0451-4657-a0ca-cbdbeeb7f237", "embedding": null, "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "original_text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9364e07-dc15-47ba-96b5-75de90875e02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c17c28684202988209afc3f2fc4451d0d927792dc5284050b2890453d9c114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65d5b5b0-3eee-4144-9fc2-f8a843da5e7c", "node_type": "1", "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57bfbc17f7c357d55fe09ff07b6cce6530dac1abb79ab2eee4c03af6b2902624", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "211cf7c3-43bd-4d98-a63a-6e0328470c20", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "original_text": "Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n"}, "hash": "bffbde246d50c392829fcb1b566e27bc972743e99d0983c4af2be8bb81bc8676", "class_name": "RelatedNodeInfo"}}, "text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "start_char_idx": 1081, "end_char_idx": 1137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "211cf7c3-43bd-4d98-a63a-6e0328470c20": {"__data__": {"id_": "211cf7c3-43bd-4d98-a63a-6e0328470c20", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "original_text": "Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9364e07-dc15-47ba-96b5-75de90875e02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c17c28684202988209afc3f2fc4451d0d927792dc5284050b2890453d9c114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9ccbd9a-0451-4657-a0ca-cbdbeeb7f237", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "original_text": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f355298b81d84fd78bcbe8ca4a036876d146011bfd953434c6b0025a6ddbf5dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d83bee9-ee1d-496e-b84b-3ec76839accf", "node_type": "1", "metadata": {"window": "LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "3d50b27623a465fdc8d9c29aed26ecf63e33b9cc6c2fc0b62720874d9b3fec42", "class_name": "RelatedNodeInfo"}}, "text": "Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "start_char_idx": 1137, "end_char_idx": 1197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d83bee9-ee1d-496e-b84b-3ec76839accf": {"__data__": {"id_": "0d83bee9-ee1d-496e-b84b-3ec76839accf", "embedding": null, "metadata": {"window": "LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9364e07-dc15-47ba-96b5-75de90875e02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c17c28684202988209afc3f2fc4451d0d927792dc5284050b2890453d9c114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "211cf7c3-43bd-4d98-a63a-6e0328470c20", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "original_text": "Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9abad8ea7de59c2e7b78400f2470c45bc241a5344db63d14d283d756c0eb6cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7615220-df24-4af1-9c35-c796fc90ff10", "node_type": "1", "metadata": {"window": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "original_text": "LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  "}, "hash": "e969bdf3c8fb5b2929317f5c2a9656d51c9ca227a623da70d67817ebff61817e", "class_name": "RelatedNodeInfo"}}, "text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1197, "end_char_idx": 1249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7615220-df24-4af1-9c35-c796fc90ff10": {"__data__": {"id_": "d7615220-df24-4af1-9c35-c796fc90ff10", "embedding": null, "metadata": {"window": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "original_text": "LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9364e07-dc15-47ba-96b5-75de90875e02", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c17c28684202988209afc3f2fc4451d0d927792dc5284050b2890453d9c114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d83bee9-ee1d-496e-b84b-3ec76839accf", "node_type": "1", "metadata": {"window": "LLC  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nLisa C. Gil l \nAnalyst, JPMorgan Securities LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c539af8208f8a885b39358fdc112df0d26193b238c4e81f45d8e5057fedfab96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "978d241e-ce10-4784-8a77-788120fedd81", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms. ", "original_text": "McKesson Corp.  "}, "hash": "bd121bc17b1ac5aa07303a17278a5b8a9ea0c648d444179318ca50e4b789f4fc", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "start_char_idx": 1249, "end_char_idx": 1357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "978d241e-ce10-4784-8a77-788120fedd81": {"__data__": {"id_": "978d241e-ce10-4784-8a77-788120fedd81", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7615220-df24-4af1-9c35-c796fc90ff10", "node_type": "1", "metadata": {"window": "George Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Steven James Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "original_text": "LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nElizabeth Anderson  \nAnalyst, Evercore ISI  \n  ", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f18aae036f7f5ad04cbcfc08f216bd03a3fce8bc4dc938126cb608bb237756e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f3313d5-334e-4295-8362-f271498801e8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call. "}, "hash": "98b94e503343d3a4ba56ad58fadc4bdf90347f83b08825bcf3fc3e3c1ac0f322", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f3313d5-334e-4295-8362-f271498801e8": {"__data__": {"id_": "8f3313d5-334e-4295-8362-f271498801e8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "978d241e-ce10-4784-8a77-788120fedd81", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0588a15a738c4d4c0f4509040b9e4e5b10ff2ad060b637ef7ec063b9470ce4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2128b17-6472-449e-8939-f240d981ccec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n ", "original_text": "This conference is being recorded.  \n \n"}, "hash": "1d1042dd4512b452869eb75ef6754345aebad1dcfbd9e720ec8ba2f4d14e01b5", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call. ", "start_char_idx": 16, "end_char_idx": 268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2128b17-6472-449e-8939-f240d981ccec": {"__data__": {"id_": "c2128b17-6472-449e-8939-f240d981ccec", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n ", "original_text": "This conference is being recorded.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f3313d5-334e-4295-8362-f271498801e8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d68082404d3ecf9c250207745a7167dd655a9e9b63d55ae70b5842b025d98074", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e0912d4-d061-4b02-977c-ce1479c11588", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "At this time, I'd like to turn over the call to Ms. "}, "hash": "07c9a87ae96c92013f87503b338feecd40678f4f290dbb8f07d2690fa5044b3a", "class_name": "RelatedNodeInfo"}}, "text": "This conference is being recorded.  \n \n", "start_char_idx": 268, "end_char_idx": 307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e0912d4-d061-4b02-977c-ce1479c11588": {"__data__": {"id_": "1e0912d4-d061-4b02-977c-ce1479c11588", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "At this time, I'd like to turn over the call to Ms. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2128b17-6472-449e-8939-f240d981ccec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n ", "original_text": "This conference is being recorded.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1c1011421e3c0b4ef5f8b3026efe89af05dc066faca223ba390f87d3f3d2068", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90c1e3bc-f9d1-4919-ab2b-51fea9441b59", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul. ", "original_text": "Holly Weiss. "}, "hash": "35187e01569f641bbaf5806d99afb6aa0d37704b2b459db8ab0829ef95794650", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I'd like to turn over the call to Ms. ", "start_char_idx": 307, "end_char_idx": 359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90c1e3bc-f9d1-4919-ab2b-51fea9441b59": {"__data__": {"id_": "90c1e3bc-f9d1-4919-ab2b-51fea9441b59", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul. ", "original_text": "Holly Weiss. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e0912d4-d061-4b02-977c-ce1479c11588", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "At this time, I'd like to turn over the call to Ms. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ced9e3e153ceedca34cd68853cfe88577789d14c60fb4b5f031bfa909dfa8e58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2559ea3-b524-4586-a74a-0acd02d5bfab", "node_type": "1", "metadata": {"window": "This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall. ", "original_text": "Please, go ahead.  \n "}, "hash": "0483c436a8f33a2558bfe9af0a975e498bc0377bf5ca13406bff4a75cd45c04a", "class_name": "RelatedNodeInfo"}}, "text": "Holly Weiss. ", "start_char_idx": 359, "end_char_idx": 372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2559ea3-b524-4586-a74a-0acd02d5bfab": {"__data__": {"id_": "e2559ea3-b524-4586-a74a-0acd02d5bfab", "embedding": null, "metadata": {"window": "This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall. ", "original_text": "Please, go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90c1e3bc-f9d1-4919-ab2b-51fea9441b59", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul. ", "original_text": "Holly Weiss. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "327b3bf8e06b3f1b634778f9ce4fe50ddc6fca161bd69442fc92fac8b9bacab9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d11f05a2-24ed-4095-a543-046c29916d40", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n"}, "hash": "bd672374ff6f72adb3660ef375344981b401f174d89ff6b6f5413a40356fc98d", "class_name": "RelatedNodeInfo"}}, "text": "Please, go ahead.  \n ", "start_char_idx": 372, "end_char_idx": 393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d11f05a2-24ed-4095-a543-046c29916d40": {"__data__": {"id_": "d11f05a2-24ed-4095-a543-046c29916d40", "embedding": null, "metadata": {"window": "At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2559ea3-b524-4586-a74a-0acd02d5bfab", "node_type": "1", "metadata": {"window": "This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall. ", "original_text": "Please, go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b074a34a87c0a1713f1336c5f4ad3cd14df4cccfc94cdb6bcece4147de7cb2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d11269d0-a319-420a-8c69-6894073cdefd", "node_type": "1", "metadata": {"window": "Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Raul. "}, "hash": "7c8d19035388b8d862c324b1325b1f4a729a3d616860631c3c4b43f0b96ff08e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "start_char_idx": 393, "end_char_idx": 724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d11269d0-a319-420a-8c69-6894073cdefd": {"__data__": {"id_": "d11269d0-a319-420a-8c69-6894073cdefd", "embedding": null, "metadata": {"window": "Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Raul. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d11f05a2-24ed-4095-a543-046c29916d40", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn over the call to Ms.  Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afd894446191428c8d7b2b47333cdaec47fa33a441ac67551355d075073f153c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96997316-b758-4bc7-955f-dae5b426a931", "node_type": "1", "metadata": {"window": "Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall. "}, "hash": "76177c333347b384c387b302d52e8a4867f68b5e4257e578a5ef2626c35a9f65", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Raul. ", "start_char_idx": 724, "end_char_idx": 741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96997316-b758-4bc7-955f-dae5b426a931": {"__data__": {"id_": "96997316-b758-4bc7-955f-dae5b426a931", "embedding": null, "metadata": {"window": "Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d11269d0-a319-420a-8c69-6894073cdefd", "node_type": "1", "metadata": {"window": "Holly Weiss.  Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Raul. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ed9c473bab687d01d86afd798fb9d6f5e52607d4d9593a148df4dfc9f85aa56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b65b8129-12d1-4816-b8a4-0a2ed5d4067a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n"}, "hash": "e15f6641ebcb3e73a8d2f83d1efe1c8bb1911fb70efd02dffca19be19eb0c57c", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall. ", "start_char_idx": 741, "end_char_idx": 835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b65b8129-12d1-4816-b8a4-0a2ed5d4067a": {"__data__": {"id_": "b65b8129-12d1-4816-b8a4-0a2ed5d4067a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96997316-b758-4bc7-955f-dae5b426a931", "node_type": "1", "metadata": {"window": "Please, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf817b0d85432693ef39db6fbe3b1c1bfba399cda526077672bff2fcd79e6623", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c17328d-94b2-4108-9d4c-7b5dd9b7232f", "node_type": "1", "metadata": {"window": "Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n"}, "hash": "f5a797b0aa6aa12f7cdc0eb4fd106194367d1e02a5162ea12d619f580fa0d33d", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "start_char_idx": 835, "end_char_idx": 948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c17328d-94b2-4108-9d4c-7b5dd9b7232f": {"__data__": {"id_": "1c17328d-94b2-4108-9d4c-7b5dd9b7232f", "embedding": null, "metadata": {"window": "Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b65b8129-12d1-4816-b8a4-0a2ed5d4067a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77a76e8ad31b5d6a3d7534f7e7ca5dfcf5a8e41097a71990183c042489b8b11e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78274872-e763-4d78-80d0-253106120cd2", "node_type": "1", "metadata": {"window": "Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. "}, "hash": "08c05625931e77e9f3531c394a53dce62354032a029928a8816c2487752c2c9f", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "start_char_idx": 948, "end_char_idx": 1049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78274872-e763-4d78-80d0-253106120cd2": {"__data__": {"id_": "78274872-e763-4d78-80d0-253106120cd2", "embedding": null, "metadata": {"window": "Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c17328d-94b2-4108-9d4c-7b5dd9b7232f", "node_type": "1", "metadata": {"window": "Thank you, Raul.  Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c2e6866ecd76036b3d295c5f85e4142f6483c1643ba26c011201d374893c0ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd72bdd7-4b99-4119-9c6c-a97f3416b3ee", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n"}, "hash": "fd015bb52a543ef8e83476d508e14e5215e96dbd585cc8f1276ad1742912adb0", "class_name": "RelatedNodeInfo"}}, "text": "Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "start_char_idx": 1049, "end_char_idx": 1177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd72bdd7-4b99-4119-9c6c-a97f3416b3ee": {"__data__": {"id_": "dd72bdd7-4b99-4119-9c6c-a97f3416b3ee", "embedding": null, "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78274872-e763-4d78-80d0-253106120cd2", "node_type": "1", "metadata": {"window": "Good morning, and welcome, everyone, to McKesson's Second Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdea1aa9287c9451a119ef8b73faa84b17f47399abd07dfa407c32a7e491c23a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a36632fb-658e-4f94-9d8b-9f6b6c6cd1eb", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. "}, "hash": "3eefffb717d28a6bdbc15fd0c31d5cf06421162c6a4fc752c0436ff040e84c6f", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "start_char_idx": 1177, "end_char_idx": 1493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a36632fb-658e-4f94-9d8b-9f6b6c6cd1eb": {"__data__": {"id_": "a36632fb-658e-4f94-9d8b-9f6b6c6cd1eb", "embedding": null, "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd72bdd7-4b99-4119-9c6c-a97f3416b3ee", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06338d4ead37c1798f5b7958ff915c1590010970f415a2f272f5a74114e11b92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52879760-07ff-4c74-b5d7-e79e7a119d96", "node_type": "1", "metadata": {"window": "Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody. ", "original_text": "Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n"}, "hash": "e0f315b56bbe1e40c7beb8b6ac27f6b0582e8f67a80ae7426c12b16ac8ea744b", "class_name": "RelatedNodeInfo"}}, "text": "During this call, we will discuss non -GAAP financial measures. ", "start_char_idx": 1493, "end_char_idx": 1557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52879760-07ff-4c74-b5d7-e79e7a119d96": {"__data__": {"id_": "52879760-07ff-4c74-b5d7-e79e7a119d96", "embedding": null, "metadata": {"window": "Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody. ", "original_text": "Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a36632fb-658e-4f94-9d8b-9f6b6c6cd1eb", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a44762205bb34633baa6193857114af21f2c7394e5b7538804c47d050473929c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "453ff5dd-392d-4a61-baf0-bfb34e965d26", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates. ", "original_text": "With that, let me turn it ov er to Brian.  \n "}, "hash": "b77943dfb76070fcae87bfbc2d25e01d7f3c090da165714e0b35f5ce11d299d6", "class_name": "RelatedNodeInfo"}}, "text": "Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "start_char_idx": 1557, "end_char_idx": 1812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "453ff5dd-392d-4a61-baf0-bfb34e965d26": {"__data__": {"id_": "453ff5dd-392d-4a61-baf0-bfb34e965d26", "embedding": null, "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates. ", "original_text": "With that, let me turn it ov er to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52879760-07ff-4c74-b5d7-e79e7a119d96", "node_type": "1", "metadata": {"window": "Today 's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody. ", "original_text": "Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e3fc840571f4896ae467d1c1f733ab2057839c00c91b47de3f1013cade53b12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7966551d-66fe-4893-9eff-9953f5093e6a", "node_type": "1", "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "59dc2ed3b4eaccd564364660427c4b0e0f40391d82601685ea1e69e0a0117f2f", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it ov er to Brian.  \n ", "start_char_idx": 1812, "end_char_idx": 1857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7966551d-66fe-4893-9eff-9953f5093e6a": {"__data__": {"id_": "7966551d-66fe-4893-9eff-9953f5093e6a", "embedding": null, "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "453ff5dd-392d-4a61-baf0-bfb34e965d26", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our per iodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates. ", "original_text": "With that, let me turn it ov er to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "384ea9ea9c601dc94a358e7b3204f67feaea500426befdcfa9922c20b88e0667", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8ff732e-8c44-440d-bebd-61981b6a6928", "node_type": "1", "metadata": {"window": "Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n", "original_text": "Thank you, Holly; and good morning, everybody. "}, "hash": "b6d869b388d00b4febe4e87817235906c57245bec302bc4653b9b138dcc3a4bd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 1857, "end_char_idx": 2184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8ff732e-8c44-440d-bebd-61981b6a6928": {"__data__": {"id_": "b8ff732e-8c44-440d-bebd-61981b6a6928", "embedding": null, "metadata": {"window": "Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n", "original_text": "Thank you, Holly; and good morning, everybody. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7966551d-66fe-4893-9eff-9953f5093e6a", "node_type": "1", "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0a99c33a3a2eeb8366877f84615c399dabf29bbcc1c681c9e93e8b05c0f585a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec7c15a1-5c47-49b5-aed3-9608c56c9f45", "node_type": "1", "metadata": {"window": "With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August. ", "original_text": "Thank you for joining us on [audio gap] (01:25) in the United \nStates. "}, "hash": "9a77f8fa0305fcb1dc6e434a1ad30ed6e7d6cb9032212d435fbe40068d63585d", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Holly; and good morning, everybody. ", "start_char_idx": 2184, "end_char_idx": 2231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec7c15a1-5c47-49b5-aed3-9608c56c9f45": {"__data__": {"id_": "ec7c15a1-5c47-49b5-aed3-9608c56c9f45", "embedding": null, "metadata": {"window": "With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August. ", "original_text": "Thank you for joining us on [audio gap] (01:25) in the United \nStates. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8ff732e-8c44-440d-bebd-61981b6a6928", "node_type": "1", "metadata": {"window": "Additional informati on about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n", "original_text": "Thank you, Holly; and good morning, everybody. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "592f59beab07215ed43e4accea9c6656ae0b73b114dab0bf7a57e0b896e9b850", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b929044c-248b-42b1-9011-c44b6b980842", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n", "original_text": "Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n"}, "hash": "9acc53c311d4907c0218d9491b59dc66caa6f3011dddb46c5a4cc291fc03e09a", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for joining us on [audio gap] (01:25) in the United \nStates. ", "start_char_idx": 2231, "end_char_idx": 2302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b929044c-248b-42b1-9011-c44b6b980842": {"__data__": {"id_": "b929044c-248b-42b1-9011-c44b6b980842", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n", "original_text": "Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec7c15a1-5c47-49b5-aed3-9608c56c9f45", "node_type": "1", "metadata": {"window": "With that, let me turn it ov er to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August. ", "original_text": "Thank you for joining us on [audio gap] (01:25) in the United \nStates. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcf6ab2afa26a28872e6c2f384428323ecb3d5b802f6674f4be73e74fecdf2c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa78d77c-d5ec-419a-9b69-0a5f178c745e", "node_type": "1", "metadata": {"window": "Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay. ", "original_text": "Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n"}, "hash": "afc3e71f27bca741f2d12e1ff8e416ff793d5cda3c012ec9132b8de66e18d403", "class_name": "RelatedNodeInfo"}}, "text": "Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n", "start_char_idx": 2302, "end_char_idx": 2440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa78d77c-d5ec-419a-9b69-0a5f178c745e": {"__data__": {"id_": "fa78d77c-d5ec-419a-9b69-0a5f178c745e", "embedding": null, "metadata": {"window": "Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay. ", "original_text": "Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b929044c-248b-42b1-9011-c44b6b980842", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n", "original_text": "Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6de3a88e513e84db8fbb854c563eda599430fedb85f40f51a5ea37fbf3a6a9dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d524128a-bbae-4ef7-86f8-35759f762b21", "node_type": "1", "metadata": {"window": "Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n", "original_text": "Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August. "}, "hash": "bc16a7ad2dd3ca4adca086459d7b46aa962644fdf8469631597a71ff72367226", "class_name": "RelatedNodeInfo"}}, "text": "Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n", "start_char_idx": 2440, "end_char_idx": 2736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d524128a-bbae-4ef7-86f8-35759f762b21": {"__data__": {"id_": "d524128a-bbae-4ef7-86f8-35759f762b21", "embedding": null, "metadata": {"window": "Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n", "original_text": "Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa78d77c-d5ec-419a-9b69-0a5f178c745e", "node_type": "1", "metadata": {"window": "Thank you, Holly; and good morning, everybody.  Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay. ", "original_text": "Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea0aa8dda3a59c8acf41594714c43854aaf8f34c0a1bbd10e4fffc54253334bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90b08ef3-2288-47e1-9773-7e80bbe19cb5", "node_type": "1", "metadata": {"window": "Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter. ", "original_text": "I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n"}, "hash": "3be4fc17564469edfb52ed7a9e485ec884ed927e2be323573925b582bd9e1224", "class_name": "RelatedNodeInfo"}}, "text": "Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August. ", "start_char_idx": 2736, "end_char_idx": 2939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90b08ef3-2288-47e1-9773-7e80bbe19cb5": {"__data__": {"id_": "90b08ef3-2288-47e1-9773-7e80bbe19cb5", "embedding": null, "metadata": {"window": "Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter. ", "original_text": "I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d524128a-bbae-4ef7-86f8-35759f762b21", "node_type": "1", "metadata": {"window": "Thank you for joining us on [audio gap] (01:25) in the United \nStates.  Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n", "original_text": "Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbbe159744eae432b8b8d42d2de534a42059dccd973d1e1d8917d460ba0431f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4faaa692-c4ed-4ebf-a292-7be17cba0201", "node_type": "1", "metadata": {"window": "Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter.  While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "original_text": "The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay. "}, "hash": "56593ee3d1d78632cf743a8744db39ff6b12895ebad05bd551a77e0927a1cd0f", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n", "start_char_idx": 2939, "end_char_idx": 3096, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4faaa692-c4ed-4ebf-a292-7be17cba0201": {"__data__": {"id_": "4faaa692-c4ed-4ebf-a292-7be17cba0201", "embedding": null, "metadata": {"window": "Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter.  While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "original_text": "The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90b08ef3-2288-47e1-9773-7e80bbe19cb5", "node_type": "1", "metadata": {"window": "Today is obviously an important day, a day, which every c itizen can vote, should have the opportunity to \nexercise this civic right.  \n \n Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter. ", "original_text": "I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e1f5072e0100b0020a345fe9ab77be00a60852e6cdfa23d0223a50b93309f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5653ee3-f0c2-45fa-9d1f-981577a2f96c", "node_type": "1", "metadata": {"window": "Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter.  While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "original_text": "You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n"}, "hash": "fa45dd96f97017e6ee286ae8a1ed263410304778ebff14ecc66f304226ea9187", "class_name": "RelatedNodeInfo"}}, "text": "The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay. ", "start_char_idx": 3096, "end_char_idx": 3222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5653ee3-f0c2-45fa-9d1f-981577a2f96c": {"__data__": {"id_": "e5653ee3-f0c2-45fa-9d1f-981577a2f96c", "embedding": null, "metadata": {"window": "Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter.  While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "original_text": "You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4faaa692-c4ed-4ebf-a292-7be17cba0201", "node_type": "1", "metadata": {"window": "Regardless of who's in the White House, we look forward to working with the administration and the new \nCongress to ensure a strong and safe economic recovery, while keeping the hea lthcare supply chain running and \ncontinuing to deliver for our customers on the frontlines of this pandemic.  \n \n Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter.  While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "original_text": "The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "267335d62d172ed5d38daa2814d5b43a29737e5b0c1b1316bd0c846720212516", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec34d79b-527b-43c8-a94f-f7839eb38867", "node_type": "1", "metadata": {"window": "I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter.  While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "original_text": "In our second quarter, we again saw volume s increase compared to the low points early in the first quarter. "}, "hash": "aac38d0db5f40ae8c850a9c550f4f13f7e79d866f5e910a95b8e544d7b9d1fd6", "class_name": "RelatedNodeInfo"}}, "text": "You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n", "start_char_idx": 3222, "end_char_idx": 3359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec34d79b-527b-43c8-a94f-f7839eb38867": {"__data__": {"id_": "ec34d79b-527b-43c8-a94f-f7839eb38867", "embedding": null, "metadata": {"window": "I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter.  While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "original_text": "In our second quarter, we again saw volume s increase compared to the low points early in the first quarter. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5653ee3-f0c2-45fa-9d1f-981577a2f96c", "node_type": "1", "metadata": {"window": "Today, we reported second quarter total company revenues of $60.8 billion and adjusted earnings per diluted \nshare of $4.80, both ahead of prior ye ar and our revised expectations we laid out in August.  I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter.  While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "original_text": "You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77386416cb5e5d7b4216479f74a56d441c2ba1d5793825f92f3caaf9f010e8ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92ba47b9-f66f-4c56-9ba7-727f3c428fdf", "node_type": "1", "metadata": {"window": "The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter.  While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "original_text": "While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be "}, "hash": "4405f1a4064bcbff44d6839228d05f715e192bcd7c0f601fbe806f7735d43ed0", "class_name": "RelatedNodeInfo"}}, "text": "In our second quarter, we again saw volume s increase compared to the low points early in the first quarter. ", "start_char_idx": 3359, "end_char_idx": 3468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92ba47b9-f66f-4c56-9ba7-727f3c428fdf": {"__data__": {"id_": "92ba47b9-f66f-4c56-9ba7-727f3c428fdf", "embedding": null, "metadata": {"window": "The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter.  While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "original_text": "While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4918134e-30b2-42ef-aabf-32bbcb34951a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2941eb676a9bb61471d0c1f522ded6778a393fcd474a654f81a53d91109ba6a3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec34d79b-527b-43c8-a94f-f7839eb38867", "node_type": "1", "metadata": {"window": "I'd like to thank the \npeople who make up team McKesson for their resilience, their dedication, their flexibility and ability to manage \nthrough change.  \n \n The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter.  While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "original_text": "In our second quarter, we again saw volume s increase compared to the low points early in the first quarter. ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd68bcdd5d746fe3ee3ca413663e8186b69a85f75b82b27db9b1630c11781ab1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01403a4f-c183-4d6a-957d-0af9a86c9df3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs. ", "original_text": "McKesson Corp.  "}, "hash": "295885c098078b91811a00d02d13ffc1b5264e6148c5b55f4530f5fcceea7525", "class_name": "RelatedNodeInfo"}}, "text": "While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "start_char_idx": 3468, "end_char_idx": 3579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01403a4f-c183-4d6a-957d-0af9a86c9df3": {"__data__": {"id_": "01403a4f-c183-4d6a-957d-0af9a86c9df3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92ba47b9-f66f-4c56-9ba7-727f3c428fdf", "node_type": "1", "metadata": {"window": "The first half of fiscal 2021 has certainly played out differently than the original expectations we provided to you in \nMay.  You'll recall that based on the positive signs of recovery at the end of our first quarter, we raised our \nguidance for fiscal 2021.  \n \n In our second quarter, we again saw volume s increase compared to the low points early in the first quarter.  While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "original_text": "While \npatient mobility and prescription volume showed improvement and stability, the recovery continues to be ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5aa97fe98990def7cdfb2cce939a0bb91225dcce491e4708520edb1227d363ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75907d43-1f18-4a40-a47d-2292fb907a32", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted. "}, "hash": "0ed049b045f31b039d9b62cad8021520d66e6a8fd4f344da9ef281175a45831b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75907d43-1f18-4a40-a47d-2292fb907a32": {"__data__": {"id_": "75907d43-1f18-4a40-a47d-2292fb907a32", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01403a4f-c183-4d6a-957d-0af9a86c9df3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81f37e401700258fb6539a313357d8b750b06144b8e11ccd4b5e2565b006765f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "792349b9-fb36-4663-a7d0-c8b104f4639c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date. ", "original_text": "And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n"}, "hash": "db93af9224a3081e2e06d341eaf657bfc4b408c95bf4b71b98b2de3aa960e1e2", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted. ", "start_char_idx": 16, "end_char_idx": 217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "792349b9-fb36-4663-a7d0-c8b104f4639c": {"__data__": {"id_": "792349b9-fb36-4663-a7d0-c8b104f4639c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date. ", "original_text": "And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75907d43-1f18-4a40-a47d-2292fb907a32", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10c630da2dca2f7e9912b96ae615c86807ce772beabd3cd3143ccceb276ee7fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8b9a543-ceff-4d5d-8252-5d5aa6a1955b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n", "original_text": "In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs. "}, "hash": "187dc8896c97c41b0d2450575fffc9812a474de9b93b6521ef123328938db39d", "class_name": "RelatedNodeInfo"}}, "text": "And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n", "start_char_idx": 217, "end_char_idx": 345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8b9a543-ceff-4d5d-8252-5d5aa6a1955b": {"__data__": {"id_": "e8b9a543-ceff-4d5d-8252-5d5aa6a1955b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n", "original_text": "In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "792349b9-fb36-4663-a7d0-c8b104f4639c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date. ", "original_text": "And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a31f22e3f8ce384ac78f19ac644312292711208fb01560aa191a6795a0782e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13a1e639-68cc-45a9-9e7a-34e6e5957ee6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics. ", "original_text": "Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n"}, "hash": "42dc606b2af1f51a4f05c23e7c65f6326ebde04ef988900a7768654ad1e172aa", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs. ", "start_char_idx": 345, "end_char_idx": 478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13a1e639-68cc-45a9-9e7a-34e6e5957ee6": {"__data__": {"id_": "13a1e639-68cc-45a9-9e7a-34e6e5957ee6", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics. ", "original_text": "Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8b9a543-ceff-4d5d-8252-5d5aa6a1955b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n", "original_text": "In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac10ff38f89375078c4cfcf12bc0b5dbb9e796f491432d1955f49f66a0f11959", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01667e9b-d436-464d-83da-eda4b1086442", "node_type": "1", "metadata": {"window": "And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May. ", "original_text": "New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date. "}, "hash": "6313e31f227109d45b9731a0a107d45cdce4738c346b563dcd5ea45409ddff01", "class_name": "RelatedNodeInfo"}}, "text": "Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n", "start_char_idx": 478, "end_char_idx": 657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01667e9b-d436-464d-83da-eda4b1086442": {"__data__": {"id_": "01667e9b-d436-464d-83da-eda4b1086442", "embedding": null, "metadata": {"window": "And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May. ", "original_text": "New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13a1e639-68cc-45a9-9e7a-34e6e5957ee6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics. ", "original_text": "Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96db6735ff3485fdd278aaddad79e445a106dc29abb392b367bd5a8a6da49841", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0eb1dc3f-2306-495a-8067-8f6a6cdd0810", "node_type": "1", "metadata": {"window": "In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021. ", "original_text": "While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n"}, "hash": "97f3035f4f3b5ee9c1657f8c274080af0eeef3cfa0186373f8d60839bfcf86ff", "class_name": "RelatedNodeInfo"}}, "text": "New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date. ", "start_char_idx": 657, "end_char_idx": 807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0eb1dc3f-2306-495a-8067-8f6a6cdd0810": {"__data__": {"id_": "0eb1dc3f-2306-495a-8067-8f6a6cdd0810", "embedding": null, "metadata": {"window": "In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021. ", "original_text": "While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01667e9b-d436-464d-83da-eda4b1086442", "node_type": "1", "metadata": {"window": "And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May. ", "original_text": "New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cffdff80a87f28bc70142fed83ce8cbbbaa43c40f8c96f447d60edbfbe37fca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89eb22f4-99f4-4e42-a0a7-117674472fe2", "node_type": "1", "metadata": {"window": "Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n", "original_text": "Our results year -to-date are underpinned by three dynamics. "}, "hash": "e9d03ec6ed9a93a95c71bcc8e4fd655f438a6e3e57561c6e8149e5803ffa71de", "class_name": "RelatedNodeInfo"}}, "text": "While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n", "start_char_idx": 807, "end_char_idx": 926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89eb22f4-99f4-4e42-a0a7-117674472fe2": {"__data__": {"id_": "89eb22f4-99f4-4e42-a0a7-117674472fe2", "embedding": null, "metadata": {"window": "Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n", "original_text": "Our results year -to-date are underpinned by three dynamics. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0eb1dc3f-2306-495a-8067-8f6a6cdd0810", "node_type": "1", "metadata": {"window": "In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs.  Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021. ", "original_text": "While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79e35fd312a6b4de9750a241a029e4479d114aabbd50e20e51bb079103a308f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "217ec653-a35d-4e80-b4a4-b237aeb7ceac", "node_type": "1", "metadata": {"window": "New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve. ", "original_text": "First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May. "}, "hash": "2f95c68178e01a5a8ab2920304c3c8fcf22cc50477221dcce6fbe4d80882f722", "class_name": "RelatedNodeInfo"}}, "text": "Our results year -to-date are underpinned by three dynamics. ", "start_char_idx": 926, "end_char_idx": 987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "217ec653-a35d-4e80-b4a4-b237aeb7ceac": {"__data__": {"id_": "217ec653-a35d-4e80-b4a4-b237aeb7ceac", "embedding": null, "metadata": {"window": "New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve. ", "original_text": "First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89eb22f4-99f4-4e42-a0a7-117674472fe2", "node_type": "1", "metadata": {"window": "Investments in the business and customer rel ationships, particularly in our \nmedical business, have positioned us well to serve our customers during this unprecedented time.  \n \n New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n", "original_text": "Our results year -to-date are underpinned by three dynamics. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f76759364d161b5a0879b65ee2005c717c9409200432b3263d1ac64b26b2237", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "159be188-4a87-46e0-b33e-e86c68822a30", "node_type": "1", "metadata": {"window": "While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n", "original_text": "Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021. "}, "hash": "a3b3c1e73ea033bc1865f47b9445fca93e9ff173bfa3f8d97121efa6a2833c7c", "class_name": "RelatedNodeInfo"}}, "text": "First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May. ", "start_char_idx": 987, "end_char_idx": 1107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "159be188-4a87-46e0-b33e-e86c68822a30": {"__data__": {"id_": "159be188-4a87-46e0-b33e-e86c68822a30", "embedding": null, "metadata": {"window": "While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n", "original_text": "Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "217ec653-a35d-4e80-b4a4-b237aeb7ceac", "node_type": "1", "metadata": {"window": "New demand for product categories, such as COVID -19 tests, and elevated demand for PPE have contributed \nmeaningfully to our re sults year -to-date.  While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve. ", "original_text": "First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "360df2371c069349583a52e743554439bd47cf469d573069fe5cddd996d82313", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b89c3c52-4f18-4e8d-846e-85e855133ab4", "node_type": "1", "metadata": {"window": "Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n", "original_text": "And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n"}, "hash": "9c597f734028678f2cef4eb382f90de2edca5e6e35f1a3aaf82516e3c0cd0e47", "class_name": "RelatedNodeInfo"}}, "text": "Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021. ", "start_char_idx": 1107, "end_char_idx": 1357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b89c3c52-4f18-4e8d-846e-85e855133ab4": {"__data__": {"id_": "b89c3c52-4f18-4e8d-846e-85e855133ab4", "embedding": null, "metadata": {"window": "Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n", "original_text": "And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "159be188-4a87-46e0-b33e-e86c68822a30", "node_type": "1", "metadata": {"window": "While short -term upside, we do not anticipate the elevated levels of \ndemand for these products in the long term.  \n \n Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n", "original_text": "Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1dcb00e6055d941689787579235a2fc249d659e0fbcc209fcd7b01fda71da1ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5b8adbd-bb09-4186-a243-9904aab15541", "node_type": "1", "metadata": {"window": "First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n", "original_text": "Second, the fundamentals in the business remain solid and our execution has continued to improve. "}, "hash": "8656290b83724ba1da26492561be2557a29f5f689eea1980742700736e9ebc49", "class_name": "RelatedNodeInfo"}}, "text": "And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n", "start_char_idx": 1357, "end_char_idx": 1451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5b8adbd-bb09-4186-a243-9904aab15541": {"__data__": {"id_": "b5b8adbd-bb09-4186-a243-9904aab15541", "embedding": null, "metadata": {"window": "First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n", "original_text": "Second, the fundamentals in the business remain solid and our execution has continued to improve. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b89c3c52-4f18-4e8d-846e-85e855133ab4", "node_type": "1", "metadata": {"window": "Our results year -to-date are underpinned by three dynamics.  First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n", "original_text": "And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "903a92a5caddc233b7e17085279287f98e93d180f9ef1aad87f18770680099cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eec6d4f3-1e1d-490e-97f4-e3b26eecd029", "node_type": "1", "metadata": {"window": "Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented. ", "original_text": "Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n"}, "hash": "848bbb6e504738ff7b9f23b284135714465ab661c9fbc8ccc3591d4155c565d2", "class_name": "RelatedNodeInfo"}}, "text": "Second, the fundamentals in the business remain solid and our execution has continued to improve. ", "start_char_idx": 1451, "end_char_idx": 1549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eec6d4f3-1e1d-490e-97f4-e3b26eecd029": {"__data__": {"id_": "eec6d4f3-1e1d-490e-97f4-e3b26eecd029", "embedding": null, "metadata": {"window": "Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented. ", "original_text": "Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5b8adbd-bb09-4186-a243-9904aab15541", "node_type": "1", "metadata": {"window": "First and foremost, the shape and pace of the \nrecovery has bee n different than we had originally contemplated in May.  Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n", "original_text": "Second, the fundamentals in the business remain solid and our execution has continued to improve. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3e8108c7c2bbf1b1577dc871f547723630033729b6035c7dbe669e0f928c7df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be85fbee-c97e-49bc-abf6-bc508cb41225", "node_type": "1", "metadata": {"window": "And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US. ", "original_text": "As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n"}, "hash": "73758cb3d5be898ebf4df212a515b059481a688d06b6aa0fafa71b8a8b6cb464", "class_name": "RelatedNodeInfo"}}, "text": "Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n", "start_char_idx": 1549, "end_char_idx": 1687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be85fbee-c97e-49bc-abf6-bc508cb41225": {"__data__": {"id_": "be85fbee-c97e-49bc-abf6-bc508cb41225", "embedding": null, "metadata": {"window": "And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US. ", "original_text": "As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eec6d4f3-1e1d-490e-97f4-e3b26eecd029", "node_type": "1", "metadata": {"window": "Following a sharp recovery to the end of \nthe first quarter, we continue to see modest improvement in the second quarter, but with signs the recovery will \nnot fully happen in our fiscal 2021, most like ly extending well into the calendar year 2021.  And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented. ", "original_text": "Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "894d681a49496f7f093cec8fd804c907c2a96c6b2bc9b5f1cd64058d585b7db5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb8f314e-1034-4bcd-ab18-ae5c5c13c040", "node_type": "1", "metadata": {"window": "Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n", "original_text": "This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n"}, "hash": "62bc05a8fa5284fb09dece99ff44f3b3e942e0501cc98adf6898c1fcd620c040", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n", "start_char_idx": 1687, "end_char_idx": 1914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb8f314e-1034-4bcd-ab18-ae5c5c13c040": {"__data__": {"id_": "fb8f314e-1034-4bcd-ab18-ae5c5c13c040", "embedding": null, "metadata": {"window": "Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n", "original_text": "This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be85fbee-c97e-49bc-abf6-bc508cb41225", "node_type": "1", "metadata": {"window": "And given current \nCOVID -19 infection rate volatility, we expect a non -linear recovery.  \n \n Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US. ", "original_text": "As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2abb120db8bc105d8f1d2eaf1e57caa167869c06ff0234085e090feb0eef1094", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f421750d-025c-432c-9af2-59730b621e0b", "node_type": "1", "metadata": {"window": "Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines. ", "original_text": "Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented. "}, "hash": "076b2f3b10c0750299b8934d9bb1153df7e5c94c08f9d316597e462e60aa9a6f", "class_name": "RelatedNodeInfo"}}, "text": "This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n", "start_char_idx": 1914, "end_char_idx": 1992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f421750d-025c-432c-9af2-59730b621e0b": {"__data__": {"id_": "f421750d-025c-432c-9af2-59730b621e0b", "embedding": null, "metadata": {"window": "Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines. ", "original_text": "Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb8f314e-1034-4bcd-ab18-ae5c5c13c040", "node_type": "1", "metadata": {"window": "Second, the fundamentals in the business remain solid and our execution has continued to improve.  Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n", "original_text": "This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "914a27a87ad8e826166e4b3b06e2e636dae796e1fbe037a39102b930133ac88d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a59173e5-8dcf-48a0-9662-05ff58f0dc65", "node_type": "1", "metadata": {"window": "As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n", "original_text": "This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US. "}, "hash": "d2a44ff3c4634897a01336afdd7e7442a14455b1648a4230cd0f6ba642c44428", "class_name": "RelatedNodeInfo"}}, "text": "Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented. ", "start_char_idx": 1992, "end_char_idx": 2233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a59173e5-8dcf-48a0-9662-05ff58f0dc65": {"__data__": {"id_": "a59173e5-8dcf-48a0-9662-05ff58f0dc65", "embedding": null, "metadata": {"window": "As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n", "original_text": "This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f421750d-025c-432c-9af2-59730b621e0b", "node_type": "1", "metadata": {"window": "Lastly, \ndiscrete one -time gains in the second quarter and short -term opportunities present near -term upside for the fiscal \nyear.  \n \n As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines. ", "original_text": "Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "204611ca689c4ac5398e5dec0968480a030cdb52b1d5283453f746190ad2a0b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "beda16bd-81fe-4517-9f4e-1d24e6c33aeb", "node_type": "1", "metadata": {"window": "This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed. ", "original_text": "Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n"}, "hash": "2ecabd85320676089f0a2a387ed883079867a2a7613df055f1525601c6c995a7", "class_name": "RelatedNodeInfo"}}, "text": "This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US. ", "start_char_idx": 2233, "end_char_idx": 2463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "beda16bd-81fe-4517-9f4e-1d24e6c33aeb": {"__data__": {"id_": "beda16bd-81fe-4517-9f4e-1d24e6c33aeb", "embedding": null, "metadata": {"window": "This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed. ", "original_text": "Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a59173e5-8dcf-48a0-9662-05ff58f0dc65", "node_type": "1", "metadata": {"window": "As a result of our performance in the quarter and our improved outlook across the business, we are raising and \nnarrowing our fiscal 2021 adjusted ear nings per diluted share guidance range to $16 to $16.50 per diluted share. \n This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n", "original_text": "This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b401fed427662077495af4378a7ae838181996f824adf3b659a7c0439c9d89a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0eced27-752c-4b58-83f4-fda3dfe4dbd4", "node_type": "1", "metadata": {"window": "Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA. ", "original_text": "Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines. "}, "hash": "73eaf7e0327e582a39aec8c33ef1e059eacd7f6d8afc803e0aea6dbf7f1258a2", "class_name": "RelatedNodeInfo"}}, "text": "Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n", "start_char_idx": 2463, "end_char_idx": 2629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0eced27-752c-4b58-83f4-fda3dfe4dbd4": {"__data__": {"id_": "a0eced27-752c-4b58-83f4-fda3dfe4dbd4", "embedding": null, "metadata": {"window": "Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA. ", "original_text": "Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "beda16bd-81fe-4517-9f4e-1d24e6c33aeb", "node_type": "1", "metadata": {"window": "This is up from our previous range of $14.70 to $15.50 per diluted share.  \n \n Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed. ", "original_text": "Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "593f64c5ada68e5dd20d8bb05e2685665d0d97607e33849a1165739218c89aa4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa96991a-ebf0-4e68-8e80-2c8095c4ea1f", "node_type": "1", "metadata": {"window": "This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n", "original_text": "McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n"}, "hash": "ad985dfaa765bb1e29b7f419e934357ca9421057b9d844f1dcea632d93e95cb0", "class_name": "RelatedNodeInfo"}}, "text": "Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines. ", "start_char_idx": 2629, "end_char_idx": 3008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa96991a-ebf0-4e68-8e80-2c8095c4ea1f": {"__data__": {"id_": "fa96991a-ebf0-4e68-8e80-2c8095c4ea1f", "embedding": null, "metadata": {"window": "This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n", "original_text": "McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0eced27-752c-4b58-83f4-fda3dfe4dbd4", "node_type": "1", "metadata": {"window": "Since the onset of the pandemic, McKesson has partnered with government agencies at the federal state and \nlocal level, along with other industry leaders, to help find solutions to the most complex and pressing issues the \ncrisis presented.  This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA. ", "original_text": "Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "364c2813920e20a63b464ac1ea2cf0539c9e18dc437fb4101ff2406bc1ac95c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d68c2e67-142d-46f1-8819-dec121e7da03", "node_type": "1", "metadata": {"window": "Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country. ", "original_text": "I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed. "}, "hash": "3630f08016718ac1f9893f57a706769c645c3f1be0b1e4290ce3450965ac3610", "class_name": "RelatedNodeInfo"}}, "text": "McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n", "start_char_idx": 3008, "end_char_idx": 3220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d68c2e67-142d-46f1-8819-dec121e7da03": {"__data__": {"id_": "d68c2e67-142d-46f1-8819-dec121e7da03", "embedding": null, "metadata": {"window": "Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country. ", "original_text": "I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa96991a-ebf0-4e68-8e80-2c8095c4ea1f", "node_type": "1", "metadata": {"window": "This critical work once again speaks to the important role we play in the healthcare supply chain \nand to the depth of McKes son's expertise in sourcing, picking, packing and distributing supplies to sites of care \nacross the US.  Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n", "original_text": "McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b94069fb4cd9c042d85f34459d9d2e42df4bdffb0793c0ae97c86541c9cd84fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3dd03da-299d-4c58-b893-5b59f49373c0", "node_type": "1", "metadata": {"window": "Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location. ", "original_text": "We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA. "}, "hash": "781a41e0132223f222927dc38afd2f6805d7f3da2470b7582b97b80e67751962", "class_name": "RelatedNodeInfo"}}, "text": "I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed. ", "start_char_idx": 3220, "end_char_idx": 3324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3dd03da-299d-4c58-b893-5b59f49373c0": {"__data__": {"id_": "a3dd03da-299d-4c58-b893-5b59f49373c0", "embedding": null, "metadata": {"window": "Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location. ", "original_text": "We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d68c2e67-142d-46f1-8819-dec121e7da03", "node_type": "1", "metadata": {"window": "Our role in the supply chain was highlighted in the quarter through expanded partnerships with the \nUS government, specifically supporting Operation Warp  Speed.  \n \n Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country. ", "original_text": "I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b94e819923866543a4a73fa50e65192aea57621ab0eb752f04048521d2148f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94ee9b4f-3cff-4d56-8bac-7c39a6c93693", "node_type": "1", "metadata": {"window": "McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location.  While it's st ill early in the ", "original_text": "Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n"}, "hash": "2ab3fdd9da2ecf31c7c2fe1771d47ea8373cc02694588c5ad5ecdce2f953e8ef", "class_name": "RelatedNodeInfo"}}, "text": "We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA. ", "start_char_idx": 3324, "end_char_idx": 3433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94ee9b4f-3cff-4d56-8bac-7c39a6c93693": {"__data__": {"id_": "94ee9b4f-3cff-4d56-8bac-7c39a6c93693", "embedding": null, "metadata": {"window": "McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location.  While it's st ill early in the ", "original_text": "Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3dd03da-299d-4c58-b893-5b59f49373c0", "node_type": "1", "metadata": {"window": "Similar to our role in the 2009 to 2010 period, the H1N1 pandemic, the Centers for Disease Control and \nPrevention engaged us to expand our existing partnership under the Vaccines for Children Program to support \nthe US government's Operation Warp S peed team as a centralized distributor of future COVID -19 vaccines and \nancillary supplies needed to administer those vaccines.  McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location. ", "original_text": "We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "943ee3f020eb224726fe2f80ce2446dae7d06ea88e921f37771abc82a8ac019c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c51f5b47-d4ba-41ce-b6a3-dcfea731212c", "node_type": "1", "metadata": {"window": "I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location.  While it's st ill early in the ", "original_text": "In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country. "}, "hash": "5f6a0ab0d85b69c622f7ed9ff7d2cdf70331ed0c4a653e9b6df1d889b0e16fa3", "class_name": "RelatedNodeInfo"}}, "text": "Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n", "start_char_idx": 3433, "end_char_idx": 3602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c51f5b47-d4ba-41ce-b6a3-dcfea731212c": {"__data__": {"id_": "c51f5b47-d4ba-41ce-b6a3-dcfea731212c", "embedding": null, "metadata": {"window": "I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location.  While it's st ill early in the ", "original_text": "In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94ee9b4f-3cff-4d56-8bac-7c39a6c93693", "node_type": "1", "metadata": {"window": "McKesson's role in the H1N1 response was a proud \nmoment in our history over 10 years ago, and we're very honored to serve in a si milar capacity as we help support \nthe fight against the COVID -19 pandemic.  \n \n I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location.  While it's st ill early in the ", "original_text": "Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1c99cb6077ff4be27659a839a0d7b78d18a427d6933aff0726e38217ad97d6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa768a22-2ae8-4edf-bd74-840e83a47126", "node_type": "1", "metadata": {"window": "We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location.  While it's st ill early in the ", "original_text": "McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location. "}, "hash": "c0622c06ccb34dc44d1e53f3bd3d7eeb821769ac0d77541adf39bf3cb42de8b3", "class_name": "RelatedNodeInfo"}}, "text": "In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country. ", "start_char_idx": 3602, "end_char_idx": 3766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa768a22-2ae8-4edf-bd74-840e83a47126": {"__data__": {"id_": "fa768a22-2ae8-4edf-bd74-840e83a47126", "embedding": null, "metadata": {"window": "We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location.  While it's st ill early in the ", "original_text": "McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c51f5b47-d4ba-41ce-b6a3-dcfea731212c", "node_type": "1", "metadata": {"window": "I do want to take a moment to just clarify the scope of McKesson's involvement in Operation Warp Speed.  We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location.  While it's st ill early in the ", "original_text": "In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e49533f8cc9e4c6514f92bfc58e6e72f8e732fae00b39c7c1ec4e43f69f30b21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46555894-7e9b-4c08-a6e2-67bdb18edbdd", "node_type": "1", "metadata": {"window": "Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location.  While it's st ill early in the ", "original_text": "While it's st ill early in the "}, "hash": "f90be6986c929d2a5c1dcb6e4af9e94e5527134068b660f4e724dd452e19e27b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location. ", "start_char_idx": 3766, "end_char_idx": 3911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46555894-7e9b-4c08-a6e2-67bdb18edbdd": {"__data__": {"id_": "46555894-7e9b-4c08-a6e2-67bdb18edbdd", "embedding": null, "metadata": {"window": "Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location.  While it's st ill early in the ", "original_text": "While it's st ill early in the ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0133d1327c1bd33e74fc64933b2911b3502b90a3c036331e9aaae240e15a0e3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa768a22-2ae8-4edf-bd74-840e83a47126", "node_type": "1", "metadata": {"window": "We will \nbe the centralized distributor for refrigerated and frozen vaccine t ypes once approved by the FDA.  Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location.  While it's st ill early in the ", "original_text": "McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location. ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58630eff43f5b41808c745b4207f818c2fd39540638401306941d8816af302e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b58f1b9-2469-4d1f-b4fa-2e6582e98a61", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook. ", "original_text": "McKesson Corp.  "}, "hash": "ad9db928f2145f43e00e3d49c78cf1f7bd246c71dc7681adaa239620c225d12a", "class_name": "RelatedNodeInfo"}}, "text": "While it's st ill early in the ", "start_char_idx": 3911, "end_char_idx": 3942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b58f1b9-2469-4d1f-b4fa-2e6582e98a61": {"__data__": {"id_": "9b58f1b9-2469-4d1f-b4fa-2e6582e98a61", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46555894-7e9b-4c08-a6e2-67bdb18edbdd", "node_type": "1", "metadata": {"window": "Ultra -frozen \nvaccines, which are those requiring temperatures of minus 60 degrees Celsius or colder are not within the scope \nof McKesson's contract with the CDC.  \n \n In the centralized model, the US government directs McKesson o n the distribution of the vaccines and related \nsupplies to point -of-care sites across the country.  McKesson will make no allocation or prioritization decisions, \nand we will not have any influence on which vaccine is shipped to which location.  While it's st ill early in the ", "original_text": "While it's st ill early in the ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b35c83381ea8e601467d31a3bb41a73e3db79a1a3b81455dd556f8d6edd9f2dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1beb06c2-80c0-4bce-8c7f-1a71bb151bd3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n"}, "hash": "8e5ec98a428aa92fd977112f3307e9b39f1e21f9d728c95a8681ac9a56d43a71", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1beb06c2-80c0-4bce-8c7f-1a71bb151bd3": {"__data__": {"id_": "1beb06c2-80c0-4bce-8c7f-1a71bb151bd3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b58f1b9-2469-4d1f-b4fa-2e6582e98a61", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ddce76f43c98e7d1c9cd01ffd7ce11afdbf729e3ee82bfae94635f0a0a5dd478", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8a45a34-3b28-447e-b13e-a02512b32278", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable. ", "original_text": "We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available. "}, "hash": "997d474c2528670c5f80d4f55dc47a35fe60215ff230b912d728c661020f72aa", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n", "start_char_idx": 16, "end_char_idx": 389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8a45a34-3b28-447e-b13e-a02512b32278": {"__data__": {"id_": "c8a45a34-3b28-447e-b13e-a02512b32278", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable. ", "original_text": "We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1beb06c2-80c0-4bce-8c7f-1a71bb151bd3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d362f96cbe788b1785be9f08131d30bc12481ee9b12ea4bba3c06389f799b6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2e78921-fa04-46d8-9ba8-1fa0cdc21e3a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country. ", "original_text": "Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook. "}, "hash": "b36a8aa42ca0ceb0b73ed78a68f9d363e0fb82d5edb0a5d4edc4cfb416c92f32", "class_name": "RelatedNodeInfo"}}, "text": "We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available. ", "start_char_idx": 389, "end_char_idx": 526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2e78921-fa04-46d8-9ba8-1fa0cdc21e3a": {"__data__": {"id_": "a2e78921-fa04-46d8-9ba8-1fa0cdc21e3a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country. ", "original_text": "Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8a45a34-3b28-447e-b13e-a02512b32278", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable. ", "original_text": "We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d19c70a21f6ad949fc53d4960c2bd46559399f50aa36c59047053376d7df380", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b89867ca-346f-45d4-97fa-597aa7276bee", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved. ", "original_text": "McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n"}, "hash": "5d7c158b02fb1bf7d77e76ef3b7afa8a5643dc594b909ef36bdf70fc40e731ef", "class_name": "RelatedNodeInfo"}}, "text": "Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook. ", "start_char_idx": 526, "end_char_idx": 774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b89867ca-346f-45d4-97fa-597aa7276bee": {"__data__": {"id_": "b89867ca-346f-45d4-97fa-597aa7276bee", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved. ", "original_text": "McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2e78921-fa04-46d8-9ba8-1fa0cdc21e3a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country. ", "original_text": "Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e7dc481a8622091ebec8fb4571f632416635aacc4876ae8eaab4a0ae725969d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b71177c-939c-4cd9-bdc4-4fd8bf4a5c76", "node_type": "1", "metadata": {"window": "We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n", "original_text": "We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable. "}, "hash": "a17c6a6e6a2c6bcce2ea78c4db6f7e5706a22eb8344ce076a814d07da29e755a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n", "start_char_idx": 774, "end_char_idx": 945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b71177c-939c-4cd9-bdc4-4fd8bf4a5c76": {"__data__": {"id_": "7b71177c-939c-4cd9-bdc4-4fd8bf4a5c76", "embedding": null, "metadata": {"window": "We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n", "original_text": "We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b89867ca-346f-45d4-97fa-597aa7276bee", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved. ", "original_text": "McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0b38f9b5fad5a6308b567b437ba7a847008c9b10e86236a02a3379aa1dbf95a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d06f08d-51cc-4928-bbb4-25a1f3d5ad29", "node_type": "1", "metadata": {"window": "Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved. ", "original_text": "Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country. "}, "hash": "dea475b81204e366fc16e115b4620879ed91a13864a35d4235ca60ffd88ba55f", "class_name": "RelatedNodeInfo"}}, "text": "We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable. ", "start_char_idx": 945, "end_char_idx": 1169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d06f08d-51cc-4928-bbb4-25a1f3d5ad29": {"__data__": {"id_": "3d06f08d-51cc-4928-bbb4-25a1f3d5ad29", "embedding": null, "metadata": {"window": "Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved. ", "original_text": "Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b71177c-939c-4cd9-bdc4-4fd8bf4a5c76", "node_type": "1", "metadata": {"window": "We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n", "original_text": "We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8247f3a07099cd1ffdc361b2f3bfb1279d63751c716b245d8bc48deab908690d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dda7f2b-d0ee-4b05-83bf-2bf7c6267252", "node_type": "1", "metadata": {"window": "McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n", "original_text": "We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved. "}, "hash": "ef5378329cb975c270aa4fed6088bc7841cd3ee05f125fc4b987e2c320ee25be", "class_name": "RelatedNodeInfo"}}, "text": "Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country. ", "start_char_idx": 1169, "end_char_idx": 1369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dda7f2b-d0ee-4b05-83bf-2bf7c6267252": {"__data__": {"id_": "2dda7f2b-d0ee-4b05-83bf-2bf7c6267252", "embedding": null, "metadata": {"window": "McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n", "original_text": "We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d06f08d-51cc-4928-bbb4-25a1f3d5ad29", "node_type": "1", "metadata": {"window": "Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook.  McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved. ", "original_text": "Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9008b95b3fef2e87275b9892f9291944a56b4999b220ce18ecb37ad0add79c8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39ba1757-a428-4e8a-9cbd-e55d9db2c942", "node_type": "1", "metadata": {"window": "We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n", "original_text": "Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n"}, "hash": "a7790933d45e16d8808b7279bd815b2cf11469c16ba99cd9ba769d6d15fa52a9", "class_name": "RelatedNodeInfo"}}, "text": "We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved. ", "start_char_idx": 1369, "end_char_idx": 1585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39ba1757-a428-4e8a-9cbd-e55d9db2c942": {"__data__": {"id_": "39ba1757-a428-4e8a-9cbd-e55d9db2c942", "embedding": null, "metadata": {"window": "We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n", "original_text": "Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dda7f2b-d0ee-4b05-83bf-2bf7c6267252", "node_type": "1", "metadata": {"window": "McKesson was also selected by the US government to manage the \nassembly and distribution of the ancillary supplies needed to administer the future COVID -19 vaccines.  \n \n We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n", "original_text": "We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b1b0d41deb0b8b3779bde8487b945925d6db4bd9258471c707ebd1483c54bbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fd6e858-d5a7-4817-b6b8-9440be130d30", "node_type": "1", "metadata": {"window": "Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n", "original_text": "Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved. "}, "hash": "75a72b78c0552ea45174451d32fcbd54d4bc02bcdfbcb99de943bf01270add15", "class_name": "RelatedNodeInfo"}}, "text": "Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n", "start_char_idx": 1585, "end_char_idx": 1681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fd6e858-d5a7-4817-b6b8-9440be130d30": {"__data__": {"id_": "6fd6e858-d5a7-4817-b6b8-9440be130d30", "embedding": null, "metadata": {"window": "Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n", "original_text": "Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39ba1757-a428-4e8a-9cbd-e55d9db2c942", "node_type": "1", "metadata": {"window": "We're partnering with the Department of Health and Human Services, or HHS, to help equip healthcare \nprofessionals with the supplies they need to safely and efficiently administer COVID -19 vaccines once they're \navailable.  Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n", "original_text": "Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73968054e81860b033bb06ff3364a1e2d974c4554166ac54a33d0c69a414ded5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e8e6fb3-fb47-4cb6-b85e-23fe6ac13fc0", "node_type": "1", "metadata": {"window": "We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director. ", "original_text": "Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n"}, "hash": "d644f9dec5fb2a0935fc0ce84d3a4eed8a471a341782d610df8f921e422e6583", "class_name": "RelatedNodeInfo"}}, "text": "Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved. ", "start_char_idx": 1681, "end_char_idx": 1803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e8e6fb3-fb47-4cb6-b85e-23fe6ac13fc0": {"__data__": {"id_": "2e8e6fb3-fb47-4cb6-b85e-23fe6ac13fc0", "embedding": null, "metadata": {"window": "We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director. ", "original_text": "Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fd6e858-d5a7-4817-b6b8-9440be130d30", "node_type": "1", "metadata": {"window": "Supplies like syringes, alcohol, pr ep pads, face shields and more will be selected and grouped together \nas directed by the HHS for future distribution to point -of-care settings across the country.  We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n", "original_text": "Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "276fd4defa0e1b74204e8ae453fa9c0958ee37453941745166127e1b2fa99cb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bf27108-e6b5-477c-bbfe-e7753cd3014e", "node_type": "1", "metadata": {"window": "Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio. ", "original_text": "We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n"}, "hash": "2434456b9879e227c9a9521ead5c4a59cce8e3bc0aca79b27ab7410b82dfee0d", "class_name": "RelatedNodeInfo"}}, "text": "Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n", "start_char_idx": 1803, "end_char_idx": 1984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bf27108-e6b5-477c-bbfe-e7753cd3014e": {"__data__": {"id_": "0bf27108-e6b5-477c-bbfe-e7753cd3014e", "embedding": null, "metadata": {"window": "Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio. ", "original_text": "We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e8e6fb3-fb47-4cb6-b85e-23fe6ac13fc0", "node_type": "1", "metadata": {"window": "We quickly ramped up \nour capacity outfitting and staffing four distribution center locations f or assembling and storing the ancillary kits to \nbe used in the administration of the COVID -19 vaccines once approved.  Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director. ", "original_text": "Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e552db84023de9ea119d666cdfc9f449f446e83608cf7573f68966ec477a692", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09f89967-f6f1-4c2a-8248-178af3867765", "node_type": "1", "metadata": {"window": "Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n", "original_text": "Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n"}, "hash": "3be1119fe7f544bf997fc8e37391caa88aa5845466943ee9a56ce5c40c9541e7", "class_name": "RelatedNodeInfo"}}, "text": "We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n", "start_char_idx": 1984, "end_char_idx": 2197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09f89967-f6f1-4c2a-8248-178af3867765": {"__data__": {"id_": "09f89967-f6f1-4c2a-8248-178af3867765", "embedding": null, "metadata": {"window": "Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n", "original_text": "Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bf27108-e6b5-477c-bbfe-e7753cd3014e", "node_type": "1", "metadata": {"window": "Each kit contains enough supplies to be \nused for the administration of 100 -plus vaccines.  \n \n Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio. ", "original_text": "We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a7c9dc9ba54cdd1931ab621d2d4c45a00bfc5408a41fa76c30351493acd92ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6d17bf4-a02a-4313-aa2d-c2ce7cab50f1", "node_type": "1", "metadata": {"window": "Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n", "original_text": "In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director. "}, "hash": "2c420085c8387e392b389e48c83a7bf4b5213aa105b1df458cc7513a190d27b5", "class_name": "RelatedNodeInfo"}}, "text": "Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n", "start_char_idx": 2197, "end_char_idx": 2316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6d17bf4-a02a-4313-aa2d-c2ce7cab50f1": {"__data__": {"id_": "a6d17bf4-a02a-4313-aa2d-c2ce7cab50f1", "embedding": null, "metadata": {"window": "Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n", "original_text": "In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09f89967-f6f1-4c2a-8248-178af3867765", "node_type": "1", "metadata": {"window": "Our teams have been hard at work assembling the se kits as part of the preparation needed for when a vaccine's \napproved.  Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n", "original_text": "Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c82dd4a077d9fcb145333570993c84e6c3b8c7485ccd6f688462ca630ff1e9c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b915ce9c-0b46-469f-8dbf-9b6c37f03419", "node_type": "1", "metadata": {"window": "We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business. ", "original_text": "Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio. "}, "hash": "e3662bbea27a1bc4b9c3ea5b090a2378d0ff1a0b4ac8735be2ba42f66992d18f", "class_name": "RelatedNodeInfo"}}, "text": "In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director. ", "start_char_idx": 2316, "end_char_idx": 2409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b915ce9c-0b46-469f-8dbf-9b6c37f03419": {"__data__": {"id_": "b915ce9c-0b46-469f-8dbf-9b6c37f03419", "embedding": null, "metadata": {"window": "We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business. ", "original_text": "Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6d17bf4-a02a-4313-aa2d-c2ce7cab50f1", "node_type": "1", "metadata": {"window": "Given the scope of our work with the HHS is well -defined and that the work has begun, the economics \nfrom this contract are factored into our improved outlook for fiscal 2021.  \n \n We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n", "original_text": "In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b1263f88fb18a3e33cb3b97312933cadf1d966f5245f8397f2b8be01e1307bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91b88300-59dc-450a-8b4b-1276f89c348a", "node_type": "1", "metadata": {"window": "Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July. ", "original_text": "She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n"}, "hash": "e737cbb894cbf1cd826e64ba8c79597620c98bc446c062189433bbd5e6fb1323", "class_name": "RelatedNodeInfo"}}, "text": "Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio. ", "start_char_idx": 2409, "end_char_idx": 2645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91b88300-59dc-450a-8b4b-1276f89c348a": {"__data__": {"id_": "91b88300-59dc-450a-8b4b-1276f89c348a", "embedding": null, "metadata": {"window": "Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July. ", "original_text": "She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b915ce9c-0b46-469f-8dbf-9b6c37f03419", "node_type": "1", "metadata": {"window": "We are honored and proud to serve the US government in this dual role, and we believe it will help streamline \ndelivery to frontline and provide the most expeditious access possible to the COVID -19 vaccines.  \n \n Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business. ", "original_text": "Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b373aa08e77bbb858d3165808d29d8ea880f3449c0dbc31f742ff5a920660a7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12d51299-4caf-41b3-80a3-61284fbc85d7", "node_type": "1", "metadata": {"window": "In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n", "original_text": "Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n"}, "hash": "d9ba5c3b4defbad85fe65db13d4428c2ece372d5a4de31049258bed2e7cc907c", "class_name": "RelatedNodeInfo"}}, "text": "She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n", "start_char_idx": 2645, "end_char_idx": 2760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12d51299-4caf-41b3-80a3-61284fbc85d7": {"__data__": {"id_": "12d51299-4caf-41b3-80a3-61284fbc85d7", "embedding": null, "metadata": {"window": "In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n", "original_text": "Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91b88300-59dc-450a-8b4b-1276f89c348a", "node_type": "1", "metadata": {"window": "Before I elaborate on our second quarter results, I wan ted to provide just a brief update on our board of directors. \n In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July. ", "original_text": "She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa3cd7aa0481498af46e45535558c5f79084be6fdec36ed6c81f4e8ef7a2f507", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68828cb9-6c0a-4d48-b3d7-eb97b6f32041", "node_type": "1", "metadata": {"window": "Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S. ", "original_text": "Now let's get into the business. "}, "hash": "29a9824a81505c1898ce72c801ee219b3adb57dc2644fa3c8e31aab300a97c54", "class_name": "RelatedNodeInfo"}}, "text": "Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n", "start_char_idx": 2760, "end_char_idx": 2909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68828cb9-6c0a-4d48-b3d7-eb97b6f32041": {"__data__": {"id_": "68828cb9-6c0a-4d48-b3d7-eb97b6f32041", "embedding": null, "metadata": {"window": "Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S. ", "original_text": "Now let's get into the business. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12d51299-4caf-41b3-80a3-61284fbc85d7", "node_type": "1", "metadata": {"window": "In mid -October, our board of directors welcomed Linda Mantia as a new Independent Director.  Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n", "original_text": "Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78a3d08bfaf7020ea7700679cbbdea1a27065f1c948ce781dbe127a23f3d956d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d342053-5756-4a9a-a83a-bfbe2891d354", "node_type": "1", "metadata": {"window": "She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter. ", "original_text": "I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July. "}, "hash": "f82a837746289411be3ef39f3d4b8a47abc4da74e4a7185c3c5ddae7798459b0", "class_name": "RelatedNodeInfo"}}, "text": "Now let's get into the business. ", "start_char_idx": 2909, "end_char_idx": 2942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d342053-5756-4a9a-a83a-bfbe2891d354": {"__data__": {"id_": "9d342053-5756-4a9a-a83a-bfbe2891d354", "embedding": null, "metadata": {"window": "She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter. ", "original_text": "I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68828cb9-6c0a-4d48-b3d7-eb97b6f32041", "node_type": "1", "metadata": {"window": "Linda most \nrecently served as the Senior Vice President and Chief Operating Officer for Manulife Finan cial Corporation, \nwhere she played a critical role in defining Manulife's corporate strategy and oversaw its innovation portfolio.  She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S. ", "original_text": "Now let's get into the business. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a65703790a58540911c19de97717da30fd5b845ddfc6689596ea69629df742a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8032eb5-67ef-44dd-b72c-43339a9118fd", "node_type": "1", "metadata": {"window": "Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic. ", "original_text": "I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n"}, "hash": "df70c830141f9f7f6358fdff4a9b84f3b5b3e7f38a78bc53aec7beaeb80d33e5", "class_name": "RelatedNodeInfo"}}, "text": "I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July. ", "start_char_idx": 2942, "end_char_idx": 3057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8032eb5-67ef-44dd-b72c-43339a9118fd": {"__data__": {"id_": "f8032eb5-67ef-44dd-b72c-43339a9118fd", "embedding": null, "metadata": {"window": "Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic. ", "original_text": "I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d342053-5756-4a9a-a83a-bfbe2891d354", "node_type": "1", "metadata": {"window": "She \nbrings over 25 years of experience managing extensive financial services, operations and digital technology. \n Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter. ", "original_text": "I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b5e947259f3e043cf858c93f4f3a5ef980f1747c82d4b29a4993e04a1067fee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10c11773-a09c-4f04-9003-275abfa23c4f", "node_type": "1", "metadata": {"window": "Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n", "original_text": "U.S. "}, "hash": "1ec0c1bff71c824d97333aa9be299b1cb4569497be5e154a04fc1b50139129c6", "class_name": "RelatedNodeInfo"}}, "text": "I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n", "start_char_idx": 3057, "end_char_idx": 3158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10c11773-a09c-4f04-9003-275abfa23c4f": {"__data__": {"id_": "10c11773-a09c-4f04-9003-275abfa23c4f", "embedding": null, "metadata": {"window": "Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n", "original_text": "U.S. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8032eb5-67ef-44dd-b72c-43339a9118fd", "node_type": "1", "metadata": {"window": "Linda's appo intment demonstrates our continuing commitment to refresh and diversify the experience, \nbackgrounds and perspectives on our board.  \n \n Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic. ", "original_text": "I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8fe15cb8ee7c3f38e62d813534b41d29944c31f3f25d64e7f83cabffe35ec6c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "557abd74-169a-4351-ac5e-3ed6af2f6af4", "node_type": "1", "metadata": {"window": "I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone. ", "original_text": "Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter. "}, "hash": "b12660361f175e2b544ed38410f85e964b9fd48520ffcb5f9d663d438d1beb46", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 3158, "end_char_idx": 3163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "557abd74-169a-4351-ac5e-3ed6af2f6af4": {"__data__": {"id_": "557abd74-169a-4351-ac5e-3ed6af2f6af4", "embedding": null, "metadata": {"window": "I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone. ", "original_text": "Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10c11773-a09c-4f04-9003-275abfa23c4f", "node_type": "1", "metadata": {"window": "Now let's get into the business.  I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n", "original_text": "U.S. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d350c537bdda814d4a6653d57456d58e9781c354419f0c736a0a17170fe1e39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0c49e85-2a11-4780-b182-9cedf32e81d3", "node_type": "1", "metadata": {"window": "I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies. ", "original_text": "Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic. "}, "hash": "3abb90c25685a112cf79f78c3d8b1f65987a1721da1274ecef4c2f3f90585f2b", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter. ", "start_char_idx": 3163, "end_char_idx": 3342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0c49e85-2a11-4780-b182-9cedf32e81d3": {"__data__": {"id_": "e0c49e85-2a11-4780-b182-9cedf32e81d3", "embedding": null, "metadata": {"window": "I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies. ", "original_text": "Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "557abd74-169a-4351-ac5e-3ed6af2f6af4", "node_type": "1", "metadata": {"window": "I'll remind you that this is our first quarter reporting in the new segment structure \nwe an nounced back in July.  I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone. ", "original_text": "Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3fe4d421a93f0ccbd6e524f966bce1126c5aa5d425acb34bab7367e3b09241c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf574893-bc69-4742-86db-cde785edf694", "node_type": "1", "metadata": {"window": "U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies.  This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "original_text": "Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n"}, "hash": "1d94fea3f1fa32a83cc6a238bd3cb63d91a73289e3051eb0d74c695633a54042", "class_name": "RelatedNodeInfo"}}, "text": "Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic. ", "start_char_idx": 3342, "end_char_idx": 3441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf574893-bc69-4742-86db-cde785edf694": {"__data__": {"id_": "cf574893-bc69-4742-86db-cde785edf694", "embedding": null, "metadata": {"window": "U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies.  This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "original_text": "Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0c49e85-2a11-4780-b182-9cedf32e81d3", "node_type": "1", "metadata": {"window": "I'll summarize the second quarter, and then I'll turn it over to Britt to provide more \ndetails.  \n \n U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies. ", "original_text": "Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2197ca56d0238e631324ef4edad33a72e3dd988a037f713a42745a7a512a2cc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9da630ce-fe3a-44b4-99c4-3ed774519aa4", "node_type": "1", "metadata": {"window": "Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies.  This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "original_text": "Our US oncology research team recently celebrated a significant milestone. "}, "hash": "bea0c9e7f65005b23e3b94464125da89d82c77b8f22161214981c78c80ba2da8", "class_name": "RelatedNodeInfo"}}, "text": "Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n", "start_char_idx": 3441, "end_char_idx": 3710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9da630ce-fe3a-44b4-99c4-3ed774519aa4": {"__data__": {"id_": "9da630ce-fe3a-44b4-99c4-3ed774519aa4", "embedding": null, "metadata": {"window": "Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies.  This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "original_text": "Our US oncology research team recently celebrated a significant milestone. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf574893-bc69-4742-86db-cde785edf694", "node_type": "1", "metadata": {"window": "U.S.  Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies.  This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "original_text": "Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54cbda947ad28deda4531e0e02efbe2156cd69f6ccebe0529ca28e364964666f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37ad1863-9ac5-4598-adb9-831f0eb682d3", "node_type": "1", "metadata": {"window": "Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies.  This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "original_text": "We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies. "}, "hash": "9a3e639aaa087685f1769149f10d5bcd132db1baf29fa400d95a8699c208164a", "class_name": "RelatedNodeInfo"}}, "text": "Our US oncology research team recently celebrated a significant milestone. ", "start_char_idx": 3710, "end_char_idx": 3785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37ad1863-9ac5-4598-adb9-831f0eb682d3": {"__data__": {"id_": "37ad1863-9ac5-4598-adb9-831f0eb682d3", "embedding": null, "metadata": {"window": "Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies.  This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "original_text": "We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9da630ce-fe3a-44b4-99c4-3ed774519aa4", "node_type": "1", "metadata": {"window": "Pharmaceutical's results in the quarter exceeded our expectations and reflect improved script and patient \nmobility trends versus the  levels we experienced in the first quarter.  Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies.  This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "original_text": "Our US oncology research team recently celebrated a significant milestone. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7aafee9b35866fff9dd0b0a3bb9b26ebaf7248424fbc7417f751a455c8326f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03ce59c9-fdcd-4cd6-bc46-fc848b8131cc", "node_type": "1", "metadata": {"window": "Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies.  This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "original_text": "This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n "}, "hash": "c581560f39d6227235108d4e28659b978dad556da4b92d1cabd9b467b15ef566", "class_name": "RelatedNodeInfo"}}, "text": "We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies. ", "start_char_idx": 3785, "end_char_idx": 3870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03ce59c9-fdcd-4cd6-bc46-fc848b8131cc": {"__data__": {"id_": "03ce59c9-fdcd-4cd6-bc46-fc848b8131cc", "embedding": null, "metadata": {"window": "Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies.  This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "original_text": "This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11dec0603c1fe31e194e21014438b627d4c151894ddee740df973dcb2c0c62db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37ad1863-9ac5-4598-adb9-831f0eb682d3", "node_type": "1", "metadata": {"window": "Specialty volumes, particularly oncology, \nhave continued to be resilient throughout the pandemic.  Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies.  This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "original_text": "We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies. ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05e811da28557db92bbf78f800f29475edbe65262705596aef46d3faba292c11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb122474-0272-4582-8d26-aef23e492659", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "f6c330a8f5182532b1bdbe0bac6a64997257e997a54a4f89f894af1dad2c7291", "class_name": "RelatedNodeInfo"}}, "text": "This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "start_char_idx": 3870, "end_char_idx": 4069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb122474-0272-4582-8d26-aef23e492659": {"__data__": {"id_": "bb122474-0272-4582-8d26-aef23e492659", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03ce59c9-fdcd-4cd6-bc46-fc848b8131cc", "node_type": "1", "metadata": {"window": "Oncology patient visits, inclusive of telehealth visits, \nreturned to pre -COVID levels in the quarter, and our pro vider solutions and US oncology business continue to \ngrow and are well -positioned as innovative specialty products and biosimilars come to market.  \n \n Our US oncology research team recently celebrated a significant milestone.  We have now been part of the tria l \nprocess for 100 FDA -approved cancer therapies.  This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "original_text": "This achievement is a result of the hard work and the dedication \nto research for more than 165 research locations, conducting and participating in over 1,600 clinical trials for \ncancer therapy.  \n ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f45aed163079f95fc15c44af71a63b8b2accfe9e5dd9db28c6644ec981012bad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "447fd27a-400c-453b-968e-5860d0dd737e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n"}, "hash": "e36824c68f640168b451689378333b6493180d5ec97597397b44655a7634ed68", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "447fd27a-400c-453b-968e-5860d0dd737e": {"__data__": {"id_": "447fd27a-400c-453b-968e-5860d0dd737e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb122474-0272-4582-8d26-aef23e492659", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64da17606fcd7f4404489b10f47986a6a93c937ddd0d4f7741c072c7fc0d1a9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01d00602-0657-43aa-a299-966c45055e39", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August. ", "original_text": "Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe. "}, "hash": "2075b58b885a80d9558baac935e646075394069b71c405435d2f5df31cf9e76e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n", "start_char_idx": 16, "end_char_idx": 387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01d00602-0657-43aa-a299-966c45055e39": {"__data__": {"id_": "01d00602-0657-43aa-a299-966c45055e39", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August. ", "original_text": "Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "447fd27a-400c-453b-968e-5860d0dd737e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "096435a1d4f22bd2c9301afd89a7964084da3d4574ddc15892c646d587a7a3bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "484b6787-a8bf-4266-bc4b-b864e4ffbc45", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n", "original_text": "Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n"}, "hash": "0603331f31003e5ff798ecf82ed297fd6caa3b2a353bf9c4dd6f55752b71cbd3", "class_name": "RelatedNodeInfo"}}, "text": "Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe. ", "start_char_idx": 387, "end_char_idx": 587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "484b6787-a8bf-4266-bc4b-b864e4ffbc45": {"__data__": {"id_": "484b6787-a8bf-4266-bc4b-b864e4ffbc45", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n", "original_text": "Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01d00602-0657-43aa-a299-966c45055e39", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August. ", "original_text": "Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02c59de987ad7e5f8409b781dd178e9a0db08e5c487031a72118fad911869d8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98b954ae-5c78-4c57-ba85-81375fa8f1e0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe. ", "original_text": "I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada. "}, "hash": "f282830cec9cfec23ca59f7383c0d1dc6c1a428fea733ca8543e367c130f3b29", "class_name": "RelatedNodeInfo"}}, "text": "Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n", "start_char_idx": 587, "end_char_idx": 778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98b954ae-5c78-4c57-ba85-81375fa8f1e0": {"__data__": {"id_": "98b954ae-5c78-4c57-ba85-81375fa8f1e0", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe. ", "original_text": "I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "484b6787-a8bf-4266-bc4b-b864e4ffbc45", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n", "original_text": "Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f2187c81551e9f4c03fcff55a24be32325d8a9b21469f26d48964c037453721", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f922f7c8-1b59-4ba0-908a-5812f27efce5", "node_type": "1", "metadata": {"window": "Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms. ", "original_text": "She succeeded Dominic Pilla, who retired in August. "}, "hash": "f310808afb7eba1ba0a33e035bf929187b53a79950aff393241a1df716d5dbdb", "class_name": "RelatedNodeInfo"}}, "text": "I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada. ", "start_char_idx": 778, "end_char_idx": 915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f922f7c8-1b59-4ba0-908a-5812f27efce5": {"__data__": {"id_": "f922f7c8-1b59-4ba0-908a-5812f27efce5", "embedding": null, "metadata": {"window": "Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms. ", "original_text": "She succeeded Dominic Pilla, who retired in August. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98b954ae-5c78-4c57-ba85-81375fa8f1e0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe. ", "original_text": "I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "210346c51bf491cca86a4097c75f1c518520d964327d936a2d97a00a29513fe9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b0c9310-8d76-4c8a-a60b-0151e6befd71", "node_type": "1", "metadata": {"window": "Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience. ", "original_text": "I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n"}, "hash": "9c36ccc6ef363fc18ee6244c770e955eebdecac22275fca0f731229468b2eaa2", "class_name": "RelatedNodeInfo"}}, "text": "She succeeded Dominic Pilla, who retired in August. ", "start_char_idx": 915, "end_char_idx": 967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b0c9310-8d76-4c8a-a60b-0151e6befd71": {"__data__": {"id_": "0b0c9310-8d76-4c8a-a60b-0151e6befd71", "embedding": null, "metadata": {"window": "Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience. ", "original_text": "I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f922f7c8-1b59-4ba0-908a-5812f27efce5", "node_type": "1", "metadata": {"window": "Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms. ", "original_text": "She succeeded Dominic Pilla, who retired in August. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de6bd3427344c013177c98c8bd48f55a5e52038387e692febac0486826e1e12f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fef7e26a-ed63-4480-acdc-c904f24988e5", "node_type": "1", "metadata": {"window": "I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n", "original_text": "We continue to invest in the digitization of healthcare in both Canada and Europe. "}, "hash": "687823a09ded04ab5c7237cc0f9a315ee73efaabed84a674f2092df2f8633c7f", "class_name": "RelatedNodeInfo"}}, "text": "I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n", "start_char_idx": 967, "end_char_idx": 1116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fef7e26a-ed63-4480-acdc-c904f24988e5": {"__data__": {"id_": "fef7e26a-ed63-4480-acdc-c904f24988e5", "embedding": null, "metadata": {"window": "I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n", "original_text": "We continue to invest in the digitization of healthcare in both Canada and Europe. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b0c9310-8d76-4c8a-a60b-0151e6befd71", "node_type": "1", "metadata": {"window": "Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience. ", "original_text": "I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc9ae9fe25a8f21c1b1e7f89436fe3d560c80882e4d43c933e491a6e39cd5db7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e0e04a8-14f1-4110-a089-8439922003d5", "node_type": "1", "metadata": {"window": "She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany. ", "original_text": "We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms. "}, "hash": "b1ce23a3bf13e3dea0e282f73b048e34978c2e4e0b6d0edc50e88d38ab2c82a2", "class_name": "RelatedNodeInfo"}}, "text": "We continue to invest in the digitization of healthcare in both Canada and Europe. ", "start_char_idx": 1116, "end_char_idx": 1199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e0e04a8-14f1-4110-a089-8439922003d5": {"__data__": {"id_": "7e0e04a8-14f1-4110-a089-8439922003d5", "embedding": null, "metadata": {"window": "She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany. ", "original_text": "We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fef7e26a-ed63-4480-acdc-c904f24988e5", "node_type": "1", "metadata": {"window": "I remind you, as part of the reorganization in August, we named Rebecca McKillican, as the Chief Executive \nOfficer for McKesson Canada.  She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n", "original_text": "We continue to invest in the digitization of healthcare in both Canada and Europe. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e50a9e74cd9aec9d55a3e63adbd322b4ccf4c0265a0ab57d83bcae5d370e7050", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd4b8e71-0f7a-4e9f-982e-da653868d40d", "node_type": "1", "metadata": {"window": "I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest. ", "original_text": "In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience. "}, "hash": "4cf825655e78c94d4f23b96f0d7130e62f20571bb2cf782ffdad2b3d68048a87", "class_name": "RelatedNodeInfo"}}, "text": "We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms. ", "start_char_idx": 1199, "end_char_idx": 1317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd4b8e71-0f7a-4e9f-982e-da653868d40d": {"__data__": {"id_": "dd4b8e71-0f7a-4e9f-982e-da653868d40d", "embedding": null, "metadata": {"window": "I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest. ", "original_text": "In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e0e04a8-14f1-4110-a089-8439922003d5", "node_type": "1", "metadata": {"window": "She succeeded Dominic Pilla, who retired in August.  I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany. ", "original_text": "We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e485a404a2fa70f1f77610fe0a7ebeec09930869e79b3450f306812175b4f765", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4041fb0c-ae9e-412e-8fb5-02e2ced8a06b", "node_type": "1", "metadata": {"window": "We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy. ", "original_text": "And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n"}, "hash": "0f2608aaf522b6d8b13cda66285ccfa41f1742591ab436751882405bfaa8efdf", "class_name": "RelatedNodeInfo"}}, "text": "In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience. ", "start_char_idx": 1317, "end_char_idx": 1438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4041fb0c-ae9e-412e-8fb5-02e2ced8a06b": {"__data__": {"id_": "4041fb0c-ae9e-412e-8fb5-02e2ced8a06b", "embedding": null, "metadata": {"window": "We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy. ", "original_text": "And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd4b8e71-0f7a-4e9f-982e-da653868d40d", "node_type": "1", "metadata": {"window": "I'm enco uraged by the \nperformance of our International business as we found ways to meet the changing customer demands and \ncontain our costs.  \n \n We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest. ", "original_text": "In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41126c1bb86cc70a099613ad6f7dd5583ce56316ca942e261405e737b24c358b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cc1e46b-a2b9-4bb8-b152-c12427c89d1a", "node_type": "1", "metadata": {"window": "We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses. ", "original_text": "I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany. "}, "hash": "f87a3eed911cf17adf4608cc1c81347fc7b86b427a512e5698c36366a54e8355", "class_name": "RelatedNodeInfo"}}, "text": "And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n", "start_char_idx": 1438, "end_char_idx": 1549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cc1e46b-a2b9-4bb8-b152-c12427c89d1a": {"__data__": {"id_": "8cc1e46b-a2b9-4bb8-b152-c12427c89d1a", "embedding": null, "metadata": {"window": "We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses. ", "original_text": "I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4041fb0c-ae9e-412e-8fb5-02e2ced8a06b", "node_type": "1", "metadata": {"window": "We continue to invest in the digitization of healthcare in both Canada and Europe.  We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy. ", "original_text": "And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e349d9f5ec304b9ce6823c1c0e69474ae26f04bb8d9fa5f15420b4b217d7f73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85470ae1-ab08-4bd0-904d-8ced01c5e327", "node_type": "1", "metadata": {"window": "In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n", "original_text": "As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest. "}, "hash": "383acf3801ddaf58fd002cffee39bdf3c074acf2253e8f534f9a6af454228d07", "class_name": "RelatedNodeInfo"}}, "text": "I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany. ", "start_char_idx": 1549, "end_char_idx": 1732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85470ae1-ab08-4bd0-904d-8ced01c5e327": {"__data__": {"id_": "85470ae1-ab08-4bd0-904d-8ced01c5e327", "embedding": null, "metadata": {"window": "In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n", "original_text": "As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cc1e46b-a2b9-4bb8-b152-c12427c89d1a", "node_type": "1", "metadata": {"window": "We've invested in new state -of-\nthe-art distribution centers to support digital growth in our e -commerce platforms.  In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses. ", "original_text": "I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dff56f2b0d322bfbb9de8dbb7baa3ff1dda720780282afeec14b2058403193d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20996a86-179c-4124-b4c5-ad53616661b4", "node_type": "1", "metadata": {"window": "And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical. ", "original_text": "We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy. "}, "hash": "08bc3650fd7667a097c838410fec173df8a785d063bff959e4767d09916c0b2e", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest. ", "start_char_idx": 1732, "end_char_idx": 1871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20996a86-179c-4124-b4c5-ad53616661b4": {"__data__": {"id_": "20996a86-179c-4124-b4c5-ad53616661b4", "embedding": null, "metadata": {"window": "And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical. ", "original_text": "We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85470ae1-ab08-4bd0-904d-8ced01c5e327", "node_type": "1", "metadata": {"window": "In Canada, our Well.ca \nbusiness was recognized for the second year in a row as a leader in digital customer experience.  And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n", "original_text": "As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d24e1c1948992dbc462939219ded42b5a1dfdedf0ec994b7d453ea2ca260bd0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5648997c-0402-4542-a16c-ed89921e828a", "node_type": "1", "metadata": {"window": "I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US. ", "original_text": "Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses. "}, "hash": "3c6254f996956e62c9cb35845db4ce1929ccfeeded83f22fe407a4b4ff6d33af", "class_name": "RelatedNodeInfo"}}, "text": "We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy. ", "start_char_idx": 1871, "end_char_idx": 1974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5648997c-0402-4542-a16c-ed89921e828a": {"__data__": {"id_": "5648997c-0402-4542-a16c-ed89921e828a", "embedding": null, "metadata": {"window": "I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US. ", "original_text": "Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20996a86-179c-4124-b4c5-ad53616661b4", "node_type": "1", "metadata": {"window": "And in Europe, \nour Echo by LloydsPharmacy platform in the U K remains the UK's fastest -growing pharmacy.  \n \n I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical. ", "original_text": "We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5123744408d869169803b51b51de402cd9e6e246585e30e2016c2f3eaff9dfe4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bf5634e-29d9-46a1-a2b8-79002497850a", "node_type": "1", "metadata": {"window": "As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n", "original_text": "The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n"}, "hash": "229db7efb42444f046fe1841d652bceba4d6e7605b9511fa845e72e1eb8375ee", "class_name": "RelatedNodeInfo"}}, "text": "Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses. ", "start_char_idx": 1974, "end_char_idx": 2246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bf5634e-29d9-46a1-a2b8-79002497850a": {"__data__": {"id_": "0bf5634e-29d9-46a1-a2b8-79002497850a", "embedding": null, "metadata": {"window": "As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n", "original_text": "The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5648997c-0402-4542-a16c-ed89921e828a", "node_type": "1", "metadata": {"window": "I'm pleased to announce that on November 1, we completed the creation of a joint venture with Walgreens Boots \nAlliance to combine our pharmaceutical wholesale businesses in Germany.  As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US. ", "original_text": "Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d95c22619a8707c6763fb79dd2a0294683b2ae45d1a4a6cee54e00527c05f90f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59d5af51-1c5d-4fb2-adc3-1f49da83e9cf", "node_type": "1", "metadata": {"window": "We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n", "original_text": "Let me move to Medical. "}, "hash": "3fada07e0239c4e60fc6a10ed1161aeec2888b1123c8e1951b2f1661c56e38ae", "class_name": "RelatedNodeInfo"}}, "text": "The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n", "start_char_idx": 2246, "end_char_idx": 2444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59d5af51-1c5d-4fb2-adc3-1f49da83e9cf": {"__data__": {"id_": "59d5af51-1c5d-4fb2-adc3-1f49da83e9cf", "embedding": null, "metadata": {"window": "We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n", "original_text": "Let me move to Medical. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bf5634e-29d9-46a1-a2b8-79002497850a", "node_type": "1", "metadata": {"window": "As a reminder, WBA owns a 70 % \ncontrolling equity interest in the joint venture, and McKesson holds the remaining 30% ownership interest.  We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n", "original_text": "The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6309461f5bdcf509ca30233a50184a94f239014a1ccef29215de1f884e1c8300", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1113f56-34dc-4a30-a210-62ef4adc371c", "node_type": "1", "metadata": {"window": "Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes. ", "original_text": "Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US. "}, "hash": "19ef4037b6d8e393c9e0f5755cecf3bdef3a95d531155d2ffe792855f3e6a39d", "class_name": "RelatedNodeInfo"}}, "text": "Let me move to Medical. ", "start_char_idx": 2444, "end_char_idx": 2468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1113f56-34dc-4a30-a210-62ef4adc371c": {"__data__": {"id_": "b1113f56-34dc-4a30-a210-62ef4adc371c", "embedding": null, "metadata": {"window": "Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes. ", "original_text": "Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59d5af51-1c5d-4fb2-adc3-1f49da83e9cf", "node_type": "1", "metadata": {"window": "We \nhave a continuous process in place to look at, review and evaluate our portfolio and our strategy.  Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n", "original_text": "Let me move to Medical. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86005b2151cc12d487df14ccbfe01a289e58db48a70bc46a913b12447b407976", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec05ca3e-b3a0-47aa-9767-01f9b8f618b0", "node_type": "1", "metadata": {"window": "The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n", "original_text": "The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n"}, "hash": "321ef19e3d9fffd480837a0a79649f6099d06b58ec073af538de6cffc12ebcef", "class_name": "RelatedNodeInfo"}}, "text": "Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US. ", "start_char_idx": 2468, "end_char_idx": 2579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec05ca3e-b3a0-47aa-9767-01f9b8f618b0": {"__data__": {"id_": "ec05ca3e-b3a0-47aa-9767-01f9b8f618b0", "embedding": null, "metadata": {"window": "The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n", "original_text": "The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1113f56-34dc-4a30-a210-62ef4adc371c", "node_type": "1", "metadata": {"window": "Sometimes, the \noutcome is we find assets that  we're not the natural owner of, or as was the case in this transaction, we believe \nthat combining our German wholesale businesses with that of WBA is the right decision to secure the long -term \nsuccess of both businesses.  The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes. ", "original_text": "Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8169eac50c11902aacc3a5e276b2985986c6682fed19d957688d6972d655f199", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ded22ea-6e44-4929-9c1d-3c972fe46057", "node_type": "1", "metadata": {"window": "Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe. ", "original_text": "We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n"}, "hash": "1f3c9f3b9bedd8a63977bd09cc3aacc06e58bf822cb0f2314a67b1173f2c5247", "class_name": "RelatedNodeInfo"}}, "text": "The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n", "start_char_idx": 2579, "end_char_idx": 2795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ded22ea-6e44-4929-9c1d-3c972fe46057": {"__data__": {"id_": "6ded22ea-6e44-4929-9c1d-3c972fe46057", "embedding": null, "metadata": {"window": "Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe. ", "original_text": "We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec05ca3e-b3a0-47aa-9767-01f9b8f618b0", "node_type": "1", "metadata": {"window": "The combined businesses will stren gthen the ability to compete and deliver high \ncustomer satisfaction through evolving our customer value proposition and delivering on operational excellence.  \n \n Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n", "original_text": "The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b82af118c1389e47de49cf7b11f9bc23886202081ae83643b3cb55bcde9f1606", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c89da44e-4797-431d-9dc6-ce28e181f175", "node_type": "1", "metadata": {"window": "Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers. ", "original_text": "Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes. "}, "hash": "cfbc3d3ec9d9b9fdb02034aaa9685a5b8ccba9f1e2987f1ba7eb149ac570eb61", "class_name": "RelatedNodeInfo"}}, "text": "We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n", "start_char_idx": 2795, "end_char_idx": 2910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c89da44e-4797-431d-9dc6-ce28e181f175": {"__data__": {"id_": "c89da44e-4797-431d-9dc6-ce28e181f175", "embedding": null, "metadata": {"window": "Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers. ", "original_text": "Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ded22ea-6e44-4929-9c1d-3c972fe46057", "node_type": "1", "metadata": {"window": "Let me move to Medical.  Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe. ", "original_text": "We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d1b69cd1d12b3d74c2325c9bdb4b37467b5387b863243c14abbedd7ef756705", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40314b4d-a7bf-4b4c-a183-2deca2b36d40", "node_type": "1", "metadata": {"window": "The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n", "original_text": "Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n"}, "hash": "ef718e7afd7d02589988d58777809b6d1c4a135e184da0bd34598b0c8b1b2574", "class_name": "RelatedNodeInfo"}}, "text": "Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes. ", "start_char_idx": 2910, "end_char_idx": 3089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40314b4d-a7bf-4b4c-a183-2deca2b36d40": {"__data__": {"id_": "40314b4d-a7bf-4b4c-a183-2deca2b36d40", "embedding": null, "metadata": {"window": "The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n", "original_text": "Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c89da44e-4797-431d-9dc6-ce28e181f175", "node_type": "1", "metadata": {"window": "Demand continued to improve across the business in the quarter, as physic ian offices \nreopened across the US.  The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers. ", "original_text": "Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f993be5a6ae3b2f90cba644a0735103849360f575c4902380ad4cb350a43c06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ec2d565-505a-46f8-96a6-22ffe810147b", "node_type": "1", "metadata": {"window": "We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses. ", "original_text": "Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe. "}, "hash": "297b7027924720b1057d4fb4c6e562842efa8b89b743fcd2ee53e8d35997fc3b", "class_name": "RelatedNodeInfo"}}, "text": "Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n", "start_char_idx": 3089, "end_char_idx": 3264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ec2d565-505a-46f8-96a6-22ffe810147b": {"__data__": {"id_": "0ec2d565-505a-46f8-96a6-22ffe810147b", "embedding": null, "metadata": {"window": "We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses. ", "original_text": "Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40314b4d-a7bf-4b4c-a183-2deca2b36d40", "node_type": "1", "metadata": {"window": "The pandemic has also created new demand for products like COVID -19 tests and an \nunprecedented level of demand for PPE across the segment, both of which we view as near -term drivers of \ngrowth in the segment.  \n \n We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n", "original_text": "Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a286612d9918d6cd8454b8b8cab6ceff6848e118fc93806534557242b01e4a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0881548-b614-49ec-bcba-da5ea76b438d", "node_type": "1", "metadata": {"window": "Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses.  I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "original_text": "We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers. "}, "hash": "1fd4a2c239a82d34053dca23c36f2f2475bc9c67cb1bc5a404dfd0c85acd9304", "class_name": "RelatedNodeInfo"}}, "text": "Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe. ", "start_char_idx": 3264, "end_char_idx": 3383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0881548-b614-49ec-bcba-da5ea76b438d": {"__data__": {"id_": "e0881548-b614-49ec-bcba-da5ea76b438d", "embedding": null, "metadata": {"window": "Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses.  I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "original_text": "We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ec2d565-505a-46f8-96a6-22ffe810147b", "node_type": "1", "metadata": {"window": "We're proud  to have a leading position in the distribution of lab equipment and solutions in the provider space. \n Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses. ", "original_text": "Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46441c36fa44c961bbde584a6518a8d2442b474cc5f423887442b193b4b6ca14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13d2e301-7e95-40b6-b297-0474ead6597f", "node_type": "1", "metadata": {"window": "Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses.  I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "original_text": "Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n"}, "hash": "78a107f713ed8769da6bf8e830927650d148ef0b691e3d8ef85a61db495ffec4", "class_name": "RelatedNodeInfo"}}, "text": "We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers. ", "start_char_idx": 3383, "end_char_idx": 3533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13d2e301-7e95-40b6-b297-0474ead6597f": {"__data__": {"id_": "13d2e301-7e95-40b6-b297-0474ead6597f", "embedding": null, "metadata": {"window": "Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses.  I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "original_text": "Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0881548-b614-49ec-bcba-da5ea76b438d", "node_type": "1", "metadata": {"window": "Over the past several years, we've developed relationships with many lab partners and helped position our \nproviders with the tools they need to deliver be tter patient outcomes.  Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses.  I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "original_text": "We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05e1b0f041311914b85d38395eec90c5d656911f1c6f254496224fc06adb0fc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67860bd9-b1c2-4dc8-a059-dd2aab87878f", "node_type": "1", "metadata": {"window": "Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses.  I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "original_text": "Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses. "}, "hash": "f5ab3ebc661e341199ebfd0e1b2c7b143ff68582c079e6d2559359b67775524c", "class_name": "RelatedNodeInfo"}}, "text": "Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n", "start_char_idx": 3533, "end_char_idx": 3716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67860bd9-b1c2-4dc8-a059-dd2aab87878f": {"__data__": {"id_": "67860bd9-b1c2-4dc8-a059-dd2aab87878f", "embedding": null, "metadata": {"window": "Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses.  I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "original_text": "Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13d2e301-7e95-40b6-b297-0474ead6597f", "node_type": "1", "metadata": {"window": "Our investments in our lab business and in \nour private brand portfolio continue to position us to serve our customers' evolving needs, particularly in times like \nthese.  \n \n Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses.  I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "original_text": "Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f5d6b021d01c45589d407c232fc0e3e75d902e17a893671ae377bcbb5b3c5a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab0e6971-8356-4952-bf60-4c2bf8d0953c", "node_type": "1", "metadata": {"window": "We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses.  I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "original_text": "I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n "}, "hash": "08afe555cef4224c8862c705edd2b5e00d029bcc7f4365ee1299ffc6c2b729b3", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses. ", "start_char_idx": 3716, "end_char_idx": 3899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab0e6971-8356-4952-bf60-4c2bf8d0953c": {"__data__": {"id_": "ab0e6971-8356-4952-bf60-4c2bf8d0953c", "embedding": null, "metadata": {"window": "We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses.  I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "original_text": "I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6117d9a31009ba996d384ac1efcaad0ebc75ae7e281ef389f1cb0ed74e5b836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67860bd9-b1c2-4dc8-a059-dd2aab87878f", "node_type": "1", "metadata": {"window": "Also, to meet this incremental demand, we've worked quickly to strengthen our sourcing partnerships around the \nglobe.  We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses.  I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "original_text": "Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses. ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31b16bfabd40fbe65594bbcfdadeab8c75e6166c37ad9feae36f184bc62f287f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06be7699-8424-4c9c-8d81-95bc5eeb3ea5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "08ac56078a520a611ef87b9be1058c808a01f619ee58f54b94335d5d714f6461", "class_name": "RelatedNodeInfo"}}, "text": "I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "start_char_idx": 3899, "end_char_idx": 4016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06be7699-8424-4c9c-8d81-95bc5eeb3ea5": {"__data__": {"id_": "06be7699-8424-4c9c-8d81-95bc5eeb3ea5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab0e6971-8356-4952-bf60-4c2bf8d0953c", "node_type": "1", "metadata": {"window": "We've built our inventory across several product categories to be ready for incremental and often \nunpredictable levels of demand from our customers.  Improved patient mobility and a continuation of near -term \nopportunities for McKesson to meet our customers' evolving demands contribute to the revised outlook for the \nsegment.  \n \n Turning to Prescription Technology Solutions, we'll refer to as RxTS for shorthand, which brings together our \nRelayhealth Pharmacy,  our CoverMyMeds and our RxCrossroads businesses.  I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "original_text": "I want to just spend a minute here \non the evolution of these businesses into the reportable segment it is today.  \n ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31da02b78780295d6128612dcb800d1a67fb71dc3822f467236e78e58d7cde40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d5b48d7-85d7-4c00-88d5-8292c610eabd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n"}, "hash": "f3b8c72786df93c7bb2872054e9f0f95a6e0662304d3f7eec54f8c72af1294c8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d5b48d7-85d7-4c00-88d5-8292c610eabd": {"__data__": {"id_": "7d5b48d7-85d7-4c00-88d5-8292c610eabd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06be7699-8424-4c9c-8d81-95bc5eeb3ea5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3896dd5ee6393ff1cafeb3ab51b165133a911a89d324aa128a28d0930dcc6d35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d00b4317-f51e-461b-911a-4998c0cb96da", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n", "original_text": "RelayHealth is an asset that's been in the McKesson family dating back to 2006. "}, "hash": "bf116b27df1e7e10fa59c54f8d1f43ef7ef7e2fc4cf215bb3336ae205c055df0", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n", "start_char_idx": 16, "end_char_idx": 291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d00b4317-f51e-461b-911a-4998c0cb96da": {"__data__": {"id_": "d00b4317-f51e-461b-911a-4998c0cb96da", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n", "original_text": "RelayHealth is an asset that's been in the McKesson family dating back to 2006. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d5b48d7-85d7-4c00-88d5-8292c610eabd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "deca38182fb9adda7c062631f87030009167899fa585789427105d5f3b96bb41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17fb00bd-fdcd-4bed-ac0a-918088bdcb70", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies. ", "original_text": "This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n"}, "hash": "fe6b916fad0d4acb53a59a2ae7c97d1407b850bb01009191a014d82d9bcd7aaa", "class_name": "RelatedNodeInfo"}}, "text": "RelayHealth is an asset that's been in the McKesson family dating back to 2006. ", "start_char_idx": 291, "end_char_idx": 371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17fb00bd-fdcd-4bed-ac0a-918088bdcb70": {"__data__": {"id_": "17fb00bd-fdcd-4bed-ac0a-918088bdcb70", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies. ", "original_text": "This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d00b4317-f51e-461b-911a-4998c0cb96da", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n", "original_text": "RelayHealth is an asset that's been in the McKesson family dating back to 2006. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3230397de58519a599f9c490501ce179c13bc1ab1e394e572e06dc6db90858d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59ecd9de-9b3b-418d-a58e-2a16c4b78758", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort. ", "original_text": "In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process. "}, "hash": "5313d16f01824e709e27427c8fe54c9ea1dd25a73fbeb379b2e1c95f4ea0e064", "class_name": "RelatedNodeInfo"}}, "text": "This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n", "start_char_idx": 371, "end_char_idx": 652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59ecd9de-9b3b-418d-a58e-2a16c4b78758": {"__data__": {"id_": "59ecd9de-9b3b-418d-a58e-2a16c4b78758", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort. ", "original_text": "In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17fb00bd-fdcd-4bed-ac0a-918088bdcb70", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies. ", "original_text": "This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34f54dbb87ea35615d41e2b5869d022de2d86420d85eb0f50d610c8045f16552", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cc95782-b51b-4a2a-81b1-71b0f2588da0", "node_type": "1", "metadata": {"window": "RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n", "original_text": "This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n"}, "hash": "5ba9c6ebe69794a8cddc28610686dcad4923918cd1054d2b5f831d0629b5dd14", "class_name": "RelatedNodeInfo"}}, "text": "In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process. ", "start_char_idx": 652, "end_char_idx": 938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cc95782-b51b-4a2a-81b1-71b0f2588da0": {"__data__": {"id_": "3cc95782-b51b-4a2a-81b1-71b0f2588da0", "embedding": null, "metadata": {"window": "RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n", "original_text": "This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59ecd9de-9b3b-418d-a58e-2a16c4b78758", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort. ", "original_text": "In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3687c30bc3cae1cb39518c375f4efbcd8d51b914dea92e1ba8c06ae8a586c6fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f458862-b0ce-4d3f-8133-378c890ec6e7", "node_type": "1", "metadata": {"window": "This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days. ", "original_text": "And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies. "}, "hash": "ccb20c0664e9cdc7fcad4a81254ae0a34c6156de0cfb11a79cc8c0ebe9c8b8c4", "class_name": "RelatedNodeInfo"}}, "text": "This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n", "start_char_idx": 938, "end_char_idx": 1079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f458862-b0ce-4d3f-8133-378c890ec6e7": {"__data__": {"id_": "3f458862-b0ce-4d3f-8133-378c890ec6e7", "embedding": null, "metadata": {"window": "This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days. ", "original_text": "And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cc95782-b51b-4a2a-81b1-71b0f2588da0", "node_type": "1", "metadata": {"window": "RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n", "original_text": "This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63f30e1c05593572601192e3f2af716b1ea1509272f4942d6c02bbd4cd26afc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe3677ff-d66a-423d-a4f2-bcb1c547ac17", "node_type": "1", "metadata": {"window": "In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform. ", "original_text": "Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort. "}, "hash": "f55171954707c4cc84e7f516b1f1ce58ec4be6924559127c2a34e79a4a529bca", "class_name": "RelatedNodeInfo"}}, "text": "And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies. ", "start_char_idx": 1079, "end_char_idx": 1296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe3677ff-d66a-423d-a4f2-bcb1c547ac17": {"__data__": {"id_": "fe3677ff-d66a-423d-a4f2-bcb1c547ac17", "embedding": null, "metadata": {"window": "In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform. ", "original_text": "Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f458862-b0ce-4d3f-8133-378c890ec6e7", "node_type": "1", "metadata": {"window": "This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days. ", "original_text": "And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4c7b1d1ea525102d954149904cd38a381439255666c8272ad65ce77784ec78f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "213a8d01-729b-4925-b707-1aa53b45b4fa", "node_type": "1", "metadata": {"window": "This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n", "original_text": "Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n"}, "hash": "abebbb3d2c0f969c46e54ebb64e956ca70b9e07e3ba561368d98bf3ec03b9df5", "class_name": "RelatedNodeInfo"}}, "text": "Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort. ", "start_char_idx": 1296, "end_char_idx": 1449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "213a8d01-729b-4925-b707-1aa53b45b4fa": {"__data__": {"id_": "213a8d01-729b-4925-b707-1aa53b45b4fa", "embedding": null, "metadata": {"window": "This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n", "original_text": "Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe3677ff-d66a-423d-a4f2-bcb1c547ac17", "node_type": "1", "metadata": {"window": "In 2017, we acquired CoverMyMeds, whose mission is to help patients get access to the appropriate drugs for \ntheir care by automating and accelerating the prescription approval process known as electronic prior \nauthorization, an otherwise very manual and very time -consuming process.  This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform. ", "original_text": "Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae867a845e5c61ae43b5517bb49f1b7f147cce8f97f431be6431d85c0d8efa8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0c0c23f-a3f4-441d-8767-6b67883d0c32", "node_type": "1", "metadata": {"window": "And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter. ", "original_text": "Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days. "}, "hash": "50f6c49cddbf003ab76a735be3b2ed338678f2d9e2e1358c155e72b3ac6279d8", "class_name": "RelatedNodeInfo"}}, "text": "Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n", "start_char_idx": 1449, "end_char_idx": 1603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0c0c23f-a3f4-441d-8767-6b67883d0c32": {"__data__": {"id_": "f0c0c23f-a3f4-441d-8767-6b67883d0c32", "embedding": null, "metadata": {"window": "And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter. ", "original_text": "Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "213a8d01-729b-4925-b707-1aa53b45b4fa", "node_type": "1", "metadata": {"window": "This business gave us access to the \nworkflow of over 700,000 providers by automating the insurance approval pr ocess for drug coverage.  \n \n And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n", "original_text": "Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20e936c3c1d779d8d04319d0c5e3c0e449716c32a7784c536d4a7991414efa2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85e5f92f-9765-4151-b8d0-02dca00ff98c", "node_type": "1", "metadata": {"window": "Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n", "original_text": "Just one \nyear ag o, we had one brand on the platform. "}, "hash": "c03afdd4218dc36081af3fd2221d5e22bb5002bceffdfa3008b48afeca31a72c", "class_name": "RelatedNodeInfo"}}, "text": "Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days. ", "start_char_idx": 1603, "end_char_idx": 1817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85e5f92f-9765-4151-b8d0-02dca00ff98c": {"__data__": {"id_": "85e5f92f-9765-4151-b8d0-02dca00ff98c", "embedding": null, "metadata": {"window": "Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n", "original_text": "Just one \nyear ag o, we had one brand on the platform. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0c0c23f-a3f4-441d-8767-6b67883d0c32", "node_type": "1", "metadata": {"window": "And most recently, in 2018, we acquired RxCrossroads, a business that expanded our services and solutions for \nour biopharma partners and gave us disease -state expertise, specifically focused on specialty therapies.  Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter. ", "original_text": "Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d27f3fd6c792a38d058e8d9fa016552e357fa4e93d9eec3589cafc6e46485794", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08f13952-574e-46d8-8109-a064f88ac190", "node_type": "1", "metadata": {"window": "Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees. ", "original_text": "Today, we have several brands live and a good growing pipeline.  \n \n"}, "hash": "25415dc7f34969e7c9f14a0d5ed682b4e0d2e7ad884e18f6541919e5626e384b", "class_name": "RelatedNodeInfo"}}, "text": "Just one \nyear ag o, we had one brand on the platform. ", "start_char_idx": 1817, "end_char_idx": 1872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08f13952-574e-46d8-8109-a064f88ac190": {"__data__": {"id_": "08f13952-574e-46d8-8109-a064f88ac190", "embedding": null, "metadata": {"window": "Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees. ", "original_text": "Today, we have several brands live and a good growing pipeline.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85e5f92f-9765-4151-b8d0-02dca00ff98c", "node_type": "1", "metadata": {"window": "Bringing \nthese businesses together under one leadership team allows us to have a more cohesive strategy and a highly \ncoordinated go -to-market effort.  Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n", "original_text": "Just one \nyear ag o, we had one brand on the platform. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97a9d1aa699aec9b13f0f04ad5fb5a22666ce1a7ec5aff89d171ae3182e90e5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ce100bc-d58f-49ed-8abe-1fe597321a51", "node_type": "1", "metadata": {"window": "Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships. ", "original_text": "Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter. "}, "hash": "e8776992e550606394cfbb8ce4278c1e02bba52dcd4c8f767d8a8ed75bfe7866", "class_name": "RelatedNodeInfo"}}, "text": "Today, we have several brands live and a good growing pipeline.  \n \n", "start_char_idx": 1872, "end_char_idx": 1940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ce100bc-d58f-49ed-8abe-1fe597321a51": {"__data__": {"id_": "2ce100bc-d58f-49ed-8abe-1fe597321a51", "embedding": null, "metadata": {"window": "Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships. ", "original_text": "Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08f13952-574e-46d8-8109-a064f88ac190", "node_type": "1", "metadata": {"window": "Together, these businesses help to connect pharmacies, providers, payers and \nbiopharma for next -generation patient access  and adherence solutions.  \n \n Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees. ", "original_text": "Today, we have several brands live and a good growing pipeline.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7a31aba2f85501a5dc66d3497c5da1867f972046d3a0ab3c4958ed37a66eaff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdc1a40d-9ade-4649-acba-e41d676fce7a", "node_type": "1", "metadata": {"window": "Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n", "original_text": "As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n"}, "hash": "c207f97be9dcade0c2d3eaf012e8b12c7517cd5f1e286819f24a8ecc37b54d28", "class_name": "RelatedNodeInfo"}}, "text": "Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter. ", "start_char_idx": 1940, "end_char_idx": 2118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdc1a40d-9ade-4649-acba-e41d676fce7a": {"__data__": {"id_": "bdc1a40d-9ade-4649-acba-e41d676fce7a", "embedding": null, "metadata": {"window": "Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n", "original_text": "As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ce100bc-d58f-49ed-8abe-1fe597321a51", "node_type": "1", "metadata": {"window": "Last quarter, I talked about one of these solutions that we've continued to invest in, a product we call Access for \nMore Patients, or AMP, and how we've been able to reduce the average time to therapy by 18 days.  Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships. ", "original_text": "Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "260604736ae1def2691ee97434989236e19e7e446702ab7873665f22140fe16c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb13e090-ea4c-4ac7-a5a9-926dea001897", "node_type": "1", "metadata": {"window": "Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n", "original_text": "Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees. "}, "hash": "67a1d9577e08979f0cbbcb9474ffb7dfa9bb392b1c0e46a67ad8a6d17ecdd761", "class_name": "RelatedNodeInfo"}}, "text": "As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n", "start_char_idx": 2118, "end_char_idx": 2357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb13e090-ea4c-4ac7-a5a9-926dea001897": {"__data__": {"id_": "bb13e090-ea4c-4ac7-a5a9-926dea001897", "embedding": null, "metadata": {"window": "Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n", "original_text": "Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdc1a40d-9ade-4649-acba-e41d676fce7a", "node_type": "1", "metadata": {"window": "Just one \nyear ag o, we had one brand on the platform.  Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n", "original_text": "As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3f7a31125721938466eb1eb2b11b374cb45f432961139d1c03de36054bb7b9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58342e23-d19c-4ca9-bb29-5b5f3cdff859", "node_type": "1", "metadata": {"window": "Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations. ", "original_text": "Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships. "}, "hash": "8da95f2f14e27ff8fd8ea4f6a2b5ce6855e6f4b0a0b0596dac34895152765268", "class_name": "RelatedNodeInfo"}}, "text": "Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees. ", "start_char_idx": 2357, "end_char_idx": 2556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58342e23-d19c-4ca9-bb29-5b5f3cdff859": {"__data__": {"id_": "58342e23-d19c-4ca9-bb29-5b5f3cdff859", "embedding": null, "metadata": {"window": "Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations. ", "original_text": "Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb13e090-ea4c-4ac7-a5a9-926dea001897", "node_type": "1", "metadata": {"window": "Today, we have several brands live and a good growing pipeline.  \n \n Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n", "original_text": "Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4426dcab980ec31f4500004701598668c981d41dfbd6c1ea2685e70fe34fc3a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "881180c5-48f6-4db6-9eee-b8de937ea9df", "node_type": "1", "metadata": {"window": "As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n", "original_text": "I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n"}, "hash": "77721e68572e00fe9d9bd187c4bc75f795cacc553d6574908895f9ba7ee02dd1", "class_name": "RelatedNodeInfo"}}, "text": "Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships. ", "start_char_idx": 2556, "end_char_idx": 2673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "881180c5-48f6-4db6-9eee-b8de937ea9df": {"__data__": {"id_": "881180c5-48f6-4db6-9eee-b8de937ea9df", "embedding": null, "metadata": {"window": "As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n", "original_text": "I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58342e23-d19c-4ca9-bb29-5b5f3cdff859", "node_type": "1", "metadata": {"window": "Expanding our brand support programs for our biopharma partners helped to offset the impact of lower \nprescription volume trends, specifically new prescrip tions in the quarter.  As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations. ", "original_text": "Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f5cb1ef7839fdcab5f1d8c5c695f484273c76721f00ea9d4ed88ae18a825c2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bfce775-91e8-4c38-a42d-12fdcf8abd0c", "node_type": "1", "metadata": {"window": "Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n", "original_text": "And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n"}, "hash": "a4a85bc5db8cbbabe32662221519372cac7ea27133e2b97229b02ecd07add217", "class_name": "RelatedNodeInfo"}}, "text": "I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n", "start_char_idx": 2673, "end_char_idx": 2853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bfce775-91e8-4c38-a42d-12fdcf8abd0c": {"__data__": {"id_": "7bfce775-91e8-4c38-a42d-12fdcf8abd0c", "embedding": null, "metadata": {"window": "Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n", "original_text": "And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "881180c5-48f6-4db6-9eee-b8de937ea9df", "node_type": "1", "metadata": {"window": "As an important part of our strategy, we \nare continuing to invest in these businesses so that we can provide innovative solutions for biopharma, and these \ninvestment dollars are reflected in our results in the segment year -to-date.  \n \n Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n", "original_text": "I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae6bbfc8a92319464ba12d98e059a7a8904dc3f345e5ce1ae74187522993cabe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d72e59a3-95ad-41c5-b0e1-c721a4a1f6ca", "node_type": "1", "metadata": {"window": "Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "original_text": "I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations. "}, "hash": "294b95900e0f308900b1a5a55e4074ebed3b794e373e4917cf376f1d7919367f", "class_name": "RelatedNodeInfo"}}, "text": "And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n", "start_char_idx": 2853, "end_char_idx": 3083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d72e59a3-95ad-41c5-b0e1-c721a4a1f6ca": {"__data__": {"id_": "d72e59a3-95ad-41c5-b0e1-c721a4a1f6ca", "embedding": null, "metadata": {"window": "Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "original_text": "I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bfce775-91e8-4c38-a42d-12fdcf8abd0c", "node_type": "1", "metadata": {"window": "Summarizing at the enterprise level, while we expected challenges in the quarter, we significantly exceeded our \nexpectations, and it is, in large part, due to the execution of our 80,000 employees.  Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n", "original_text": "And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52f3c34dd144f753e8ea238c562f88c5d52bc2b592a0181f8153a44ab76eb947", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e057b55-0490-4d22-96bc-c6a1cf51f22e", "node_type": "1", "metadata": {"window": "I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "original_text": "While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n"}, "hash": "a080620477d2126270b8b6eed64c57963e0b72d0961942516f12d823b6ef860f", "class_name": "RelatedNodeInfo"}}, "text": "I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations. ", "start_char_idx": 3083, "end_char_idx": 3247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e057b55-0490-4d22-96bc-c6a1cf51f22e": {"__data__": {"id_": "8e057b55-0490-4d22-96bc-c6a1cf51f22e", "embedding": null, "metadata": {"window": "I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "original_text": "While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d72e59a3-95ad-41c5-b0e1-c721a4a1f6ca", "node_type": "1", "metadata": {"window": "Our teams move quickly and \ndecisively to react to evolving customer needs and our expanded government partnerships.  I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "original_text": "I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations. ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "845d04a4e8a40dd7147d921c7d0310430c144f815cb5860e42e165b09c9bae3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2ce4fa3-4b86-44f8-a336-bc751b03378a", "node_type": "1", "metadata": {"window": "And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "original_text": "We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n"}, "hash": "a81c7b211ad186fcb4d942b94d7394f6bd53de7c45dde970d912434842bcda14", "class_name": "RelatedNodeInfo"}}, "text": "While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n", "start_char_idx": 3247, "end_char_idx": 3484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2ce4fa3-4b86-44f8-a336-bc751b03378a": {"__data__": {"id_": "d2ce4fa3-4b86-44f8-a336-bc751b03378a", "embedding": null, "metadata": {"window": "And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "original_text": "We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e057b55-0490-4d22-96bc-c6a1cf51f22e", "node_type": "1", "metadata": {"window": "I continue to just be \nso impressed by our teammates, particularly those on the frontlines, for their unwavering focus and dedication \nduring this incredibly challenging time.  \n \n And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "original_text": "While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b33268e0e75ee4de8c14fa967f9d142b678f641c4b8dcf7f3fc4d6a8d6ce428a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1ec3cb6-983f-4b5b-ad81-f22ef4992f26", "node_type": "1", "metadata": {"window": "I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "original_text": "While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n "}, "hash": "2bf20b74adc64d0084e17b775d9b7c1d47cbb2ea47a6a7a43d13193129c03d54", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n", "start_char_idx": 3484, "end_char_idx": 3767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1ec3cb6-983f-4b5b-ad81-f22ef4992f26": {"__data__": {"id_": "b1ec3cb6-983f-4b5b-ad81-f22ef4992f26", "embedding": null, "metadata": {"window": "I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "original_text": "While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d964d354-bff0-40f6-acef-781e7ddcbda3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96121e63ce08fb33aed47e5a2e877b98378dc61427cad4bad0855353db548022", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2ce4fa3-4b86-44f8-a336-bc751b03378a", "node_type": "1", "metadata": {"window": "And as part of our appre ciation, we again made special payments to our frontline employees, recognizing their \ncourage and their service to our company, our customers and frontline caregivers over these past several \nmonths.  \n \n I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "original_text": "We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e678dc72e5dc0d84767cbf3ac7d1e036e4d005afc31c85a9f6b6f87abb03930", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81b6dcf9-bf71-40ee-8605-e21a996b6a85", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "cc086946d0b03ef47c9dee202424d45be03a8cb04d62d2b604e8f6b70565a40a", "class_name": "RelatedNodeInfo"}}, "text": "While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "start_char_idx": 3767, "end_char_idx": 3988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81b6dcf9-bf71-40ee-8605-e21a996b6a85": {"__data__": {"id_": "81b6dcf9-bf71-40ee-8605-e21a996b6a85", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1ec3cb6-983f-4b5b-ad81-f22ef4992f26", "node_type": "1", "metadata": {"window": "I mentioned how the second quarter was a good example of  the nonlinearity of the recovery as our results far \nexceeded our original and even revised expectations.  While we're encouraged by the positive trajectory of the \nrecovery, we continue to believe a full recovery back to pre -COVID levels will take longer th an we originally \ncontemplated and is unlikely to occur within our fiscal year.  \n \n We continue to expect in the second half of the year as compared to the prior year, driven by an improved market, \nnear-term demand from our customers and our current work in th e US government assembling the ancillary kits to \ngo along with future COVID vaccines once approved.  \n \n While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "original_text": "While some of the tailwinds I mentioned are expected to be near term, we believe we have made the investments \nnecessary to position us as a partner of choi ce for our customers and manufacturers throughout this time.  \n ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2ceeed4d108a10efc31d0616d35ec02d96c79af3b6351f5e07718fa26ef27ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d23e1f3c-3377-45e8-b3b3-16ae8e7dde41", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change. "}, "hash": "a54b874fb98affd7e54d95a05397ded30e8a93c35e7a02ed75ef6c1f86c1fb98", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d23e1f3c-3377-45e8-b3b3-16ae8e7dde41": {"__data__": {"id_": "d23e1f3c-3377-45e8-b3b3-16ae8e7dde41", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81b6dcf9-bf71-40ee-8605-e21a996b6a85", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "940abecdc19fbd8101816fafdd363fba8f37d3bb2680089ffdee67c191dad79d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "368d2ae2-c328-4df3-a230-c766bcde3eff", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n", "original_text": "And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities. "}, "hash": "4696421696f87c70d2f3e6acab99b60db74ea5818ed836fcdc069b6bb04c402b", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change. ", "start_char_idx": 16, "end_char_idx": 365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "368d2ae2-c328-4df3-a230-c766bcde3eff": {"__data__": {"id_": "368d2ae2-c328-4df3-a230-c766bcde3eff", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n", "original_text": "And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d23e1f3c-3377-45e8-b3b3-16ae8e7dde41", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7beec56001e0a844f39482e3ff0772013b872fadafc876685d405707d64a6dcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b2f5128-c7cf-4abf-8b89-779f0150e03a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n ", "original_text": "Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n"}, "hash": "bd1fbd613e8de2c545bf30a674a9677478c6320f9e9618b0cf54db4cb33dc402", "class_name": "RelatedNodeInfo"}}, "text": "And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities. ", "start_char_idx": 365, "end_char_idx": 493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b2f5128-c7cf-4abf-8b89-779f0150e03a": {"__data__": {"id_": "5b2f5128-c7cf-4abf-8b89-779f0150e03a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n ", "original_text": "Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "368d2ae2-c328-4df3-a230-c766bcde3eff", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n", "original_text": "And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef4b2e660f7c5cf1b11497a8569ae73ae986cc748a357b12571371931c9641be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85d687c9-672b-46e6-a53f-f809b5910d45", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view. "}, "hash": "17a97dddda539789f16ec9805d42b4391fdecbefbf7b866cb0feb8b1d07b3d0e", "class_name": "RelatedNodeInfo"}}, "text": "Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n", "start_char_idx": 493, "end_char_idx": 802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85d687c9-672b-46e6-a53f-f809b5910d45": {"__data__": {"id_": "85d687c9-672b-46e6-a53f-f809b5910d45", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b2f5128-c7cf-4abf-8b89-779f0150e03a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n ", "original_text": "Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e479b2a269ed16bc919d9df7f78cb1bcb84cb51ca0f52955a59df654f967a2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f510d8bf-f809-4956-97e9-ae5ee81437b6", "node_type": "1", "metadata": {"window": "And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone. ", "original_text": "Thank you for your time this morning.  \n \n"}, "hash": "747158bd77fbc3dd46f605285d133f5bc6d9038db55e2ad8244563bb5024a332", "class_name": "RelatedNodeInfo"}}, "text": "I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view. ", "start_char_idx": 802, "end_char_idx": 963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f510d8bf-f809-4956-97e9-ae5ee81437b6": {"__data__": {"id_": "f510d8bf-f809-4956-97e9-ae5ee81437b6", "embedding": null, "metadata": {"window": "And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone. ", "original_text": "Thank you for your time this morning.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85d687c9-672b-46e6-a53f-f809b5910d45", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc02d4cf90233833d30c920e19e0d553c731edca84173178955603742317f733", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89591fc1-cb60-4c14-9d8c-60b500014281", "node_type": "1", "metadata": {"window": "Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter. ", "original_text": "And with that, let me hand it over to Britt to elaborate.  \n "}, "hash": "43ab0329a64f26083d8ada5d9aab06a0111607e09fd54d2b45099a51caf63b9f", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for your time this morning.  \n \n", "start_char_idx": 963, "end_char_idx": 1005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89591fc1-cb60-4c14-9d8c-60b500014281": {"__data__": {"id_": "89591fc1-cb60-4c14-9d8c-60b500014281", "embedding": null, "metadata": {"window": "Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter. ", "original_text": "And with that, let me hand it over to Britt to elaborate.  \n ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f510d8bf-f809-4956-97e9-ae5ee81437b6", "node_type": "1", "metadata": {"window": "And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone. ", "original_text": "Thank you for your time this morning.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d174ce399838c8b731be3f54b15879a09ab12a0c0273b7080a0ccd7297749384", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acabfbd0-24f1-481c-8241-3cb712b65744", "node_type": "1", "metadata": {"window": "I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n"}, "hash": "079d517e35b3849324548d285c799bbb49652c49119f1229f94ac5e347a2b11b", "class_name": "RelatedNodeInfo"}}, "text": "And with that, let me hand it over to Britt to elaborate.  \n ", "start_char_idx": 1005, "end_char_idx": 1066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acabfbd0-24f1-481c-8241-3cb712b65744": {"__data__": {"id_": "acabfbd0-24f1-481c-8241-3cb712b65744", "embedding": null, "metadata": {"window": "I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89591fc1-cb60-4c14-9d8c-60b500014281", "node_type": "1", "metadata": {"window": "Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter. ", "original_text": "And with that, let me hand it over to Britt to elaborate.  \n ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c86fde2a5a9b4bb7ba477a1cf73fe000bb4d491ca9faaba3c8a4c4e2a3779c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfa7f71a-f92b-4357-b8e7-c6ab71de066e", "node_type": "1", "metadata": {"window": "Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n", "original_text": "Thank you, Brian; and good morning, everyone. "}, "hash": "f4c3efbd21185b0b37495501396c18b58a859d4d18570790edfe5bf07735cd0e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "start_char_idx": 1066, "end_char_idx": 1412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfa7f71a-f92b-4357-b8e7-c6ab71de066e": {"__data__": {"id_": "bfa7f71a-f92b-4357-b8e7-c6ab71de066e", "embedding": null, "metadata": {"window": "Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n", "original_text": "Thank you, Brian; and good morning, everyone. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acabfbd0-24f1-481c-8241-3cb712b65744", "node_type": "1", "metadata": {"window": "I'm so proud of the execution I've seen across the business in the first half of fiscal 2021 and  the dedication of our \nemployees remains unmatched in my view.  Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cce9f9457424b03eb6f5bee98eae90a1496eb4d31e0ba47b967612496f1c8d07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4da77f1-638c-45be-89b6-361004092b80", "node_type": "1", "metadata": {"window": "And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment. ", "original_text": "We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter. "}, "hash": "1914b785930b54b858df301dcca685ccc48f855e48435320ff9fe87e210e285c", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Brian; and good morning, everyone. ", "start_char_idx": 1412, "end_char_idx": 1458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4da77f1-638c-45be-89b6-361004092b80": {"__data__": {"id_": "c4da77f1-638c-45be-89b6-361004092b80", "embedding": null, "metadata": {"window": "And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment. ", "original_text": "We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfa7f71a-f92b-4357-b8e7-c6ab71de066e", "node_type": "1", "metadata": {"window": "Thank you for your time this morning.  \n \n And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n", "original_text": "Thank you, Brian; and good morning, everyone. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "326aa5f03c29cfb29a02a9f0d0be2b1915b4231161c9b8ed2d37094beef24b81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e27299bd-8f40-4c12-af8b-492a392f4e98", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic. ", "original_text": "We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment. "}, "hash": "0aa4ddd66a853d7d445ce0109ecdc1f150505d1af0b7dc78fc892066b38dfa9a", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter. ", "start_char_idx": 1458, "end_char_idx": 1571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e27299bd-8f40-4c12-af8b-492a392f4e98": {"__data__": {"id_": "e27299bd-8f40-4c12-af8b-492a392f4e98", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic. ", "original_text": "We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4da77f1-638c-45be-89b6-361004092b80", "node_type": "1", "metadata": {"window": "And with that, let me hand it over to Britt to elaborate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment. ", "original_text": "We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5a6be75c9acfd21a326253155fed9744cf803906bc42275d9a7742864598507", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31d50cda-1b18-4b92-9e91-66b42613d643", "node_type": "1", "metadata": {"window": "Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n", "original_text": "We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n"}, "hash": "17ef588e7469b9e1b82c2473df0ece5ddf033a0fadc2bbe0d73a52af5abe612c", "class_name": "RelatedNodeInfo"}}, "text": "We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment. ", "start_char_idx": 1571, "end_char_idx": 1759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31d50cda-1b18-4b92-9e91-66b42613d643": {"__data__": {"id_": "31d50cda-1b18-4b92-9e91-66b42613d643", "embedding": null, "metadata": {"window": "Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n", "original_text": "We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e27299bd-8f40-4c12-af8b-492a392f4e98", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic. ", "original_text": "We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "062343bd3206bf848dc404c5254699ad15c08925597c5b5bc42353b1f100c350", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56ca2338-383c-4156-b536-2aaf11ff5858", "node_type": "1", "metadata": {"window": "We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in. ", "original_text": "We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment. "}, "hash": "a649b5f526c0ad57be4d298306c4d89f2ff8936061c87557a2ac237c84543b0a", "class_name": "RelatedNodeInfo"}}, "text": "We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n", "start_char_idx": 1759, "end_char_idx": 1912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56ca2338-383c-4156-b536-2aaf11ff5858": {"__data__": {"id_": "56ca2338-383c-4156-b536-2aaf11ff5858", "embedding": null, "metadata": {"window": "We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in. ", "original_text": "We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31d50cda-1b18-4b92-9e91-66b42613d643", "node_type": "1", "metadata": {"window": "Thank you, Brian; and good morning, everyone.  We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n", "original_text": "We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "958e1b3e778bdf35bdf5ab4f1a20ea34853b4714f13b9a43eaf5a87395a7dbeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71333dd6-1421-4fad-bcd5-167c766fbf11", "node_type": "1", "metadata": {"window": "We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n", "original_text": "This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic. "}, "hash": "fd3068f3870a40a38303dc733d2c80a3fdec03e1c096b1bfa098703c58722259", "class_name": "RelatedNodeInfo"}}, "text": "We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment. ", "start_char_idx": 1912, "end_char_idx": 2072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71333dd6-1421-4fad-bcd5-167c766fbf11": {"__data__": {"id_": "71333dd6-1421-4fad-bcd5-167c766fbf11", "embedding": null, "metadata": {"window": "We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n", "original_text": "This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56ca2338-383c-4156-b536-2aaf11ff5858", "node_type": "1", "metadata": {"window": "We're pleased with our adjusted operating profit and adjusted \nearnings per share results in the second quarter.  We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in. ", "original_text": "We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f1abdd8526529a09f5383e3ddc072c34714040491426ee871a326bce1d64703", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ab2dedf-397b-4326-84e8-7d7243f04192", "node_type": "1", "metadata": {"window": "We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results. ", "original_text": "We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n"}, "hash": "8382e37b9da0c4d52c400844985fefd8d911e356fd77430d395db6248e0cbd67", "class_name": "RelatedNodeInfo"}}, "text": "This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic. ", "start_char_idx": 2072, "end_char_idx": 2277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ab2dedf-397b-4326-84e8-7d7243f04192": {"__data__": {"id_": "4ab2dedf-397b-4326-84e8-7d7243f04192", "embedding": null, "metadata": {"window": "We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results. ", "original_text": "We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71333dd6-1421-4fad-bcd5-167c766fbf11", "node_type": "1", "metadata": {"window": "We delivered growth over our prior -year results and exceeded \nthe expectations that we laid out on our Q1  earnings call, despite an extremely volatile and challenging \nmacroenvironment.  We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n", "original_text": "This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ded5de4cc33fac336b3995855610e345a3ecfaf125d96f580ff1916480706bc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4db34b4b-0351-4ec0-bf6b-54045210c891", "node_type": "1", "metadata": {"window": "We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n", "original_text": "As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in. "}, "hash": "f1a6e3f321add90eb40310e2c3c613e6af3072c3f8be58f81c6d4b53bd6e9816", "class_name": "RelatedNodeInfo"}}, "text": "We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n", "start_char_idx": 2277, "end_char_idx": 2410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4db34b4b-0351-4ec0-bf6b-54045210c891": {"__data__": {"id_": "4db34b4b-0351-4ec0-bf6b-54045210c891", "embedding": null, "metadata": {"window": "We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n", "original_text": "As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ab2dedf-397b-4326-84e8-7d7243f04192", "node_type": "1", "metadata": {"window": "We couldn't be more proud of the way our teams have executed and continue to deliver and \ninnovate through this unprecedented period of uncertainty.  \n \n We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results. ", "original_text": "We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a12998bbf5f126e6cbfab18cd7f0f6d4d80a902ac18c1b38b934f2395df6f15f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d8f78ec-08a1-4eca-a2fa-0e283370d169", "node_type": "1", "metadata": {"window": "This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment. ", "original_text": "However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n"}, "hash": "65a7120f729d6658cc9307ab549e69369e551c4f62d5b53c3c2b9d5bb379e611", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in. ", "start_char_idx": 2410, "end_char_idx": 2622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d8f78ec-08a1-4eca-a2fa-0e283370d169": {"__data__": {"id_": "5d8f78ec-08a1-4eca-a2fa-0e283370d169", "embedding": null, "metadata": {"window": "This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment. ", "original_text": "However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4db34b4b-0351-4ec0-bf6b-54045210c891", "node_type": "1", "metadata": {"window": "We delivered solid core per formance across our businesses in the quarter, including new product volumes and \nelevated demand in our Medical -Surgical segment.  This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n", "original_text": "As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45f436689382a36e8e72ce074705697f1ed8e3a10b3055d6bbe64949cabcbbc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9200f140-9cc6-40c7-b1a7-c0fa9769bca5", "node_type": "1", "metadata": {"window": "We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n", "original_text": "As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results. "}, "hash": "b13ee7c9c50badc9f58a0c5e079c32922d1bcf0ef9622da84822533682988902", "class_name": "RelatedNodeInfo"}}, "text": "However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n", "start_char_idx": 2622, "end_char_idx": 2749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9200f140-9cc6-40c7-b1a7-c0fa9769bca5": {"__data__": {"id_": "9200f140-9cc6-40c7-b1a7-c0fa9769bca5", "embedding": null, "metadata": {"window": "We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n", "original_text": "As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d8f78ec-08a1-4eca-a2fa-0e283370d169", "node_type": "1", "metadata": {"window": "This new volume includes an increase in the sales of COVID -\n19 tests and increased volumes in personal protective equipment, as  we continue to respond to the needs of our \ncustomers during the pandemic.  We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment. ", "original_text": "However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08022a312f03ad9dd2143b2b590bc4ba4ff2d0651f0e9056fbd0e1d1a01ad245", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "109f2840-c7ae-43f6-87d2-5a01b500b366", "node_type": "1", "metadata": {"window": "As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n", "original_text": "Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n"}, "hash": "367dd2df980175af35f270d3710875b08a900453c222e450035b908e5978eb96", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results. ", "start_char_idx": 2749, "end_char_idx": 2997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "109f2840-c7ae-43f6-87d2-5a01b500b366": {"__data__": {"id_": "109f2840-c7ae-43f6-87d2-5a01b500b366", "embedding": null, "metadata": {"window": "As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n", "original_text": "Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9200f140-9cc6-40c7-b1a7-c0fa9769bca5", "node_type": "1", "metadata": {"window": "We also recognized gains on equity investments within our McKesson Ventures \nportfolio, and I'll provide further detail on this.  \n \n As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n", "original_text": "As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5549bcd6842a1f48582c27b365833c61b394ca24ccd6dc9fbb748c568219471f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13377c9d-cd52-4502-a15d-254cbb9094e9", "node_type": "1", "metadata": {"window": "However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website. ", "original_text": "As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment. "}, "hash": "d663bef76b52805c1b93ccbd340a9f7cd31a4c64ed374ddb3db65269b1a70e97", "class_name": "RelatedNodeInfo"}}, "text": "Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n", "start_char_idx": 2997, "end_char_idx": 3217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13377c9d-cd52-4502-a15d-254cbb9094e9": {"__data__": {"id_": "13377c9d-cd52-4502-a15d-254cbb9094e9", "embedding": null, "metadata": {"window": "However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website. ", "original_text": "As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "109f2840-c7ae-43f6-87d2-5a01b500b366", "node_type": "1", "metadata": {"window": "As a reminder, in our first quarter, we were impacte d across our businesses by economic lockdowns and social \ndistancing, which led to decreased healthcare utilization across the geographies that we operate in.  However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n", "original_text": "Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be030d1636aa0de4e5245c5648e2c8d103c6f66bdf0f73f27ead272abdec599", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7da5e19e-5d32-4bef-999b-140bafbcb6dc", "node_type": "1", "metadata": {"window": "As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website.  And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "original_text": "We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n"}, "hash": "08a937b3539820550c8c81a0b4916155dcd1162646af3db82de06adea28517bc", "class_name": "RelatedNodeInfo"}}, "text": "As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment. ", "start_char_idx": 3217, "end_char_idx": 3458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7da5e19e-5d32-4bef-999b-140bafbcb6dc": {"__data__": {"id_": "7da5e19e-5d32-4bef-999b-140bafbcb6dc", "embedding": null, "metadata": {"window": "As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website.  And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "original_text": "We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13377c9d-cd52-4502-a15d-254cbb9094e9", "node_type": "1", "metadata": {"window": "However, in \nJune, we began to see an acceleration of demand as volumes recovered earlier than we o riginally anticipated.  \n \n As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website. ", "original_text": "As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f90bd7cffc993ccb919c3510734cff5d31ab040e2ef0b332d301972bd372c272", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d6a699e-d61c-4087-8ce1-5b0067369d2b", "node_type": "1", "metadata": {"window": "Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website.  And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "original_text": "This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n"}, "hash": "563b90d23891a2e9014768097c0b6c847b204ef945b8dc76f348da731ad683b6", "class_name": "RelatedNodeInfo"}}, "text": "We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n", "start_char_idx": 3458, "end_char_idx": 3607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d6a699e-d61c-4087-8ce1-5b0067369d2b": {"__data__": {"id_": "4d6a699e-d61c-4087-8ce1-5b0067369d2b", "embedding": null, "metadata": {"window": "Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website.  And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "original_text": "This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7da5e19e-5d32-4bef-999b-140bafbcb6dc", "node_type": "1", "metadata": {"window": "As I mentioned during our Q1 earnings call, we expected a nonlinear recovery from the effects of the pandemic \nover the remainder of our fiscal year, and we saw the nonlinear course of recovery continue to play out in our \nsecond quar ter results.  Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website.  And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "original_text": "We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec421c662b47d52f40359336c36dcf01955aefeb86709a9216b99fec293a5722", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "643fbba6-b279-412e-85c1-d96b9d917964", "node_type": "1", "metadata": {"window": "As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website.  And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "original_text": "Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website. "}, "hash": "ed04030fdc4bc7cdce291ce23d8d232e1676d6fcc982fa4d100a4245b098cd56", "class_name": "RelatedNodeInfo"}}, "text": "This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n", "start_char_idx": 3607, "end_char_idx": 3842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "643fbba6-b279-412e-85c1-d96b9d917964": {"__data__": {"id_": "643fbba6-b279-412e-85c1-d96b9d917964", "embedding": null, "metadata": {"window": "As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website.  And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "original_text": "Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d6a699e-d61c-4087-8ce1-5b0067369d2b", "node_type": "1", "metadata": {"window": "Prescription volumes recovered from their lowest levels earlier in our fiscal year, although \nnot back to pre -COVID levels, and primary patient visits continued to improve at a rate faster than we had \nanticipated.  \n \n As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website.  And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "original_text": "This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "208484f6369daf08d82f26b36a89991216d52c7cfcebba4d7233df7f5afa2ac4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48f80638-24c5-460a-8172-800ef8ec4f2f", "node_type": "1", "metadata": {"window": "We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website.  And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "original_text": "And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  "}, "hash": "1c96d48c35f666e2c0406bf1168dbce8ba42c847ca1186402887d26f65bb2e2f", "class_name": "RelatedNodeInfo"}}, "text": "Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website. ", "start_char_idx": 3842, "end_char_idx": 3990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48f80638-24c5-460a-8172-800ef8ec4f2f": {"__data__": {"id_": "48f80638-24c5-460a-8172-800ef8ec4f2f", "embedding": null, "metadata": {"window": "We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website.  And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "original_text": "And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13d23129-4960-4cc7-af95-389a0c0d6697", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d44c28c77090bc750e5d548c4d881c671a2f5748a7c0dfdf28451313dbfa3ab3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "643fbba6-b279-412e-85c1-d96b9d917964", "node_type": "1", "metadata": {"window": "As Brian mentioned, in the se cond quarter, we observed increased volumes for COVID -related products, \nparticularly COVID tests as we stocked up to meet demands for additional testing and supplies, including \npersonal protective equipment.  We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website.  And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "original_text": "Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website. ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0a68c15e2603c5209540e5f09c71dce731194fee812cf1e3496941fc22a0b1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99817f68-c552-4db8-8234-886f8fc6246c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "e41934984ac969f006509caed915f50f4c68eeee2224fc1796caa63b68d268a3", "class_name": "RelatedNodeInfo"}}, "text": "And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "start_char_idx": 3990, "end_char_idx": 4087, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99817f68-c552-4db8-8234-886f8fc6246c": {"__data__": {"id_": "99817f68-c552-4db8-8234-886f8fc6246c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48f80638-24c5-460a-8172-800ef8ec4f2f", "node_type": "1", "metadata": {"window": "We continue to respond to the dynamic and fluid environment, and we're pleased \nwith our execution throughout the first half of our fiscal year.  \n \n This morning, I'll provide commentary on our second quarter results and an update on the key assumptions that \nsupport our outlook for the remainder of fiscal 2 021, and my comments today will relate to our new segment \nstructure.  \n \n Let's turn now to our second quarter results, a summary of which, including updated guidance can be found in the \nInvestors section of our website.  And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "original_text": "And I'll start by pointing out two item s that impacted our GAAP -only results in the \nquarter.  ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9c80d53f2c410ac0e605253d70c56322c09111cbbf794a7b7bd4f18c94d56d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a66c3684-5e79-43a1-9690-d30d39c12d70", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S. "}, "hash": "96e185a1c5bebe4b8229c07dc6ed00b44227c47f4c443bc84dd90bb288d2eafc", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a66c3684-5e79-43a1-9690-d30d39c12d70": {"__data__": {"id_": "a66c3684-5e79-43a1-9690-d30d39c12d70", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99817f68-c552-4db8-8234-886f8fc6246c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8558044f76cf326e801d860456bff82acf946ff923cd0e27408c8121288aac74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04d626f7-cf85-4b49-b389-5c21ee79fe9e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019. ", "original_text": "Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA. "}, "hash": "09d8776cb749413423b33683792d5469833d2a861a7b62b722c641e276c7b0b4", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S. ", "start_char_idx": 16, "end_char_idx": 201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04d626f7-cf85-4b49-b389-5c21ee79fe9e": {"__data__": {"id_": "04d626f7-cf85-4b49-b389-5c21ee79fe9e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019. ", "original_text": "Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a66c3684-5e79-43a1-9690-d30d39c12d70", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c690eb2c6ddb85b4fcbf19ddebc63e8fd3dfa8f7a3e96f6778eda3dcf409b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79653d9b-dbb4-4b0b-b761-80b82f0ec569", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020. ", "original_text": "The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n"}, "hash": "00f5ab628f0a0923ee7d744c3afdd4b47abb6062119b23dcc9f068ecf7bedb0f", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA. ", "start_char_idx": 201, "end_char_idx": 351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79653d9b-dbb4-4b0b-b761-80b82f0ec569": {"__data__": {"id_": "79653d9b-dbb4-4b0b-b761-80b82f0ec569", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020. ", "original_text": "The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04d626f7-cf85-4b49-b389-5c21ee79fe9e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019. ", "original_text": "Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2303e04be8dee71891d02282a195625b5277631037961594773b1077ee4aeac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5080262e-06d0-4596-a7b6-accbce816414", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n", "original_text": "As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA. "}, "hash": "73644b6c733b3d5fcaa463468242963e8e484c2b67414a56f5e241a7ab208be3", "class_name": "RelatedNodeInfo"}}, "text": "The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n", "start_char_idx": 351, "end_char_idx": 454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5080262e-06d0-4596-a7b6-accbce816414": {"__data__": {"id_": "5080262e-06d0-4596-a7b6-accbce816414", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n", "original_text": "As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79653d9b-dbb4-4b0b-b761-80b82f0ec569", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020. ", "original_text": "The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7318af18263d87c3252eb96a90d039bd22253f52ee9e3e9d8dbd8bd0a039db8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9351f254-eeca-4f5a-bb8c-1622e3de85bd", "node_type": "1", "metadata": {"window": "Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n", "original_text": "The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019. "}, "hash": "bb8155f45305a2a21dd30a64ad0fdee75cb70bfce05ad3c226d0a5de04a2689a", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA. ", "start_char_idx": 454, "end_char_idx": 606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9351f254-eeca-4f5a-bb8c-1622e3de85bd": {"__data__": {"id_": "9351f254-eeca-4f5a-bb8c-1622e3de85bd", "embedding": null, "metadata": {"window": "Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n", "original_text": "The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5080262e-06d0-4596-a7b6-accbce816414", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n", "original_text": "As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44d414d6521a6333ce94818c61e2a0ef1503dcc63cca38da5408d17c4ac170ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41344b54-a2e9-4e16-ab59-d47b15685456", "node_type": "1", "metadata": {"window": "The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4. ", "original_text": "That ruling was reversed in September of 2020. "}, "hash": "5b669edd1bd3a879e0cca6233a8c3053adf712e1429a69262d83dcbdb9af6503", "class_name": "RelatedNodeInfo"}}, "text": "The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019. ", "start_char_idx": 606, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41344b54-a2e9-4e16-ab59-d47b15685456": {"__data__": {"id_": "41344b54-a2e9-4e16-ab59-d47b15685456", "embedding": null, "metadata": {"window": "The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4. ", "original_text": "That ruling was reversed in September of 2020. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9351f254-eeca-4f5a-bb8c-1622e3de85bd", "node_type": "1", "metadata": {"window": "Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n", "original_text": "The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe59d0513a588decdabbee47bb4c16216d60286cc16cdb5c6d4cdd39a5807d1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cad915c4-9036-4588-879d-27ea909e64f2", "node_type": "1", "metadata": {"window": "As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S. ", "original_text": "And therefore, we took a \ncharge in our fiscal second quarter.  \n \n"}, "hash": "6927abdf0b49340b78738ce6f1337b50ef238b3f6ec0cef758739428c2f3e605", "class_name": "RelatedNodeInfo"}}, "text": "That ruling was reversed in September of 2020. ", "start_char_idx": 720, "end_char_idx": 767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cad915c4-9036-4588-879d-27ea909e64f2": {"__data__": {"id_": "cad915c4-9036-4588-879d-27ea909e64f2", "embedding": null, "metadata": {"window": "As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S. ", "original_text": "And therefore, we took a \ncharge in our fiscal second quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41344b54-a2e9-4e16-ab59-d47b15685456", "node_type": "1", "metadata": {"window": "The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4. ", "original_text": "That ruling was reversed in September of 2020. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3f65409c2e87228043c8d398efac146cbd1422db22af545abe15a3f555bc084", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "284badfd-c1f3-4e57-9994-826a3f911a83", "node_type": "1", "metadata": {"window": "The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment. ", "original_text": "Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n"}, "hash": "ad56b06d693cc0a70b417f474a838ac9259a8cf02b2909c828eb045598107ee3", "class_name": "RelatedNodeInfo"}}, "text": "And therefore, we took a \ncharge in our fiscal second quarter.  \n \n", "start_char_idx": 767, "end_char_idx": 834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "284badfd-c1f3-4e57-9994-826a3f911a83": {"__data__": {"id_": "284badfd-c1f3-4e57-9994-826a3f911a83", "embedding": null, "metadata": {"window": "The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment. ", "original_text": "Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cad915c4-9036-4588-879d-27ea909e64f2", "node_type": "1", "metadata": {"window": "As a reminder, we recorded an accrual in the first and second quarter of fiscal 2019 for the estimated portion of \nthe annual assessment under the OSA.  The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S. ", "original_text": "And therefore, we took a \ncharge in our fiscal second quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9179f742dd2fc007408c08721b7645e083e1d4965fcafb7f6b65b10144f6ac57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3c43a67-0d71-4e7b-bb85-5c4ac96f81e4", "node_type": "1", "metadata": {"window": "That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S. ", "original_text": "Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4. "}, "hash": "310240f0e59b1b7700f712607dfe664649979cb6a2b8f2db5d20841247a4487d", "class_name": "RelatedNodeInfo"}}, "text": "Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n", "start_char_idx": 834, "end_char_idx": 991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3c43a67-0d71-4e7b-bb85-5c4ac96f81e4": {"__data__": {"id_": "f3c43a67-0d71-4e7b-bb85-5c4ac96f81e4", "embedding": null, "metadata": {"window": "That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S. ", "original_text": "Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "284badfd-c1f3-4e57-9994-826a3f911a83", "node_type": "1", "metadata": {"window": "The OSA was later ruled unconstitutional , and the accrual was reversed \nin the third quarter of our fiscal 2019.  That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment. ", "original_text": "Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "080bf2c2dbe2428e5fbd46a2b629632d7cc25244683bd11e9a88b77f1b74e459", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70aee11f-6346-4dce-9418-45ee0c57889a", "node_type": "1", "metadata": {"window": "And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n", "original_text": "Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S. "}, "hash": "2f2bc25b6d2ccf8da4cf752bbec9449ebf37b1ed4b644be736db6f6572dbc20e", "class_name": "RelatedNodeInfo"}}, "text": "Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4. ", "start_char_idx": 991, "end_char_idx": 1120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70aee11f-6346-4dce-9418-45ee0c57889a": {"__data__": {"id_": "70aee11f-6346-4dce-9418-45ee0c57889a", "embedding": null, "metadata": {"window": "And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n", "original_text": "Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3c43a67-0d71-4e7b-bb85-5c4ac96f81e4", "node_type": "1", "metadata": {"window": "That ruling was reversed in September of 2020.  And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S. ", "original_text": "Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24c40ff58abf5add25cb68e2b6f1b513043f34799e4b354568b60371fa2dd0ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b11f41b0-ba70-41c0-9854-d77fdaeb7a1d", "node_type": "1", "metadata": {"window": "Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n", "original_text": "Pharmaceutical segment. "}, "hash": "48b9c1efa1e6d9c90dee94028c3e869b24275583f4eb531c301a5471b4a651e2", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S. ", "start_char_idx": 1120, "end_char_idx": 1301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b11f41b0-ba70-41c0-9854-d77fdaeb7a1d": {"__data__": {"id_": "b11f41b0-ba70-41c0-9854-d77fdaeb7a1d", "embedding": null, "metadata": {"window": "Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n", "original_text": "Pharmaceutical segment. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70aee11f-6346-4dce-9418-45ee0c57889a", "node_type": "1", "metadata": {"window": "And therefore, we took a \ncharge in our fiscal second quarter.  \n \n Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n", "original_text": "Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9da77818d4cb92b18ddc4e55fdc39996dcb6c7bf84c8aa29860d862644f01c27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec55db0e-b7ee-4fc7-b49f-f091d34ec653", "node_type": "1", "metadata": {"window": "Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year. ", "original_text": "Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S. "}, "hash": "246408ab91c073b05c44e5a64907b342d1cc4703396a64e723c17183a41e99c0", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment. ", "start_char_idx": 1301, "end_char_idx": 1325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec55db0e-b7ee-4fc7-b49f-f091d34ec653": {"__data__": {"id_": "ec55db0e-b7ee-4fc7-b49f-f091d34ec653", "embedding": null, "metadata": {"window": "Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year. ", "original_text": "Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b11f41b0-ba70-41c0-9854-d77fdaeb7a1d", "node_type": "1", "metadata": {"window": "Secondly, within our International segment, we recorded a goodwill impairment charge of $69 million, which was \nassociated with the segment realignment.  \n \n Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n", "original_text": "Pharmaceutical segment. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11b4c6915dd59dc83d2266cf1306bd6bca2c11e8dd79906e6129ed446f9fa059", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "747068e3-cf15-436d-a008-ccdc2c0d6a29", "node_type": "1", "metadata": {"window": "Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n", "original_text": "Pharmaceutical segment.  \n \n"}, "hash": "115b799461fed417a5bd7cc213bb30a59feaaef15432ff70a0d64d3512ca18b5", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S. ", "start_char_idx": 1325, "end_char_idx": 1524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "747068e3-cf15-436d-a008-ccdc2c0d6a29": {"__data__": {"id_": "747068e3-cf15-436d-a008-ccdc2c0d6a29", "embedding": null, "metadata": {"window": "Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n", "original_text": "Pharmaceutical segment.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec55db0e-b7ee-4fc7-b49f-f091d34ec653", "node_type": "1", "metadata": {"window": "Now to a discussion of our adjusted earnings results for the second quarter, starting with our consolidated results \non slide 4.  Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year. ", "original_text": "Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c5ca0c99d3470755c66918d54d4a02cd828c895bfa4aa2c0feaa45d6fef01a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe853fa1-eafa-4b3e-a2cb-c719ffddde0c", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n", "original_text": "Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n"}, "hash": "6d458ba6016241af634a3fa0af99171a5e0eebe1d085427d5e1ba56d8207e6bf", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment.  \n \n", "start_char_idx": 1524, "end_char_idx": 1552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe853fa1-eafa-4b3e-a2cb-c719ffddde0c": {"__data__": {"id_": "fe853fa1-eafa-4b3e-a2cb-c719ffddde0c", "embedding": null, "metadata": {"window": "Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n", "original_text": "Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "747068e3-cf15-436d-a008-ccdc2c0d6a29", "node_type": "1", "metadata": {"window": "Consolidated revenues of $60.8 billion wer e up 6% compared to the prior year, primarily due to market \ngrowth and higher volumes from retail national account customers in our U.S.  Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n", "original_text": "Pharmaceutical segment.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5fd3b50ced73711cb496040d257c1590e68050b37cc5f130d9cd7cabf17bb80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ada048cf-2705-4ff6-92a9-a04d82a13d79", "node_type": "1", "metadata": {"window": "Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust. ", "original_text": "Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year. "}, "hash": "d338e749ecb3ab27ddba52a9aed2bb9a556c3e90f3792bd91bc75a5b3f6e7576", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n", "start_char_idx": 1552, "end_char_idx": 1744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ada048cf-2705-4ff6-92a9-a04d82a13d79": {"__data__": {"id_": "ada048cf-2705-4ff6-92a9-a04d82a13d79", "embedding": null, "metadata": {"window": "Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust. ", "original_text": "Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe853fa1-eafa-4b3e-a2cb-c719ffddde0c", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.  Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n", "original_text": "Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be25cd2d8c92313eb97768f3a9dcaeaeda4077425774a1657cbc33fb303b1f60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dc37204-f1a1-48e4-ba66-750c16b41da7", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n", "original_text": "When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n"}, "hash": "1077b188fe7e5732fd64e90967f6e7e3e31c6617c4fd0d385dbc2238d04701a8", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year. ", "start_char_idx": 1744, "end_char_idx": 1850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1dc37204-f1a1-48e4-ba66-750c16b41da7": {"__data__": {"id_": "1dc37204-f1a1-48e4-ba66-750c16b41da7", "embedding": null, "metadata": {"window": "Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n", "original_text": "When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ada048cf-2705-4ff6-92a9-a04d82a13d79", "node_type": "1", "metadata": {"window": "Adjusted \ngross profit increased 4% year -over-year, driven by growth in our Medical -Surgical seg ment, which saw increased \ndemand for COVID -19 tests and higher volumes from customers in the U.S.  Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust. ", "original_text": "Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b0bd97a78dc9dac88877f8e3e06a05f2fc9fc81862c71411b1d6bb876c3d6c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ac813a9-65a9-49b0-bbfd-48b1968c8d78", "node_type": "1", "metadata": {"window": "Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment. ", "original_text": "Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n"}, "hash": "2e5378fceef959c1ab7c24003d6e943a94a5df123d91c5ed2adc1931476e31f5", "class_name": "RelatedNodeInfo"}}, "text": "When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n", "start_char_idx": 1850, "end_char_idx": 2052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ac813a9-65a9-49b0-bbfd-48b1968c8d78": {"__data__": {"id_": "0ac813a9-65a9-49b0-bbfd-48b1968c8d78", "embedding": null, "metadata": {"window": "Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment. ", "original_text": "Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1dc37204-f1a1-48e4-ba66-750c16b41da7", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.  \n \n Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n", "original_text": "When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37b152f82f3c4e6843e0a2918b3935b97aa94f3ebe1baf296aaba1fc5e5f5a5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acff1dbf-0995-492d-9efb-76c3340225b7", "node_type": "1", "metadata": {"window": "Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n", "original_text": "Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust. "}, "hash": "9d89b754f53383e710869da84c470c08b38bc0f8f1016ee911e3965dd9925f87", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n", "start_char_idx": 2052, "end_char_idx": 2286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acff1dbf-0995-492d-9efb-76c3340225b7": {"__data__": {"id_": "acff1dbf-0995-492d-9efb-76c3340225b7", "embedding": null, "metadata": {"window": "Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n", "original_text": "Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ac813a9-65a9-49b0-bbfd-48b1968c8d78", "node_type": "1", "metadata": {"window": "Adjusted operating expenses increased 5% year -over-year, led by increased technology spend, which was \npartially offset by reduction i n operating expenses due to the impact of COVID -19. \n \n Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment. ", "original_text": "Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df2ca8ee38a8898c59f4b233bda8e26b8a7cb7a940729ece994346d15a3c14ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7098573-2d39-4f8d-8f0e-1b0b80e519d9", "node_type": "1", "metadata": {"window": "When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n", "original_text": "During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n"}, "hash": "80a5f23d4a60e039a950f4267e1aa0f37ea4e92141a54e4b03bdfc9179901048", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust. ", "start_char_idx": 2286, "end_char_idx": 2412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7098573-2d39-4f8d-8f0e-1b0b80e519d9": {"__data__": {"id_": "a7098573-2d39-4f8d-8f0e-1b0b80e519d9", "embedding": null, "metadata": {"window": "When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n", "original_text": "During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acff1dbf-0995-492d-9efb-76c3340225b7", "node_type": "1", "metadata": {"window": "Adjusted operating profit was $953 million for the quarter, an increase of 3% compared to the prior year.  When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n", "original_text": "Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca5e8e346b5523ce57366c6cd7d83f9773b820120f646b152af8a5e67007c353", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd52d963-2443-432a-b2da-935c79b52bd8", "node_type": "1", "metadata": {"window": "Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "original_text": "Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment. "}, "hash": "fd9f957a704e52d97cab3adbad91844155384fa0f70d61d57e2817ceedc3f265", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n", "start_char_idx": 2412, "end_char_idx": 2588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd52d963-2443-432a-b2da-935c79b52bd8": {"__data__": {"id_": "cd52d963-2443-432a-b2da-935c79b52bd8", "embedding": null, "metadata": {"window": "Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "original_text": "Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7098573-2d39-4f8d-8f0e-1b0b80e519d9", "node_type": "1", "metadata": {"window": "When \nexcluding the $39 million contributed by Change Healthcare in the prior year, which was prev iously recorded in \nOther, adjusted operating profit grew 8%, which was ahead of our expectations.  \n \n Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n", "original_text": "During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4292ddd1cf73521219779bdf1b46da26e0b0ffad79abcda8ff4caeacaa48a7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d18ef9c3-5379-4c05-8d95-af610a441cbd", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "original_text": "These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n"}, "hash": "6cab3ab612b9e3b8aa2d57902242f16cf64c5ad80daa3826d46ae90a22b538b6", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment. ", "start_char_idx": 2588, "end_char_idx": 2850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d18ef9c3-5379-4c05-8d95-af610a441cbd": {"__data__": {"id_": "d18ef9c3-5379-4c05-8d95-af610a441cbd", "embedding": null, "metadata": {"window": "Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "original_text": "These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd52d963-2443-432a-b2da-935c79b52bd8", "node_type": "1", "metadata": {"window": "Interest expense was $50 million in the quarter, a decline of 22% compared to the prior year due to lower \ncommercial paper balances and we now expect interes t expense in fiscal 2021 to be between $220 million and \n$240 million.  \n \n Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "original_text": "Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment. ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b1063eb997e096ee817ec97a5ff1539b7ba9094a78e85e1dfdcd5f69398778a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11583a9d-d48c-4db2-9a1b-fd99cae37e40", "node_type": "1", "metadata": {"window": "During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "original_text": "Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n"}, "hash": "4672f1fccd7c24702242539974c65da0e3220455ef7d517251ef800dddd3b7da", "class_name": "RelatedNodeInfo"}}, "text": "These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n", "start_char_idx": 2850, "end_char_idx": 2988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11583a9d-d48c-4db2-9a1b-fd99cae37e40": {"__data__": {"id_": "11583a9d-d48c-4db2-9a1b-fd99cae37e40", "embedding": null, "metadata": {"window": "During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "original_text": "Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d18ef9c3-5379-4c05-8d95-af610a441cbd", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 7.2% for the quarter, in the range that we indicated on our first quarter earnings call in \nAugust.  During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "original_text": "These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "147e3eec579b6809f5ba3fb7819c1fe89dac62792715ee87cc7c89a66581224b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29c9cf25-4f6b-46fb-aaaf-5960870387d8", "node_type": "1", "metadata": {"window": "Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "original_text": "Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n "}, "hash": "10f380d726519bf7fbd651ef41ef1f1ce785bd751bb50a3c9bbc5f59b5cf8bfd", "class_name": "RelatedNodeInfo"}}, "text": "Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n", "start_char_idx": 2988, "end_char_idx": 3189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29c9cf25-4f6b-46fb-aaaf-5960870387d8": {"__data__": {"id_": "29c9cf25-4f6b-46fb-aaaf-5960870387d8", "embedding": null, "metadata": {"window": "Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "original_text": "Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2989bb78-334d-425a-9ec3-3e667aa42e51", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d923daa3cf658221a352f3700279a7005ffb6a0023fec46034e09007cea4cbfa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11583a9d-d48c-4db2-9a1b-fd99cae37e40", "node_type": "1", "metadata": {"window": "During the quarter, we realized discrete tax benefits of app roximately $129 million and we continue to \nassume a full -year adjusted tax rate of approximately 18% to 20%.  \n \n Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "original_text": "Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e367be75ae0bb2b6e32e6522b891f4303b834218af72619a39b5f6a56efa8ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb452796-1e02-4c2e-96ef-a1a47e4a66be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S. ", "original_text": "McKesson Corp.  "}, "hash": "2015894168ab590208c83d05f38332a80d5edc80d4a632ada38d333c2f90bd2f", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "start_char_idx": 3189, "end_char_idx": 3525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb452796-1e02-4c2e-96ef-a1a47e4a66be": {"__data__": {"id_": "cb452796-1e02-4c2e-96ef-a1a47e4a66be", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29c9cf25-4f6b-46fb-aaaf-5960870387d8", "node_type": "1", "metadata": {"window": "Second quarter adjusted earnings per diluted share was $4.80, which was up 33% in the quarter compared to the \nprior year, driven by a lower share count, a lower tax rate, and operating performance, led by the growth in the \nMedical -Surgical Solutions segment.  These items were partially offset by the lapping of the prior -year contribution \nfrom the company's investment in Change Healthcare.  \n \n Second qua rter adjusted earnings per diluted share also includes net pre -tax gains of approximately $49 million or \n$0.22 per diluted share associated with McKesson Ventures' equity investments.  \n \n Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "original_text": "Wrapping up our consolidated results, second quarter diluted weighted a verage shares were 163 million, a \ndecrease of 11% year -over-year, which was driven by the successful exit of our investment in Change \nHealthcare, lowering our shares outstanding by approximately 15.4 million shares and due to prior -year share \nrepurchases.  \n ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "945d55d1e28511f1e6d708f61ed3ccac4e85415f3ff8b5ded7988bd0a8babb5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf683daa-014e-48b4-aeef-f5d291c1a8d4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9. "}, "hash": "4691f51d8fba008d734ea2e1a1808a306ce8c051197cb9a01180af1adfae917d", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf683daa-014e-48b4-aeef-f5d291c1a8d4": {"__data__": {"id_": "cf683daa-014e-48b4-aeef-f5d291c1a8d4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb452796-1e02-4c2e-96ef-a1a47e4a66be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "684e3fd89164f10d49e04e7fe42a8603b0825724fe90589103df69426a288802", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e686490-6e76-4e59-805a-845f9cd23c9f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S. ", "original_text": "As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure. "}, "hash": "c5c7f308beef8d14efde340dd8548c4c54b971c1f17e0897763f906c4dc1b939", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9. ", "start_char_idx": 16, "end_char_idx": 277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e686490-6e76-4e59-805a-845f9cd23c9f": {"__data__": {"id_": "0e686490-6e76-4e59-805a-845f9cd23c9f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S. ", "original_text": "As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf683daa-014e-48b4-aeef-f5d291c1a8d4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba3c4fa9974d764a83c5c8e0dcebcc682fc0e9a6358632e8522f4f6ab904a3d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca99d896-b0e4-4f85-8952-16425e808a94", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n", "original_text": "We now report \nresults in four reportable seg ments, which include U.S. "}, "hash": "6dca5b2aadc1767fb4165bdc653a2acdbd7971823bef9bcf4efb57c6f67bba5f", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure. ", "start_char_idx": 277, "end_char_idx": 393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca99d896-b0e4-4f85-8952-16425e808a94": {"__data__": {"id_": "ca99d896-b0e4-4f85-8952-16425e808a94", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n", "original_text": "We now report \nresults in four reportable seg ments, which include U.S. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e686490-6e76-4e59-805a-845f9cd23c9f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S. ", "original_text": "As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "475faba66650d0654f59353684d4004d051f660af98cfd484f6918c71f2fe74c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc333dbc-39c7-4e4c-9f8f-3dafc3f6283a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels. ", "original_text": "Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n"}, "hash": "3a8a244d315e8e9b8e02649da3b4ba330efb213929f54087fc9c80c9eaf6e102", "class_name": "RelatedNodeInfo"}}, "text": "We now report \nresults in four reportable seg ments, which include U.S. ", "start_char_idx": 393, "end_char_idx": 465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc333dbc-39c7-4e4c-9f8f-3dafc3f6283a": {"__data__": {"id_": "fc333dbc-39c7-4e4c-9f8f-3dafc3f6283a", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels. ", "original_text": "Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca99d896-b0e4-4f85-8952-16425e808a94", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n", "original_text": "We now report \nresults in four reportable seg ments, which include U.S. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c244c067a502f0159fe1ad0ee88c11e144650f73b0055780bcb877630a0bb4b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44509b68-5be1-4883-9501-91f6817d8950", "node_type": "1", "metadata": {"window": "As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives. ", "original_text": "And I'll start with U.S. "}, "hash": "bda27926fd99e71c191b7ed7cc5a43f4e5c7ad74d7fd9070220b3df07daadbd1", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n", "start_char_idx": 465, "end_char_idx": 577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44509b68-5be1-4883-9501-91f6817d8950": {"__data__": {"id_": "44509b68-5be1-4883-9501-91f6817d8950", "embedding": null, "metadata": {"window": "As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives. ", "original_text": "And I'll start with U.S. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc333dbc-39c7-4e4c-9f8f-3dafc3f6283a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels. ", "original_text": "Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c091c107ce28e0fb10b173509de7f3c4745e65ae541808598bed6ff22bee9747", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97e1b638-1ec4-43bf-b6e7-5dab6631dd54", "node_type": "1", "metadata": {"window": "We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n", "original_text": "Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n"}, "hash": "9382b8c8ace8470cfc48e556d963c823c559586341ffc4148f3f51a7549237c7", "class_name": "RelatedNodeInfo"}}, "text": "And I'll start with U.S. ", "start_char_idx": 577, "end_char_idx": 602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97e1b638-1ec4-43bf-b6e7-5dab6631dd54": {"__data__": {"id_": "97e1b638-1ec4-43bf-b6e7-5dab6631dd54", "embedding": null, "metadata": {"window": "We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n", "original_text": "Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44509b68-5be1-4883-9501-91f6817d8950", "node_type": "1", "metadata": {"window": "As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives. ", "original_text": "And I'll start with U.S. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88df865cb1f725d77ce4d2f56c08c9294a37e025ae43a009a6d69cf3138744ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "628c309b-fd15-499d-a52a-8a1a39769bfb", "node_type": "1", "metadata": {"window": "Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9. ", "original_text": "In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels. "}, "hash": "ac1e7a23b37bd9ae7b319673f475b878dae60691dc34d974cf1290563f4269c0", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n", "start_char_idx": 602, "end_char_idx": 784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "628c309b-fd15-499d-a52a-8a1a39769bfb": {"__data__": {"id_": "628c309b-fd15-499d-a52a-8a1a39769bfb", "embedding": null, "metadata": {"window": "Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9. ", "original_text": "In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97e1b638-1ec4-43bf-b6e7-5dab6631dd54", "node_type": "1", "metadata": {"window": "We now report \nresults in four reportable seg ments, which include U.S.  Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n", "original_text": "Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e086fb4376a94b09ccfe9a85add29bfde13d459b3e48c45f6c7b8b8d249274ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36f383c0-9425-49c4-a407-ced748b5eaaa", "node_type": "1", "metadata": {"window": "And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year. ", "original_text": "Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives. "}, "hash": "bb8a883d3bed9a1b328260099e366a66a19f8f4cfa5b20a71b8917c10bec3a40", "class_name": "RelatedNodeInfo"}}, "text": "In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels. ", "start_char_idx": 784, "end_char_idx": 905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36f383c0-9425-49c4-a407-ced748b5eaaa": {"__data__": {"id_": "36f383c0-9425-49c4-a407-ced748b5eaaa", "embedding": null, "metadata": {"window": "And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year. ", "original_text": "Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "628c309b-fd15-499d-a52a-8a1a39769bfb", "node_type": "1", "metadata": {"window": "Pharmaceutical, International, Medical -Surgical Solutions, \nand Prescription Technology Solutions or RxTS.  \n \n And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9. ", "original_text": "In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "285fe6bae113917cef550349c724be9d926467df9bcbead4d53877a2134dd355", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c5716e1-01ad-4ae7-942c-26fd27d46f23", "node_type": "1", "metadata": {"window": "Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year. ", "original_text": "And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n"}, "hash": "8dc0666a8646e67dde135c4a3d49523953de4c49e03a56cca0f6e9355a7d42e2", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives. ", "start_char_idx": 905, "end_char_idx": 1088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c5716e1-01ad-4ae7-942c-26fd27d46f23": {"__data__": {"id_": "1c5716e1-01ad-4ae7-942c-26fd27d46f23", "embedding": null, "metadata": {"window": "Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year. ", "original_text": "And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36f383c0-9425-49c4-a407-ced748b5eaaa", "node_type": "1", "metadata": {"window": "And I'll start with U.S.  Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year. ", "original_text": "Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3466468db9d14d810cf3fc5cc3f76f6535255eec3afe6546df9c4d4f38e0ec8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ae56136-fb7b-4aca-9b31-2e10ebeb198a", "node_type": "1", "metadata": {"window": "In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n", "original_text": "Next,  on to International, where revenues were $9. "}, "hash": "0d9674f901e80f93794cd532e4c9eba69f1e1e00d21b6c369c3cb9ae81559527", "class_name": "RelatedNodeInfo"}}, "text": "And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n", "start_char_idx": 1088, "end_char_idx": 1220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ae56136-fb7b-4aca-9b31-2e10ebeb198a": {"__data__": {"id_": "2ae56136-fb7b-4aca-9b31-2e10ebeb198a", "embedding": null, "metadata": {"window": "In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n", "original_text": "Next,  on to International, where revenues were $9. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c5716e1-01ad-4ae7-942c-26fd27d46f23", "node_type": "1", "metadata": {"window": "Pharmaceutical, where revenues were $48.1 billion, up 5%, driven by market growth and \nhigher retai l national account volumes, partially offset by brand to generic conversions.  \n \n In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year. ", "original_text": "And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b81ff8f4d5b598bcdb38e02dcb6b4da2fb2fdb4b88fddc372ef23a8b9e516481", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19e4bad6-1ee8-47ed-add4-b296aed2722a", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion. ", "original_text": "5 billion, an increase of 2% year -over-year. "}, "hash": "997b3fab74446a5ec54ea10f2e4f3e605ebd361ea724b2a67ea8ea755a46bed4", "class_name": "RelatedNodeInfo"}}, "text": "Next,  on to International, where revenues were $9. ", "start_char_idx": 1220, "end_char_idx": 1272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19e4bad6-1ee8-47ed-add4-b296aed2722a": {"__data__": {"id_": "19e4bad6-1ee8-47ed-add4-b296aed2722a", "embedding": null, "metadata": {"window": "Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion. ", "original_text": "5 billion, an increase of 2% year -over-year. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ae56136-fb7b-4aca-9b31-2e10ebeb198a", "node_type": "1", "metadata": {"window": "In our specialty businesses, particularly in our US oncology network, we saw patient visits approach pre -COVID \nlevels.  Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n", "original_text": "Next,  on to International, where revenues were $9. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db6331745aab7f7099641b0145fd13a12b68c5e08558a825f02604cde978218b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83de34a6-a573-4ef4-b851-44715005d905", "node_type": "1", "metadata": {"window": "And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19. ", "original_text": "On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year. "}, "hash": "4876ba67a96819887dcd4f3d393036ac310241fdde282d18a216fd564acfe39e", "class_name": "RelatedNodeInfo"}}, "text": "5 billion, an increase of 2% year -over-year. ", "start_char_idx": 1272, "end_char_idx": 1318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83de34a6-a573-4ef4-b851-44715005d905": {"__data__": {"id_": "83de34a6-a573-4ef4-b851-44715005d905", "embedding": null, "metadata": {"window": "And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19. ", "original_text": "On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19e4bad6-1ee8-47ed-add4-b296aed2722a", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 3% to $658 million, dr iven by growth in specialty, partially offset by \nhigher operating expenses in support of our strategic growth initiatives.  And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion. ", "original_text": "5 billion, an increase of 2% year -over-year. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0871cb574b6e84c66162b4bc5a75de35d093101c201c66a7897ce20672450ee0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "207d11e0-7b96-44c8-9089-30b630e9aee5", "node_type": "1", "metadata": {"window": "Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n", "original_text": "This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n"}, "hash": "ab75b550adbbd88ce6488d736fd4fb227f2a985122d022cbb8de06d7d1a7b87b", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year. ", "start_char_idx": 1318, "end_char_idx": 1556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "207d11e0-7b96-44c8-9089-30b630e9aee5": {"__data__": {"id_": "207d11e0-7b96-44c8-9089-30b630e9aee5", "embedding": null, "metadata": {"window": "Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n", "original_text": "This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83de34a6-a573-4ef4-b851-44715005d905", "node_type": "1", "metadata": {"window": "And the segment adjusted operating \nmargin for the second quarter was 137 basis points, which was a decrease of 3 basis points.  \n \n Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19. ", "original_text": "On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cff223eb127cc6dec3f742ee8a2f3003dd250d132ed919c74e768c1ff3a93cdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38926973-85ea-4c85-ab65-f2558b1263d1", "node_type": "1", "metadata": {"window": "5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance. ", "original_text": "Adjusted operating profit increased 20% year -over-year to $116 mi llion. "}, "hash": "142a2729e9bf79768987dc3c93128ff712d8237c622f80fd2a7889b3c7f8a570", "class_name": "RelatedNodeInfo"}}, "text": "This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n", "start_char_idx": 1556, "end_char_idx": 1682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38926973-85ea-4c85-ab65-f2558b1263d1": {"__data__": {"id_": "38926973-85ea-4c85-ab65-f2558b1263d1", "embedding": null, "metadata": {"window": "5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance. ", "original_text": "Adjusted operating profit increased 20% year -over-year to $116 mi llion. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "207d11e0-7b96-44c8-9089-30b630e9aee5", "node_type": "1", "metadata": {"window": "Next,  on to International, where revenues were $9.  5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n", "original_text": "This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a0f6b36c8aa1d271139ff93ad14344c753ba5e7b87a22c68c60b8d0a96e1145", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f78c7d7-f9ad-4d06-96e3-25eacf310247", "node_type": "1", "metadata": {"window": "On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%. ", "original_text": "On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19. "}, "hash": "5f5f2ad14e8757d7473f06215737f7b244a9384942f961a6c36e58c65b13205c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit increased 20% year -over-year to $116 mi llion. ", "start_char_idx": 1682, "end_char_idx": 1756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f78c7d7-f9ad-4d06-96e3-25eacf310247": {"__data__": {"id_": "9f78c7d7-f9ad-4d06-96e3-25eacf310247", "embedding": null, "metadata": {"window": "On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%. ", "original_text": "On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38926973-85ea-4c85-ab65-f2558b1263d1", "node_type": "1", "metadata": {"window": "5 billion, an increase of 2% year -over-year.  On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance. ", "original_text": "Adjusted operating profit increased 20% year -over-year to $116 mi llion. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f70fb0a7588a90689272e59fc446b766bf2eace76ed9a98496f48994c3e517e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3785c2f2-5351-4f11-bb22-f01099072f3a", "node_type": "1", "metadata": {"window": "This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business. ", "original_text": "The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n"}, "hash": "ef1f216664add9061d4b462e933cfa8e42cbe18456bae5d906b0d6c4ae9166f5", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19. ", "start_char_idx": 1756, "end_char_idx": 1987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3785c2f2-5351-4f11-bb22-f01099072f3a": {"__data__": {"id_": "3785c2f2-5351-4f11-bb22-f01099072f3a", "embedding": null, "metadata": {"window": "This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business. ", "original_text": "The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f78c7d7-f9ad-4d06-96e3-25eacf310247", "node_type": "1", "metadata": {"window": "On an FX -adjusted \nbasis, revenues decreased 1%, primarily driven by lower volumes in the Canadian pharmaceutical distribution \nbusiness, which was largely due to the exit of an unprofitable customer at the beginning of the fiscal year.  This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%. ", "original_text": "On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "652b6a36b0eb68574613c5d3df775fe3ccbd3a71163906d200a7ba7fec4da09a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e78f5308-0232-455c-938a-084dc27583f4", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n", "original_text": "As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance. "}, "hash": "73850fe7abf8f47ee40963f8978e994a9ff3e66f3f17d9a0d5dd447454d66183", "class_name": "RelatedNodeInfo"}}, "text": "The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n", "start_char_idx": 1987, "end_char_idx": 2118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e78f5308-0232-455c-938a-084dc27583f4": {"__data__": {"id_": "e78f5308-0232-455c-938a-084dc27583f4", "embedding": null, "metadata": {"window": "Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n", "original_text": "As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3785c2f2-5351-4f11-bb22-f01099072f3a", "node_type": "1", "metadata": {"window": "This \nwas partially offset by higher volumes in the European pharmaceutical distribution and retail pharmacy \nbusinesses.  \n \n Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business. ", "original_text": "The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb8e9dab6f19dea864a7154089003e4ab7128347a0016c41e35be7fb52b31840", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8dd868b-653d-4501-9419-f090c2b45494", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions. ", "original_text": "WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%. "}, "hash": "f16d2d93851efbe36372c77fcf6da43488455e7b75900fbbde489430d134c13a", "class_name": "RelatedNodeInfo"}}, "text": "As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance. ", "start_char_idx": 2118, "end_char_idx": 2301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8dd868b-653d-4501-9419-f090c2b45494": {"__data__": {"id_": "f8dd868b-653d-4501-9419-f090c2b45494", "embedding": null, "metadata": {"window": "On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions. ", "original_text": "WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e78f5308-0232-455c-938a-084dc27583f4", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 20% year -over-year to $116 mi llion.  On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n", "original_text": "As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2b0e01dbea2ff64deec96e6640777e90ff1ccd8c67a027bc346bf22c1a03600", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24332a6a-5bf3-487a-bf35-d4268fc80e1e", "node_type": "1", "metadata": {"window": "The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter. ", "original_text": "Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business. "}, "hash": "ad8c1f27848f0aaa7f31c9a0fd4bc1d858e9235e48bb46bccf4f60f8b967ee31", "class_name": "RelatedNodeInfo"}}, "text": "WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%. ", "start_char_idx": 2301, "end_char_idx": 2399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24332a6a-5bf3-487a-bf35-d4268fc80e1e": {"__data__": {"id_": "24332a6a-5bf3-487a-bf35-d4268fc80e1e", "embedding": null, "metadata": {"window": "The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter. ", "original_text": "Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8dd868b-653d-4501-9419-f090c2b45494", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, adjusted \noperating profit increased 19% to $115 million, driven by lower European operating expenses, including continued \ncost reduction initiatives and cost mitigation efforts in response to COVID -19.  The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions. ", "original_text": "WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1d6b79195080075ae14fb471d36e902e00962234330a970354da04e45a54fca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "235109be-f4db-4c06-b934-3a34f05656a6", "node_type": "1", "metadata": {"window": "As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n", "original_text": "We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n"}, "hash": "6d9ee74930b7f2df78881be50e31fde9d59d8ba5d811f423347df17919bec712", "class_name": "RelatedNodeInfo"}}, "text": "Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business. ", "start_char_idx": 2399, "end_char_idx": 2507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "235109be-f4db-4c06-b934-3a34f05656a6": {"__data__": {"id_": "235109be-f4db-4c06-b934-3a34f05656a6", "embedding": null, "metadata": {"window": "As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n", "original_text": "We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24332a6a-5bf3-487a-bf35-d4268fc80e1e", "node_type": "1", "metadata": {"window": "The segment adjusted o perating \nmargin for the second quarter was 122 basis points, which was an increase of 18 basis points.  \n \n As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter. ", "original_text": "Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f509809404a58a4efffe92cdec9f18a1d4fbc6b7b6e4b65f11d823cba6d9d5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "358d0956-7a0c-4cb8-a410-18de14ba5e1e", "node_type": "1", "metadata": {"window": "WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n", "original_text": "Moving on to Medical -Surgical Solutions. "}, "hash": "d2bf349b4466ef91e4b74aaa77475b6269697dc8b42781d8898cc92e6fda4494", "class_name": "RelatedNodeInfo"}}, "text": "We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n", "start_char_idx": 2507, "end_char_idx": 2623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "358d0956-7a0c-4cb8-a410-18de14ba5e1e": {"__data__": {"id_": "358d0956-7a0c-4cb8-a410-18de14ba5e1e", "embedding": null, "metadata": {"window": "WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n", "original_text": "Moving on to Medical -Surgical Solutions. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "235109be-f4db-4c06-b934-3a34f05656a6", "node_type": "1", "metadata": {"window": "As Brian mentioned in his remarks, yesterday, we announced the completed contribution of our German \nwholesale business to a newly formed joint venture with Walgreens Boots Alliance.  WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n", "original_text": "We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f0dcf951237c17d8b5da7e8c0e8ce58a599440b76ed8d467821c83583d7275d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcff213f-5433-4515-a35f-f7317fb49cf2", "node_type": "1", "metadata": {"window": "Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses. ", "original_text": "We continue to see to see trends improve during the quarter. "}, "hash": "774614d90a77d4a29c543191601dad592baa132ccb0fcf2baf2efb6eff523073", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to Medical -Surgical Solutions. ", "start_char_idx": 2623, "end_char_idx": 2665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcff213f-5433-4515-a35f-f7317fb49cf2": {"__data__": {"id_": "fcff213f-5433-4515-a35f-f7317fb49cf2", "embedding": null, "metadata": {"window": "Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses. ", "original_text": "We continue to see to see trends improve during the quarter. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "358d0956-7a0c-4cb8-a410-18de14ba5e1e", "node_type": "1", "metadata": {"window": "WBA now holds a 70% \ncontrolling equity interest in the JV, and McKesson holds the remaining 30%.  Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n", "original_text": "Moving on to Medical -Surgical Solutions. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8d5aa48a68c5cf6aee0cffda756b06e34e308f7f03940d453337b8908901a10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35552375-67ac-4520-aff3-5dbfd621ba28", "node_type": "1", "metadata": {"window": "We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business. ", "original_text": "According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n"}, "hash": "daf700d21fd6bdfa4bd33c1e053d7c56ef5c053fa549be05e3e04be5ca0a7d72", "class_name": "RelatedNodeInfo"}}, "text": "We continue to see to see trends improve during the quarter. ", "start_char_idx": 2665, "end_char_idx": 2726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35552375-67ac-4520-aff3-5dbfd621ba28": {"__data__": {"id_": "35552375-67ac-4520-aff3-5dbfd621ba28", "embedding": null, "metadata": {"window": "We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business. ", "original_text": "According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcff213f-5433-4515-a35f-f7317fb49cf2", "node_type": "1", "metadata": {"window": "Going forward, McKesson will no \nlonger consolidate the operating results of its German wholesale business.  We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses. ", "original_text": "We continue to see to see trends improve during the quarter. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c85f5aec22b561452381194a16e695a1aeb131cd2de1208fcbd63932407f3bf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f86cfa2-2645-49e9-8cd9-bafd6795adce", "node_type": "1", "metadata": {"window": "Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n", "original_text": "Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n"}, "hash": "18e6684f8b4836919e119f88da9f7083da71b5d33e2487ee086e269d373d4a2f", "class_name": "RelatedNodeInfo"}}, "text": "According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n", "start_char_idx": 2726, "end_char_idx": 2849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f86cfa2-2645-49e9-8cd9-bafd6795adce": {"__data__": {"id_": "5f86cfa2-2645-49e9-8cd9-bafd6795adce", "embedding": null, "metadata": {"window": "Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n", "original_text": "Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35552375-67ac-4520-aff3-5dbfd621ba28", "node_type": "1", "metadata": {"window": "We'll recognize the 3 0% share of the \nJV earnings and losses in other income within our International segment.  \n \n Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business. ", "original_text": "According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae54e03b9ba78d15bd13995d88e5a752ac87eba59bfec4dc3ed18c14d81b30cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "385e4aee-1f66-4237-afa2-2e8194fe24e2", "node_type": "1", "metadata": {"window": "We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions. ", "original_text": "Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses. "}, "hash": "8f26dc59eaf3c978d8cf4f3871f657d51b789399a461e6cd4b123e7d22c9c099", "class_name": "RelatedNodeInfo"}}, "text": "Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n", "start_char_idx": 2849, "end_char_idx": 3050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "385e4aee-1f66-4237-afa2-2e8194fe24e2": {"__data__": {"id_": "385e4aee-1f66-4237-afa2-2e8194fe24e2", "embedding": null, "metadata": {"window": "We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions. ", "original_text": "Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f86cfa2-2645-49e9-8cd9-bafd6795adce", "node_type": "1", "metadata": {"window": "Moving on to Medical -Surgical Solutions.  We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n", "original_text": "Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a67e8fc736f6b1b97ee74b58cf191ff4905520e1aaeefc6e217dc350f33ac585", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af591777-70f0-43e7-8ce7-93bbcc37218b", "node_type": "1", "metadata": {"window": "According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends. ", "original_text": "Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business. "}, "hash": "0e7c169956848e1af8815df5df9bd0c9d72157f1c7d8661e13a49119a9696946", "class_name": "RelatedNodeInfo"}}, "text": "Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses. ", "start_char_idx": 3050, "end_char_idx": 3236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af591777-70f0-43e7-8ce7-93bbcc37218b": {"__data__": {"id_": "af591777-70f0-43e7-8ce7-93bbcc37218b", "embedding": null, "metadata": {"window": "According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends. ", "original_text": "Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "385e4aee-1f66-4237-afa2-2e8194fe24e2", "node_type": "1", "metadata": {"window": "We continue to see to see trends improve during the quarter.  According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions. ", "original_text": "Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6693302426f327eddfe6d20e3f5c7ec8941cb700c0ec1b425cd1961dbe3ed0b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8714f82c-f055-473a-864f-73be59998030", "node_type": "1", "metadata": {"window": "Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n", "original_text": "And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n"}, "hash": "300604d4fd6568a78bea7ac0decaba82e415d335dba82a2a14c59de674ceeaa1", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business. ", "start_char_idx": 3236, "end_char_idx": 3409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8714f82c-f055-473a-864f-73be59998030": {"__data__": {"id_": "8714f82c-f055-473a-864f-73be59998030", "embedding": null, "metadata": {"window": "Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n", "original_text": "And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af591777-70f0-43e7-8ce7-93bbcc37218b", "node_type": "1", "metadata": {"window": "According \nto an October IQVIA report, primary care patient visit s reached approximately 91% of the pre -COVID baseline. \n Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends. ", "original_text": "Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "646d0dfaa5c98271401f0263356247201d92e04f44502b33ab1952f2b38731f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afee8698-a687-42da-8a9a-5a67060b6ec8", "node_type": "1", "metadata": {"window": "Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth. ", "original_text": "Next, Prescription Technology Solutions. "}, "hash": "6de4f3cb8d2d526586543b03f726392fec1d6524753826c8c0d934e8e00ae030", "class_name": "RelatedNodeInfo"}}, "text": "And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n", "start_char_idx": 3409, "end_char_idx": 3510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afee8698-a687-42da-8a9a-5a67060b6ec8": {"__data__": {"id_": "afee8698-a687-42da-8a9a-5a67060b6ec8", "embedding": null, "metadata": {"window": "Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth. ", "original_text": "Next, Prescription Technology Solutions. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8714f82c-f055-473a-864f-73be59998030", "node_type": "1", "metadata": {"window": "Our Medical -Surgical business continues to play a vital role in the COVID -19 pandemic, ramping up to meet \ncustomer demand with our delivery of COVID -19 tests and personal protective equipment.  \n \n Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n", "original_text": "And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9785291bc4658d4c20139e76055ba01eacaeb7e4c56ea543e0f6b704d8bda5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "004f8e69-16b9-41f3-adad-47b7b657a1cb", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth.  We expect to continu e to invest in the expansion ", "original_text": "Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends. "}, "hash": "4beb0434fcbedb9b2154e1bf610fdfffe42b0a7eb925e8c7b7bac34cf31cd14b", "class_name": "RelatedNodeInfo"}}, "text": "Next, Prescription Technology Solutions. ", "start_char_idx": 3510, "end_char_idx": 3551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "004f8e69-16b9-41f3-adad-47b7b657a1cb": {"__data__": {"id_": "004f8e69-16b9-41f3-adad-47b7b657a1cb", "embedding": null, "metadata": {"window": "Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth.  We expect to continu e to invest in the expansion ", "original_text": "Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afee8698-a687-42da-8a9a-5a67060b6ec8", "node_type": "1", "metadata": {"window": "Revenue s were $2.5 billion in the quarter, up 23%, driven by higher volumes of COVID -19 tests and personal \nprotective equipment in both our primary care and extended care businesses.  Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth. ", "original_text": "Next, Prescription Technology Solutions. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c42d9ece743ec54ac374b7b73d122bd60e81c47c306c57caea98a5f033817f26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cc7f4eb-9a05-4043-930c-da1977280c55", "node_type": "1", "metadata": {"window": "And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth.  We expect to continu e to invest in the expansion ", "original_text": "Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n"}, "hash": "279b1cb2e9cc74986a7e75fb44f2a6bb8034745b48137259d487872aaac67d53", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends. ", "start_char_idx": 3551, "end_char_idx": 3716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cc7f4eb-9a05-4043-930c-da1977280c55": {"__data__": {"id_": "9cc7f4eb-9a05-4043-930c-da1977280c55", "embedding": null, "metadata": {"window": "And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth.  We expect to continu e to invest in the expansion ", "original_text": "Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "004f8e69-16b9-41f3-adad-47b7b657a1cb", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased \n27% to $210 million, driven by demand for CO VID-19 tests, early flu season volumes and contributions from the \nextended care business.  And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth.  We expect to continu e to invest in the expansion ", "original_text": "Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00b07954b26cfe52e41bd06fe400c4c54df5f98ad1cea7a98d88144d6fb67633", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d0eb489-fd65-4005-a43a-2b68cf4e6f91", "node_type": "1", "metadata": {"window": "Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth.  We expect to continu e to invest in the expansion ", "original_text": "For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth. "}, "hash": "9bb7c27b90aff1f358989452960d8c6a021da9b79ea4d7367e0f354ea48f72cf", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n", "start_char_idx": 3716, "end_char_idx": 3898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d0eb489-fd65-4005-a43a-2b68cf4e6f91": {"__data__": {"id_": "0d0eb489-fd65-4005-a43a-2b68cf4e6f91", "embedding": null, "metadata": {"window": "Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth.  We expect to continu e to invest in the expansion ", "original_text": "For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cc7f4eb-9a05-4043-930c-da1977280c55", "node_type": "1", "metadata": {"window": "And the segment adjusted operating margin was 829 basis points, an increase of 22 \nbasis points.  \n \n Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth.  We expect to continu e to invest in the expansion ", "original_text": "Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f4cd88956b228053c5a4b0173fc119500d68d5565ca739a03e69d58bc1a8a19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71dbbf7c-f364-4d5a-9477-59fc1ade8521", "node_type": "1", "metadata": {"window": "Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth.  We expect to continu e to invest in the expansion ", "original_text": "We expect to continu e to invest in the expansion "}, "hash": "69457d0c540c5a1dbd2c3d0b0a0e79e0ca7ce929191f42c25b9a1015bfb25480", "class_name": "RelatedNodeInfo"}}, "text": "For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth. ", "start_char_idx": 3898, "end_char_idx": 4079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71dbbf7c-f364-4d5a-9477-59fc1ade8521": {"__data__": {"id_": "71dbbf7c-f364-4d5a-9477-59fc1ade8521", "embedding": null, "metadata": {"window": "Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth.  We expect to continu e to invest in the expansion ", "original_text": "We expect to continu e to invest in the expansion ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85640953a280d7bae9f2baef378e3b77c85eba80218af9348bc8a848744900f6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d0eb489-fd65-4005-a43a-2b68cf4e6f91", "node_type": "1", "metadata": {"window": "Next, Prescription Technology Solutions.  Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth.  We expect to continu e to invest in the expansion ", "original_text": "For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth. ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42d7958456cc7543ef124b2e3990f08ad0d8cc87d4c0b044e984d045460444b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34497735-d302-4efd-a43d-29b3886ce3b6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate. ", "original_text": "McKesson Corp.  "}, "hash": "e06ff38159cc2e5a163163c42384794aea56b20c93e50326a1131d3514520ae8", "class_name": "RelatedNodeInfo"}}, "text": "We expect to continu e to invest in the expansion ", "start_char_idx": 4079, "end_char_idx": 4129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34497735-d302-4efd-a43d-29b3886ce3b6": {"__data__": {"id_": "34497735-d302-4efd-a43d-29b3886ce3b6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71dbbf7c-f364-4d5a-9477-59fc1ade8521", "node_type": "1", "metadata": {"window": "Revenues were $668 million, an increase of 7%, driven by new brand \nsupport programs, which were partially offset by the impact of lower prescription volume trends.  Adjusted \noperating profit decreased 10% to $104 million, which was driven by higher operating expense investment to \nsupp ort the company's biopharma service growth initiative.  \n \n For the past several quarters, we've outlined our strategic investment into the products and services within RxTS, \nresulting in higher operating expenses to support future growth.  We expect to continu e to invest in the expansion ", "original_text": "We expect to continu e to invest in the expansion ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a154d2c35948bc41ae95db0ebee80d4b3b295a573bc1152b3f2c8b30c546726", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6ea87a8-d9fb-4648-a4aa-681eda4d4da1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment. "}, "hash": "7262359eb704111248404e0dea849857d4667e01e85c9569c392d603b7378a19", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6ea87a8-d9fb-4648-a4aa-681eda4d4da1": {"__data__": {"id_": "d6ea87a8-d9fb-4648-a4aa-681eda4d4da1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34497735-d302-4efd-a43d-29b3886ce3b6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c8d900257b69c90d3c473d1fb686d4f8596d63563f9c10db81d8c8da7f70fcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4737085b-5ee4-49ce-b203-056e77e3fa18", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n", "original_text": "The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n"}, "hash": "8e87e1f03390f6332c0fb25bea86365512b78e4c7fe90aa5e7ca455a6e980243", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment. ", "start_char_idx": 16, "end_char_idx": 312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4737085b-5ee4-49ce-b203-056e77e3fa18": {"__data__": {"id_": "4737085b-5ee4-49ce-b203-056e77e3fa18", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n", "original_text": "The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6ea87a8-d9fb-4648-a4aa-681eda4d4da1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbff555d00d8766c673d0681ef94fc532f1d75ac42127a8bb3ad961db2b6937a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79292547-fd87-43b9-9426-4403d6687deb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained. ", "original_text": "And moving on to corporate. "}, "hash": "cb099a45e2ae9245277f67e80bed7ccf5bf35de7eac12536f6b5f0ef7660a902", "class_name": "RelatedNodeInfo"}}, "text": "The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n", "start_char_idx": 312, "end_char_idx": 426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79292547-fd87-43b9-9426-4403d6687deb": {"__data__": {"id_": "79292547-fd87-43b9-9426-4403d6687deb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained. ", "original_text": "And moving on to corporate. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4737085b-5ee4-49ce-b203-056e77e3fa18", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n", "original_text": "The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d73d3f06c75e9dc31581ad7f26e21735973d77dda3de6af8a4492e0e1893673", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf7fd448-8a96-4c37-81cf-1e9b5686a15b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n", "original_text": "McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income. "}, "hash": "407971033b5f304bf60142a49bdc13827151827e2537cc9d4f76527817456cb5", "class_name": "RelatedNodeInfo"}}, "text": "And moving on to corporate. ", "start_char_idx": 426, "end_char_idx": 454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf7fd448-8a96-4c37-81cf-1e9b5686a15b": {"__data__": {"id_": "bf7fd448-8a96-4c37-81cf-1e9b5686a15b", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n", "original_text": "McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79292547-fd87-43b9-9426-4403d6687deb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained. ", "original_text": "And moving on to corporate. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3608c1fff0dbd2df66cb15949ac9536da766411f0c30499ade3f9e97d6b5e63b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfc199ae-e89c-4ee4-9510-506e85967d84", "node_type": "1", "metadata": {"window": "The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment. ", "original_text": "This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n"}, "hash": "41066421a1a976b78a013a0515b8e279566214658c17388716808ed62350976c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income. ", "start_char_idx": 454, "end_char_idx": 642, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfc199ae-e89c-4ee4-9510-506e85967d84": {"__data__": {"id_": "cfc199ae-e89c-4ee4-9510-506e85967d84", "embedding": null, "metadata": {"window": "The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment. ", "original_text": "This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf7fd448-8a96-4c37-81cf-1e9b5686a15b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n", "original_text": "McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "785301dccff07f52d437f68a68c4362a1e95282212d9b8d18c0089ece7066e00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0d59686-f80b-42b8-93bc-f9af021287be", "node_type": "1", "metadata": {"window": "And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n", "original_text": "Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained. "}, "hash": "4c1392afa84edee16061cbac4e6fd72e4044e7850133465e44b92d042db0a4c4", "class_name": "RelatedNodeInfo"}}, "text": "This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n", "start_char_idx": 642, "end_char_idx": 786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0d59686-f80b-42b8-93bc-f9af021287be": {"__data__": {"id_": "f0d59686-f80b-42b8-93bc-f9af021287be", "embedding": null, "metadata": {"window": "And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n", "original_text": "Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfc199ae-e89c-4ee4-9510-506e85967d84", "node_type": "1", "metadata": {"window": "The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment. ", "original_text": "This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247aef636f845de207e772bc97e339d593d28ab215650ba39d8c80d1cb262647", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82d75c38-fa59-416f-81ea-b1c1249fe97e", "node_type": "1", "metadata": {"window": "McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter. ", "original_text": "While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n"}, "hash": "a45a7c25eabe3ab6238f78a97f0c46d58d88795fbbe8d786b6030b8a10b19cad", "class_name": "RelatedNodeInfo"}}, "text": "Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained. ", "start_char_idx": 786, "end_char_idx": 981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82d75c38-fa59-416f-81ea-b1c1249fe97e": {"__data__": {"id_": "82d75c38-fa59-416f-81ea-b1c1249fe97e", "embedding": null, "metadata": {"window": "McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter. ", "original_text": "While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0d59686-f80b-42b8-93bc-f9af021287be", "node_type": "1", "metadata": {"window": "And moving on to corporate.  McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n", "original_text": "Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "730a38a5d21871e853e942da36f649fdc3b64a083970fd20fd0da1569d969629", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "304ed8b9-9b6d-42c4-9b55-86d780ac1351", "node_type": "1", "metadata": {"window": "This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n", "original_text": "As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment. "}, "hash": "a0485e345b45634eaae4108540e494bfcbae3053e604a5fcd3bf40f043b8afcf", "class_name": "RelatedNodeInfo"}}, "text": "While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n", "start_char_idx": 981, "end_char_idx": 1216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "304ed8b9-9b6d-42c4-9b55-86d780ac1351": {"__data__": {"id_": "304ed8b9-9b6d-42c4-9b55-86d780ac1351", "embedding": null, "metadata": {"window": "This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n", "original_text": "As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82d75c38-fa59-416f-81ea-b1c1249fe97e", "node_type": "1", "metadata": {"window": "McKesson recorded $135 million in adjusted corporate expenses in the quarter, an \nincrease of 2% year -over-year, primarily driven by increased technology costs and lower interest income.  This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter. ", "original_text": "While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f8ec769a2d1143dd66f66a9622b85b84abe61e9550a0443bccb83ac906448c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f95db83-e739-40fb-9f0d-ce8888a1331c", "node_type": "1", "metadata": {"window": "Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11. ", "original_text": "It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n"}, "hash": "2339ee314a2df08565693d132b9111cf62be31cfd2e87466d814b2b386937f35", "class_name": "RelatedNodeInfo"}}, "text": "As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment. ", "start_char_idx": 1216, "end_char_idx": 1348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f95db83-e739-40fb-9f0d-ce8888a1331c": {"__data__": {"id_": "4f95db83-e739-40fb-9f0d-ce8888a1331c", "embedding": null, "metadata": {"window": "Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11. ", "original_text": "It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "304ed8b9-9b6d-42c4-9b55-86d780ac1351", "node_type": "1", "metadata": {"window": "This \nincrease was largely off set by net gains of approximately $49 million on equity investments within our McKesson \nVentures portfolio.  \n \n Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n", "original_text": "As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1caa2fc9d6e1d7cbcdb6012887ea25f56b0c78d12060b931add89382aae90695", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "469849f5-3d85-4edb-ba11-15cbded7c081", "node_type": "1", "metadata": {"window": "While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n", "original_text": "And finally, we reported opioid -related litigation expenses of $41 million in the quarter. "}, "hash": "a58d8500cdb9440c606378f3d9b421b97065c14206f010e0063de07ddd0cf134", "class_name": "RelatedNodeInfo"}}, "text": "It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n", "start_char_idx": 1348, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "469849f5-3d85-4edb-ba11-15cbded7c081": {"__data__": {"id_": "469849f5-3d85-4edb-ba11-15cbded7c081", "embedding": null, "metadata": {"window": "While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n", "original_text": "And finally, we reported opioid -related litigation expenses of $41 million in the quarter. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f95db83-e739-40fb-9f0d-ce8888a1331c", "node_type": "1", "metadata": {"window": "Our McKesson Ventures portfolio holds equity investments in several growth stage, digital health and services \ncompanies, and we're pleased with the  portfolio results and the insights obtained.  While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11. ", "original_text": "It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f38918b3e4dffb80ffe84b1557ce64469d298000ffb07882679880f86d0572b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b41b73c-4ac6-4d0f-af01-fa1dbf1f1331", "node_type": "1", "metadata": {"window": "As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million. ", "original_text": "And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n"}, "hash": "85774617a73f41d65525ec398d55a71b7540bfdfbd0c89beb7c500bbaff8419b", "class_name": "RelatedNodeInfo"}}, "text": "And finally, we reported opioid -related litigation expenses of $41 million in the quarter. ", "start_char_idx": 1562, "end_char_idx": 1654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b41b73c-4ac6-4d0f-af01-fa1dbf1f1331": {"__data__": {"id_": "6b41b73c-4ac6-4d0f-af01-fa1dbf1f1331", "embedding": null, "metadata": {"window": "As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million. ", "original_text": "And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "469849f5-3d85-4edb-ba11-15cbded7c081", "node_type": "1", "metadata": {"window": "While mark -to-market \nvaluations in this quarter resulted in gains from three of our investments, the impacts to our consolidated \nfinancials can be influenced by the performance of each individual investment qua rter-to-quarter.  \n \n As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n", "original_text": "And finally, we reported opioid -related litigation expenses of $41 million in the quarter. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffa75b27df53ae41bb8b494989f556625bfa227b914f420fbb89a732772c838a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d24c778f-3266-4d84-8941-b31595241abc", "node_type": "1", "metadata": {"window": "It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n", "original_text": "Turning now to cash, which can be found on slide 11. "}, "hash": "0aeb63f79f0c8432d2c7073207e901e6621453ec17c2991e1814bd6bd625afb8", "class_name": "RelatedNodeInfo"}}, "text": "And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n", "start_char_idx": 1654, "end_char_idx": 1775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d24c778f-3266-4d84-8941-b31595241abc": {"__data__": {"id_": "d24c778f-3266-4d84-8941-b31595241abc", "embedding": null, "metadata": {"window": "It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n", "original_text": "Turning now to cash, which can be found on slide 11. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b41b73c-4ac6-4d0f-af01-fa1dbf1f1331", "node_type": "1", "metadata": {"window": "As a result, McKesson's investments may result in gains or losses, the timing and magnitude of which can vary for \neach investment.  It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million. ", "original_text": "And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7194922bdae51c5dc88df2e23164e6b03644eaa633baac5019e605e965ae54ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbc48e75-b81f-403e-ba5d-8c9199f8dc94", "node_type": "1", "metadata": {"window": "And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed. ", "original_text": "We ended the quarter with a cash balance of $3.1 billion. \n"}, "hash": "88821ea46784a1089dafd4818ae5e8af7523b547a9c2d1faed5aef1dc132b6a6", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to cash, which can be found on slide 11. ", "start_char_idx": 1775, "end_char_idx": 1828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbc48e75-b81f-403e-ba5d-8c9199f8dc94": {"__data__": {"id_": "fbc48e75-b81f-403e-ba5d-8c9199f8dc94", "embedding": null, "metadata": {"window": "And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed. ", "original_text": "We ended the quarter with a cash balance of $3.1 billion. \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d24c778f-3266-4d84-8941-b31595241abc", "node_type": "1", "metadata": {"window": "It's difficult to predict when gains or losses on our venture portfolio companies may occur, and \ntherefore,  our practice has been and will continue to not include ventures portfolio activity in our guidance.  \n \n And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n", "original_text": "Turning now to cash, which can be found on slide 11. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "464dfe749b76ad070de40069a39f5e7234a1983e2bdd21a418560a4fa8eafd54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad589ec3-105f-404b-971e-3b8f381b311c", "node_type": "1", "metadata": {"window": "And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n", "original_text": "For the first half of fiscal 2021, we had negative free cash flow of $306 million. "}, "hash": "15a05c1a1dee87fb4c5c76babd447a8f3f6ec4fd930edbf4d5b97f2923383aa9", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with a cash balance of $3.1 billion. \n", "start_char_idx": 1828, "end_char_idx": 1887, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad589ec3-105f-404b-971e-3b8f381b311c": {"__data__": {"id_": "ad589ec3-105f-404b-971e-3b8f381b311c", "embedding": null, "metadata": {"window": "And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n", "original_text": "For the first half of fiscal 2021, we had negative free cash flow of $306 million. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbc48e75-b81f-403e-ba5d-8c9199f8dc94", "node_type": "1", "metadata": {"window": "And finally, we reported opioid -related litigation expenses of $41 million in the quarter.  And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed. ", "original_text": "We ended the quarter with a cash balance of $3.1 billion. \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e5d805fd23fba4860d25ccf25f9fab1191e2323b2095651a8d6972feda18616", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b72c5771-c5ba-489d-a2e1-8b9a2895839c", "node_type": "1", "metadata": {"window": "Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives. ", "original_text": "Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n"}, "hash": "338c73c5c7e99ac5846e035846757db765e44ee7f6f226bfba0e838821433713", "class_name": "RelatedNodeInfo"}}, "text": "For the first half of fiscal 2021, we had negative free cash flow of $306 million. ", "start_char_idx": 1887, "end_char_idx": 1970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b72c5771-c5ba-489d-a2e1-8b9a2895839c": {"__data__": {"id_": "b72c5771-c5ba-489d-a2e1-8b9a2895839c", "embedding": null, "metadata": {"window": "Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives. ", "original_text": "Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad589ec3-105f-404b-971e-3b8f381b311c", "node_type": "1", "metadata": {"window": "And for fiscal 2021, we \ncontinue to anticipate that opioid -related legal costs will be approximately $160 million.  \n \n Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n", "original_text": "For the first half of fiscal 2021, we had negative free cash flow of $306 million. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a93536dec2cdc52e04014e66566ee1d94c641ba3657722bdcec44c05856b6486", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e734949-51d9-4955-9c77-0e7f02cfc427", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise. ", "original_text": "Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed. "}, "hash": "b936d23c0f23f65fcc292ba2639aab0523eeb923385acfd6f39228d0267a6f19", "class_name": "RelatedNodeInfo"}}, "text": "Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n", "start_char_idx": 1970, "end_char_idx": 2156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e734949-51d9-4955-9c77-0e7f02cfc427": {"__data__": {"id_": "1e734949-51d9-4955-9c77-0e7f02cfc427", "embedding": null, "metadata": {"window": "We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise. ", "original_text": "Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b72c5771-c5ba-489d-a2e1-8b9a2895839c", "node_type": "1", "metadata": {"window": "Turning now to cash, which can be found on slide 11.  We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives. ", "original_text": "Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fd43623a343e88bc81c4f5986e2afdf3322696cd3e8cbe61cbeac5677696418", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9375b3dc-e28c-478f-9b27-7238535e1dae", "node_type": "1", "metadata": {"window": "For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n", "original_text": "As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n"}, "hash": "7c8295418ab9d3bba6ed1eb222adddb19556f93d5a85cf74dd9fffd5839d4895", "class_name": "RelatedNodeInfo"}}, "text": "Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed. ", "start_char_idx": 2156, "end_char_idx": 2390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9375b3dc-e28c-478f-9b27-7238535e1dae": {"__data__": {"id_": "9375b3dc-e28c-478f-9b27-7238535e1dae", "embedding": null, "metadata": {"window": "For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n", "original_text": "As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e734949-51d9-4955-9c77-0e7f02cfc427", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance of $3.1 billion. \n For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise. ", "original_text": "Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d1dd171e970fc5e8b34b3f4a35a2ace10ee36b2b2c52653f0666da7c2e2d90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03b563c3-e182-4507-80b2-be8c301e8c00", "node_type": "1", "metadata": {"window": "Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n", "original_text": "Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives. "}, "hash": "b75ff59111f0b3db0b38d070ca96800e65464c83882f0c3b25122a55b207e9c4", "class_name": "RelatedNodeInfo"}}, "text": "As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n", "start_char_idx": 2390, "end_char_idx": 2567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03b563c3-e182-4507-80b2-be8c301e8c00": {"__data__": {"id_": "03b563c3-e182-4507-80b2-be8c301e8c00", "embedding": null, "metadata": {"window": "Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n", "original_text": "Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9375b3dc-e28c-478f-9b27-7238535e1dae", "node_type": "1", "metadata": {"window": "For the first half of fiscal 2021, we had negative free cash flow of $306 million.  Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n", "original_text": "As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9de473130668d5862fd32ac66ffb37d451fe6c09e225bd949c50814e89f25389", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1cea6d1-9186-4f69-b981-59217e0ce3e1", "node_type": "1", "metadata": {"window": "Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021. ", "original_text": "We also made inv estments in data and \nanalytics capabilities across the enterprise. "}, "hash": "01455a797b57f094d67331482e1d427f1929a79872f2cfe104fe18f6349d51c3", "class_name": "RelatedNodeInfo"}}, "text": "Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives. ", "start_char_idx": 2567, "end_char_idx": 2747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1cea6d1-9186-4f69-b981-59217e0ce3e1": {"__data__": {"id_": "e1cea6d1-9186-4f69-b981-59217e0ce3e1", "embedding": null, "metadata": {"window": "Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021. ", "original_text": "We also made inv estments in data and \nanalytics capabilities across the enterprise. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03b563c3-e182-4507-80b2-be8c301e8c00", "node_type": "1", "metadata": {"window": "Our worki ng capital metrics and \nresulting free cash flow vary from quarter to quarter and are impacted by timing, including the day of the week that \nmarks the close of a quarter.  \n \n Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n", "original_text": "Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e9be29d800268d34ed94092b20f987b5bf286ea73c08864c94385ac7713810f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4f877dc-4cef-4c00-91cc-e6d76982494a", "node_type": "1", "metadata": {"window": "As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n", "original_text": "For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n"}, "hash": "4bc80000ef1f2761051596a0f5ff9bdfb6b708a2658de978a268f4c44a9c7588", "class_name": "RelatedNodeInfo"}}, "text": "We also made inv estments in data and \nanalytics capabilities across the enterprise. ", "start_char_idx": 2747, "end_char_idx": 2832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4f877dc-4cef-4c00-91cc-e6d76982494a": {"__data__": {"id_": "e4f877dc-4cef-4c00-91cc-e6d76982494a", "embedding": null, "metadata": {"window": "As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n", "original_text": "For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1cea6d1-9186-4f69-b981-59217e0ce3e1", "node_type": "1", "metadata": {"window": "Looking at the cash flow dynamics, we saw higher levels of inventory this quarter, pr imarily resulting from the \nincreased quantities of COVID testing and personal protective equipment and our participation in Operation Warp \nSpeed.  As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021. ", "original_text": "We also made inv estments in data and \nanalytics capabilities across the enterprise. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89f1c634854abf75e273225f9298dd8bdf9644ff709de1f3a5cd1d07a180d18d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "697ed088-6026-46dc-9879-6ab3487fb66c", "node_type": "1", "metadata": {"window": "Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today. ", "original_text": "We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n"}, "hash": "4725c2fda97361a9bd0d0d85902f05b985626e6f00235e32cc1aa1dc292caaa0", "class_name": "RelatedNodeInfo"}}, "text": "For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n", "start_char_idx": 2832, "end_char_idx": 3020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "697ed088-6026-46dc-9879-6ab3487fb66c": {"__data__": {"id_": "697ed088-6026-46dc-9879-6ab3487fb66c", "embedding": null, "metadata": {"window": "Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today. ", "original_text": "We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4f877dc-4cef-4c00-91cc-e6d76982494a", "node_type": "1", "metadata": {"window": "As we prepare for continued larger quantities of personal protective equipment and Operation Warp \nSpeed activi ty, we may experience additional working capital volatility.  \n \n Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n", "original_text": "For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "024afb2a64a091f8b5a5045aa2b028432bc12cc88dc3c6d49e2c21af2497f015", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "107ad55c-a6b4-46fe-a50f-58d4b0318d80", "node_type": "1", "metadata": {"window": "We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n", "original_text": "Let me now turn to our outlook for the balance of fiscal 2021. "}, "hash": "3452df18bc414a06c755dfc2e0b9e0a3104fc8e4177c7fddb70e8d80eac5387b", "class_name": "RelatedNodeInfo"}}, "text": "We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n", "start_char_idx": 3020, "end_char_idx": 3201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "107ad55c-a6b4-46fe-a50f-58d4b0318d80": {"__data__": {"id_": "107ad55c-a6b4-46fe-a50f-58d4b0318d80", "embedding": null, "metadata": {"window": "We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n", "original_text": "Let me now turn to our outlook for the balance of fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "697ed088-6026-46dc-9879-6ab3487fb66c", "node_type": "1", "metadata": {"window": "Year -to-date, we made $265 million of capital expenditures, led by internal investments in areas such as \ntechnology and continued investment in our strategic growth initiatives.  We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today. ", "original_text": "We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5ab773f4e0b9f7f06b41bafa7987a916591a994dfd5532ea230ae269b84f98b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4dfc77f-3058-4c8e-b96d-a513dafefb84", "node_type": "1", "metadata": {"window": "For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events. ", "original_text": "As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n"}, "hash": "70680a4a220aa86759050e779ccfb0049a325b9e045070abf3b9eb3986da1ad3", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to our outlook for the balance of fiscal 2021. ", "start_char_idx": 3201, "end_char_idx": 3264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4dfc77f-3058-4c8e-b96d-a513dafefb84": {"__data__": {"id_": "f4dfc77f-3058-4c8e-b96d-a513dafefb84", "embedding": null, "metadata": {"window": "For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events. ", "original_text": "As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "107ad55c-a6b4-46fe-a50f-58d4b0318d80", "node_type": "1", "metadata": {"window": "We also made inv estments in data and \nanalytics capabilities across the enterprise.  For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n", "original_text": "Let me now turn to our outlook for the balance of fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "694c7a15ff86a5f993e61f9874391ffee70adc953bc744a0a7843bcb1945c2e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3efceb1-ef42-4dcb-a662-cbcdbbc80547", "node_type": "1", "metadata": {"window": "We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events.  We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "original_text": "On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today. "}, "hash": "9d14cfa784bbbd1430cc7fec28862ae1ddcf1a8aba56ded332f59df977c28a1a", "class_name": "RelatedNodeInfo"}}, "text": "As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n", "start_char_idx": 3264, "end_char_idx": 3459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3efceb1-ef42-4dcb-a662-cbcdbbc80547": {"__data__": {"id_": "c3efceb1-ef42-4dcb-a662-cbcdbbc80547", "embedding": null, "metadata": {"window": "We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events.  We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "original_text": "On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4dfc77f-3058-4c8e-b96d-a513dafefb84", "node_type": "1", "metadata": {"window": "For the first six months of the fiscal year, we returned $388 million of \ncash to our shareholders through $248 million of share repurchases and the payment of $140 million in dividends. \n We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events. ", "original_text": "As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af334bd9e9bb938861bd480d6437a325edc131994df9e5f4a1278fcc8113283d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3662475-0c68-4d97-853f-c15e6ea2901c", "node_type": "1", "metadata": {"window": "Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events.  We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "original_text": "First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n"}, "hash": "69595b243079e3c507e9f8d4cc390257e6818ad9e39d4d74c3a7119ee75a79de", "class_name": "RelatedNodeInfo"}}, "text": "On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today. ", "start_char_idx": 3459, "end_char_idx": 3604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3662475-0c68-4d97-853f-c15e6ea2901c": {"__data__": {"id_": "d3662475-0c68-4d97-853f-c15e6ea2901c", "embedding": null, "metadata": {"window": "Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events.  We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "original_text": "First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3efceb1-ef42-4dcb-a662-cbcdbbc80547", "node_type": "1", "metadata": {"window": "We have $1.3 billion remaining on our share repurchase authorization, and we continue to expect diluted \nweighted shares outstanding in the range of 161 million to 163 million.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events.  We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "original_text": "On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a821628f787c887051b305db327c4b5b83c258e222bab4b0a72af33b7295b6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcc94ab3-2d4b-46c2-822a-d30d2efd300e", "node_type": "1", "metadata": {"window": "As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events.  We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "original_text": "And second, we do not assume any systemic customer insolvency events. "}, "hash": "14928735a110e653c38777c8430f0806ec4b471e269e6f723681a2481cf80506", "class_name": "RelatedNodeInfo"}}, "text": "First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n", "start_char_idx": 3604, "end_char_idx": 3794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcc94ab3-2d4b-46c2-822a-d30d2efd300e": {"__data__": {"id_": "bcc94ab3-2d4b-46c2-822a-d30d2efd300e", "embedding": null, "metadata": {"window": "As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events.  We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "original_text": "And second, we do not assume any systemic customer insolvency events. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3662475-0c68-4d97-853f-c15e6ea2901c", "node_type": "1", "metadata": {"window": "Let me now turn to our outlook for the balance of fiscal 2021.  As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events.  We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "original_text": "First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b791b47acf3281dff404e02c2c72d3427a45464042f59f176e04424d307088b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ae10751-f739-46ba-b288-d626f4b472a9", "node_type": "1", "metadata": {"window": "On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events.  We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "original_text": "We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  "}, "hash": "9780e331813b6d418d2779b4aef9330b612285ea3d626dbb7aec822bb1b7ba57", "class_name": "RelatedNodeInfo"}}, "text": "And second, we do not assume any systemic customer insolvency events. ", "start_char_idx": 3794, "end_char_idx": 3864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ae10751-f739-46ba-b288-d626f4b472a9": {"__data__": {"id_": "3ae10751-f739-46ba-b288-d626f4b472a9", "embedding": null, "metadata": {"window": "On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events.  We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "original_text": "We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9626c25a-11b2-47e0-b378-5811bb4653a6", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77e13f106a07b09a2f03fea545054014178755a0b90797709b1c20086722acf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcc94ab3-2d4b-46c2-822a-d30d2efd300e", "node_type": "1", "metadata": {"window": "As we've seen over the past several months, the \ntrajectory of the COVID virus can change quickly as evidenced by recent increases in case numbers in many \nparts of North America and Europe.  \n \n On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events.  We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "original_text": "And second, we do not assume any systemic customer insolvency events. ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e9457717fa11d9123291913310e2cd6c0428fc91393a9878ea2a0e3f66cf8a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b69d287-7fa4-4682-89ba-fbc935be6917", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly. ", "original_text": "McKesson Corp.  "}, "hash": "7e3dbb70e43f5beca7c2bc0d9f437f5bfd9699f7e3ef725073dc6d7b51ba4e95", "class_name": "RelatedNodeInfo"}}, "text": "We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "start_char_idx": 3864, "end_char_idx": 4058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b69d287-7fa4-4682-89ba-fbc935be6917": {"__data__": {"id_": "2b69d287-7fa4-4682-89ba-fbc935be6917", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ae10751-f739-46ba-b288-d626f4b472a9", "node_type": "1", "metadata": {"window": "On our Q4 FY 2020 and Q1 earnings calls, we outlined two assumptions that underlie ou r guidance for fiscal 2021 \nthat we are reiterating today.  First, we do not assume a new wave of COVID -19, which would lead to shelter -at-\nhome and economic lockdowns, which would preclude patient mobility and consumption of healthcare services. \n And second, we do not assume any systemic customer insolvency events.  We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "original_text": "We continue to believe that the \nrecovery will take longer than initially anticipated and it will not be linear as the full impact of the pandemic is likely \nto persist beyond the fiscal year.  ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e479ef32ec0f9f14e399180f0fba48389d1f3539ebc0f763e09d8866f692aa7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e99d861-5dd0-432d-a064-ee9cb69a4ed9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter. "}, "hash": "073afb1688aacc7de528bfa6983410837c80177002a8217346a4b30e7603a970", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e99d861-5dd0-432d-a064-ee9cb69a4ed9": {"__data__": {"id_": "7e99d861-5dd0-432d-a064-ee9cb69a4ed9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b69d287-7fa4-4682-89ba-fbc935be6917", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "221cf22827f087623e2a14d8d3d29b72735f5c6d241a5fa38b3a150371312fe0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8db7d773-1cde-4087-8c2f-78d55e867c60", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021. ", "original_text": "As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n"}, "hash": "b4a5f6a0f8836129f8711b28245c31f7c51762930438c69d6e68c9238b959ac9", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter. ", "start_char_idx": 16, "end_char_idx": 254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8db7d773-1cde-4087-8c2f-78d55e867c60": {"__data__": {"id_": "8db7d773-1cde-4087-8c2f-78d55e867c60", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021. ", "original_text": "As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e99d861-5dd0-432d-a064-ee9cb69a4ed9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd642730ae3e7b57e72665951b586e8a89b105d9b5cd3787f1b88e12587f69b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be7f5bfb-1606-4da9-94f4-34315c9451fc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S. ", "original_text": "While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly. "}, "hash": "6b87c5a811711979b2eb51bf0b9cff615a17d0c3920b96e5866285107a3effb9", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n", "start_char_idx": 254, "end_char_idx": 531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be7f5bfb-1606-4da9-94f4-34315c9451fc": {"__data__": {"id_": "be7f5bfb-1606-4da9-94f4-34315c9451fc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S. ", "original_text": "While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8db7d773-1cde-4087-8c2f-78d55e867c60", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021. ", "original_text": "As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b681b153fe82d02ee1b70b03776c5da141b84188a3a7e2e1a52eeb9f24b5644", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "883d0e3f-9b00-4ba5-b5b2-d6a3df2afc36", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year. ", "original_text": "We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%. "}, "hash": "faffeaf6eecafa82a0f2185796f4ec214ac2676efd18f47ec1b5ffa57485765b", "class_name": "RelatedNodeInfo"}}, "text": "While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly. ", "start_char_idx": 531, "end_char_idx": 781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "883d0e3f-9b00-4ba5-b5b2-d6a3df2afc36": {"__data__": {"id_": "883d0e3f-9b00-4ba5-b5b2-d6a3df2afc36", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year. ", "original_text": "We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be7f5bfb-1606-4da9-94f4-34315c9451fc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S. ", "original_text": "While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1863bc118830d4830c85de6c505a64e3309da33041ffbd3cbc742f751a544cf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "104a1641-04bf-4d1a-bcb2-d2252e4502ea", "node_type": "1", "metadata": {"window": "As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses. ", "original_text": "We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021. "}, "hash": "618c8f6713f43697e92c4a604668823ea791a01a57158cca8de84c91e3c77330", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%. ", "start_char_idx": 781, "end_char_idx": 1093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "104a1641-04bf-4d1a-bcb2-d2252e4502ea": {"__data__": {"id_": "104a1641-04bf-4d1a-bcb2-d2252e4502ea", "embedding": null, "metadata": {"window": "As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses. ", "original_text": "We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "883d0e3f-9b00-4ba5-b5b2-d6a3df2afc36", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year. ", "original_text": "We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b32da01020766a467d6d98e78d468ecb6ba1b657575556a7487b25afaa1d160", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76c2234a-2fab-446c-aa82-1a88569fea67", "node_type": "1", "metadata": {"window": "While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n", "original_text": "And now on \nto the segment s. \n \nIn our U.S. "}, "hash": "11a96f1121bfb82abae040e82ac372da19c70f475000f2bcabe10331ea183906", "class_name": "RelatedNodeInfo"}}, "text": "We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021. ", "start_char_idx": 1093, "end_char_idx": 1202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76c2234a-2fab-446c-aa82-1a88569fea67": {"__data__": {"id_": "76c2234a-2fab-446c-aa82-1a88569fea67", "embedding": null, "metadata": {"window": "While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n", "original_text": "And now on \nto the segment s. \n \nIn our U.S. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "104a1641-04bf-4d1a-bcb2-d2252e4502ea", "node_type": "1", "metadata": {"window": "As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses. ", "original_text": "We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc0c16db5bc8143330dfe2954d5e90b2f33531741ef35829132a5397692f9358", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca030fd1-c851-4234-bc2a-f77a8ae36586", "node_type": "1", "metadata": {"window": "We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent. ", "original_text": "Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year. "}, "hash": "220291f07a1abc43a8853671d9c5f49ced3de8ea270787be9669853cd711af20", "class_name": "RelatedNodeInfo"}}, "text": "And now on \nto the segment s. \n \nIn our U.S. ", "start_char_idx": 1202, "end_char_idx": 1247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca030fd1-c851-4234-bc2a-f77a8ae36586": {"__data__": {"id_": "ca030fd1-c851-4234-bc2a-f77a8ae36586", "embedding": null, "metadata": {"window": "We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent. ", "original_text": "Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76c2234a-2fab-446c-aa82-1a88569fea67", "node_type": "1", "metadata": {"window": "While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly.  We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n", "original_text": "And now on \nto the segment s. \n \nIn our U.S. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50f755ff2f7143800aa0f762d1a5440177a0fe6b86b03c6679f12e26d901a44b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9751d62-ebff-471c-954f-271abd1b5410", "node_type": "1", "metadata": {"window": "We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests. ", "original_text": "This takes into account improved volumes, particularly in our \nspecialty businesses. "}, "hash": "ed9dbf1a82c6737ef8b3f22a46b8d6479b3ffbf7f83f9c74f2beec767e9c0d1b", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year. ", "start_char_idx": 1247, "end_char_idx": 1392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9751d62-ebff-471c-954f-271abd1b5410": {"__data__": {"id_": "d9751d62-ebff-471c-954f-271abd1b5410", "embedding": null, "metadata": {"window": "We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests. ", "original_text": "This takes into account improved volumes, particularly in our \nspecialty businesses. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca030fd1-c851-4234-bc2a-f77a8ae36586", "node_type": "1", "metadata": {"window": "We anticipate consolidated revenues to increase 2% to 4% for fiscal 2021, and we now \nexpect the consolidated adjusted operating profit will grow 2% to 6% for the full year when excluding  the results of \nChange Healthcare from the prior year, an increase from our prior guidance of a decline between 1% and 4%.  We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent. ", "original_text": "Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b17622c5360c4fb365f52333abef19dbfd89bf8a6cda3a0b4a8fe578c32617c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "492e82bd-5524-494e-8393-207e178452f7", "node_type": "1", "metadata": {"window": "And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n", "original_text": "In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n"}, "hash": "edcaf5114c469d57ebec1366236ca688e8c5910b0cc2dd70d93cbd8a799a0db0", "class_name": "RelatedNodeInfo"}}, "text": "This takes into account improved volumes, particularly in our \nspecialty businesses. ", "start_char_idx": 1392, "end_char_idx": 1477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "492e82bd-5524-494e-8393-207e178452f7": {"__data__": {"id_": "492e82bd-5524-494e-8393-207e178452f7", "embedding": null, "metadata": {"window": "And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n", "original_text": "In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9751d62-ebff-471c-954f-271abd1b5410", "node_type": "1", "metadata": {"window": "We \ncontinue to anticipate enterprise adjusted operating profit to grow sequentially throughout fiscal 2021.  And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests. ", "original_text": "This takes into account improved volumes, particularly in our \nspecialty businesses. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b7a84783031c6c82258342eb8514f6085160269f16556fe4160ae13079c36df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "430f2993-01bd-412a-a81c-e447b9375336", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment. ", "original_text": "Let me now provide some details on our Medical -Surgical segm ent. "}, "hash": "32104c1ba884185352f1d1fc9418d50a17de1b4bc4f998aafbb58935d9365ac1", "class_name": "RelatedNodeInfo"}}, "text": "In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n", "start_char_idx": 1477, "end_char_idx": 1686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "430f2993-01bd-412a-a81c-e447b9375336": {"__data__": {"id_": "430f2993-01bd-412a-a81c-e447b9375336", "embedding": null, "metadata": {"window": "Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment. ", "original_text": "Let me now provide some details on our Medical -Surgical segm ent. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "492e82bd-5524-494e-8393-207e178452f7", "node_type": "1", "metadata": {"window": "And now on \nto the segment s. \n \nIn our U.S.  Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n", "original_text": "In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afdf255fd341e40d68650f5f016b6ef96fffcd9bfd197d6fe3b75a11c181de40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9732e4ec-c16b-4328-9478-d68b089f64fb", "node_type": "1", "metadata": {"window": "This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic. ", "original_text": "As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests. "}, "hash": "70f53c7fd74b487bbe81a84e3329bb81a4bc975e94769dd01dda933a9653e17a", "class_name": "RelatedNodeInfo"}}, "text": "Let me now provide some details on our Medical -Surgical segm ent. ", "start_char_idx": 1686, "end_char_idx": 1753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9732e4ec-c16b-4328-9478-d68b089f64fb": {"__data__": {"id_": "9732e4ec-c16b-4328-9478-d68b089f64fb", "embedding": null, "metadata": {"window": "This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic. ", "original_text": "As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "430f2993-01bd-412a-a81c-e447b9375336", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, we expect revenue growth of 3% to 6% and segment adjusted operating \nprofit to grow 1% to 4% compared to the prior year.  This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment. ", "original_text": "Let me now provide some details on our Medical -Surgical segm ent. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "161cb3b1697587e276a9dcdb006d28d615895a0d3f40b02b30a499a301d10a4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f83493c3-d368-4a19-a4f4-4130be60582e", "node_type": "1", "metadata": {"window": "In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear. ", "original_text": "We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n"}, "hash": "fa1b81b298d16690789403bd902ce130fdb3fb754e3bfa84504b061eb8cad3e2", "class_name": "RelatedNodeInfo"}}, "text": "As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests. ", "start_char_idx": 1753, "end_char_idx": 1860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f83493c3-d368-4a19-a4f4-4130be60582e": {"__data__": {"id_": "f83493c3-d368-4a19-a4f4-4130be60582e", "embedding": null, "metadata": {"window": "In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear. ", "original_text": "We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9732e4ec-c16b-4328-9478-d68b089f64fb", "node_type": "1", "metadata": {"window": "This takes into account improved volumes, particularly in our \nspecialty businesses.  In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic. ", "original_text": "As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4dbc7e88e906659ad8ae2429f9cba82a539d97632581713ecbf65eb5f6897861", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fd5e168-256e-4a30-8964-412f523a2b5c", "node_type": "1", "metadata": {"window": "Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system. ", "original_text": "We've a lso seen increased volumes of personal protective equipment. "}, "hash": "c11c95daf1ec7c7da6575296e91ff4a5aaa3ab42082a5f6e41471cbb7efdc695", "class_name": "RelatedNodeInfo"}}, "text": "We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n", "start_char_idx": 1860, "end_char_idx": 2004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fd5e168-256e-4a30-8964-412f523a2b5c": {"__data__": {"id_": "0fd5e168-256e-4a30-8964-412f523a2b5c", "embedding": null, "metadata": {"window": "Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system. ", "original_text": "We've a lso seen increased volumes of personal protective equipment. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f83493c3-d368-4a19-a4f4-4130be60582e", "node_type": "1", "metadata": {"window": "In our International segment, we expect a revenue decline of 5% to 10% year -over-year, \nand segment adjusted operating profit to be flat to 4% growth, driven by the performance in our European \nbusiness.  \n \n Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear. ", "original_text": "We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e69e11130b580974b5fe251964ab8d524c6ce3bc80e1dfa899a0e30f13ba9a9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "689be454-3a77-484b-93f2-37206fb3f37d", "node_type": "1", "metadata": {"window": "As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n", "original_text": "This category remains vital as we support \nour customers during the pandemic. "}, "hash": "29c36f113487c94969de5ac4be045921919a111d9e9d5e644e6aa83ac3123487", "class_name": "RelatedNodeInfo"}}, "text": "We've a lso seen increased volumes of personal protective equipment. ", "start_char_idx": 2004, "end_char_idx": 2073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "689be454-3a77-484b-93f2-37206fb3f37d": {"__data__": {"id_": "689be454-3a77-484b-93f2-37206fb3f37d", "embedding": null, "metadata": {"window": "As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n", "original_text": "This category remains vital as we support \nour customers during the pandemic. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fd5e168-256e-4a30-8964-412f523a2b5c", "node_type": "1", "metadata": {"window": "Let me now provide some details on our Medical -Surgical segm ent.  As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system. ", "original_text": "We've a lso seen increased volumes of personal protective equipment. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffb35552e69b079c26b6d4bdf34211d47e4d363ccfcca224140267c09d0c8800", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f21ca65-5aac-4589-8be3-a5216fc15afb", "node_type": "1", "metadata": {"window": "We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine. ", "original_text": "We expect that volumes will continue to fluctuate through the balance of the \nyear. "}, "hash": "3ef3c176321fbb6d63fa364b2ca687263f630a0bc59bb2b5183847c35bd143b5", "class_name": "RelatedNodeInfo"}}, "text": "This category remains vital as we support \nour customers during the pandemic. ", "start_char_idx": 2073, "end_char_idx": 2151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f21ca65-5aac-4589-8be3-a5216fc15afb": {"__data__": {"id_": "6f21ca65-5aac-4589-8be3-a5216fc15afb", "embedding": null, "metadata": {"window": "We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine. ", "original_text": "We expect that volumes will continue to fluctuate through the balance of the \nyear. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "689be454-3a77-484b-93f2-37206fb3f37d", "node_type": "1", "metadata": {"window": "As discussed in my opening remarks, \nthroughout the quarter, we saw increasing volumes of COVID -19 tests.  We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n", "original_text": "This category remains vital as we support \nour customers during the pandemic. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3afeee2e5fd902608b3bbd70c763e5ca4d1cc9276253a496d73fd522c22902f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24eee756-b4f3-4a11-8c06-d7ab10e8c00c", "node_type": "1", "metadata": {"window": "We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS. ", "original_text": "As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system. "}, "hash": "9c3cfec57abac3bb504d69ab19fb1191bdd2b7794271f641fe35a35e87310107", "class_name": "RelatedNodeInfo"}}, "text": "We expect that volumes will continue to fluctuate through the balance of the \nyear. ", "start_char_idx": 2151, "end_char_idx": 2235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24eee756-b4f3-4a11-8c06-d7ab10e8c00c": {"__data__": {"id_": "24eee756-b4f3-4a11-8c06-d7ab10e8c00c", "embedding": null, "metadata": {"window": "We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS. ", "original_text": "As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f21ca65-5aac-4589-8be3-a5216fc15afb", "node_type": "1", "metadata": {"window": "We expect these sales to be a near -term \nopportunity in the segment, and it's factored into our guidance for the remainder of fiscal 2021.  \n \n We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine. ", "original_text": "We expect that volumes will continue to fluctuate through the balance of the \nyear. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2490713bbe887140b1c30dcbea52d649340167a0a8bed0788ecd89995a8c86a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d406279-487c-4264-9cbf-50a89ca7544f", "node_type": "1", "metadata": {"window": "This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n", "original_text": "While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n"}, "hash": "517c0588aa5a0a6d8a341134603b99b9cc80e350ee70673639f57ec430e56e0f", "class_name": "RelatedNodeInfo"}}, "text": "As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system. ", "start_char_idx": 2235, "end_char_idx": 2454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d406279-487c-4264-9cbf-50a89ca7544f": {"__data__": {"id_": "8d406279-487c-4264-9cbf-50a89ca7544f", "embedding": null, "metadata": {"window": "This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n", "original_text": "While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24eee756-b4f3-4a11-8c06-d7ab10e8c00c", "node_type": "1", "metadata": {"window": "We've a lso seen increased volumes of personal protective equipment.  This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS. ", "original_text": "As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "233235cb5601ca95419caecb0bfd81981684944a249996f180f3871749c3a8ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34ddf94a-9bec-414f-8085-0033df113baf", "node_type": "1", "metadata": {"window": "We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat. ", "original_text": "As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine. "}, "hash": "6ed81e9c0a244dab0345ce73aa1ea710baa4f3723048e641c344689d5edaa1ce", "class_name": "RelatedNodeInfo"}}, "text": "While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n", "start_char_idx": 2454, "end_char_idx": 2588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34ddf94a-9bec-414f-8085-0033df113baf": {"__data__": {"id_": "34ddf94a-9bec-414f-8085-0033df113baf", "embedding": null, "metadata": {"window": "We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat. ", "original_text": "As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d406279-487c-4264-9cbf-50a89ca7544f", "node_type": "1", "metadata": {"window": "This category remains vital as we support \nour customers during the pandemic.  We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n", "original_text": "While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48d988b41e0abf67be75a3a19a7c566185536b86314a871d1f133e8eb6424961", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9fd8132-0535-454d-9d0f-9351da7909ff", "node_type": "1", "metadata": {"window": "As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n", "original_text": "We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS. "}, "hash": "c4851d553ca7af70cb319619bc4aaaf30fd3f5a7d68d721437d0d78354c413f3", "class_name": "RelatedNodeInfo"}}, "text": "As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine. ", "start_char_idx": 2588, "end_char_idx": 2759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9fd8132-0535-454d-9d0f-9351da7909ff": {"__data__": {"id_": "d9fd8132-0535-454d-9d0f-9351da7909ff", "embedding": null, "metadata": {"window": "As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n", "original_text": "We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34ddf94a-9bec-414f-8085-0033df113baf", "node_type": "1", "metadata": {"window": "We expect that volumes will continue to fluctuate through the balance of the \nyear.  As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat. ", "original_text": "As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "656c5f0f64b114091a4a609fc56928875990edf6b6cfcbeb9d06ae292f7747c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e4f8e28-b118-4587-876a-436fd4cfe440", "node_type": "1", "metadata": {"window": "While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment. ", "original_text": "As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n"}, "hash": "c8a778f50f8e5eeb21cc062d951a06268575b5719a3b7dd8ac9b05128a8e2158", "class_name": "RelatedNodeInfo"}}, "text": "We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS. ", "start_char_idx": 2759, "end_char_idx": 2953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e4f8e28-b118-4587-876a-436fd4cfe440": {"__data__": {"id_": "0e4f8e28-b118-4587-876a-436fd4cfe440", "embedding": null, "metadata": {"window": "While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment. ", "original_text": "As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9fd8132-0535-454d-9d0f-9351da7909ff", "node_type": "1", "metadata": {"window": "As the largest seasonal flu vaccine  distributor in the US, we continue to prepare for the influenza season, \nwhich is particularly important this year due to the impacts of COVID -19 on the nation's healthcare system.  While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n", "original_text": "We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a19142d04259ff6a4df403cdf5a55ad49eb1109a7dd8cf918a9d54c7492d3498", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22073531-06c5-48bc-8cf5-cc133bf1c945", "node_type": "1", "metadata": {"window": "As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses. ", "original_text": "In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat. "}, "hash": "d58d1af33c7f5436e50a298de134e2744b420799180fdab95cc773a94886e441", "class_name": "RelatedNodeInfo"}}, "text": "As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n", "start_char_idx": 2953, "end_char_idx": 3138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22073531-06c5-48bc-8cf5-cc133bf1c945": {"__data__": {"id_": "22073531-06c5-48bc-8cf5-cc133bf1c945", "embedding": null, "metadata": {"window": "As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses. ", "original_text": "In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e4f8e28-b118-4587-876a-436fd4cfe440", "node_type": "1", "metadata": {"window": "While \nit's too early to predict how the flu season will progress, we're act ively preparing to meet the needs of our \ncustomers.  \n \n As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment. ", "original_text": "As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cdafce466b1d07c367f9ae158f1f637850626dddf0ec91619227d64c1934f1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3694065-ccbe-4066-8c4c-ae88effa2f69", "node_type": "1", "metadata": {"window": "We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations. ", "original_text": "We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n"}, "hash": "157675f2752535ec5f51bb2ad06960ff4a90d8717b4c89831c03f57f3ff85433", "class_name": "RelatedNodeInfo"}}, "text": "In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat. ", "start_char_idx": 3138, "end_char_idx": 3305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3694065-ccbe-4066-8c4c-ae88effa2f69": {"__data__": {"id_": "e3694065-ccbe-4066-8c4c-ae88effa2f69", "embedding": null, "metadata": {"window": "We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations. ", "original_text": "We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22073531-06c5-48bc-8cf5-cc133bf1c945", "node_type": "1", "metadata": {"window": "As Brian mentioned in his remarks, we're also partnering with HHS on preparing and storing ancillary kits to be \nused in the administration of a future COVID -19 vaccine.  We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses. ", "original_text": "In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08087b016f4ebe1517ebd402bf49e90e1d5e1ed1a122bc45a201d154110bfb37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a3cab22-b2fb-42a1-b3d3-37eb902b9b2a", "node_type": "1", "metadata": {"window": "As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations.  Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "original_text": "As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment. "}, "hash": "cbfc6cced479ac970e30b54ac2d06ba03a9c2ba054db8648a6a44a59bee1b43b", "class_name": "RelatedNodeInfo"}}, "text": "We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n", "start_char_idx": 3305, "end_char_idx": 3457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a3cab22-b2fb-42a1-b3d3-37eb902b9b2a": {"__data__": {"id_": "4a3cab22-b2fb-42a1-b3d3-37eb902b9b2a", "embedding": null, "metadata": {"window": "As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations.  Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "original_text": "As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3694065-ccbe-4066-8c4c-ae88effa2f69", "node_type": "1", "metadata": {"window": "We've included in our guidance a n et benefit to adjusted \nearnings per diluted share of approximately $0.15 to $0.20 in the second half of our fiscal year related to our \npartnership with HHS.  As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations. ", "original_text": "We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e6bbdeef4c770daadfee9155a7bde2e478a9c5e30e186bf3b02f2188cea70a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65038fc3-505a-4c36-a921-46e6d62d0047", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations.  Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "original_text": "Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses. "}, "hash": "00f36aea60669c5e84b49087baf9f050ca59b55eece5463df321c0934e815fde", "class_name": "RelatedNodeInfo"}}, "text": "As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment. ", "start_char_idx": 3457, "end_char_idx": 3611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65038fc3-505a-4c36-a921-46e6d62d0047": {"__data__": {"id_": "65038fc3-505a-4c36-a921-46e6d62d0047", "embedding": null, "metadata": {"window": "In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations.  Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "original_text": "Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a3cab22-b2fb-42a1-b3d3-37eb902b9b2a", "node_type": "1", "metadata": {"window": "As a result, we now expect fiscal 2021 Medical -Surgical segment revenue to increase \nbetween 20% and  25%, and segment adjusted operating profit to grow in the range of 8% to 18%.  \n \n In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations.  Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "original_text": "As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4de1b6895a32066c6cf18cd5f8ff79f8f584786f65021432862da3012b942a9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c759395-b778-4b80-855c-37852cededb2", "node_type": "1", "metadata": {"window": "We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations.  Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "original_text": "Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations. "}, "hash": "e931c15c14f02055d931faa6159ce57a483b8b623b7c5c78e8c269cf94e63ec5", "class_name": "RelatedNodeInfo"}}, "text": "Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses. ", "start_char_idx": 3611, "end_char_idx": 3743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c759395-b778-4b80-855c-37852cededb2": {"__data__": {"id_": "5c759395-b778-4b80-855c-37852cededb2", "embedding": null, "metadata": {"window": "We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations.  Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "original_text": "Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65038fc3-505a-4c36-a921-46e6d62d0047", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, we expect segment revenue to grow 5% to 10%, and segment \nadjusted operating profit in the range of down 5% to flat.  We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations.  Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "original_text": "Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "391c3d9feed1fe0dc68b5c4b5e88254c36041bedde92f2970f1cce44f7ebe225", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a208060f-ce6f-4573-b55d-30c9efbdcf16", "node_type": "1", "metadata": {"window": "As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations.  Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "original_text": "Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n "}, "hash": "64d09cd6372d8af5da54678b093594f10a3034bcae6eca9635267d972a495e62", "class_name": "RelatedNodeInfo"}}, "text": "Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations. ", "start_char_idx": 3743, "end_char_idx": 3874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a208060f-ce6f-4573-b55d-30c9efbdcf16": {"__data__": {"id_": "a208060f-ce6f-4573-b55d-30c9efbdcf16", "embedding": null, "metadata": {"window": "As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations.  Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "original_text": "Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ad061ca3d7e71b696cf0582bf38123b785e47de49b37f94980813ede89ce896", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c759395-b778-4b80-855c-37852cededb2", "node_type": "1", "metadata": {"window": "We expect improvement in this segment over the second \nhalf of the fiscal year as we continue to realize the benefits of our strategic investments.  \n \n As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations.  Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "original_text": "Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations. ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc345108065c8f55eeee8727f0d0fcd7a77097cbac424d7fcd7213e5e118443e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bce708e3-7103-4f4c-a87a-5e89b7005199", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "2429bf7bf86ab909126b4a0df1d249c15a7e1a845bab9a272137a9247cead2f7", "class_name": "RelatedNodeInfo"}}, "text": "Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "start_char_idx": 3874, "end_char_idx": 4038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bce708e3-7103-4f4c-a87a-5e89b7005199": {"__data__": {"id_": "bce708e3-7103-4f4c-a87a-5e89b7005199", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a208060f-ce6f-4573-b55d-30c9efbdcf16", "node_type": "1", "metadata": {"window": "As this is our first quarter reporting Prescription Technology Solutions segment, I want to provide some \nbackground on  the drivers within this segment.  Brian discussed in his remarks how this segment brings together \nour RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses.  Volumes in our RelayHealth and \nCoverMyMeds businesses are driven by pharmaceutical transact ions, including prior authorizations.  Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "original_text": "Volumes in \nthese businesses are also driven by adding drug brands to the existing platforms and services that we offer to our \nbiopharma and pharmacy partners.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783cafe0c8281b107a8141d2de02b0cc7d0b4721a2ef8b22bc001db70af48cfa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fbd4b4f-7c30-4d15-858f-adfd8078e25f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate. "}, "hash": "6ef4ae638ff1279bf6efee5832e331d95ddc49fb180a352de41ce39fa0580a8a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fbd4b4f-7c30-4d15-858f-adfd8078e25f": {"__data__": {"id_": "0fbd4b4f-7c30-4d15-858f-adfd8078e25f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bce708e3-7103-4f4c-a87a-5e89b7005199", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fcdd2356408735e712b570b07e7425d85a0ff1f83356c1d36de2dc86f3466f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "525c1d4a-4f43-41d3-8004-2f52267f8378", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion. ", "original_text": "We now expect corporate expenses i n the range of $625 million to $675 million. "}, "hash": "690c98ca87f4958ba64cfed3d90420fbe296ce13c172a78448f1fda19229e531", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate. ", "start_char_idx": 16, "end_char_idx": 205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "525c1d4a-4f43-41d3-8004-2f52267f8378": {"__data__": {"id_": "525c1d4a-4f43-41d3-8004-2f52267f8378", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion. ", "original_text": "We now expect corporate expenses i n the range of $625 million to $675 million. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fbd4b4f-7c30-4d15-858f-adfd8078e25f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "000ae1bd68098c849e40bfae5438b029edf7f5a8edb6b7a3e868bd1c3a9bfa86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbac8b95-974f-47e4-8c53-b0a882dba469", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. ", "original_text": "Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n"}, "hash": "c4384648de0e0d00ca095a9ab9dcab2f57b15da35311c4ead8f3bf364fec255f", "class_name": "RelatedNodeInfo"}}, "text": "We now expect corporate expenses i n the range of $625 million to $675 million. ", "start_char_idx": 205, "end_char_idx": 285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbac8b95-974f-47e4-8c53-b0a882dba469": {"__data__": {"id_": "cbac8b95-974f-47e4-8c53-b0a882dba469", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. ", "original_text": "Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "525c1d4a-4f43-41d3-8004-2f52267f8378", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion. ", "original_text": "We now expect corporate expenses i n the range of $625 million to $675 million. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27112a5c55a429f887318d0186cf5c3dd0c5f5972cadec12ae0fb34895a07abf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c311d376-9ee9-49ab-ba79-9c18cc34cb50", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n", "original_text": "Let me wrap up  our outlook by turning to cash flow. "}, "hash": "da4b1753c331137577901e8c37bdfadb26c2fda894e1f83694f8cb8bd8b28177", "class_name": "RelatedNodeInfo"}}, "text": "Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n", "start_char_idx": 285, "end_char_idx": 487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c311d376-9ee9-49ab-ba79-9c18cc34cb50": {"__data__": {"id_": "c311d376-9ee9-49ab-ba79-9c18cc34cb50", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n", "original_text": "Let me wrap up  our outlook by turning to cash flow. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbac8b95-974f-47e4-8c53-b0a882dba469", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. ", "original_text": "Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20f3d54742c1bc4083c5be9b70e5851c2c55763ace696005b173dfc8a0e6389f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b133e3e5-95bf-4a8d-8bda-7edd9a37b013", "node_type": "1", "metadata": {"window": "We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility. ", "original_text": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion. "}, "hash": "02f1a79c85cfe222568e3acd4a8daa9e176ce45213c9c992650774224f0eabfd", "class_name": "RelatedNodeInfo"}}, "text": "Let me wrap up  our outlook by turning to cash flow. ", "start_char_idx": 487, "end_char_idx": 540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b133e3e5-95bf-4a8d-8bda-7edd9a37b013": {"__data__": {"id_": "b133e3e5-95bf-4a8d-8bda-7edd9a37b013", "embedding": null, "metadata": {"window": "We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility. ", "original_text": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c311d376-9ee9-49ab-ba79-9c18cc34cb50", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n", "original_text": "Let me wrap up  our outlook by turning to cash flow. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "346c6cc5a0c91c3598314f81d2f7a62c37436ed47c42dba58fe93147533cf53f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef33d0f6-5f22-4dc7-8c93-d5717d839aaf", "node_type": "1", "metadata": {"window": "Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year. ", "original_text": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. "}, "hash": "35d3cd2ed984cf8781d4a2a9d5ab702f07e5b4c325945d496969df631dc97fc8", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion. ", "start_char_idx": 540, "end_char_idx": 625, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef33d0f6-5f22-4dc7-8c93-d5717d839aaf": {"__data__": {"id_": "ef33d0f6-5f22-4dc7-8c93-d5717d839aaf", "embedding": null, "metadata": {"window": "Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year. ", "original_text": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b133e3e5-95bf-4a8d-8bda-7edd9a37b013", "node_type": "1", "metadata": {"window": "We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility. ", "original_text": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f078f40d8c87b9550fae5b130888932fce62ce32ef335ef7af4ccdb0a2b13ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f3867f1-0076-4c8a-b852-d89d639b3be5", "node_type": "1", "metadata": {"window": "Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition. ", "original_text": "This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n"}, "hash": "3ec9238771ec264a4c143402d5bdbfbec54ed63fac9c7143f615067d9d339670", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. ", "start_char_idx": 625, "end_char_idx": 739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f3867f1-0076-4c8a-b852-d89d639b3be5": {"__data__": {"id_": "7f3867f1-0076-4c8a-b852-d89d639b3be5", "embedding": null, "metadata": {"window": "Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition. ", "original_text": "This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef33d0f6-5f22-4dc7-8c93-d5717d839aaf", "node_type": "1", "metadata": {"window": "Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year. ", "original_text": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7aec040872d402cfad84a84c4413c9832a7fee42e2f28d6ebe0ad05550d7b499", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1644836e-3914-41dc-bc40-79d7eb82dac3", "node_type": "1", "metadata": {"window": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n", "original_text": "Our investment -grade credit rating remains a priority and underpins our financial flexibility. "}, "hash": "adb7bb67b7fba7cf46329e9b4d80b831cdba9fc5049823bbff51d3f6f0fedf42", "class_name": "RelatedNodeInfo"}}, "text": "This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n", "start_char_idx": 739, "end_char_idx": 919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1644836e-3914-41dc-bc40-79d7eb82dac3": {"__data__": {"id_": "1644836e-3914-41dc-bc40-79d7eb82dac3", "embedding": null, "metadata": {"window": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n", "original_text": "Our investment -grade credit rating remains a priority and underpins our financial flexibility. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f3867f1-0076-4c8a-b852-d89d639b3be5", "node_type": "1", "metadata": {"window": "Let me wrap up  our outlook by turning to cash flow.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition. ", "original_text": "This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3fa1c53650f8635979fa881abdc489fc09fa4c625b18a4410c85805fe4a8a6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f297ce9a-27a7-455b-a56c-ca9d6a9e0b18", "node_type": "1", "metadata": {"window": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year. ", "original_text": "We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year. "}, "hash": "c633267689beee3f8aca8dfa057180ffa6340cde4c9d8566a2d62139959adf4c", "class_name": "RelatedNodeInfo"}}, "text": "Our investment -grade credit rating remains a priority and underpins our financial flexibility. ", "start_char_idx": 919, "end_char_idx": 1015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f297ce9a-27a7-455b-a56c-ca9d6a9e0b18": {"__data__": {"id_": "f297ce9a-27a7-455b-a56c-ca9d6a9e0b18", "embedding": null, "metadata": {"window": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year. ", "original_text": "We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1644836e-3914-41dc-bc40-79d7eb82dac3", "node_type": "1", "metadata": {"window": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 billion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n", "original_text": "Our investment -grade credit rating remains a priority and underpins our financial flexibility. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "420452e7ae2313432a2631f0b4ad43469808ec0339964609c0e19904a9b1ebe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4dae317-6674-46cc-a0ad-ceb22b74526d", "node_type": "1", "metadata": {"window": "This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment. ", "original_text": "We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition. "}, "hash": "7e39704bd8187bba3e5f3605ffa9268c09832a3e1817e11f04427a76e9a329d7", "class_name": "RelatedNodeInfo"}}, "text": "We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year. ", "start_char_idx": 1015, "end_char_idx": 1127, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4dae317-6674-46cc-a0ad-ceb22b74526d": {"__data__": {"id_": "d4dae317-6674-46cc-a0ad-ceb22b74526d", "embedding": null, "metadata": {"window": "This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment. ", "original_text": "We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f297ce9a-27a7-455b-a56c-ca9d6a9e0b18", "node_type": "1", "metadata": {"window": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year. ", "original_text": "We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d04dce5f6c94b010b235d2c159411154f11f371dd6191a96ab608e1c0afa7005", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7466c40-eff8-4514-8ab0-a05e3000cded", "node_type": "1", "metadata": {"window": "Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices. ", "original_text": "And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n"}, "hash": "c645aa0cb4a12e25800ebc4310961350899a4d8aa09553da9734e4f19e720dae", "class_name": "RelatedNodeInfo"}}, "text": "We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition. ", "start_char_idx": 1127, "end_char_idx": 1290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7466c40-eff8-4514-8ab0-a05e3000cded": {"__data__": {"id_": "e7466c40-eff8-4514-8ab0-a05e3000cded", "embedding": null, "metadata": {"window": "Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices. ", "original_text": "And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4dae317-6674-46cc-a0ad-ceb22b74526d", "node_type": "1", "metadata": {"window": "This consistent cash flow generation provides the financial flexibility to continue investing in our \nstrategic initiatives, which position our business for long -term growth.  \n \n Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment. ", "original_text": "We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6af9d6a10628766e296b63cb9a8b9363c90c3615a4189dbdc8d567592edf843d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d82a48d-3bc1-46c6-972e-21262b0821cc", "node_type": "1", "metadata": {"window": "We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n", "original_text": "In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year. "}, "hash": "49e2c5d590d246b0231079fa9ac0f41b53dc4461e717e22f4b52596c6516bffb", "class_name": "RelatedNodeInfo"}}, "text": "And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n", "start_char_idx": 1290, "end_char_idx": 1410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d82a48d-3bc1-46c6-972e-21262b0821cc": {"__data__": {"id_": "6d82a48d-3bc1-46c6-972e-21262b0821cc", "embedding": null, "metadata": {"window": "We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n", "original_text": "In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7466c40-eff8-4514-8ab0-a05e3000cded", "node_type": "1", "metadata": {"window": "Our investment -grade credit rating remains a priority and underpins our financial flexibility.  We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices. ", "original_text": "And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6740e5469a647fa13d0d14406187a0ff20f6ecff3a7b4eda5b6c78b00c7444a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "251f4a41-6beb-4b54-b368-c7a1bd9808ce", "node_type": "1", "metadata": {"window": "We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment. "}, "hash": "45a895bff6bb398ac8071c1de83b40d7ecd6f249358a331c95e18cd54e13ad66", "class_name": "RelatedNodeInfo"}}, "text": "In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year. ", "start_char_idx": 1410, "end_char_idx": 1566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "251f4a41-6beb-4b54-b368-c7a1bd9808ce": {"__data__": {"id_": "251f4a41-6beb-4b54-b368-c7a1bd9808ce", "embedding": null, "metadata": {"window": "We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d82a48d-3bc1-46c6-972e-21262b0821cc", "node_type": "1", "metadata": {"window": "We have  two bonds \ntotaling approximately $1 billion, which matured during the second half of our fiscal year.  We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n", "original_text": "In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9975d8d362e8bd332b8cc7e5df9e45d2df8e816ee989a94cf45161ef7fdd9dc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d86f7aab-b552-4bbe-91a3-415d25aef9bb", "node_type": "1", "metadata": {"window": "And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you. ", "original_text": "We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices. "}, "hash": "c580e0483aabd80e2ddb9871ad179e88213484ca7801da138db949052e84e7a0", "class_name": "RelatedNodeInfo"}}, "text": "Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment. ", "start_char_idx": 1566, "end_char_idx": 1700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d86f7aab-b552-4bbe-91a3-415d25aef9bb": {"__data__": {"id_": "d86f7aab-b552-4bbe-91a3-415d25aef9bb", "embedding": null, "metadata": {"window": "And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you. ", "original_text": "We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "251f4a41-6beb-4b54-b368-c7a1bd9808ce", "node_type": "1", "metadata": {"window": "We intend to utilize a \nportion of our free cash flow to modestly delever by up to $500 million, further strengthening our balance sheet \nand financial pos ition.  And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b75f738073c6f52dcd793a87b9864ac54a9bcd24f15c4217ea8f0340e0735691", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b23e89c7-3707-4c86-a935-b774e3baa6c2", "node_type": "1", "metadata": {"window": "In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions. ", "original_text": "We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n"}, "hash": "25609427ceac7ac828275345d50344d6326b76f02fa6a2e11b24a33ecfb8096c", "class_name": "RelatedNodeInfo"}}, "text": "We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices. ", "start_char_idx": 1700, "end_char_idx": 1880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b23e89c7-3707-4c86-a935-b774e3baa6c2": {"__data__": {"id_": "b23e89c7-3707-4c86-a935-b774e3baa6c2", "embedding": null, "metadata": {"window": "In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions. ", "original_text": "We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d86f7aab-b552-4bbe-91a3-415d25aef9bb", "node_type": "1", "metadata": {"window": "And we remain committed to returning capital to shareholders through a modest dividend \nand through share buybacks.  \n \n In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you. ", "original_text": "We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1fb92f36c689a673b125a59fd46a6f530f6b815b3adf62b39aaf08c6a1ca499", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80438911-4b64-402a-b16d-a6b822eebb49", "node_type": "1", "metadata": {"window": "Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate. ", "original_text": "And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n"}, "hash": "1698d18c9bb5d61567e66b264a778e9649c86ab253aebdf2835c4c9fa7187526", "class_name": "RelatedNodeInfo"}}, "text": "We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n", "start_char_idx": 1880, "end_char_idx": 2068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80438911-4b64-402a-b16d-a6b822eebb49": {"__data__": {"id_": "80438911-4b64-402a-b16d-a6b822eebb49", "embedding": null, "metadata": {"window": "Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate. ", "original_text": "And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b23e89c7-3707-4c86-a935-b774e3baa6c2", "node_type": "1", "metadata": {"window": "In closing, we're pleased with the results of our fiscal second quarter, and we're confident in our updated outlook \nfor the remainder  of the fiscal year.  Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions. ", "original_text": "We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0475b454103c59ca750833ff486f402033acd13fccb1f9c229e0577b0f410d75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcba99af-1ca1-4db5-a588-7b0b2a924684", "node_type": "1", "metadata": {"window": "We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n ", "original_text": "Thank you. "}, "hash": "18b729cf5244fc0472c84cdddb6ef550407180a585bd76c5384a4d58901e063f", "class_name": "RelatedNodeInfo"}}, "text": "And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "start_char_idx": 2068, "end_char_idx": 2465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcba99af-1ca1-4db5-a588-7b0b2a924684": {"__data__": {"id_": "dcba99af-1ca1-4db5-a588-7b0b2a924684", "embedding": null, "metadata": {"window": "We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n ", "original_text": "Thank you. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80438911-4b64-402a-b16d-a6b822eebb49", "node_type": "1", "metadata": {"window": "Our focus and execution should drive another full year of operating profit \ngrowth despite a challenging and competitive environment.  We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate. ", "original_text": "And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28043faaf4046fa48d17b3b0c60c1ce59eaa02bdc4bc660b993fead4228190b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a96cfa5-c5c7-4a3b-9f18-f0bb67cd4989", "node_type": "1", "metadata": {"window": "We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "We will now take questions. "}, "hash": "dfb3a1ea3ff4b4a78e58f7908d28ae3f8bb8793f3def4319e68b66b6b07715a3", "class_name": "RelatedNodeInfo"}}, "text": "Thank you. ", "start_char_idx": 2465, "end_char_idx": 2476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a96cfa5-c5c7-4a3b-9f18-f0bb67cd4989": {"__data__": {"id_": "3a96cfa5-c5c7-4a3b-9f18-f0bb67cd4989", "embedding": null, "metadata": {"window": "We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "We will now take questions. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcba99af-1ca1-4db5-a588-7b0b2a924684", "node_type": "1", "metadata": {"window": "We will continue to invest in high -growth, high -margin \nmarkets and strategic areas that will further l everage our differentiated positions in oncology and biopharma \nservices.  We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n ", "original_text": "Thank you. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52da4e3676596cc1478dd29b28a22c8e15c2eec57c1a113900c834e5f333304f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c3db873-b00d-4c53-8fb9-c2413c448c9a", "node_type": "1", "metadata": {"window": "And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Operator, can we go to questions, please?  \n  ", "original_text": "In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate. "}, "hash": "0713e843d7d85ce1b3659ec7f3b11c6aa391164a719b60b0bcbb34ba0ca3ae69", "class_name": "RelatedNodeInfo"}}, "text": "We will now take questions. ", "start_char_idx": 2476, "end_char_idx": 2504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c3db873-b00d-4c53-8fb9-c2413c448c9a": {"__data__": {"id_": "2c3db873-b00d-4c53-8fb9-c2413c448c9a", "embedding": null, "metadata": {"window": "And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Operator, can we go to questions, please?  \n  ", "original_text": "In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a96cfa5-c5c7-4a3b-9f18-f0bb67cd4989", "node_type": "1", "metadata": {"window": "We're proud of our expanding partnerships as we work on the COVID -19 vaccine effort and continue to \nbe an important part of the pandemic response to maintain supply chain stability.  \n \n And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "We will now take questions. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9e15ff55fa82bad947dc00f710d505f9014cfd6e81a4e4db452907b4ae70b78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "454a9c20-ba63-4c50-af45-1edaa9e936d8", "node_type": "1", "metadata": {"window": "Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Operator, can we go to questions, please?  \n  ", "original_text": "Operator?  \n "}, "hash": "7a9fe73b99040d06fb894888b5b0e559b21805416cb325ed8a88076bf6ac1325", "class_name": "RelatedNodeInfo"}}, "text": "In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate. ", "start_char_idx": 2504, "end_char_idx": 2620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "454a9c20-ba63-4c50-af45-1edaa9e936d8": {"__data__": {"id_": "454a9c20-ba63-4c50-af45-1edaa9e936d8", "embedding": null, "metadata": {"window": "Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Operator, can we go to questions, please?  \n  ", "original_text": "Operator?  \n ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c3db873-b00d-4c53-8fb9-c2413c448c9a", "node_type": "1", "metadata": {"window": "And with that, Holly, let me turn the call back to you for Q&A  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Operator, can we go to questions, please?  \n  ", "original_text": "In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate. ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e258ce161ea61fcf5d7f11daf29cf73def8cbc4d3864fadfbab21b4a0624239", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7a746b9-7698-4cce-a2d3-d546bd47059f", "node_type": "1", "metadata": {"window": "We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Operator, can we go to questions, please?  \n  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "80f331306f77e5b8c5e2c24c56f24b4f881a63b228cdc010ef489cbd3293cf37", "class_name": "RelatedNodeInfo"}}, "text": "Operator?  \n ", "start_char_idx": 2620, "end_char_idx": 2633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7a746b9-7698-4cce-a2d3-d546bd47059f": {"__data__": {"id_": "b7a746b9-7698-4cce-a2d3-d546bd47059f", "embedding": null, "metadata": {"window": "We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Operator, can we go to questions, please?  \n  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "454a9c20-ba63-4c50-af45-1edaa9e936d8", "node_type": "1", "metadata": {"window": "Thank you.  We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Operator, can we go to questions, please?  \n  ", "original_text": "Operator?  \n ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34c91039baa0ae13e088a34f51d7d7be12fe51e70a4f94cf1c189505aec03ab7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86cb85c8-02f1-4bc8-b8fb-8b50aade4aff", "node_type": "1", "metadata": {"window": "In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Operator, can we go to questions, please?  \n  ", "original_text": "Operator, can we go to questions, please?  \n  "}, "hash": "4c77cd6dc2c20129c29b9c9725e3288226825fe506284eca22c944c4bdade739", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 2633, "end_char_idx": 2960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86cb85c8-02f1-4bc8-b8fb-8b50aade4aff": {"__data__": {"id_": "86cb85c8-02f1-4bc8-b8fb-8b50aade4aff", "embedding": null, "metadata": {"window": "In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Operator, can we go to questions, please?  \n  ", "original_text": "Operator, can we go to questions, please?  \n  ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a40d09fc0a26a8fffd9fb1df4cfa8171bb2d7cfb00bbe2ff5224f0d4f0fd3f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7a746b9-7698-4cce-a2d3-d546bd47059f", "node_type": "1", "metadata": {"window": "We will now take questions.  In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Operator, can we go to questions, please?  \n  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79754b2856b8d84eb61cafc6aa991e9c411f8127ade5f3d46fd35b6a220b594c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d198b7ae-1903-4fd0-adad-c80e1df97d9b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n ", "original_text": "McKesson Corp.  "}, "hash": "5fb4ae80591d785cb201136b714c4e4e945ac310d1cc9a563228318854e64a23", "class_name": "RelatedNodeInfo"}}, "text": "Operator, can we go to questions, please?  \n  ", "start_char_idx": 2960, "end_char_idx": 3006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d198b7ae-1903-4fd0-adad-c80e1df97d9b": {"__data__": {"id_": "d198b7ae-1903-4fd0-adad-c80e1df97d9b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86cb85c8-02f1-4bc8-b8fb-8b50aade4aff", "node_type": "1", "metadata": {"window": "In the interest of time, please limit yourself to just one question to allow \nothers an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Operator, can we go to questions, please?  \n  ", "original_text": "Operator, can we go to questions, please?  \n  ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37f28e6bc1437731071edd6cfdd4053d0a7a5f1f3b3a9a719a9820626ba4e501", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08919262-c666-4298-9f5f-deadd6d00ee9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you. "}, "hash": "a75f57d2150e3bb27b4f3be41e10437ad32cdca7bbb81c3d31a5bc5093342d9a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08919262-c666-4298-9f5f-deadd6d00ee9": {"__data__": {"id_": "08919262-c666-4298-9f5f-deadd6d00ee9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d198b7ae-1903-4fd0-adad-c80e1df97d9b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff5bb35873b654a536d359013043581d1c1ce6340e4d84ecefa27bb7670ed8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a68c8f72-47d8-4538-a4ab-3fd1416fb421", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest. ", "original_text": "[Operator Instructions] Our first question will come from Eric Percher from Nephron Research. "}, "hash": "a9afe5b46ef354802674a9245b61c47d5c289392bde413641b2c1a99883e3af2", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you. ", "start_char_idx": 16, "end_char_idx": 230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a68c8f72-47d8-4538-a4ab-3fd1416fb421": {"__data__": {"id_": "a68c8f72-47d8-4538-a4ab-3fd1416fb421", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest. ", "original_text": "[Operator Instructions] Our first question will come from Eric Percher from Nephron Research. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08919262-c666-4298-9f5f-deadd6d00ee9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03dd1dfb066e7f46b1a155cc89542c42462b98f64932c1512959a3bc79d3109c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30d609df-dfd5-4e95-98f6-53b24813fdf6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally? ", "original_text": "Your \nline is now open.  \n "}, "hash": "0d1e71b44b56866d915652764ebc8f45ed7bb59c813bd97a5f580dc290668f8e", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] Our first question will come from Eric Percher from Nephron Research. ", "start_char_idx": 230, "end_char_idx": 324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30d609df-dfd5-4e95-98f6-53b24813fdf6": {"__data__": {"id_": "30d609df-dfd5-4e95-98f6-53b24813fdf6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally? ", "original_text": "Your \nline is now open.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a68c8f72-47d8-4538-a4ab-3fd1416fb421", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest. ", "original_text": "[Operator Instructions] Our first question will come from Eric Percher from Nephron Research. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d7e4e2b08495d8ece50e1cc3298cba2f1ba3da6ce3d705afd31c35c7c406e71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74304ce1-f520-40d4-8cb3-794b2be40f37", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. "}, "hash": "b4ede3e22278936ce8593690450a4e273e33bfad3b3870f8d161b0bcbe0e9e1d", "class_name": "RelatedNodeInfo"}}, "text": "Your \nline is now open.  \n ", "start_char_idx": 324, "end_char_idx": 351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74304ce1-f520-40d4-8cb3-794b2be40f37": {"__data__": {"id_": "74304ce1-f520-40d4-8cb3-794b2be40f37", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30d609df-dfd5-4e95-98f6-53b24813fdf6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally? ", "original_text": "Your \nline is now open.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974faf66e0924494965eec4b5500a336270a764622dd9c0314ae63ee3b3490be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4a4fd84-176e-4cd0-b243-69c5c5cb5c31", "node_type": "1", "metadata": {"window": "[Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type? ", "original_text": "Your role enabling the vaccination distribution is of great interest. "}, "hash": "2ac77b467ca4bb0c74429eda6c66cd3974edc590e3ea66f7a317782fdcd2cdce", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "start_char_idx": 351, "end_char_idx": 668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4a4fd84-176e-4cd0-b243-69c5c5cb5c31": {"__data__": {"id_": "b4a4fd84-176e-4cd0-b243-69c5c5cb5c31", "embedding": null, "metadata": {"window": "[Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type? ", "original_text": "Your role enabling the vaccination distribution is of great interest. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74304ce1-f520-40d4-8cb3-794b2be40f37", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cb618cfc4f0cfccf3511c7fc717923886f00e72a35145d1da0ca7e79030ef01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9da12cae-b6bb-4318-aed6-b6b18860a4a6", "node_type": "1", "metadata": {"window": "Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L? ", "original_text": "Brian, can you help us understand \nwhat's required operatio nally? "}, "hash": "249d334706e31bf8de42825214e3d8d738a4f81da21182c114b4ce908d89eaab", "class_name": "RelatedNodeInfo"}}, "text": "Your role enabling the vaccination distribution is of great interest. ", "start_char_idx": 668, "end_char_idx": 738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9da12cae-b6bb-4318-aed6-b6b18860a4a6": {"__data__": {"id_": "9da12cae-b6bb-4318-aed6-b6b18860a4a6", "embedding": null, "metadata": {"window": "Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L? ", "original_text": "Brian, can you help us understand \nwhat's required operatio nally? ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4a4fd84-176e-4cd0-b243-69c5c5cb5c31", "node_type": "1", "metadata": {"window": "[Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type? ", "original_text": "Your role enabling the vaccination distribution is of great interest. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b1760ce8d3881c699fa773e872ec5bff870356cdc87a33033539447dc1dc912", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9433b1c-d7fc-40db-b94b-1440859b4ff7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation? ", "original_text": "It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n"}, "hash": "b29eac2a42ba30e120e1dd0f0cb74d8fd3f82e54b61ea93fb712c7589765f7be", "class_name": "RelatedNodeInfo"}}, "text": "Brian, can you help us understand \nwhat's required operatio nally? ", "start_char_idx": 738, "end_char_idx": 805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9433b1c-d7fc-40db-b94b-1440859b4ff7": {"__data__": {"id_": "b9433b1c-d7fc-40db-b94b-1440859b4ff7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation? ", "original_text": "It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9da12cae-b6bb-4318-aed6-b6b18860a4a6", "node_type": "1", "metadata": {"window": "Your \nline is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L? ", "original_text": "Brian, can you help us understand \nwhat's required operatio nally? ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "945bb266c8d75530c8942abf6ffa0f5bde3535b788feae02b464233e5f23f7ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9603f71d-5a51-4198-bae9-c44de78c5a08", "node_type": "1", "metadata": {"window": "Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n ", "original_text": "And then, Britt, can you help us understand the financial flows from a government contract of this type? "}, "hash": "60e927000639b898f0e4061eef659338fbba983957c1a9ecec89e66fa41fb25e", "class_name": "RelatedNodeInfo"}}, "text": "It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n", "start_char_idx": 805, "end_char_idx": 910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9603f71d-5a51-4198-bae9-c44de78c5a08": {"__data__": {"id_": "9603f71d-5a51-4198-bae9-c44de78c5a08", "embedding": null, "metadata": {"window": "Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n ", "original_text": "And then, Britt, can you help us understand the financial flows from a government contract of this type? ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9433b1c-d7fc-40db-b94b-1440859b4ff7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation? ", "original_text": "It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9914a47c85cf322e9cf4b2cb0a062486db936e9ae528a463d78c72632e8c0532", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed767a5e-e2e0-4b74-b95c-abb091755063", "node_type": "1", "metadata": {"window": "Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Does \nsome of the initial government investm ent flow through the P&L? "}, "hash": "89c929cb0501d4749233a543cc3ec509c40e7afc3fe0b1fbdcffa36bb8a9c022", "class_name": "RelatedNodeInfo"}}, "text": "And then, Britt, can you help us understand the financial flows from a government contract of this type? ", "start_char_idx": 910, "end_char_idx": 1015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed767a5e-e2e0-4b74-b95c-abb091755063": {"__data__": {"id_": "ed767a5e-e2e0-4b74-b95c-abb091755063", "embedding": null, "metadata": {"window": "Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Does \nsome of the initial government investm ent flow through the P&L? ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9603f71d-5a51-4198-bae9-c44de78c5a08", "node_type": "1", "metadata": {"window": "Your role enabling the vaccination distribution is of great interest.  Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n ", "original_text": "And then, Britt, can you help us understand the financial flows from a government contract of this type? ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76cbefb029064d26222164a32f53dadaeb86edb5b768531d48ff65ef97a28799", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73246742-8cea-4ba5-8805-b4c3a458d355", "node_type": "1", "metadata": {"window": "It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric. ", "original_text": "And should we think of this as paid for \npreparation? "}, "hash": "2c115f74e9614c08c288871f3c6a3582dc0217a132d7cb8a0a987fe5be7166f3", "class_name": "RelatedNodeInfo"}}, "text": "Does \nsome of the initial government investm ent flow through the P&L? ", "start_char_idx": 1015, "end_char_idx": 1086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73246742-8cea-4ba5-8805-b4c3a458d355": {"__data__": {"id_": "73246742-8cea-4ba5-8805-b4c3a458d355", "embedding": null, "metadata": {"window": "It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric. ", "original_text": "And should we think of this as paid for \npreparation? ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed767a5e-e2e0-4b74-b95c-abb091755063", "node_type": "1", "metadata": {"window": "Brian, can you help us understand \nwhat's required operatio nally?  It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Does \nsome of the initial government investm ent flow through the P&L? ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "466dae1e16f807f22386b6a0cbdef38f9d1691a633b13fd0687d570ff96e2aa6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad2c18a0-d210-4478-bed9-f5373d63d586", "node_type": "1", "metadata": {"window": "And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question. ", "original_text": "Or is it really tied to the amount of volume that ultimately moves through?  \n "}, "hash": "e1504a1f46362f0527be9e8735f274b60694e99491e4d06d9425d572d792889f", "class_name": "RelatedNodeInfo"}}, "text": "And should we think of this as paid for \npreparation? ", "start_char_idx": 1086, "end_char_idx": 1140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad2c18a0-d210-4478-bed9-f5373d63d586": {"__data__": {"id_": "ad2c18a0-d210-4478-bed9-f5373d63d586", "embedding": null, "metadata": {"window": "And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question. ", "original_text": "Or is it really tied to the amount of volume that ultimately moves through?  \n ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73246742-8cea-4ba5-8805-b4c3a458d355", "node_type": "1", "metadata": {"window": "It sounds like you're developing some new DCs as well as using some of the \nexisting infrastructure.  \n \n And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric. ", "original_text": "And should we think of this as paid for \npreparation? ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ebcd6ffb6637684ada37e266ac0200bfd74ce5a011d887f5b6279418fd0e23be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a068e472-1b21-4466-80ab-8c41105b38ba", "node_type": "1", "metadata": {"window": "Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "60975884b768d4a69e17b93acacd4c2bc102028d0324e3c0d13400a841fc2c30", "class_name": "RelatedNodeInfo"}}, "text": "Or is it really tied to the amount of volume that ultimately moves through?  \n ", "start_char_idx": 1140, "end_char_idx": 1219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a068e472-1b21-4466-80ab-8c41105b38ba": {"__data__": {"id_": "a068e472-1b21-4466-80ab-8c41105b38ba", "embedding": null, "metadata": {"window": "Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad2c18a0-d210-4478-bed9-f5373d63d586", "node_type": "1", "metadata": {"window": "And then, Britt, can you help us understand the financial flows from a government contract of this type?  Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question. ", "original_text": "Or is it really tied to the amount of volume that ultimately moves through?  \n ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd9a72f00b7e93f9ffd42799d627fe6706d567fc3f41260c6c09e2dc5770ad42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "970ded1d-eb35-4306-8fb5-3e07ab0ca50e", "node_type": "1", "metadata": {"window": "And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage. ", "original_text": "A \nWell, good morning, Eric. "}, "hash": "7fb7da9f65d43fd1eb6a6c1d537ae6face1b81932519b91c24bc2cf7de986f04", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1219, "end_char_idx": 1545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "970ded1d-eb35-4306-8fb5-3e07ab0ca50e": {"__data__": {"id_": "970ded1d-eb35-4306-8fb5-3e07ab0ca50e", "embedding": null, "metadata": {"window": "And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage. ", "original_text": "A \nWell, good morning, Eric. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a068e472-1b21-4466-80ab-8c41105b38ba", "node_type": "1", "metadata": {"window": "Does \nsome of the initial government investm ent flow through the P&L?  And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57acc63755f42a37c88c6cb7ac9217b12d0a6e143caf428829ca6204ddc4a33a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "569fdabb-4cca-4cd2-8fd7-98111ca55de4", "node_type": "1", "metadata": {"window": "Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking. ", "original_text": "Than k you for the question. "}, "hash": "508980025b6518f52a4e2f8c775f5a1c654e4d1a0f93c740834ed8731012f936", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, good morning, Eric. ", "start_char_idx": 1545, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "569fdabb-4cca-4cd2-8fd7-98111ca55de4": {"__data__": {"id_": "569fdabb-4cca-4cd2-8fd7-98111ca55de4", "embedding": null, "metadata": {"window": "Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking. ", "original_text": "Than k you for the question. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "970ded1d-eb35-4306-8fb5-3e07ab0ca50e", "node_type": "1", "metadata": {"window": "And should we think of this as paid for \npreparation?  Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage. ", "original_text": "A \nWell, good morning, Eric. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8cf0606d27b41c6d459c1961949ccc53d514b159fa4cc97c70b5c883727bcfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c250e829-a07f-4203-b08c-fc167bde1375", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n ", "original_text": "We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute. "}, "hash": "6ecfd0d2f958e0299a3fe25681daf13817d8b232f214d5feda209af43f84e966", "class_name": "RelatedNodeInfo"}}, "text": "Than k you for the question. ", "start_char_idx": 1574, "end_char_idx": 1603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c250e829-a07f-4203-b08c-fc167bde1375": {"__data__": {"id_": "c250e829-a07f-4203-b08c-fc167bde1375", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n ", "original_text": "We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "569fdabb-4cca-4cd2-8fd7-98111ca55de4", "node_type": "1", "metadata": {"window": "Or is it really tied to the amount of volume that ultimately moves through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking. ", "original_text": "Than k you for the question. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79a47024b2a32781a89da6af46029bcb9a3c874f4b30437000d46ea51d6f6916", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecbf4371-65bd-4d00-a71c-cb004cb3b5b3", "node_type": "1", "metadata": {"window": "A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage. "}, "hash": "3bfaaf5cc677e6c7a50b520992e19a0a66550327bb2164e3cc5ad9ad70b04a96", "class_name": "RelatedNodeInfo"}}, "text": "We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute. ", "start_char_idx": 1603, "end_char_idx": 1736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecbf4371-65bd-4d00-a71c-cb004cb3b5b3": {"__data__": {"id_": "ecbf4371-65bd-4d00-a71c-cb004cb3b5b3", "embedding": null, "metadata": {"window": "A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c250e829-a07f-4203-b08c-fc167bde1375", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n ", "original_text": "We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "226da995ed428f0efcd1ab3d408f26d0850e6f989c6f33b25c48e40dc86ec491", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a7eb11b-938e-42bb-bbc5-7f81fb645db0", "node_type": "1", "metadata": {"window": "Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question. ", "original_text": "That is all in -flight on plan tracking. "}, "hash": "5f21d7b0e70b01a24aa2d11118a62777391d1e35c69337d32741eb70128ecd6c", "class_name": "RelatedNodeInfo"}}, "text": "Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage. ", "start_char_idx": 1736, "end_char_idx": 1953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a7eb11b-938e-42bb-bbc5-7f81fb645db0": {"__data__": {"id_": "1a7eb11b-938e-42bb-bbc5-7f81fb645db0", "embedding": null, "metadata": {"window": "Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question. ", "original_text": "That is all in -flight on plan tracking. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecbf4371-65bd-4d00-a71c-cb004cb3b5b3", "node_type": "1", "metadata": {"window": "A \nWell, good morning, Eric.  Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8f1d19125416877a8f9c3b9ef27bd0fa2a8939f9cccb17f43a85d6f7524c149", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adb983bf-fc80-4a3d-8f85-816393097273", "node_type": "1", "metadata": {"window": "We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program. ", "original_text": "But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n "}, "hash": "8a00d690152348e3bd2985a6f04cf0d38e08e31a40e296c83f5c388c49388fd6", "class_name": "RelatedNodeInfo"}}, "text": "That is all in -flight on plan tracking. ", "start_char_idx": 1953, "end_char_idx": 1994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adb983bf-fc80-4a3d-8f85-816393097273": {"__data__": {"id_": "adb983bf-fc80-4a3d-8f85-816393097273", "embedding": null, "metadata": {"window": "We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program. ", "original_text": "But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a7eb11b-938e-42bb-bbc5-7f81fb645db0", "node_type": "1", "metadata": {"window": "Than k you for the question.  We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question. ", "original_text": "That is all in -flight on plan tracking. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94407438f4227a8cf8206718bc0bbe4ab9d3a42182ac1e9ac441096e775ff616", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f071b475-2dfa-4b72-8386-d4696468bde3", "node_type": "1", "metadata": {"window": "Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "0a25057032f48b9c753ad27d1bbf42ef02509c2d44ae5c7d842b195645bbca90", "class_name": "RelatedNodeInfo"}}, "text": "But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n ", "start_char_idx": 1994, "end_char_idx": 2168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f071b475-2dfa-4b72-8386-d4696468bde3": {"__data__": {"id_": "f071b475-2dfa-4b72-8386-d4696468bde3", "embedding": null, "metadata": {"window": "Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adb983bf-fc80-4a3d-8f85-816393097273", "node_type": "1", "metadata": {"window": "We're fortunate to have had the H1N1 experience about a \ndecade ago and provided a bit of a roadmap or a playbook for us to execute.  Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program. ", "original_text": "But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa657f634a83ae3d7206582ea4b7d2cbffe6dd555d563330c51e6d5cd19198a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81f3b4d3-6ac3-416c-b961-9ef04ef19fab", "node_type": "1", "metadata": {"window": "That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider. ", "original_text": "A \nEric, let me address your second question. "}, "hash": "19e5af794ebd259196a6c1dc29759166b41347b4398b2ad7c6e83de81bbe8016", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2168, "end_char_idx": 2513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81f3b4d3-6ac3-416c-b961-9ef04ef19fab": {"__data__": {"id_": "81f3b4d3-6ac3-416c-b961-9ef04ef19fab", "embedding": null, "metadata": {"window": "That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider. ", "original_text": "A \nEric, let me address your second question. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f071b475-2dfa-4b72-8386-d4696468bde3", "node_type": "1", "metadata": {"window": "Based on the volumes that we've \nbeen given and projections, we have quickly been engaged in standing  up some new facilities, both for the \nvaccine distribution and for the kitting and frankly for just some storage.  That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f62305ee482d8072100abd9eaca3e8a5aa3403e5d0b1899b2b85a4260dc0b379", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c696ca8-0be5-43a8-9886-85182f864bee", "node_type": "1", "metadata": {"window": "But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side. ", "original_text": "There's a couple of different elements to this program. "}, "hash": "7591ef4f648ec9b7cae7d21d9f79ce4d88b182013bb90bbebabc7b0c8a904d9d", "class_name": "RelatedNodeInfo"}}, "text": "A \nEric, let me address your second question. ", "start_char_idx": 2513, "end_char_idx": 2559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c696ca8-0be5-43a8-9886-85182f864bee": {"__data__": {"id_": "3c696ca8-0be5-43a8-9886-85182f864bee", "embedding": null, "metadata": {"window": "But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side. ", "original_text": "There's a couple of different elements to this program. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81f3b4d3-6ac3-416c-b961-9ef04ef19fab", "node_type": "1", "metadata": {"window": "That is all in -flight on plan tracking.  But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider. ", "original_text": "A \nEric, let me address your second question. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad2f1b78faa2b959659c309e5864a76fc4895d9da030ec6a5596761fb7b295f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "067716d8-691c-48d5-b9b3-5efb06e4d26b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved. ", "original_text": "As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities. "}, "hash": "2be8ee5ca33089a51351c4d32e27ce728e12f96dd8023272c1777f2469bdae61", "class_name": "RelatedNodeInfo"}}, "text": "There's a couple of different elements to this program. ", "start_char_idx": 2559, "end_char_idx": 2615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "067716d8-691c-48d5-b9b3-5efb06e4d26b": {"__data__": {"id_": "067716d8-691c-48d5-b9b3-5efb06e4d26b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved. ", "original_text": "As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c696ca8-0be5-43a8-9886-85182f864bee", "node_type": "1", "metadata": {"window": "But, \nyes, it will be \u2013 it's a big effort to stand up several new facilities and onboard a lot of new e mployees, but \nsomething that we've successfully done in the past.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side. ", "original_text": "There's a couple of different elements to this program. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7f02ff68eb2abcda1baed9b7d3916f8248c961af100ac84ef35f4eb81e9973a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f231061c-2542-4519-b0ec-77c822c172fb", "node_type": "1", "metadata": {"window": "A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n ", "original_text": "We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider. "}, "hash": "aad1b7abaa8dd51a022fb07914ad43f3c93f2b8e38d0359b9967a30f6e1706b0", "class_name": "RelatedNodeInfo"}}, "text": "As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities. ", "start_char_idx": 2615, "end_char_idx": 2723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f231061c-2542-4519-b0ec-77c822c172fb": {"__data__": {"id_": "f231061c-2542-4519-b0ec-77c822c172fb", "embedding": null, "metadata": {"window": "A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n ", "original_text": "We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "067716d8-691c-48d5-b9b3-5efb06e4d26b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved. ", "original_text": "As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ccb041a6f880d859fdd4f41b550b468b21114b980982ca3e03d16221ac013e35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b8d3836-7571-45c7-85d9-8bdc7a651e77", "node_type": "1", "metadata": {"window": "There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "That's on the vaccine side. "}, "hash": "8c12ebbdf4979e1f0fdd7e8506c77665adb5a4ff3d57572deecc88fb0e26775a", "class_name": "RelatedNodeInfo"}}, "text": "We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider. ", "start_char_idx": 2723, "end_char_idx": 2901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b8d3836-7571-45c7-85d9-8bdc7a651e77": {"__data__": {"id_": "9b8d3836-7571-45c7-85d9-8bdc7a651e77", "embedding": null, "metadata": {"window": "There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "That's on the vaccine side. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f231061c-2542-4519-b0ec-77c822c172fb", "node_type": "1", "metadata": {"window": "A \nEric, let me address your second question.  There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n ", "original_text": "We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65f0fa096ee88b9976e68bb383142564d729dc7a24464839927b578cb53f0f3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c06fb672-a916-4321-bcf3-f7ef000f8862", "node_type": "1", "metadata": {"window": "As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n ", "original_text": "Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved. "}, "hash": "da53bab975f05970d5b5748f13d661c780eac08cfecfd1091f5de75a34ecacd7", "class_name": "RelatedNodeInfo"}}, "text": "That's on the vaccine side. ", "start_char_idx": 2901, "end_char_idx": 2929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c06fb672-a916-4321-bcf3-f7ef000f8862": {"__data__": {"id_": "c06fb672-a916-4321-bcf3-f7ef000f8862", "embedding": null, "metadata": {"window": "As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n ", "original_text": "Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b8d3836-7571-45c7-85d9-8bdc7a651e77", "node_type": "1", "metadata": {"window": "There's a couple of different elements to this program.  As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "That's on the vaccine side. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a62f30fa7bdb5d482ce11fa5fd193e718d03be3b0cb56cb5dc999a78991d2a14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b46de158-df7f-488d-a164-44f031858c9f", "node_type": "1", "metadata": {"window": "We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs. ", "original_text": "On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n "}, "hash": "d5d692cdfa6314c6dfefd2ea6f758c569ae6c6ebd44c2e492de2a1e5fb01dcf9", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved. ", "start_char_idx": 2929, "end_char_idx": 3023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b46de158-df7f-488d-a164-44f031858c9f": {"__data__": {"id_": "b46de158-df7f-488d-a164-44f031858c9f", "embedding": null, "metadata": {"window": "We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs. ", "original_text": "On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c06fb672-a916-4321-bcf3-f7ef000f8862", "node_type": "1", "metadata": {"window": "As we've talked \nabout previously, we were reimbursed for some of the costs to set up these new facilities.  We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n ", "original_text": "Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc414b87370d62f1f6b1073e5ec05a3c92a4cb930c74a039588186a422f0186a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "269b903f-d595-482b-875b-f8d4979dbb30", "node_type": "1", "metadata": {"window": "That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "115e90f21411edc7fa73b4e99460d117e663289a81910a3ca04d95babe6d8f12", "class_name": "RelatedNodeInfo"}}, "text": "On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n ", "start_char_idx": 3023, "end_char_idx": 3224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "269b903f-d595-482b-875b-f8d4979dbb30": {"__data__": {"id_": "269b903f-d595-482b-875b-f8d4979dbb30", "embedding": null, "metadata": {"window": "That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b46de158-df7f-488d-a164-44f031858c9f", "node_type": "1", "metadata": {"window": "We will also, when a \nvaccine is approved and we begin distribution, we'll recognize a fair value for the services that we perform similar \nto a third -party logistics provider.  That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs. ", "original_text": "On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8b05e3d389d1326947230b751d8737bf0edf12c00fc16a3979d46ac436a128a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91899606-e6e1-4bd3-8047-221bf6322263", "node_type": "1", "metadata": {"window": "Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "A \nNext question, operator?  \n "}, "hash": "cdb10cbf93260222279072ce590b3299fdc62abd2f15d1b024a3e85852ab130e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 3224, "end_char_idx": 3554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91899606-e6e1-4bd3-8047-221bf6322263": {"__data__": {"id_": "91899606-e6e1-4bd3-8047-221bf6322263", "embedding": null, "metadata": {"window": "Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "A \nNext question, operator?  \n ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "269b903f-d595-482b-875b-f8d4979dbb30", "node_type": "1", "metadata": {"window": "That's on the vaccine side.  Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "475af3221e678e8284c2348432e022ad5f347c6bf29e4fbe0dba022120e33635", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "660a32db-9859-46af-9b58-f719324a3981", "node_type": "1", "metadata": {"window": "On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs. "}, "hash": "eac5c6d7b06d9f4d014812d7383bdc79c3bf630608b69ac5fa88fe7a36afabec", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, operator?  \n ", "start_char_idx": 3554, "end_char_idx": 3585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "660a32db-9859-46af-9b58-f719324a3981": {"__data__": {"id_": "660a32db-9859-46af-9b58-f719324a3981", "embedding": null, "metadata": {"window": "On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91899606-e6e1-4bd3-8047-221bf6322263", "node_type": "1", "metadata": {"window": "Obviously, that hasn't started yet as the \u2013 there's not \nbeen a vaccine that's been approved.  On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "A \nNext question, operator?  \n ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06295f54d29be7acebb456cb8cee41bfcf84fa0394db1264d94a085a9b93301c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e62903ca-1cde-4899-a770-0d7fdf3c0999", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Your li ne is now open.  \n "}, "hash": "3741f3e144331951a3af4fdb3dbf618f3a29c9e9b905b9f1e379193fa9bdc893", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs. ", "start_char_idx": 3585, "end_char_idx": 3905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e62903ca-1cde-4899-a770-0d7fdf3c0999": {"__data__": {"id_": "e62903ca-1cde-4899-a770-0d7fdf3c0999", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Your li ne is now open.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "660a32db-9859-46af-9b58-f719324a3981", "node_type": "1", "metadata": {"window": "On the kitting side, it'll be very similar to how we prepare kits that we did in \nH1N1, as we prepare kits and  produce those kits, we'll recognize revenue as those kits are prepared and \nproduced.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs. ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8aced22ffd2db00b8bc7c9ccfd3d8b47f9b675ca379a5a1e8e9fdd76d24f8b56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72e02a3b-0d91-442c-ab7f-456edb67ca2d", "node_type": "1", "metadata": {"window": "A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "b70a910808aee596395071f4053764b720f768db95dc54e4215249983ea47d1d", "class_name": "RelatedNodeInfo"}}, "text": "Your li ne is now open.  \n ", "start_char_idx": 3905, "end_char_idx": 3932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72e02a3b-0d91-442c-ab7f-456edb67ca2d": {"__data__": {"id_": "72e02a3b-0d91-442c-ab7f-456edb67ca2d", "embedding": null, "metadata": {"window": "A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65245c90ec204380f78491d62fd7453f9363e52d4aeeca8da20bd4470b4684a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e62903ca-1cde-4899-a770-0d7fdf3c0999", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Your li ne is now open.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70221dc3421b98f60909589ebdcbd934e29a3c6227bedb77d376b28eafdc9e4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28ac2ad2-2ded-40da-b03e-31bf0181ded8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question. ", "original_text": "McKesson Corp.  "}, "hash": "320eae7bc1363f7bf9d78795c41ea9490a9c784ca6e9cf760e18744998e5ab96", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 351, "end_char_idx": 607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28ac2ad2-2ded-40da-b03e-31bf0181ded8": {"__data__": {"id_": "28ac2ad2-2ded-40da-b03e-31bf0181ded8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72e02a3b-0d91-442c-ab7f-456edb67ca2d", "node_type": "1", "metadata": {"window": "A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones from Goldman Sachs.  Your li ne is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9f9b5e354e4a1c63883e8f851a627456bcd2ce34af5873d95ed28e4f2314a20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f8706ac-902a-4bf2-9d05-93025a7b0702", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "5dc72214c85edcc0648194d39ef7dc6233680c91cbc50475e127195c4bb9e044", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f8706ac-902a-4bf2-9d05-93025a7b0702": {"__data__": {"id_": "9f8706ac-902a-4bf2-9d05-93025a7b0702", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28ac2ad2-2ded-40da-b03e-31bf0181ded8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9d609f92b3c5e01f657aa4f3a03bfd396f0fdd28d293d52cf84de1391f45be0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0967196-a6e7-45bc-bf55-2b7d25cd52d3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE. ", "original_text": "LLC  Q \nGreat. "}, "hash": "e94bf03889c8c5ae97acaecd57ee61f5f2d9198690034cad485b9a53cc149d94", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 16, "end_char_idx": 228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0967196-a6e7-45bc-bf55-2b7d25cd52d3": {"__data__": {"id_": "e0967196-a6e7-45bc-bf55-2b7d25cd52d3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE. ", "original_text": "LLC  Q \nGreat. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f8706ac-902a-4bf2-9d05-93025a7b0702", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ed368e355fb717bf9d285030afcedbc29e9b76317ef347f75a0097b2f31d258", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27256c29-4245-4bc3-9370-f0ad86d8f7f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n ", "original_text": "Thanks for the question. "}, "hash": "1483251483fd030d83168f5245e761f4304ea4ac5a2d608dac4f7320cb30379f", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nGreat. ", "start_char_idx": 228, "end_char_idx": 243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27256c29-4245-4bc3-9370-f0ad86d8f7f7": {"__data__": {"id_": "27256c29-4245-4bc3-9370-f0ad86d8f7f7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n ", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0967196-a6e7-45bc-bf55-2b7d25cd52d3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE. ", "original_text": "LLC  Q \nGreat. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "930a529185e214ef2051868da3421c4abaa9ed0762cc5867a542437e6bac8f50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c498d0ed-8234-4c09-adfe-b759638d6d60", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.  ", "original_text": "I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n"}, "hash": "57d9732f276330ec4393296240b662d468aab12610da87370e97f50a3cb301ba", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 243, "end_char_idx": 268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c498d0ed-8234-4c09-adfe-b759638d6d60": {"__data__": {"id_": "c498d0ed-8234-4c09-adfe-b759638d6d60", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.  ", "original_text": "I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27256c29-4245-4bc3-9370-f0ad86d8f7f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n ", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c36e3193faa9568741ed6c098bb2b68d33dc46516d0e89c73332862059968c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d635ec5-4a12-45bb-819d-0956a72f8560", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure. ", "original_text": "Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE. "}, "hash": "fe88635b6f6976605d1454f09d5d10d1f6547c46ccd9ba35f44b29ce043416db", "class_name": "RelatedNodeInfo"}}, "text": "I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n", "start_char_idx": 268, "end_char_idx": 545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d635ec5-4a12-45bb-819d-0956a72f8560": {"__data__": {"id_": "6d635ec5-4a12-45bb-819d-0956a72f8560", "embedding": null, "metadata": {"window": "LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure. ", "original_text": "Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c498d0ed-8234-4c09-adfe-b759638d6d60", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.  ", "original_text": "I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c655f6a1b19671dcc748c928e662838c265e57ccd5901d1c790b620ca40d0cfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee4137e9-6a1c-4f4f-9b77-c3a1dde4d264", "node_type": "1", "metadata": {"window": "Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question. ", "original_text": "Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n "}, "hash": "a4443d4e1af4574b714e454588c294b8f181526f25e93a4b361332f713ee3721", "class_name": "RelatedNodeInfo"}}, "text": "Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE. ", "start_char_idx": 545, "end_char_idx": 740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee4137e9-6a1c-4f4f-9b77-c3a1dde4d264": {"__data__": {"id_": "ee4137e9-6a1c-4f4f-9b77-c3a1dde4d264", "embedding": null, "metadata": {"window": "Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question. ", "original_text": "Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d635ec5-4a12-45bb-819d-0956a72f8560", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure. ", "original_text": "Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "112204b4a4d975a844f87b550dabcae771aaaedcab3323a98c1dc411e258dcb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c5a93cc-a44b-4977-abb3-0c2e7ab30c7e", "node_type": "1", "metadata": {"window": "I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question.  I'll start. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.  "}, "hash": "db156955f736f6c97e8b57eb3d92df5ee2882ba6f5d4dc1aac60f5d1fd9c4529", "class_name": "RelatedNodeInfo"}}, "text": "Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n ", "start_char_idx": 740, "end_char_idx": 893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c5a93cc-a44b-4977-abb3-0c2e7ab30c7e": {"__data__": {"id_": "7c5a93cc-a44b-4977-abb3-0c2e7ab30c7e", "embedding": null, "metadata": {"window": "I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question.  I'll start. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee4137e9-6a1c-4f4f-9b77-c3a1dde4d264", "node_type": "1", "metadata": {"window": "Thanks for the question.  I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question. ", "original_text": "Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b0ab760479cdf0d49182b2f2ce457947f1016394924bd651a2bb7f855ef2b44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94884a65-f0ea-49c7-83f0-1cb7ffdc278f", "node_type": "1", "metadata": {"window": "Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment. ", "original_text": "A \nSure. "}, "hash": "5747bbe7f993400e30c597b88f215012afcfd29002a074b2fd687093417f4a87", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.  ", "start_char_idx": 893, "end_char_idx": 1220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94884a65-f0ea-49c7-83f0-1cb7ffdc278f": {"__data__": {"id_": "94884a65-f0ea-49c7-83f0-1cb7ffdc278f", "embedding": null, "metadata": {"window": "Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment. ", "original_text": "A \nSure. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c5a93cc-a44b-4977-abb3-0c2e7ab30c7e", "node_type": "1", "metadata": {"window": "I guess maybe just to stick with COVID, but looking at the Med -Surg segment, it \nappeared that EBIT in the quarter came in, I don't know, somewhere roughly  around $50 million higher than what \nwas implied relative to the back half guidance you guys had given previously.  \n \n Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question.  I'll start. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0400c26fadbcaca687ce2ccd761e9823438e18aadfed8824f303709355c8b502", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5ecaa08-f479-474e-92af-f8b7d22eb988", "node_type": "1", "metadata": {"window": "Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter. ", "original_text": "Thanks for the question. "}, "hash": "e958ebf333727d145ee9866751626e9f9c543aa6860e2ece370986ef869d1305", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 1220, "end_char_idx": 1229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5ecaa08-f479-474e-92af-f8b7d22eb988": {"__data__": {"id_": "d5ecaa08-f479-474e-92af-f8b7d22eb988", "embedding": null, "metadata": {"window": "Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter. ", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94884a65-f0ea-49c7-83f0-1cb7ffdc278f", "node_type": "1", "metadata": {"window": "Just wanted to see if you could share or help us understand what drove the performance as it relates to the \nincrease in COVID -19 test that y ou mentioned and then the increased demand for PPE.  Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment. ", "original_text": "A \nSure. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c765442813c2fbb018f72da331596b1008bda411e4f129b03b8e6a68f7e9cd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "748a7a2d-f33b-4fca-995c-b53c6d5880d7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that. ", "original_text": "I'll start. "}, "hash": "01bae27a19a725e03a32a7300272798fc28ad474e58ffa06042d5b35ce0c766e", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 243, "end_char_idx": 268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "748a7a2d-f33b-4fca-995c-b53c6d5880d7": {"__data__": {"id_": "748a7a2d-f33b-4fca-995c-b53c6d5880d7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that. ", "original_text": "I'll start. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5ecaa08-f479-474e-92af-f8b7d22eb988", "node_type": "1", "metadata": {"window": "Just trying to really get \nsome context around just what the contribution has looked like in that segment from COVID tests and PPE would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter. ", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b0a0ff31469c3e125613a35c337e815944f6811155b906ad4d237219fde9182", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5e788c4-f952-4cd6-8cc0-d6f335d0d961", "node_type": "1", "metadata": {"window": "A \nSure.  Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n", "original_text": "Certainly, as the year has progressed, we've seen some momentum in the \nsegment. "}, "hash": "9b7c04302b009cc0a6f4925d88815121b08cd9efd89289c3712032180e762171", "class_name": "RelatedNodeInfo"}}, "text": "I'll start. ", "start_char_idx": 1254, "end_char_idx": 1266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5e788c4-f952-4cd6-8cc0-d6f335d0d961": {"__data__": {"id_": "e5e788c4-f952-4cd6-8cc0-d6f335d0d961", "embedding": null, "metadata": {"window": "A \nSure.  Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n", "original_text": "Certainly, as the year has progressed, we've seen some momentum in the \nsegment. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "748a7a2d-f33b-4fca-995c-b53c6d5880d7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McK esson Corp.   A \nSure.  Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that. ", "original_text": "I'll start. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b781f193fbfb703d5f60a9a2f1bd55c572fb35339a2e4aeb5c5999026ea045d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be5b1b35-253a-404f-a333-442874d7e4a3", "node_type": "1", "metadata": {"window": "Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter. ", "original_text": "What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter. "}, "hash": "e0e9f9384a2ea8d106d768ca6c369d3902dec6785d42a9e0321100788129fbd1", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, as the year has progressed, we've seen some momentum in the \nsegment. ", "start_char_idx": 1266, "end_char_idx": 1347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be5b1b35-253a-404f-a333-442874d7e4a3": {"__data__": {"id_": "be5b1b35-253a-404f-a333-442874d7e4a3", "embedding": null, "metadata": {"window": "Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter. ", "original_text": "What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5e788c4-f952-4cd6-8cc0-d6f335d0d961", "node_type": "1", "metadata": {"window": "A \nSure.  Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n", "original_text": "Certainly, as the year has progressed, we've seen some momentum in the \nsegment. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5244bb4669bab4505f40b9ca57eb300cb1ca874858577c144f7d3e9de202c9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7a95356-4b98-4daf-a03d-171201c33f80", "node_type": "1", "metadata": {"window": "I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business. ", "original_text": "So they're a \nkey driver for that. "}, "hash": "c4c828b610bff69ef7758c31d3f96b717c9ef9129841b5445d5df0270a9068b8", "class_name": "RelatedNodeInfo"}}, "text": "What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter. ", "start_char_idx": 1347, "end_char_idx": 1548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7a95356-4b98-4daf-a03d-171201c33f80": {"__data__": {"id_": "c7a95356-4b98-4daf-a03d-171201c33f80", "embedding": null, "metadata": {"window": "I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business. ", "original_text": "So they're a \nkey driver for that. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be5b1b35-253a-404f-a333-442874d7e4a3", "node_type": "1", "metadata": {"window": "Thanks for the question.  I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter. ", "original_text": "What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00579004e9405f14375b1c300df4736e1c75b9913a5161dd1a3f09e992cbcf9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ab9153c-62a4-4a1b-8f8a-6cd4a7a48aa6", "node_type": "1", "metadata": {"window": "Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits. ", "original_text": "I also touched on early vaccine \u2013 flu vaccine sales.  \n \n"}, "hash": "0c414a0711dc1e1804d12c394108e66d0d947a06b95eeea6f60348c6db0c8411", "class_name": "RelatedNodeInfo"}}, "text": "So they're a \nkey driver for that. ", "start_char_idx": 1548, "end_char_idx": 1583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ab9153c-62a4-4a1b-8f8a-6cd4a7a48aa6": {"__data__": {"id_": "8ab9153c-62a4-4a1b-8f8a-6cd4a7a48aa6", "embedding": null, "metadata": {"window": "Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits. ", "original_text": "I also touched on early vaccine \u2013 flu vaccine sales.  \n \n", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7a95356-4b98-4daf-a03d-171201c33f80", "node_type": "1", "metadata": {"window": "I'll start.  Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business. ", "original_text": "So they're a \nkey driver for that. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e533a5d2a1b1215b0ab07cf417af4fbca21c6cde94bc0f948ee8bd7e6be7359", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e3daa55-de69-46aa-b25c-2b53b2ccdd24", "node_type": "1", "metadata": {"window": "What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n", "original_text": "So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter. "}, "hash": "147f3f0ba7e3574ce9dd0a6baa92a2ff107d012196652b4b71623f356e983b43", "class_name": "RelatedNodeInfo"}}, "text": "I also touched on early vaccine \u2013 flu vaccine sales.  \n \n", "start_char_idx": 1583, "end_char_idx": 1640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e3daa55-de69-46aa-b25c-2b53b2ccdd24": {"__data__": {"id_": "5e3daa55-de69-46aa-b25c-2b53b2ccdd24", "embedding": null, "metadata": {"window": "What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n", "original_text": "So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ab9153c-62a4-4a1b-8f8a-6cd4a7a48aa6", "node_type": "1", "metadata": {"window": "Certainly, as the year has progressed, we've seen some momentum in the \nsegment.  What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits. ", "original_text": "I also touched on early vaccine \u2013 flu vaccine sales.  \n \n", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fcf2ceb1a6474c7588321601567f1067b385a7bc226dee46e8bbc70260a4fd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "267df6a6-2283-4aa5-9a15-de18bdf91455", "node_type": "1", "metadata": {"window": "So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together. ", "original_text": "And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business. "}, "hash": "d88978dd7be581ddb71cb638edb2c012e4df49bb22f121a112465b69ad2aab1e", "class_name": "RelatedNodeInfo"}}, "text": "So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter. ", "start_char_idx": 1640, "end_char_idx": 1807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "267df6a6-2283-4aa5-9a15-de18bdf91455": {"__data__": {"id_": "267df6a6-2283-4aa5-9a15-de18bdf91455", "embedding": null, "metadata": {"window": "So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together. ", "original_text": "And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e3daa55-de69-46aa-b25c-2b53b2ccdd24", "node_type": "1", "metadata": {"window": "What we talked about in both of our comments and what we've seen through our second quarter is that \nCOVID -19 tests and  personal protective equipment have increased in volume throughout the quarter.  So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n", "original_text": "So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "043975070e1e05c2d102acd6eaa92e545c72450bd0c5e0d97eba6c255a67fe2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f407262d-7c13-4949-8849-a6103972a6e2", "node_type": "1", "metadata": {"window": "I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n ", "original_text": "It drives more \nprimary care visits. "}, "hash": "d9cbc45663535e4c74716050bb402116572833eab27181f7e75cf1c1254b0b61", "class_name": "RelatedNodeInfo"}}, "text": "And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business. ", "start_char_idx": 1807, "end_char_idx": 1970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f407262d-7c13-4949-8849-a6103972a6e2": {"__data__": {"id_": "f407262d-7c13-4949-8849-a6103972a6e2", "embedding": null, "metadata": {"window": "I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n ", "original_text": "It drives more \nprimary care visits. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "267df6a6-2283-4aa5-9a15-de18bdf91455", "node_type": "1", "metadata": {"window": "So they're a \nkey driver for that.  I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together. ", "original_text": "And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "601862d2839bf31015d3967c3f8a0d1d8da2f974f5d91dab3ea14ed20262d926", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc6011b1-2b3d-40b9-9755-62ce3c32ec01", "node_type": "1", "metadata": {"window": "So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "It drives more supplies within our core business.  \n \n"}, "hash": "95881effdc4bde186968fa6e4cc5832bf1e2eb154eb8abf90501e5650c7dbad1", "class_name": "RelatedNodeInfo"}}, "text": "It drives more \nprimary care visits. ", "start_char_idx": 1970, "end_char_idx": 2007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc6011b1-2b3d-40b9-9755-62ce3c32ec01": {"__data__": {"id_": "cc6011b1-2b3d-40b9-9755-62ce3c32ec01", "embedding": null, "metadata": {"window": "So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "It drives more supplies within our core business.  \n \n", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f407262d-7c13-4949-8849-a6103972a6e2", "node_type": "1", "metadata": {"window": "I also touched on early vaccine \u2013 flu vaccine sales.  \n \n So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n ", "original_text": "It drives more \nprimary care visits. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "909b444627791769cd288ed65b42e1f47ade9ea9c01ab497e7255565fd301972", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c54c4ff7-3dc2-4071-8c47-aa2b7c34a707", "node_type": "1", "metadata": {"window": "And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n ", "original_text": "So I think all of those things really play together. "}, "hash": "fdfa399e2aee7c4b2830fe17801a71d3f08330484494f1d4ee0f04217b8db26c", "class_name": "RelatedNodeInfo"}}, "text": "It drives more supplies within our core business.  \n \n", "start_char_idx": 2007, "end_char_idx": 2061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c54c4ff7-3dc2-4071-8c47-aa2b7c34a707": {"__data__": {"id_": "c54c4ff7-3dc2-4071-8c47-aa2b7c34a707", "embedding": null, "metadata": {"window": "And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n ", "original_text": "So I think all of those things really play together. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc6011b1-2b3d-40b9-9755-62ce3c32ec01", "node_type": "1", "metadata": {"window": "So too early to call the flu season, but we did see earlier flu vaccine sales than we ha d anticipated, a little bit \nstronger than we had anticipated in the quarter.  And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "It drives more supplies within our core business.  \n \n", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ca975fc0cdc90f105df658f4bc18cd84348001836f1d358459834a5cc1c325e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37c8a389-7d51-4686-889e-82473d148328", "node_type": "1", "metadata": {"window": "It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research. ", "original_text": "But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n "}, "hash": "a3b56378f54cbef079559d68f0cc1e475b6ef2495311775f73fd2aed065d1edb", "class_name": "RelatedNodeInfo"}}, "text": "So I think all of those things really play together. ", "start_char_idx": 2061, "end_char_idx": 2114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37c8a389-7d51-4686-889e-82473d148328": {"__data__": {"id_": "37c8a389-7d51-4686-889e-82473d148328", "embedding": null, "metadata": {"window": "It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research. ", "original_text": "But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c54c4ff7-3dc2-4071-8c47-aa2b7c34a707", "node_type": "1", "metadata": {"window": "And we're seeing really strong underlying performance as flu \nvaccine sales start to pick up, as COVID -19 test kits pick up, that really helps the core business.  It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n ", "original_text": "So I think all of those things really play together. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3779fd65f08864b588a85b7653d9f6ae7f80b6086488e1453de3f1dc9d29fc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6329dde-1100-410e-8c63-28b4653eb53a", "node_type": "1", "metadata": {"window": "It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "4576d84f1da368ad74990ff54d697adad63d3b8f8383ee8af6ad9627574529ec", "class_name": "RelatedNodeInfo"}}, "text": "But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n ", "start_char_idx": 2114, "end_char_idx": 2255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6329dde-1100-410e-8c63-28b4653eb53a": {"__data__": {"id_": "c6329dde-1100-410e-8c63-28b4653eb53a", "embedding": null, "metadata": {"window": "It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37c8a389-7d51-4686-889e-82473d148328", "node_type": "1", "metadata": {"window": "It drives more \nprimary care visits.  It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research. ", "original_text": "But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3cabe0359fba8d1d4ebfaddf0171ece092166abfb8765dd61efc8dbe4f425a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a8194a4-04a7-495a-b502-3ecfa1c1df71", "node_type": "1", "metadata": {"window": "So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks. ", "original_text": "A \nNext question, operator?  \n "}, "hash": "cc36392dd8ddbf480b31318dfbbf4cce5fed73618a2631b39f5dddc57a9367e0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 2255, "end_char_idx": 2585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a8194a4-04a7-495a-b502-3ecfa1c1df71": {"__data__": {"id_": "9a8194a4-04a7-495a-b502-3ecfa1c1df71", "embedding": null, "metadata": {"window": "So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks. ", "original_text": "A \nNext question, operator?  \n ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6329dde-1100-410e-8c63-28b4653eb53a", "node_type": "1", "metadata": {"window": "It drives more supplies within our core business.  \n \n So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a06b066b3ca5bcd681aa70e72345adc07fc21373a268dc05e24892831aa11332", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75c48052-a4e2-4869-9696-f8bf4edf5622", "node_type": "1", "metadata": {"window": "But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research. "}, "hash": "176d347810aaa0d7ca7c95dfe5ce4207dd28824ec660940d8368bebecab8c80e", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, operator?  \n ", "start_char_idx": 2585, "end_char_idx": 2616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75c48052-a4e2-4869-9696-f8bf4edf5622": {"__data__": {"id_": "75c48052-a4e2-4869-9696-f8bf4edf5622", "embedding": null, "metadata": {"window": "But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a8194a4-04a7-495a-b502-3ecfa1c1df71", "node_type": "1", "metadata": {"window": "So I think all of those things really play together.  But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks. ", "original_text": "A \nNext question, operator?  \n ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e9d3124b9c5d502f5a8402d1babd61ae4dcd320ff019adc3f0121a0520f3c34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0220677f-e0f6-4885-978f-08f2f811043b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2. ", "original_text": "Sir, your line is now open.  \n "}, "hash": "cf68c48a4b8c7b094793334f6b7b88f6798131195f05b081698f319611563ba1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research. ", "start_char_idx": 2616, "end_char_idx": 2935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0220677f-e0f6-4885-978f-08f2f811043b": {"__data__": {"id_": "0220677f-e0f6-4885-978f-08f2f811043b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2. ", "original_text": "Sir, your line is now open.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75c48052-a4e2-4869-9696-f8bf4edf5622", "node_type": "1", "metadata": {"window": "But, certainly, COVID -19 tests in personal protective equipment \nare key drivers in the quarter and key drivers for our full year raise . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e76b35ede87e0e12f56d25ce19b55784f37134b2ab2fd2a514bcfab27c402a15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0c7caba-81a6-477a-b66d-224da74a8bc0", "node_type": "1", "metadata": {"window": "A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks. "}, "hash": "57aa3cf33d6a6c0dee5b6e127fd664829262763662a0488b4dba2391ba04acea", "class_name": "RelatedNodeInfo"}}, "text": "Sir, your line is now open.  \n ", "start_char_idx": 2935, "end_char_idx": 2966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0c7caba-81a6-477a-b66d-224da74a8bc0": {"__data__": {"id_": "e0c7caba-81a6-477a-b66d-224da74a8bc0", "embedding": null, "metadata": {"window": "A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0220677f-e0f6-4885-978f-08f2f811043b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2. ", "original_text": "Sir, your line is now open.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91a158b40b4f1bb33c80e6d25bf27bc3d9a40bcc24b0f3e4a639183bbc7fba74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f8e253a-b7a5-46ab-a4e8-bf2c30724176", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business? ", "original_text": "Wanted to ask about the trajectory and the seasonality of the Prescription Technology business. "}, "hash": "096388fd1c0f54791b48983a8476ab4acf0281f2919a124d73bee605f33dca9b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks. ", "start_char_idx": 2966, "end_char_idx": 3284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f8e253a-b7a5-46ab-a4e8-bf2c30724176": {"__data__": {"id_": "2f8e253a-b7a5-46ab-a4e8-bf2c30724176", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business? ", "original_text": "Wanted to ask about the trajectory and the seasonality of the Prescription Technology business. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0c7caba-81a6-477a-b66d-224da74a8bc0", "node_type": "1", "metadata": {"window": "A \nNext question, operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c8f83ac05d051b09fe87b58cd06422690bc7f0f7085273cccc61ae37be0bec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c694b8a-edc5-401a-83ff-59050c4a8eeb", "node_type": "1", "metadata": {"window": "Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind? ", "original_text": "It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2. "}, "hash": "a85ea2d5551f2b7f4f8f7a89a1f7580ae73874e1156390653958c29fd2d3462f", "class_name": "RelatedNodeInfo"}}, "text": "Wanted to ask about the trajectory and the seasonality of the Prescription Technology business. ", "start_char_idx": 3284, "end_char_idx": 3380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c694b8a-edc5-401a-83ff-59050c4a8eeb": {"__data__": {"id_": "6c694b8a-edc5-401a-83ff-59050c4a8eeb", "embedding": null, "metadata": {"window": "Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind? ", "original_text": "It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f8e253a-b7a5-46ab-a4e8-bf2c30724176", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Stephen Baxter from Wolfe Research.  Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business? ", "original_text": "Wanted to ask about the trajectory and the seasonality of the Prescription Technology business. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f81cec4cc7ffc6985e9ab70f963cf2371c39e075bf201ec729b2e4788f5688b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe0ddabc-fd4b-4091-bac8-c057e2184b56", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n ", "original_text": "So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n"}, "hash": "e88e3cf0e1c880cffded12beab709aecfd89c6472f06fbb8bee34547d7803bf9", "class_name": "RelatedNodeInfo"}}, "text": "It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2. ", "start_char_idx": 3380, "end_char_idx": 3497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe0ddabc-fd4b-4091-bac8-c057e2184b56": {"__data__": {"id_": "fe0ddabc-fd4b-4091-bac8-c057e2184b56", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n ", "original_text": "So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c694b8a-edc5-401a-83ff-59050c4a8eeb", "node_type": "1", "metadata": {"window": "Sir, your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind? ", "original_text": "It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2. ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e2a5936adbe46e41a93dc4ec10de84ac048d766218dfce02886f888b971b4c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26747cc6-7dc3-4f10-8418-5b1c18df0b31", "node_type": "1", "metadata": {"window": "Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  ", "original_text": "And then just in general, what's the right way to think about seasonality in this business? "}, "hash": "b2765aea8232fd8127a1a5a0c1a9a5521da421420d1af8b54b28238e2bd55a5b", "class_name": "RelatedNodeInfo"}}, "text": "So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n", "start_char_idx": 3497, "end_char_idx": 3698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26747cc6-7dc3-4f10-8418-5b1c18df0b31": {"__data__": {"id_": "26747cc6-7dc3-4f10-8418-5b1c18df0b31", "embedding": null, "metadata": {"window": "Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  ", "original_text": "And then just in general, what's the right way to think about seasonality in this business? ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe0ddabc-fd4b-4091-bac8-c057e2184b56", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi, thanks.  Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n ", "original_text": "So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7617d427d8359a51b1950ca611b0cd466087e3645f6569b198ae2da94de5741a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e697210-982a-46b9-bb30-2d11ea1a3fd6", "node_type": "1", "metadata": {"window": "It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A ", "original_text": "Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind? "}, "hash": "dc506c5565ce8a9c1208f34bf2104b0d5cac9a6c514036b6b130c29ebde361f3", "class_name": "RelatedNodeInfo"}}, "text": "And then just in general, what's the right way to think about seasonality in this business? ", "start_char_idx": 3698, "end_char_idx": 3790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e697210-982a-46b9-bb30-2d11ea1a3fd6": {"__data__": {"id_": "5e697210-982a-46b9-bb30-2d11ea1a3fd6", "embedding": null, "metadata": {"window": "It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A ", "original_text": "Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind? ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26747cc6-7dc3-4f10-8418-5b1c18df0b31", "node_type": "1", "metadata": {"window": "Wanted to ask about the trajectory and the seasonality of the Prescription Technology business.  It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  ", "original_text": "And then just in general, what's the right way to think about seasonality in this business? ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c34a640a05e15f2423e4612e841ddbbfcf7d39f2f993a2b02d4bddc0abac5fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78e8b9b0-f173-4d85-93ff-b7207e4e7462", "node_type": "1", "metadata": {"window": "So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A ", "original_text": "Thanks.  \n "}, "hash": "2ddcbd18be6ea021ed966a1ffdfce9ef3359b44b9684dd743d9401432aa9dd3d", "class_name": "RelatedNodeInfo"}}, "text": "Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind? ", "start_char_idx": 3790, "end_char_idx": 3982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78e8b9b0-f173-4d85-93ff-b7207e4e7462": {"__data__": {"id_": "78e8b9b0-f173-4d85-93ff-b7207e4e7462", "embedding": null, "metadata": {"window": "So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e697210-982a-46b9-bb30-2d11ea1a3fd6", "node_type": "1", "metadata": {"window": "It \nseems like the full year guidance implies a pretty big step -up in EBIT relative to what you just posted for Q2.  So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A ", "original_text": "Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind? ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f90dad722fe957b4d26e30a8f4aa6f1f0f1ada31c4dbc075752eeb3a2426d678", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e4cfc30-5871-4b3d-9ccf-6dc34cb29542", "node_type": "1", "metadata": {"window": "And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  "}, "hash": "b34275e8db5d1fa5ba767e59dcf7df923a09c6c179d6ae1c9c25c66230adabc9", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 3982, "end_char_idx": 3993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e4cfc30-5871-4b3d-9ccf-6dc34cb29542": {"__data__": {"id_": "1e4cfc30-5871-4b3d-9ccf-6dc34cb29542", "embedding": null, "metadata": {"window": "And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78e8b9b0-f173-4d85-93ff-b7207e4e7462", "node_type": "1", "metadata": {"window": "So I \nwas hoping you could talk a little bit a bout the factors driving this increase, whether there's anything to do with \nsome of the timing of investment spend that you've cited in the release?  \n \n And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "741b3ea58c352296a92a6fdac90aec3566ef76bacd1e923fe979598485f1c9c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acc53dbe-4107-4c48-997b-8495124eac69", "node_type": "1", "metadata": {"window": "Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A ", "original_text": "A "}, "hash": "4c806a7c2f5a555f3eef3201925e1b1f3079871b729efb30333c7522f159b0ed", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  ", "start_char_idx": 3993, "end_char_idx": 4339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acc53dbe-4107-4c48-997b-8495124eac69": {"__data__": {"id_": "acc53dbe-4107-4c48-997b-8495124eac69", "embedding": null, "metadata": {"window": "Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A ", "original_text": "A ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e0272ebc-50c0-4c16-af25-22cbfd264179", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708500ee9b34c565a694984c4787608d41a9f962a6ac34ad7be2da8caf474113", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e4cfc30-5871-4b3d-9ccf-6dc34cb29542", "node_type": "1", "metadata": {"window": "And then just in general, what's the right way to think about seasonality in this business?  Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2445e25b0e666c27b1dab610996e1e22dd8cae018eb06b5f6941a03bb512ab31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c5c6056-d497-45a1-9572-bcbec6b7d294", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business. ", "original_text": "McKesson Corp.  "}, "hash": "75444c3b8069e96e1754f218ea932d1708424de9a5ff38937827cf53aa3bdfa0", "class_name": "RelatedNodeInfo"}}, "text": "A ", "start_char_idx": 1220, "end_char_idx": 1222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c5c6056-d497-45a1-9572-bcbec6b7d294": {"__data__": {"id_": "9c5c6056-d497-45a1-9572-bcbec6b7d294", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acc53dbe-4107-4c48-997b-8495124eac69", "node_type": "1", "metadata": {"window": "Trying to unde rstand \nwhat we should be thinking about future periods using the second half of fiscal 2021 as a baseline or if there's \nother consideration that we should be keeping on mind?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, M cKesson Corp.   A ", "original_text": "A ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b027de2047449fa7ea26477c544c106cd3619060d8b753a4d87bf87837b22ef0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fb789ab-a4a2-423c-b15c-cfc1dd40aabb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question. "}, "hash": "886e4155de637e98ecab5b63efa3f116773a80025e19feaadc823050fc35922d", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fb789ab-a4a2-423c-b15c-cfc1dd40aabb": {"__data__": {"id_": "2fb789ab-a4a2-423c-b15c-cfc1dd40aabb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c5c6056-d497-45a1-9572-bcbec6b7d294", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "825a507544eedc39306a4f64b778a7190583d611c0702655e36ae94aab87fb9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdbd590d-fe5d-4eb5-8ee6-ca7dc5c008aa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n", "original_text": "I'll start and then Brian can certainly elaborate. "}, "hash": "45561686134bbf0dd5bc15c63a73073cfe7b1e384cb6ea1b64ef54cdfb068e4d", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question. ", "start_char_idx": 16, "end_char_idx": 213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdbd590d-fe5d-4eb5-8ee6-ca7dc5c008aa": {"__data__": {"id_": "fdbd590d-fe5d-4eb5-8ee6-ca7dc5c008aa", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n", "original_text": "I'll start and then Brian can certainly elaborate. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fb789ab-a4a2-423c-b15c-cfc1dd40aabb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3447f0b94a9dec1213afc8904e9c87e42a497b7e3ae2e107da62ad4f0eda55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db9d0db2-0d30-4a58-9e99-a7bb01cb25a9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n", "original_text": "We have been making \ninvestments into this business. "}, "hash": "b22a1c7b75cc3f695e33ba8cf0eaccbff96a9491a29214cc0cdb6b2c29391e77", "class_name": "RelatedNodeInfo"}}, "text": "I'll start and then Brian can certainly elaborate. ", "start_char_idx": 213, "end_char_idx": 264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db9d0db2-0d30-4a58-9e99-a7bb01cb25a9": {"__data__": {"id_": "db9d0db2-0d30-4a58-9e99-a7bb01cb25a9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n", "original_text": "We have been making \ninvestments into this business. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdbd590d-fe5d-4eb5-8ee6-ca7dc5c008aa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n", "original_text": "I'll start and then Brian can certainly elaborate. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9db356af55b025eabe4a6e06d73adf96e9cce44066c652203b9dc0cc8eae5ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a898b39a-b6fa-47ab-8fe1-bf800c18026d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth. ", "original_text": "We think that this is a business where innovation can happen. "}, "hash": "3c512fbcd9e3c5329e232b112671b7ce040c673f91aea223c6f4b780413d6b4f", "class_name": "RelatedNodeInfo"}}, "text": "We have been making \ninvestments into this business. ", "start_char_idx": 264, "end_char_idx": 317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a898b39a-b6fa-47ab-8fe1-bf800c18026d": {"__data__": {"id_": "a898b39a-b6fa-47ab-8fe1-bf800c18026d", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth. ", "original_text": "We think that this is a business where innovation can happen. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db9d0db2-0d30-4a58-9e99-a7bb01cb25a9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n", "original_text": "We have been making \ninvestments into this business. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a0fe68065a63b2c90597fb906608758888147dc09bbd2a38bbb36d08cf1074d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddb6d2b7-2e14-47ec-b299-769ddc716015", "node_type": "1", "metadata": {"window": "I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters. ", "original_text": "And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n"}, "hash": "0d2188de2f7aa57b371414476993129f9980d4640af5e0da93138023b8a0b79a", "class_name": "RelatedNodeInfo"}}, "text": "We think that this is a business where innovation can happen. ", "start_char_idx": 317, "end_char_idx": 379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddb6d2b7-2e14-47ec-b299-769ddc716015": {"__data__": {"id_": "ddb6d2b7-2e14-47ec-b299-769ddc716015", "embedding": null, "metadata": {"window": "I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters. ", "original_text": "And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a898b39a-b6fa-47ab-8fe1-bf800c18026d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth. ", "original_text": "We think that this is a business where innovation can happen. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5504d00f6014ac2cebb4d6f098892f4569a4cc132f4f40bccf7f2a0d01db203", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80a3d7e0-1b13-429c-b36e-c086739f2dac", "node_type": "1", "metadata": {"window": "We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things. ", "original_text": "Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n"}, "hash": "9fa04bd290b2d51f9dd5d90932b8de0434927eb4926414ab4b457b131d79632d", "class_name": "RelatedNodeInfo"}}, "text": "And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n", "start_char_idx": 379, "end_char_idx": 486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80a3d7e0-1b13-429c-b36e-c086739f2dac": {"__data__": {"id_": "80a3d7e0-1b13-429c-b36e-c086739f2dac", "embedding": null, "metadata": {"window": "We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things. ", "original_text": "Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddb6d2b7-2e14-47ec-b299-769ddc716015", "node_type": "1", "metadata": {"window": "I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters. ", "original_text": "And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "428b1ea29be2dc920f52d958e558cf42e9ff1bf69e38fc765666623bd7a4353e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4634cdd-4dca-41c3-8e48-8b343ca8ff5a", "node_type": "1", "metadata": {"window": "We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year. ", "original_text": "We do expect that the second half of the year, we'll see some very strong growth. "}, "hash": "c9bc28592927d18a7a2d64285ebb35f82e70d551106a64bba3145ad62ab8e2d7", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n", "start_char_idx": 486, "end_char_idx": 734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4634cdd-4dca-41c3-8e48-8b343ca8ff5a": {"__data__": {"id_": "f4634cdd-4dca-41c3-8e48-8b343ca8ff5a", "embedding": null, "metadata": {"window": "We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year. ", "original_text": "We do expect that the second half of the year, we'll see some very strong growth. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80a3d7e0-1b13-429c-b36e-c086739f2dac", "node_type": "1", "metadata": {"window": "We have been making \ninvestments into this business.  We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things. ", "original_text": "Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ecdbb9170afdcb0ee8cc72cf83ed557464e0cdcd4c8c2e64a5883abb582c050", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "553b5d83-2cf9-446a-8878-05bad1bcff00", "node_type": "1", "metadata": {"window": "And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation. ", "original_text": "And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters. "}, "hash": "a5355cab87463106a9a7fa2844bcc2a61c8745d81831b6bb0ad772a860c6a324", "class_name": "RelatedNodeInfo"}}, "text": "We do expect that the second half of the year, we'll see some very strong growth. ", "start_char_idx": 734, "end_char_idx": 816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "553b5d83-2cf9-446a-8878-05bad1bcff00": {"__data__": {"id_": "553b5d83-2cf9-446a-8878-05bad1bcff00", "embedding": null, "metadata": {"window": "And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation. ", "original_text": "And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4634cdd-4dca-41c3-8e48-8b343ca8ff5a", "node_type": "1", "metadata": {"window": "We think that this is a business where innovation can happen.  And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year. ", "original_text": "We do expect that the second half of the year, we'll see some very strong growth. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05cc1c9bd2792fb12941c50f87a7c20a5b078235350f5d30fb3b54f2db58270f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "965218ce-8521-41ad-9852-58140423a408", "node_type": "1", "metadata": {"window": "Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger. ", "original_text": "So I think it's \na few things. "}, "hash": "bc7afad2a59119f8b3b1dcd8e868b0e370fefc1da1f10ac8e2097627e3d376f0", "class_name": "RelatedNodeInfo"}}, "text": "And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters. ", "start_char_idx": 816, "end_char_idx": 956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "965218ce-8521-41ad-9852-58140423a408": {"__data__": {"id_": "965218ce-8521-41ad-9852-58140423a408", "embedding": null, "metadata": {"window": "Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger. ", "original_text": "So I think it's \na few things. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "553b5d83-2cf9-446a-8878-05bad1bcff00", "node_type": "1", "metadata": {"window": "And so we've been \nincreasing our investments over the last year or so, and we'll continue to do that.  \n \n Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation. ", "original_text": "And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d67be44b1964cae54f40ad11063d5086f8aec6d85bfbf1ea37b7ef3fd6cfb79f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5512b3da-092b-463d-a3a2-b8001c27492a", "node_type": "1", "metadata": {"window": "We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n ", "original_text": "It's been the lower prescription volume trends year -over-year. "}, "hash": "6fc9d6387d8cfb4d6821b2802b604655f6f1356548cd854b552987be1a86a6b8", "class_name": "RelatedNodeInfo"}}, "text": "So I think it's \na few things. ", "start_char_idx": 956, "end_char_idx": 987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5512b3da-092b-463d-a3a2-b8001c27492a": {"__data__": {"id_": "5512b3da-092b-463d-a3a2-b8001c27492a", "embedding": null, "metadata": {"window": "We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n ", "original_text": "It's been the lower prescription volume trends year -over-year. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "965218ce-8521-41ad-9852-58140423a408", "node_type": "1", "metadata": {"window": "Certainly, one of the things that we've noticed here is that lower prescription volume trends versus the prior year, \nparticularly new prescriptions or new branded prescriptions, has had an impact on that business from a top line \nperspective.  \n \n We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger. ", "original_text": "So I think it's \na few things. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a41f7a24862572c930ebd0d68e035b19fe3d01ce8cb07ffff413879dddc28e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "532c4d51-400d-411f-aea2-c17f8c127fd2", "node_type": "1", "metadata": {"window": "And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "It's investments that we've continued \nto make in the business to drive new brand programs and innovation. "}, "hash": "290a6d174b096e224b609a65577bd1026e61d5640c04337b3794c4d7c8cfc3ba", "class_name": "RelatedNodeInfo"}}, "text": "It's been the lower prescription volume trends year -over-year. ", "start_char_idx": 987, "end_char_idx": 1051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "532c4d51-400d-411f-aea2-c17f8c127fd2": {"__data__": {"id_": "532c4d51-400d-411f-aea2-c17f8c127fd2", "embedding": null, "metadata": {"window": "And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "It's investments that we've continued \nto make in the business to drive new brand programs and innovation. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5512b3da-092b-463d-a3a2-b8001c27492a", "node_type": "1", "metadata": {"window": "We do expect that the second half of the year, we'll see some very strong growth.  And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n ", "original_text": "It's been the lower prescription volume trends year -over-year. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7e6bbdcf391fdf5a0ac661a1db9f73ee68221fdb13fe2f9edb93a591d341de2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b63520f-7cdf-4206-81eb-fa2a2d48fe9d", "node_type": "1", "metadata": {"window": "So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states. ", "original_text": "And then we expect that the back ha lf of the \nyear will be stronger. "}, "hash": "6b9d55fda1cd0811da8fceda717ae318d3f8483a316f690b232b758d21741c41", "class_name": "RelatedNodeInfo"}}, "text": "It's investments that we've continued \nto make in the business to drive new brand programs and innovation. ", "start_char_idx": 1051, "end_char_idx": 1158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b63520f-7cdf-4206-81eb-fa2a2d48fe9d": {"__data__": {"id_": "5b63520f-7cdf-4206-81eb-fa2a2d48fe9d", "embedding": null, "metadata": {"window": "So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states. ", "original_text": "And then we expect that the back ha lf of the \nyear will be stronger. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "532c4d51-400d-411f-aea2-c17f8c127fd2", "node_type": "1", "metadata": {"window": "And typically, in this business, \nyou can expect that the fourth quarter is a little bit stronger seasonally than the other three quarters.  So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "It's investments that we've continued \nto make in the business to drive new brand programs and innovation. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb02513e7c481911a53c4d1576216e184c705f318d7e3e1972d0775295256199", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39647126-04c2-4c96-a634-0360f35e7692", "node_type": "1", "metadata": {"window": "It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n ", "original_text": "And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n "}, "hash": "14520798478838cdd9d259c609266e50de8aa475b4d3fafbce5da6108cdc5f6e", "class_name": "RelatedNodeInfo"}}, "text": "And then we expect that the back ha lf of the \nyear will be stronger. ", "start_char_idx": 1158, "end_char_idx": 1228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39647126-04c2-4c96-a634-0360f35e7692": {"__data__": {"id_": "39647126-04c2-4c96-a634-0360f35e7692", "embedding": null, "metadata": {"window": "It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n ", "original_text": "And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b63520f-7cdf-4206-81eb-fa2a2d48fe9d", "node_type": "1", "metadata": {"window": "So I think it's \na few things.  It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states. ", "original_text": "And then we expect that the back ha lf of the \nyear will be stronger. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "815e9606deaddd91b382389a15045738d380999ec6a3ca97cf2ae622e3646cc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "effab34a-b17c-42f7-b8bc-36e4dc71a1e2", "node_type": "1", "metadata": {"window": "It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "76081ad3fa094d3de7428b53fbdc6f580232ac65fc33e358f0eed79304587f06", "class_name": "RelatedNodeInfo"}}, "text": "And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n ", "start_char_idx": 1228, "end_char_idx": 1329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "effab34a-b17c-42f7-b8bc-36e4dc71a1e2": {"__data__": {"id_": "effab34a-b17c-42f7-b8bc-36e4dc71a1e2", "embedding": null, "metadata": {"window": "It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39647126-04c2-4c96-a634-0360f35e7692", "node_type": "1", "metadata": {"window": "It's been the lower prescription volume trends year -over-year.  It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n ", "original_text": "And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1770d603882c9c17f7137bda2ead83a27f7cf2a3db72b859d2c4b6722c44334", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad864e59-9c5d-40fa-af99-5410bfcb3878", "node_type": "1", "metadata": {"window": "And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states. "}, "hash": "85305c2f82d3653f1449ccc3a772702a1bc93ce7136eaba49b29b01f0267ef5a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1329, "end_char_idx": 1655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad864e59-9c5d-40fa-af99-5410bfcb3878": {"__data__": {"id_": "ad864e59-9c5d-40fa-af99-5410bfcb3878", "embedding": null, "metadata": {"window": "And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "effab34a-b17c-42f7-b8bc-36e4dc71a1e2", "node_type": "1", "metadata": {"window": "It's investments that we've continued \nto make in the business to drive new brand programs and innovation.  And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "211335f121f34a0ee80037af727dc54858e9f7659105123202bb43a1cc0b3074", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5c67827-89f4-40f0-b747-ec080e541fed", "node_type": "1", "metadata": {"window": "And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS. ", "original_text": "We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n "}, "hash": "e5fcc59b5fc27ed6d3aef4249ffd87a47a22481536f7b03f072748551037005f", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states. ", "start_char_idx": 1655, "end_char_idx": 1918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5c67827-89f4-40f0-b747-ec080e541fed": {"__data__": {"id_": "e5c67827-89f4-40f0-b747-ec080e541fed", "embedding": null, "metadata": {"window": "And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS. ", "original_text": "We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad864e59-9c5d-40fa-af99-5410bfcb3878", "node_type": "1", "metadata": {"window": "And then we expect that the back ha lf of the \nyear will be stronger.  And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be57fb66f02223f60302522037f3c7f5e5fe28dc0fcf7053044b02e22cba1d06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b928ce8-7d26-4947-8f93-8af90acada3d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "9866940a5218ad8e6abb18fbdf1bb6a88cddf361bd648fa5affc1a1a9b035ffa", "class_name": "RelatedNodeInfo"}}, "text": "We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n ", "start_char_idx": 1918, "end_char_idx": 2147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b928ce8-7d26-4947-8f93-8af90acada3d": {"__data__": {"id_": "2b928ce8-7d26-4947-8f93-8af90acada3d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5c67827-89f4-40f0-b747-ec080e541fed", "node_type": "1", "metadata": {"window": "And typically, seasonally, Q4 is a little bit stronger than the other three quarters of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS. ", "original_text": "We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ba7c2bc8ff55d069d5a1836e4fb66b850e53af4b1955536970be7f2248e8f6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "423edd0c-89c7-4172-8947-0cf406b4a587", "node_type": "1", "metadata": {"window": "A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. ", "original_text": "A \nNext question?  \n "}, "hash": "b1156b86feed4afef270024218909612290e09a4a7412be396cb3be43eb07034", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 2147, "end_char_idx": 2477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "423edd0c-89c7-4172-8947-0cf406b4a587": {"__data__": {"id_": "423edd0c-89c7-4172-8947-0cf406b4a587", "embedding": null, "metadata": {"window": "A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. ", "original_text": "A \nNext question?  \n ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b928ce8-7d26-4947-8f93-8af90acada3d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be6494f8d60e7553bddf4c05e5f32e4ff1467f8b0c54310e4e672053e8451142", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "860ea337-c813-4922-9578-b3f557b2d079", "node_type": "1", "metadata": {"window": "We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS. "}, "hash": "0970ba5f819224e099398dc7d0adcaa810f1de6768bb86039deccbfcedf38d8a", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question?  \n ", "start_char_idx": 2477, "end_char_idx": 2498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "860ea337-c813-4922-9578-b3f557b2d079": {"__data__": {"id_": "860ea337-c813-4922-9578-b3f557b2d079", "embedding": null, "metadata": {"window": "We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "423edd0c-89c7-4172-8947-0cf406b4a587", "node_type": "1", "metadata": {"window": "A \nAnd not much to add to that other than we do think as we bring these businesses together and look at the \nconnectivity we have into providers and pharmacies, we look at the automation, experience and tools we have \nand the expertise in various disease states.  We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. ", "original_text": "A \nNext question?  \n ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8da050e656c15658a2ee6f108a75fee5f8d66d9115e1b0a8e9d1edb4c9772289", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d72f4b2c-2318-407f-9875-fbdb38e81a2c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up. ", "original_text": "Your line is now open.  \n "}, "hash": "ab5dd185574509e656ef1702b55f317e9fd710f3d28ef69862853803beb635e1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS. ", "start_char_idx": 2498, "end_char_idx": 2810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d72f4b2c-2318-407f-9875-fbdb38e81a2c": {"__data__": {"id_": "d72f4b2c-2318-407f-9875-fbdb38e81a2c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up. ", "original_text": "Your line is now open.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "860ea337-c813-4922-9578-b3f557b2d079", "node_type": "1", "metadata": {"window": "We think this is a growing part of the market, and t here we have \nopportunities to invest internally in innovation that will deliver superior returns over time, and we continue and are \ncommitted to making those investments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be45398890f9c4314b19fb27bb6b4d92abf041092f29337ffdfc39d97e545962", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4832c9de-a31c-4675-936c-009d8a2e2907", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. "}, "hash": "9b069a69f7bb2b990fe96574e7cd6893973678969a492e0b773a0903538a9c9c", "class_name": "RelatedNodeInfo"}}, "text": "Your line is now open.  \n ", "start_char_idx": 2810, "end_char_idx": 2836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4832c9de-a31c-4675-936c-009d8a2e2907": {"__data__": {"id_": "4832c9de-a31c-4675-936c-009d8a2e2907", "embedding": null, "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d72f4b2c-2318-407f-9875-fbdb38e81a2c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up. ", "original_text": "Your line is now open.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19aa2b7f61557fd716633c123323f7c8b348df28cd616c666263ce78797917c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f392a4a-bec7-4817-b88a-87626b6654d6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit. ", "original_text": "And thanks for taking my call. "}, "hash": "494da65ac1bc4502cd855d2866bb6000db92cac25dd8ffa7421e0b0b3e86b893", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. ", "start_char_idx": 2836, "end_char_idx": 3150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f392a4a-bec7-4817-b88a-87626b6654d6": {"__data__": {"id_": "3f392a4a-bec7-4817-b88a-87626b6654d6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit. ", "original_text": "And thanks for taking my call. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4832c9de-a31c-4675-936c-009d8a2e2907", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a282f2be51635f9f2f54af13a80e9dfa6c1530bb12410bc9f401141668ab4a62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca9c7b12-8f3f-4740-882e-f3f369b45330", "node_type": "1", "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit. ", "original_text": "Just a PPE question, you're saying demand has gone up. "}, "hash": "f63fe5d011bcce2b30eb9f19f6c64c4ccc93ecc5e04562f6c3d33958f616f678", "class_name": "RelatedNodeInfo"}}, "text": "And thanks for taking my call. ", "start_char_idx": 3150, "end_char_idx": 3181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca9c7b12-8f3f-4740-882e-f3f369b45330": {"__data__": {"id_": "ca9c7b12-8f3f-4740-882e-f3f369b45330", "embedding": null, "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit. ", "original_text": "Just a PPE question, you're saying demand has gone up. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f392a4a-bec7-4817-b88a-87626b6654d6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo from UBS.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit. ", "original_text": "And thanks for taking my call. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "253d15c041bb191032b0b5697b6da589fc56aed7db4e741ff15f6fc8e4fbf4e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "908b6883-3f55-403b-b00c-928f25738a9f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves. ", "original_text": "Your inventory \nlevels have  gone up. "}, "hash": "69b0b976d4c476f9f0fdf53c0087798f62a5d9343f88f0f517d6a6ee45fd60a0", "class_name": "RelatedNodeInfo"}}, "text": "Just a PPE question, you're saying demand has gone up. ", "start_char_idx": 3181, "end_char_idx": 3236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "908b6883-3f55-403b-b00c-928f25738a9f": {"__data__": {"id_": "908b6883-3f55-403b-b00c-928f25738a9f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves. ", "original_text": "Your inventory \nlevels have  gone up. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca9c7b12-8f3f-4740-882e-f3f369b45330", "node_type": "1", "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit. ", "original_text": "Just a PPE question, you're saying demand has gone up. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ea424ff172c706cde04982261e45df84ae8b948ca03ecc20be5825f72c5e406", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b530ef0-319f-41f6-8113-36b68ca9e953", "node_type": "1", "metadata": {"window": "And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n ", "original_text": "I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit. "}, "hash": "048a85332bbdb91c395811b7f628cd8018ab79321c37503843b722e09f492591", "class_name": "RelatedNodeInfo"}}, "text": "Your inventory \nlevels have  gone up. ", "start_char_idx": 3236, "end_char_idx": 3274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b530ef0-319f-41f6-8113-36b68ca9e953": {"__data__": {"id_": "4b530ef0-319f-41f6-8113-36b68ca9e953", "embedding": null, "metadata": {"window": "And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n ", "original_text": "I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "908b6883-3f55-403b-b00c-928f25738a9f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves. ", "original_text": "Your inventory \nlevels have  gone up. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3d9c86f7867ab6a6c0e5c42202ee9aa898d4c78e72971557b9535a3e53b3277", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4ceed05-6a00-4e0a-a57c-1bf5104d6baa", "node_type": "1", "metadata": {"window": "Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "PPE prices seem to be stabilizing or maybe coming down a little bit. "}, "hash": "405d6f4da853e3599d9e41b5f24928a2bfbe9369cc993716dc4cc61e85f79479", "class_name": "RelatedNodeInfo"}}, "text": "I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit. ", "start_char_idx": 3274, "end_char_idx": 3396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4ceed05-6a00-4e0a-a57c-1bf5104d6baa": {"__data__": {"id_": "e4ceed05-6a00-4e0a-a57c-1bf5104d6baa", "embedding": null, "metadata": {"window": "Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "PPE prices seem to be stabilizing or maybe coming down a little bit. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b530ef0-319f-41f6-8113-36b68ca9e953", "node_type": "1", "metadata": {"window": "And thanks for taking my call.  Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n ", "original_text": "I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f524b5e5845810a640f7346f3e90c96c92f948459ff028e788e5db975a24f6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45932477-dfc5-4998-bf63-ec15a1c0d406", "node_type": "1", "metadata": {"window": "Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure. ", "original_text": "And also, we're \nhearing there's a shortage of nitrile gl oves. "}, "hash": "7436b7578f33a95b87ed128b50b57a8b6989b5b4b9f3facb37a8b4520349ee74", "class_name": "RelatedNodeInfo"}}, "text": "PPE prices seem to be stabilizing or maybe coming down a little bit. ", "start_char_idx": 3396, "end_char_idx": 3465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45932477-dfc5-4998-bf63-ec15a1c0d406": {"__data__": {"id_": "45932477-dfc5-4998-bf63-ec15a1c0d406", "embedding": null, "metadata": {"window": "Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure. ", "original_text": "And also, we're \nhearing there's a shortage of nitrile gl oves. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4ceed05-6a00-4e0a-a57c-1bf5104d6baa", "node_type": "1", "metadata": {"window": "Just a PPE question, you're saying demand has gone up.  Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "PPE prices seem to be stabilizing or maybe coming down a little bit. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ce54aad2b6d2f2ca3074e324c7abd16624beb27c1f4ce0d1b717aed1999e426", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d869fe8-27e4-4a9e-bb54-dc7976adb53c", "node_type": "1", "metadata": {"window": "I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments. ", "original_text": "Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n "}, "hash": "7a9d945fdb0622cbc02d7f10881895186ebd90ac89a2e14d39d3337b53a81615", "class_name": "RelatedNodeInfo"}}, "text": "And also, we're \nhearing there's a shortage of nitrile gl oves. ", "start_char_idx": 3465, "end_char_idx": 3529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d869fe8-27e4-4a9e-bb54-dc7976adb53c": {"__data__": {"id_": "5d869fe8-27e4-4a9e-bb54-dc7976adb53c", "embedding": null, "metadata": {"window": "I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments. ", "original_text": "Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45932477-dfc5-4998-bf63-ec15a1c0d406", "node_type": "1", "metadata": {"window": "Your inventory \nlevels have  gone up.  I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure. ", "original_text": "And also, we're \nhearing there's a shortage of nitrile gl oves. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b73d72a468352dadb0ddaa139b7ae5c5be0466bbd85b4b056988156fb577dc6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ba6b5e2-be2c-4628-9d99-174bd7677bb4", "node_type": "1", "metadata": {"window": "PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "a4efb95a5fe1e365d0e051bde2fd0aa0cc2eb7b0751727448093a907f5f1d938", "class_name": "RelatedNodeInfo"}}, "text": "Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n ", "start_char_idx": 3529, "end_char_idx": 3624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ba6b5e2-be2c-4628-9d99-174bd7677bb4": {"__data__": {"id_": "2ba6b5e2-be2c-4628-9d99-174bd7677bb4", "embedding": null, "metadata": {"window": "PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d869fe8-27e4-4a9e-bb54-dc7976adb53c", "node_type": "1", "metadata": {"window": "I guess, I'd like to understand the dynamics around the pricing of PPE and how that affects \nyour revenues and/or profit.  PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments. ", "original_text": "Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e5dafd22bafd90874f4463485ed75e1de2cc370217936e3892f7b3ebed85a83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fe567d8-c335-42c5-bfae-27cb9253b607", "node_type": "1", "metadata": {"window": "And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n", "original_text": "A \nYeah, sure. "}, "hash": "07eda885df3e9e70753e8a7bb4bebfbb4e28975db62daab8c8f5e71086f06316", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1329, "end_char_idx": 1655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fe567d8-c335-42c5-bfae-27cb9253b607": {"__data__": {"id_": "1fe567d8-c335-42c5-bfae-27cb9253b607", "embedding": null, "metadata": {"window": "And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n", "original_text": "A \nYeah, sure. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ba6b5e2-be2c-4628-9d99-174bd7677bb4", "node_type": "1", "metadata": {"window": "PPE prices seem to be stabilizing or maybe coming down a little bit.  And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06413d1f3cb44778ed23ffaf3fc625fbaaa9a1c756546ce70e62124e53767159", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19be509d-6b26-4501-93d5-33e03855d76e", "node_type": "1", "metadata": {"window": "Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers. ", "original_text": "Maybe I'll just make a couple of general comments. "}, "hash": "27e3c0111b0647ba1ecfd5999414769cd97ff9d552f7f141ba4d55fc91462019", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, sure. ", "start_char_idx": 3950, "end_char_idx": 3965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19be509d-6b26-4501-93d5-33e03855d76e": {"__data__": {"id_": "19be509d-6b26-4501-93d5-33e03855d76e", "embedding": null, "metadata": {"window": "Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers. ", "original_text": "Maybe I'll just make a couple of general comments. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fe567d8-c335-42c5-bfae-27cb9253b607", "node_type": "1", "metadata": {"window": "And also, we're \nhearing there's a shortage of nitrile gl oves.  Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n", "original_text": "A \nYeah, sure. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2f733087441f1be7b0e075b615a63420ba27c5ec8796bbb3464b34f270b6b5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccf3f1dd-f01d-4a78-ba39-b4c3f0425393", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively. ", "original_text": "We certainly have seen hi gher demand for these \nproducts over the course of the year. "}, "hash": "fad43244c13ccb50ecf9a3e77bb70f5883890dcddb314e151be2046ae885db41", "class_name": "RelatedNodeInfo"}}, "text": "Maybe I'll just make a couple of general comments. ", "start_char_idx": 3965, "end_char_idx": 4016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccf3f1dd-f01d-4a78-ba39-b4c3f0425393": {"__data__": {"id_": "ccf3f1dd-f01d-4a78-ba39-b4c3f0425393", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively. ", "original_text": "We certainly have seen hi gher demand for these \nproducts over the course of the year. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19be509d-6b26-4501-93d5-33e03855d76e", "node_type": "1", "metadata": {"window": "Can you just talk a little bit how pricing dynamics change your profit in \nthe PPE segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers. ", "original_text": "Maybe I'll just make a couple of general comments. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef1c0308714ba15a10bdd19fa68ce9f0b8969d0776a51e4e21a333aa36dffc21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10a56380-0ca5-4303-8248-2de4647e32c5", "node_type": "1", "metadata": {"window": "A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside. ", "original_text": "That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n"}, "hash": "ac32b3eeed2f30a9d0d046128942a8d2e22bd31dabc004f10adc3907dd2ceee0", "class_name": "RelatedNodeInfo"}}, "text": "We certainly have seen hi gher demand for these \nproducts over the course of the year. ", "start_char_idx": 4016, "end_char_idx": 4103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10a56380-0ca5-4303-8248-2de4647e32c5": {"__data__": {"id_": "10a56380-0ca5-4303-8248-2de4647e32c5", "embedding": null, "metadata": {"window": "A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside. ", "original_text": "That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccf3f1dd-f01d-4a78-ba39-b4c3f0425393", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively. ", "original_text": "We certainly have seen hi gher demand for these \nproducts over the course of the year. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7d9b58519f7423545f33ddf902b0164a3de20fba9f2ce6c2fe3c003a6de9fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1441197e-591f-46db-9315-e1ae12772806", "node_type": "1", "metadata": {"window": "Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside.  But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "original_text": "Look, we have very good and solid relationships from  a logistics perspective with many different suppliers. "}, "hash": "3ee9d2eebb2972385d36a457e133f1f34ad16cb3f6d604693683f06ab301155b", "class_name": "RelatedNodeInfo"}}, "text": "That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n", "start_char_idx": 4103, "end_char_idx": 4252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1441197e-591f-46db-9315-e1ae12772806": {"__data__": {"id_": "1441197e-591f-46db-9315-e1ae12772806", "embedding": null, "metadata": {"window": "Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside.  But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "original_text": "Look, we have very good and solid relationships from  a logistics perspective with many different suppliers. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10a56380-0ca5-4303-8248-2de4647e32c5", "node_type": "1", "metadata": {"window": "A \nYeah, sure.  Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside. ", "original_text": "That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d5312e854dd929cfbee5b993f8309c9667ee24925e396f2c241282ade253125", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab116df6-e7cd-42bc-90ff-0ba38088c40f", "node_type": "1", "metadata": {"window": "We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside.  But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "original_text": "We \nbelieve that that allows us to source competitively. "}, "hash": "d40042e34b8832fd0ab6e7e47b5f950c752c14d9ed782a9614989ad7ff3360e8", "class_name": "RelatedNodeInfo"}}, "text": "Look, we have very good and solid relationships from  a logistics perspective with many different suppliers. ", "start_char_idx": 4252, "end_char_idx": 4361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab116df6-e7cd-42bc-90ff-0ba38088c40f": {"__data__": {"id_": "ab116df6-e7cd-42bc-90ff-0ba38088c40f", "embedding": null, "metadata": {"window": "We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside.  But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "original_text": "We \nbelieve that that allows us to source competitively. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1441197e-591f-46db-9315-e1ae12772806", "node_type": "1", "metadata": {"window": "Maybe I'll just make a couple of general comments.  We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside.  But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "original_text": "Look, we have very good and solid relationships from  a logistics perspective with many different suppliers. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "506258fdbb2a531425191dc8487092bba14de16cf2ee3cdb3017b51732d36324", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02fd1170-7c2f-4943-a9a3-09438c0218b1", "node_type": "1", "metadata": {"window": "That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside.  But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "original_text": "And clearly, the market is \u2013 it's a competitive market on the sell \nside. "}, "hash": "c3508ca80385ca8599d25444c20d74a3b861dad8ebf734be65c576f7b8d86d0d", "class_name": "RelatedNodeInfo"}}, "text": "We \nbelieve that that allows us to source competitively. ", "start_char_idx": 4361, "end_char_idx": 4418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02fd1170-7c2f-4943-a9a3-09438c0218b1": {"__data__": {"id_": "02fd1170-7c2f-4943-a9a3-09438c0218b1", "embedding": null, "metadata": {"window": "That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside.  But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "original_text": "And clearly, the market is \u2013 it's a competitive market on the sell \nside. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab116df6-e7cd-42bc-90ff-0ba38088c40f", "node_type": "1", "metadata": {"window": "We certainly have seen hi gher demand for these \nproducts over the course of the year.  That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside.  But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "original_text": "We \nbelieve that that allows us to source competitively. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05cd28e4e195e08d7898b43c7a5dff7b137de3b6b7faca91ac760d032c3c044f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a8129d7-017b-4e31-a7ae-70b914957b2b", "node_type": "1", "metadata": {"window": "Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside.  But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "original_text": "But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n "}, "hash": "316cfd195d37dd0d6fc1d882a27e0e57f06b1f05c1186b1437aeefae5060c1a8", "class_name": "RelatedNodeInfo"}}, "text": "And clearly, the market is \u2013 it's a competitive market on the sell \nside. ", "start_char_idx": 4418, "end_char_idx": 4492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a8129d7-017b-4e31-a7ae-70b914957b2b": {"__data__": {"id_": "6a8129d7-017b-4e31-a7ae-70b914957b2b", "embedding": null, "metadata": {"window": "Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside.  But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "original_text": "But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "154241d4c90b8fbb107e2e9f39c56feea6df1d565d0b9772c8e9efe48b7874c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02fd1170-7c2f-4943-a9a3-09438c0218b1", "node_type": "1", "metadata": {"window": "That demand continued through the second quarter, more in the COVID -19 \ntest kits in the second quarter, but PPE has been heavy demand as well.  \n \n Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside.  But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "original_text": "And clearly, the market is \u2013 it's a competitive market on the sell \nside. ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "412e6aa31ea26f4ca4d1e4d9b1f15abcff1aec94bdfff9e49f2ebfc5776aa0f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2aaeb0a5-589d-4de7-81b5-2114961eb165", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n ", "original_text": "McKesson Corp.  "}, "hash": "13217a5bc1856b5fb4be9376e551928ea82337d2877473a8936b6c7120ef9b0e", "class_name": "RelatedNodeInfo"}}, "text": "But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "start_char_idx": 4492, "end_char_idx": 4607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2aaeb0a5-589d-4de7-81b5-2114961eb165": {"__data__": {"id_": "2aaeb0a5-589d-4de7-81b5-2114961eb165", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a8129d7-017b-4e31-a7ae-70b914957b2b", "node_type": "1", "metadata": {"window": "Look, we have very good and solid relationships from  a logistics perspective with many different suppliers.  We \nbelieve that that allows us to source competitively.  And clearly, the market is \u2013 it's a competitive market on the sell \nside.  But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "original_text": "But, again, we've seen some stability in the pricing in the first half of the year, but it's a volatile market.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd76f4f71ef5f35c31ac5854bc5384d09aac088c8d2a7196ac336736359e2e12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5db4b3e-2635-4913-a011-b1e6b0233e92", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that. "}, "hash": "033262706c1607d2520aad1c7c899f215de22021fa1469c9cfcc2bd5a0c6e25c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5db4b3e-2635-4913-a011-b1e6b0233e92": {"__data__": {"id_": "c5db4b3e-2635-4913-a011-b1e6b0233e92", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2aaeb0a5-589d-4de7-81b5-2114961eb165", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec1727a3b048ef98120f7004e21fd3554701b5562a66a7838eb345bf0f45945f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d88e2a7-efcf-4c1d-ac84-4de2125fe996", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year . "}, "hash": "e7b6f3c2e199e8e55038c23aae2fea9ed619eee1b653f32cb97456a81ec9636b", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that. ", "start_char_idx": 16, "end_char_idx": 282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d88e2a7-efcf-4c1d-ac84-4de2125fe996": {"__data__": {"id_": "2d88e2a7-efcf-4c1d-ac84-4de2125fe996", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year . ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5db4b3e-2635-4913-a011-b1e6b0233e92", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c001671124c6f0a1e9286d27f57c1e8d387774e6051f254844c71a556141317", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "216af6f7-8578-42da-9068-171d3cef9877", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "original_text": "It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n "}, "hash": "51cf42b0b3aee1be6d27b9b4c06d546528c44b3678a2cd5aa6899d9cc858cc39", "class_name": "RelatedNodeInfo"}}, "text": "And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year . ", "start_char_idx": 282, "end_char_idx": 399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "216af6f7-8578-42da-9068-171d3cef9877": {"__data__": {"id_": "216af6f7-8578-42da-9068-171d3cef9877", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "original_text": "It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d88e2a7-efcf-4c1d-ac84-4de2125fe996", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year . ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d23f624b056b051a2e2efa8e436ade681ab2275b96ed3c8c23c8506dd3a12bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff22aa49-5557-4d52-b4e2-9cb5d057dd9f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "2dd535b54e82f2d1e6cd30061fce109036ba3dad7e876fa52a73c314eb322d84", "class_name": "RelatedNodeInfo"}}, "text": "It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n ", "start_char_idx": 399, "end_char_idx": 673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff22aa49-5557-4d52-b4e2-9cb5d057dd9f": {"__data__": {"id_": "ff22aa49-5557-4d52-b4e2-9cb5d057dd9f", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "216af6f7-8578-42da-9068-171d3cef9877", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "original_text": "It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "178f3e440693a9b1d29bb47374d00c8492e3bff963e343d4a18fced2ee13774f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d7fbdf6-4fd1-4f6d-bfbe-36ccb665f8fd", "node_type": "1", "metadata": {"window": "And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question. ", "original_text": "A \nNext question?  \n "}, "hash": "cae7ed72dae6106b05309135c05b907c932c09ab4feab62d37419463c5c4a695", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 673, "end_char_idx": 1003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d7fbdf6-4fd1-4f6d-bfbe-36ccb665f8fd": {"__data__": {"id_": "2d7fbdf6-4fd1-4f6d-bfbe-36ccb665f8fd", "embedding": null, "metadata": {"window": "And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question. ", "original_text": "A \nNext question?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff22aa49-5557-4d52-b4e2-9cb5d057dd9f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c5c59acf8238984a3f1c0fba28d505640160a9c1825ccdbcc44729a1e43e85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95cdc8ee-24d6-486e-8a3b-9dc8440911ac", "node_type": "1", "metadata": {"window": "It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan. "}, "hash": "165851543e9df2abb53d24b7603316d1d7984389a529e23e50649f7f560a0342", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question?  \n ", "start_char_idx": 1003, "end_char_idx": 1024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95cdc8ee-24d6-486e-8a3b-9dc8440911ac": {"__data__": {"id_": "95cdc8ee-24d6-486e-8a3b-9dc8440911ac", "embedding": null, "metadata": {"window": "It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d7fbdf6-4fd1-4f6d-bfbe-36ccb665f8fd", "node_type": "1", "metadata": {"window": "And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question. ", "original_text": "A \nNext question?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "278232520acb4d9a9d3efa47b94a6e11b950c77582c3a68a7736c80cbd2cc0a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c43c63a8-ac50-49f8-8615-d31a8c310236", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter? ", "original_text": "Your line is now open.  \n "}, "hash": "56aa5834f9c1d2362c690611439379db98ac3bfe6d9a9145f1516aaa619067b1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "start_char_idx": 1024, "end_char_idx": 1336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c43c63a8-ac50-49f8-8615-d31a8c310236": {"__data__": {"id_": "c43c63a8-ac50-49f8-8615-d31a8c310236", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter? ", "original_text": "Your line is now open.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95cdc8ee-24d6-486e-8a3b-9dc8440911ac", "node_type": "1", "metadata": {"window": "It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a83322521c8937624dc7f7b490d713b804692c95b8f613656589c9e1af00d07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e76c317-276e-4f2e-9382-f2c24caa51a3", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question. "}, "hash": "b283d19214ac02d0a0223e075b8b56e40077c62881aab3a5be89901800636f01", "class_name": "RelatedNodeInfo"}}, "text": "Your line is now open.  \n ", "start_char_idx": 1336, "end_char_idx": 1362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e76c317-276e-4f2e-9382-f2c24caa51a3": {"__data__": {"id_": "9e76c317-276e-4f2e-9382-f2c24caa51a3", "embedding": null, "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c43c63a8-ac50-49f8-8615-d31a8c310236", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter? ", "original_text": "Your line is now open.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2bbf4602ea37cb00a721ed32f5e011986da7167ac851e9ad893c5ea37e9c48f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "093a216e-b8a6-4d0b-ace3-20716a5c1167", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Brian, just going back to your comments around specialty and \nthe resilience on the oncology side. "}, "hash": "d9d09e18effbd5117d4abfc29b68af8ab3b10c2059a2fd2e0850ebffb36d4d70", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question. ", "start_char_idx": 1362, "end_char_idx": 1719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "093a216e-b8a6-4d0b-ace3-20716a5c1167": {"__data__": {"id_": "093a216e-b8a6-4d0b-ace3-20716a5c1167", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Brian, just going back to your comments around specialty and \nthe resilience on the oncology side. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e76c317-276e-4f2e-9382-f2c24caa51a3", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce63d244cf036cf45372260d6d0a32d0ed241b4c2d13b3fbd9975d7cb557c9c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20010948-eafb-4867-bd6a-91499c7f582f", "node_type": "1", "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter? "}, "hash": "5c35a17eb1653787c2287dcd6b0c0a7ff4cf82a49bd563ea6202a7b44627dbbe", "class_name": "RelatedNodeInfo"}}, "text": "Brian, just going back to your comments around specialty and \nthe resilience on the oncology side. ", "start_char_idx": 1719, "end_char_idx": 1818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20010948-eafb-4867-bd6a-91499c7f582f": {"__data__": {"id_": "20010948-eafb-4867-bd6a-91499c7f582f", "embedding": null, "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter? ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "093a216e-b8a6-4d0b-ace3-20716a5c1167", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Lisa Gill with JPMorgan.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Brian, just going back to your comments around specialty and \nthe resilience on the oncology side. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ad076a594f4313b3cb039ff3e1f327b05cddf01307ae7a5b4c6204f3688b56f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1054f49-879f-41cf-869d-5839345048f4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology. ", "original_text": "And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n "}, "hash": "8408d983140d7a241989b9f230479e8ae5155a2fb7a7d03af89c96e3d04b2468", "class_name": "RelatedNodeInfo"}}, "text": "If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter? ", "start_char_idx": 1818, "end_char_idx": 1996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1054f49-879f-41cf-869d-5839345048f4": {"__data__": {"id_": "d1054f49-879f-41cf-869d-5839345048f4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology. ", "original_text": "And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20010948-eafb-4867-bd6a-91499c7f582f", "node_type": "1", "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter? ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb5743f0fcd1498d7cccaf18f6aae911c9d51b6d242d99daa770589c1d5ce36a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5dc21fa-3031-47d5-8f59-e462ba5ec667", "node_type": "1", "metadata": {"window": "Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "e18b73b549b7276d1d8fa96255a76de60e7351b9aa0d4903a0d958f7b634b922", "class_name": "RelatedNodeInfo"}}, "text": "And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n ", "start_char_idx": 1996, "end_char_idx": 2185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5dc21fa-3031-47d5-8f59-e462ba5ec667": {"__data__": {"id_": "a5dc21fa-3031-47d5-8f59-e462ba5ec667", "embedding": null, "metadata": {"window": "Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1054f49-879f-41cf-869d-5839345048f4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGood morning and thanks for taking my question.  Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology. ", "original_text": "And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "153d04715bc6a937403bb888131c66fe5b1e9bd80cb3a234c9158ce0bbd79efe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60bffb39-a7e5-4797-a394-cd5846f0cfd7", "node_type": "1", "metadata": {"window": "If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties. ", "original_text": "A \nSure. "}, "hash": "2933c53cf33a3c0b4f803d535ab93a405921b5a7f5da4d3c562ea3afd0ac651f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2185, "end_char_idx": 2530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60bffb39-a7e5-4797-a394-cd5846f0cfd7": {"__data__": {"id_": "60bffb39-a7e5-4797-a394-cd5846f0cfd7", "embedding": null, "metadata": {"window": "If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties. ", "original_text": "A \nSure. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5dc21fa-3031-47d5-8f59-e462ba5ec667", "node_type": "1", "metadata": {"window": "Brian, just going back to your comments around specialty and \nthe resilience on the oncology side.  If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f456bbbfec4d7b3acce89e073da6c777b429a44d23b500e2da620bb4583604b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddb99fdf-8637-43c1-8316-53cd70f356e9", "node_type": "1", "metadata": {"window": "And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n", "original_text": "Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology. "}, "hash": "e70ea3caff33d3a3b864f7efe47e9be129c9d2a6c49e5a6606a0ad2f4da3b6c3", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 2530, "end_char_idx": 2539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddb99fdf-8637-43c1-8316-53cd70f356e9": {"__data__": {"id_": "ddb99fdf-8637-43c1-8316-53cd70f356e9", "embedding": null, "metadata": {"window": "And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n", "original_text": "Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60bffb39-a7e5-4797-a394-cd5846f0cfd7", "node_type": "1", "metadata": {"window": "If I start to think about biosimilars coming to the market, especially in the \noncology area; one, can you talk about if there were any  benefit from biosimilars in the quarter?  And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties. ", "original_text": "A \nSure. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33f8464e078cf1f21280e855a33725eb01c32abc7df4282d58839fcac99f5cb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7eb400b7-77a0-4805-9e0e-2c9ee4da08c3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business. ", "original_text": "The oncology business in  particular, I think, has been \npretty resilient.  \n \n"}, "hash": "cd026dada2fa3e55b99cde1117c51f4a33fba504841e0a142bad26b00c3a651b", "class_name": "RelatedNodeInfo"}}, "text": "Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology. ", "start_char_idx": 2539, "end_char_idx": 2708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7eb400b7-77a0-4805-9e0e-2c9ee4da08c3": {"__data__": {"id_": "7eb400b7-77a0-4805-9e0e-2c9ee4da08c3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business. ", "original_text": "The oncology business in  particular, I think, has been \npretty resilient.  \n \n", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddb99fdf-8637-43c1-8316-53cd70f356e9", "node_type": "1", "metadata": {"window": "And then, \nsecondly, if you or Britt can help us to understand the margin differential and the opportunity around biosimilars as \nwe think about the strength in your specialty business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n", "original_text": "Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3394b74c70d07811d6052371848adcd7a269fd75c800a7bc1475720f2c6249d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d5ce72e-5d04-41c5-a0a6-ffcffc8858a1", "node_type": "1", "metadata": {"window": "A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets. ", "original_text": "Probably visits even at the trough period were relatively stronger than many of the other specialties. "}, "hash": "2509469d9c906b6b05b12d448d365b1e0c1fa64c6044ea4e26d3b1ea8e11fb92", "class_name": "RelatedNodeInfo"}}, "text": "The oncology business in  particular, I think, has been \npretty resilient.  \n \n", "start_char_idx": 2708, "end_char_idx": 2787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d5ce72e-5d04-41c5-a0a6-ffcffc8858a1": {"__data__": {"id_": "8d5ce72e-5d04-41c5-a0a6-ffcffc8858a1", "embedding": null, "metadata": {"window": "A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets. ", "original_text": "Probably visits even at the trough period were relatively stronger than many of the other specialties. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7eb400b7-77a0-4805-9e0e-2c9ee4da08c3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business. ", "original_text": "The oncology business in  particular, I think, has been \npretty resilient.  \n \n", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd15cf03375699aee297881b3a6f6d13f90b9a1cc64b3e269e6d981dd976a286", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "215ad2a5-4aba-4df3-88e7-94a01ef29edc", "node_type": "1", "metadata": {"window": "Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n", "original_text": "And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n"}, "hash": "fabee62ac9c55f3fe13dd085762e0cc45e3de9f0b65e0e9ad1b17dbb2dc8e663", "class_name": "RelatedNodeInfo"}}, "text": "Probably visits even at the trough period were relatively stronger than many of the other specialties. ", "start_char_idx": 2787, "end_char_idx": 2890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "215ad2a5-4aba-4df3-88e7-94a01ef29edc": {"__data__": {"id_": "215ad2a5-4aba-4df3-88e7-94a01ef29edc", "embedding": null, "metadata": {"window": "Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n", "original_text": "And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d5ce72e-5d04-41c5-a0a6-ffcffc8858a1", "node_type": "1", "metadata": {"window": "A \nSure.  Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets. ", "original_text": "Probably visits even at the trough period were relatively stronger than many of the other specialties. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09dfdb6436346a3f644401afbe9eb72b01c1edf4253f696e02c756c04b4b8858", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "282d9598-72da-4796-8184-e578cbabc78f", "node_type": "1", "metadata": {"window": "The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n ", "original_text": "And we have a tremendous footprint in that business. "}, "hash": "cca1cad50e505a73fdfd2945a717880eaf5460bd0bf7c0a39fe67155430706a1", "class_name": "RelatedNodeInfo"}}, "text": "And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n", "start_char_idx": 2890, "end_char_idx": 3067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "282d9598-72da-4796-8184-e578cbabc78f": {"__data__": {"id_": "282d9598-72da-4796-8184-e578cbabc78f", "embedding": null, "metadata": {"window": "The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n ", "original_text": "And we have a tremendous footprint in that business. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "215ad2a5-4aba-4df3-88e7-94a01ef29edc", "node_type": "1", "metadata": {"window": "Well, we've got a very strong provider base for specialty products, and that's our \u2013 what we call sometimes \nour non -affiliated or non -US oncology and/or US oncology.  The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n", "original_text": "And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e476726eeba05bffd4584637a6b64bd2c651fc9749d5d3de3534d3344f107254", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4f56e62-e43a-4671-bcd8-1650e43ebaf3", "node_type": "1", "metadata": {"window": "Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We have a broad set of scaled assets. "}, "hash": "28030d6aeb9c337d9c2f17a8b3efef22e6e544dffe8ea8afdf3a3e312509298b", "class_name": "RelatedNodeInfo"}}, "text": "And we have a tremendous footprint in that business. ", "start_char_idx": 3067, "end_char_idx": 3120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4f56e62-e43a-4671-bcd8-1650e43ebaf3": {"__data__": {"id_": "e4f56e62-e43a-4671-bcd8-1650e43ebaf3", "embedding": null, "metadata": {"window": "Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We have a broad set of scaled assets. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "282d9598-72da-4796-8184-e578cbabc78f", "node_type": "1", "metadata": {"window": "The oncology business in  particular, I think, has been \npretty resilient.  \n \n Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n ", "original_text": "And we have a tremendous footprint in that business. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34f63c2d0a2bc06c069f04f10d12e42af7b4789bc5545b091feedf838609b90a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60b2b852-ceb5-4ee9-80a4-59ca073b37d7", "node_type": "1", "metadata": {"window": "And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part. ", "original_text": "And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n"}, "hash": "2ade8b79e2d0a633a6e4ff84cd0180f5918997ad31ec27dcc55eb5f51ecaaacd", "class_name": "RelatedNodeInfo"}}, "text": "We have a broad set of scaled assets. ", "start_char_idx": 3120, "end_char_idx": 3158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60b2b852-ceb5-4ee9-80a4-59ca073b37d7": {"__data__": {"id_": "60b2b852-ceb5-4ee9-80a4-59ca073b37d7", "embedding": null, "metadata": {"window": "And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part. ", "original_text": "And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4f56e62-e43a-4671-bcd8-1650e43ebaf3", "node_type": "1", "metadata": {"window": "Probably visits even at the trough period were relatively stronger than many of the other specialties.  And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We have a broad set of scaled assets. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d14a1ba73222d2a7f94027e366e8ab17e64d040f2f77a06c427c6fa20fc942f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbf30737-0edc-47df-abc6-364f5e400d23", "node_type": "1", "metadata": {"window": "And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year. ", "original_text": "So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n "}, "hash": "b3d0fe8a43bf6326b97f6aefa3ee20708b37ea3784830fb520479dc174fd521c", "class_name": "RelatedNodeInfo"}}, "text": "And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n", "start_char_idx": 3158, "end_char_idx": 3387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbf30737-0edc-47df-abc6-364f5e400d23": {"__data__": {"id_": "dbf30737-0edc-47df-abc6-364f5e400d23", "embedding": null, "metadata": {"window": "And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year. ", "original_text": "So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60b2b852-ceb5-4ee9-80a4-59ca073b37d7", "node_type": "1", "metadata": {"window": "And what \nwe're seeing now is that combined, the physical patient visits with the telehealth activities,  we're seeing volumes \nreally get back almost to pre -COVID levels.  \n \n And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part. ", "original_text": "And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c7c007d3f6f6b8e656188eae81a8e7a26c365a87ce838044a6d8d115e5995ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "916ff713-4525-4385-88e4-c95058045699", "node_type": "1", "metadata": {"window": "We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "314a6f7fe1d4c965b19a3dd07cb7b7388de22253573641c021049275acd6a823", "class_name": "RelatedNodeInfo"}}, "text": "So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n ", "start_char_idx": 3387, "end_char_idx": 3640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "916ff713-4525-4385-88e4-c95058045699": {"__data__": {"id_": "916ff713-4525-4385-88e4-c95058045699", "embedding": null, "metadata": {"window": "We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbf30737-0edc-47df-abc6-364f5e400d23", "node_type": "1", "metadata": {"window": "And we have a tremendous footprint in that business.  We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year. ", "original_text": "So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30cbc32dead22264f5e7b075eaaa7cf6e4014661f82154fc9049389caa48ec0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1afdc28f-e8c6-4471-800c-55ab929b6701", "node_type": "1", "metadata": {"window": "And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win. ", "original_text": "A \nAnd, Lisa, maybe just to touch on your \u2013 the last part. "}, "hash": "89a6bb96d85aee65308f340ab3ab8801df390d22f997fdee756921f0031055f9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3640, "end_char_idx": 3966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1afdc28f-e8c6-4471-800c-55ab929b6701": {"__data__": {"id_": "1afdc28f-e8c6-4471-800c-55ab929b6701", "embedding": null, "metadata": {"window": "And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win. ", "original_text": "A \nAnd, Lisa, maybe just to touch on your \u2013 the last part. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "916ff713-4525-4385-88e4-c95058045699", "node_type": "1", "metadata": {"window": "We have a broad set of scaled assets.  And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d09bedc6cb732720ba85631067399a6de1fa6d99671c7f3c7d38d52d66cd5155", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d165e6e6-d04a-47c6-9a49-1ef46b641609", "node_type": "1", "metadata": {"window": "So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients. ", "original_text": "We've seen that biosimilars have grown this year. "}, "hash": "bb432e50cd325fd9ffd8abe486e62e8d836657ca760eb2f11020ed71bac4e37e", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd, Lisa, maybe just to touch on your \u2013 the last part. ", "start_char_idx": 3966, "end_char_idx": 4025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d165e6e6-d04a-47c6-9a49-1ef46b641609": {"__data__": {"id_": "d165e6e6-d04a-47c6-9a49-1ef46b641609", "embedding": null, "metadata": {"window": "So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients. ", "original_text": "We've seen that biosimilars have grown this year. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1afdc28f-e8c6-4471-800c-55ab929b6701", "node_type": "1", "metadata": {"window": "And one of the \nthings that we're \u2013 I think we will be able to do and are doing and will continue t o expand over time is take \nadvantage of not just biosimilars, but other new specialty products that launch into that space.  \n \n So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win. ", "original_text": "A \nAnd, Lisa, maybe just to touch on your \u2013 the last part. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f5a95e34dcfd85529c3af3ad9da0bd5187de57babe6791526eb30dfccf660b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53046e13-95d7-470e-bea0-29676f629017", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n", "original_text": "We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology. "}, "hash": "020decc406715d3915eedbbc72e09465f914e673422d2282801a84ba43963a96", "class_name": "RelatedNodeInfo"}}, "text": "We've seen that biosimilars have grown this year. ", "start_char_idx": 4025, "end_char_idx": 4075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53046e13-95d7-470e-bea0-29676f629017": {"__data__": {"id_": "53046e13-95d7-470e-bea0-29676f629017", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n", "original_text": "We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d165e6e6-d04a-47c6-9a49-1ef46b641609", "node_type": "1", "metadata": {"window": "So you know our conviction in the community provider settings and how \u2013 what important role we think it plays in \nthe healthcare lan dscape, and we continue to invest and expand our offerings to position us to take advantage of \nthose opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients. ", "original_text": "We've seen that biosimilars have grown this year. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00415e643b6ea7752d4fc963ac89f51e422ec1e65e87fb2e9874043ec6ef2b3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26e3c629-25ee-4806-8d6f-cb1a6fc3ffdf", "node_type": "1", "metadata": {"window": "A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop. ", "original_text": "We think that \nbiosimilars are a win -win-win. "}, "hash": "b8d736f0a3467d0e915bc77f42089feb78eed2c0a376ea12a35ab9e0d7eedf9a", "class_name": "RelatedNodeInfo"}}, "text": "We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology. ", "start_char_idx": 4075, "end_char_idx": 4179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26e3c629-25ee-4806-8d6f-cb1a6fc3ffdf": {"__data__": {"id_": "26e3c629-25ee-4806-8d6f-cb1a6fc3ffdf", "embedding": null, "metadata": {"window": "A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop. ", "original_text": "We think that \nbiosimilars are a win -win-win. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53046e13-95d7-470e-bea0-29676f629017", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n", "original_text": "We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c3d248702daea6b40a6386a2889a26250d93cfdf518fabcf81b1f4f15c49a9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50a6efb0-0129-4c41-abf1-f618b7b5145b", "node_type": "1", "metadata": {"window": "We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n", "original_text": "They're lower cost opportunities for patients. "}, "hash": "4bcaa7416c6dbd84bfd07856dc527556d29680b62ae61e3d4a6f202fd6e1dce8", "class_name": "RelatedNodeInfo"}}, "text": "We think that \nbiosimilars are a win -win-win. ", "start_char_idx": 4179, "end_char_idx": 4226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50a6efb0-0129-4c41-abf1-f618b7b5145b": {"__data__": {"id_": "50a6efb0-0129-4c41-abf1-f618b7b5145b", "embedding": null, "metadata": {"window": "We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n", "original_text": "They're lower cost opportunities for patients. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26e3c629-25ee-4806-8d6f-cb1a6fc3ffdf", "node_type": "1", "metadata": {"window": "A \nAnd, Lisa, maybe just to touch on your \u2013 the last part.  We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop. ", "original_text": "We think that \nbiosimilars are a win -win-win. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b9e1362dbbadc5cddf8b9d0c8f7f1677c248ecf080630d4b3cbae3e01de5315", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "527847f0-57c9-403a-9af8-0af8e6619a54", "node_type": "1", "metadata": {"window": "We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "original_text": "They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n"}, "hash": "a4789b6541276d7824fbe9d893692da64d6410c9f6e2d6d18fdea0fa78bc8e45", "class_name": "RelatedNodeInfo"}}, "text": "They're lower cost opportunities for patients. ", "start_char_idx": 4226, "end_char_idx": 4273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "527847f0-57c9-403a-9af8-0af8e6619a54": {"__data__": {"id_": "527847f0-57c9-403a-9af8-0af8e6619a54", "embedding": null, "metadata": {"window": "We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "original_text": "They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50a6efb0-0129-4c41-abf1-f618b7b5145b", "node_type": "1", "metadata": {"window": "We've seen that biosimilars have grown this year.  We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n", "original_text": "They're lower cost opportunities for patients. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd9af0ade4620b734017a903bfb5fad45061b38f78333241b13b5da4732307d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "064cb640-629e-4b9e-9486-1d2154f584c9", "node_type": "1", "metadata": {"window": "We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "original_text": "So we like that biosimilars are continuing to develop. "}, "hash": "1892eff0d7106c334e38648e10140aa4de00514b0bf0923d724c452a273e6632", "class_name": "RelatedNodeInfo"}}, "text": "They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n", "start_char_idx": 4273, "end_char_idx": 4369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "064cb640-629e-4b9e-9486-1d2154f584c9": {"__data__": {"id_": "064cb640-629e-4b9e-9486-1d2154f584c9", "embedding": null, "metadata": {"window": "We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "original_text": "So we like that biosimilars are continuing to develop. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "527847f0-57c9-403a-9af8-0af8e6619a54", "node_type": "1", "metadata": {"window": "We've \nseen more biosimilars launch into the space, particularly in the specialty provider in oncology.  We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "original_text": "They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "410153faebbbd0f46601f31a3a4fce61394f0a937f5364ba6e3ad626f3fe91be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "765b38b6-e349-4732-be4e-4c6d5fb0d03f", "node_type": "1", "metadata": {"window": "They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "original_text": "They're not very material yet, but they do continue to grow. \n"}, "hash": "8d53f6819aa77976228df5b6a5e35a05df1d91fa8a152df3cdf2eb8f383f43d9", "class_name": "RelatedNodeInfo"}}, "text": "So we like that biosimilars are continuing to develop. ", "start_char_idx": 4369, "end_char_idx": 4424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "765b38b6-e349-4732-be4e-4c6d5fb0d03f": {"__data__": {"id_": "765b38b6-e349-4732-be4e-4c6d5fb0d03f", "embedding": null, "metadata": {"window": "They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "original_text": "They're not very material yet, but they do continue to grow. \n", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "064cb640-629e-4b9e-9486-1d2154f584c9", "node_type": "1", "metadata": {"window": "We think that \nbiosimilars are a win -win-win.  They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "original_text": "So we like that biosimilars are continuing to develop. ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c04a6e8e60125ad0479090fdec3e7c1f3894c189c4e162540a88459f6c99eb36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f84a80b6-9dda-4e02-9a8d-2ebfb859e47e", "node_type": "1", "metadata": {"window": "They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "original_text": "And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  "}, "hash": "620e270617a8fa4141819bf2d110e3ffb5de339f477a0b5dfd9ef2c1fb806e44", "class_name": "RelatedNodeInfo"}}, "text": "They're not very material yet, but they do continue to grow. \n", "start_char_idx": 4424, "end_char_idx": 4486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f84a80b6-9dda-4e02-9a8d-2ebfb859e47e": {"__data__": {"id_": "f84a80b6-9dda-4e02-9a8d-2ebfb859e47e", "embedding": null, "metadata": {"window": "They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "original_text": "And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826c9dce488ad807f09caa5ad0cbbdf8db558125c1baa2daeb4cf6f90d9dfed6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "765b38b6-e349-4732-be4e-4c6d5fb0d03f", "node_type": "1", "metadata": {"window": "They're lower cost opportunities for patients.  They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "original_text": "They're not very material yet, but they do continue to grow. \n", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ccc38cec675584818b6c7162690e1fa9458c230dcb3e36e505d54ae062dbcce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d548e97-62fc-494d-860a-619720b66b06", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse. ", "original_text": "McKesson Corp.  "}, "hash": "70444c29b12c24e799b0d2180a0b32cbb15763598dc7640fc9e071620d2452cb", "class_name": "RelatedNodeInfo"}}, "text": "And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "start_char_idx": 4486, "end_char_idx": 4602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d548e97-62fc-494d-860a-619720b66b06": {"__data__": {"id_": "5d548e97-62fc-494d-860a-619720b66b06", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f84a80b6-9dda-4e02-9a8d-2ebfb859e47e", "node_type": "1", "metadata": {"window": "They provide economics  for physicians \nand they certainly provide better economics for us.  \n \n So we like that biosimilars are continuing to develop.  They're not very material yet, but they do continue to grow. \n And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "original_text": "And certainly, they provide better cost for the patient, the physician and better margin opportunity for McKesson.  ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f515fbaf20056a9a7172e5ff197ccf57afcf039d7f2aeb949b40cfeb96303520", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79843188-dea1-4c74-a1a4-bfcdfc0ae45c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "6229eaa2943a3062583ccb0e0bcffbdcf75490493f9f0aedc8df13fb664fb0aa", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79843188-dea1-4c74-a1a4-bfcdfc0ae45c": {"__data__": {"id_": "79843188-dea1-4c74-a1a4-bfcdfc0ae45c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d548e97-62fc-494d-860a-619720b66b06", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc5bee8c60aae59601b79cde7c1a786f7dbe59bf32cd79bfada5f4e748ad1774", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f4bda3f-0512-4f7d-905c-d11767c01716", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone. ", "original_text": "A \nNext question?  \n "}, "hash": "bb14074aa990684a25444c9e3b5ec42dcfe39cec7ab306354195d0c9523ed72f", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f4bda3f-0512-4f7d-905c-d11767c01716": {"__data__": {"id_": "7f4bda3f-0512-4f7d-905c-d11767c01716", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone. ", "original_text": "A \nNext question?  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79843188-dea1-4c74-a1a4-bfcdfc0ae45c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f88a2922c1ca31966f27fc43246ff9ed192bbe42c37414c0c506c9441c2094bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "422c30fa-431f-470d-94a3-8d4f656ca883", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse. "}, "hash": "a828531e4b482e77087c9d6d88cc3a692c6503dc8b18aca13adb2aac634178d5", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question?  \n ", "start_char_idx": 254, "end_char_idx": 275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "422c30fa-431f-470d-94a3-8d4f656ca883": {"__data__": {"id_": "422c30fa-431f-470d-94a3-8d4f656ca883", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f4bda3f-0512-4f7d-905c-d11767c01716", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone. ", "original_text": "A \nNext question?  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1cefa57b6947cd71215c57a46fb59fe807316876c002f3bd461b392c4bd02ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d56f18b1-0908-45c4-adef-b683db9aa321", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half. ", "original_text": "Your line is now open.  \n "}, "hash": "390485028f95631d55e33671f8c05a53fde2244d3cefbbf7eb234e5f22d02024", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse. ", "start_char_idx": 275, "end_char_idx": 598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d56f18b1-0908-45c4-adef-b683db9aa321": {"__data__": {"id_": "d56f18b1-0908-45c4-adef-b683db9aa321", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half. ", "original_text": "Your line is now open.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "422c30fa-431f-470d-94a3-8d4f656ca883", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e7df1458ed5d3521301bc0aa90101f9bd4c15049eddd9ccb7578f501b33281d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a998a922-4d35-48c7-8d9d-7f2e9c8b686b", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone. "}, "hash": "d30b2b650d5417c3998608ff2ad10942bf70968da7c7ef6184d8e0b0a097f596", "class_name": "RelatedNodeInfo"}}, "text": "Your line is now open.  \n ", "start_char_idx": 598, "end_char_idx": 624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a998a922-4d35-48c7-8d9d-7f2e9c8b686b": {"__data__": {"id_": "a998a922-4d35-48c7-8d9d-7f2e9c8b686b", "embedding": null, "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d56f18b1-0908-45c4-adef-b683db9aa321", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half. ", "original_text": "Your line is now open.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a85be0ec4def6908aeb0262cc67c1de3b04578d4d7f23e75769f917b8e8b81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c50dbf64-b2dc-494e-b5d0-ac72ae1272b5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment. ", "original_text": "Quickly a couple of clarification on the second half versus first half outlook. "}, "hash": "ca25163e5a0504a2e841a01d444083d5c51b0351972be6bee68dfa47107ed8fd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone. ", "start_char_idx": 624, "end_char_idx": 970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c50dbf64-b2dc-494e-b5d0-ac72ae1272b5": {"__data__": {"id_": "c50dbf64-b2dc-494e-b5d0-ac72ae1272b5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment. ", "original_text": "Quickly a couple of clarification on the second half versus first half outlook. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a998a922-4d35-48c7-8d9d-7f2e9c8b686b", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc32f2146132eb46f984a6da0da7770ba546b80066c61a1b78867107ab7151e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a8dfa99-e104-4a27-a914-99814bf75d5f", "node_type": "1", "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n ", "original_text": "Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half. "}, "hash": "4a5e4942cd241a4b876ad21ff3efb243097dd8ced36a084b78b9f49305565653", "class_name": "RelatedNodeInfo"}}, "text": "Quickly a couple of clarification on the second half versus first half outlook. ", "start_char_idx": 970, "end_char_idx": 1050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a8dfa99-e104-4a27-a914-99814bf75d5f": {"__data__": {"id_": "3a8dfa99-e104-4a27-a914-99814bf75d5f", "embedding": null, "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n ", "original_text": "Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c50dbf64-b2dc-494e-b5d0-ac72ae1272b5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment. ", "original_text": "Quickly a couple of clarification on the second half versus first half outlook. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b81ecc1c8bdc0be9912ed753ab9f78e7304f9b3299a11400f7d363b90401d66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54e4c0b2-371e-43ee-9f1e-c9388dbb0aa4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half? "}, "hash": "3fe66a1980fb8efe465b22645ba0ec2e82f00a2b02db70aca101b0d41a92b0c2", "class_name": "RelatedNodeInfo"}}, "text": "Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half. ", "start_char_idx": 1050, "end_char_idx": 1173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54e4c0b2-371e-43ee-9f1e-c9388dbb0aa4": {"__data__": {"id_": "54e4c0b2-371e-43ee-9f1e-c9388dbb0aa4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half? ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a8dfa99-e104-4a27-a914-99814bf75d5f", "node_type": "1", "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n ", "original_text": "Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e97a592297ebb4e868ac6ccac307dcd1d7b033f4a0efdad9b63bd0ece7a4490d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce340f7a-8aea-4b08-88da-76ca24101d65", "node_type": "1", "metadata": {"window": "Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it. ", "original_text": "And same thing on International segment. "}, "hash": "574d12a7e37f677dfc90b6c23b53b1d05d6a2f0bd903470e754596af1346bb3a", "class_name": "RelatedNodeInfo"}}, "text": "But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half? ", "start_char_idx": 1173, "end_char_idx": 1342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce340f7a-8aea-4b08-88da-76ca24101d65": {"__data__": {"id_": "ce340f7a-8aea-4b08-88da-76ca24101d65", "embedding": null, "metadata": {"window": "Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it. ", "original_text": "And same thing on International segment. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54e4c0b2-371e-43ee-9f1e-c9388dbb0aa4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit S uisse Securities (USA) LLC  Q \nHi, thanks, everyone.  Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half? ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbf76d319006c4972e42bd367c4516efb5e5698035e6b8cd519ed1ba9919d942", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbe17c5a-d057-4f31-87d2-cbc0838c8df7", "node_type": "1", "metadata": {"window": "Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n ", "original_text": "What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n "}, "hash": "24250d46a41d3fdfe82e35eece5b47550021f9061e150ff936e5c93bcb582b18", "class_name": "RelatedNodeInfo"}}, "text": "And same thing on International segment. ", "start_char_idx": 1342, "end_char_idx": 1383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbe17c5a-d057-4f31-87d2-cbc0838c8df7": {"__data__": {"id_": "dbe17c5a-d057-4f31-87d2-cbc0838c8df7", "embedding": null, "metadata": {"window": "Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n ", "original_text": "What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce340f7a-8aea-4b08-88da-76ca24101d65", "node_type": "1", "metadata": {"window": "Quickly a couple of clarification on the second half versus first half outlook.  Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it. ", "original_text": "And same thing on International segment. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56687f161f728032fcd457aa68ff7e7355580e395bbec3e5ca999304766e3cff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "715ddbc9-5b9a-404c-85b3-1a8230b24851", "node_type": "1", "metadata": {"window": "But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "35d4d4e90299aceed4e36e27dfe8c9116f6f3f8d07461cd7e6ec8a02091b2145", "class_name": "RelatedNodeInfo"}}, "text": "What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n ", "start_char_idx": 1383, "end_char_idx": 1509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "715ddbc9-5b9a-404c-85b3-1a8230b24851": {"__data__": {"id_": "715ddbc9-5b9a-404c-85b3-1a8230b24851", "embedding": null, "metadata": {"window": "But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbe17c5a-d057-4f31-87d2-cbc0838c8df7", "node_type": "1", "metadata": {"window": "Your Medical -\nSurgical segment revenues, of course, it now includes the benefit from vaccine distribution in second half.  But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n ", "original_text": "What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64ee0416cd3e9d9ed1dcf158d726d340c40a6466d864e3f3e878e70c1e95b2b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20412bbc-695a-4713-acbc-f1b25483a914", "node_type": "1", "metadata": {"window": "And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight. ", "original_text": "A \nThank you for the question, and I'll let Britt respond to it. "}, "hash": "7e50540d3a6b0260bf5cd9009e4053599a4e90edece4b810b8e6da29c43f370b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1509, "end_char_idx": 1835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20412bbc-695a-4713-acbc-f1b25483a914": {"__data__": {"id_": "20412bbc-695a-4713-acbc-f1b25483a914", "embedding": null, "metadata": {"window": "And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight. ", "original_text": "A \nThank you for the question, and I'll let Britt respond to it. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "715ddbc9-5b9a-404c-85b3-1a8230b24851", "node_type": "1", "metadata": {"window": "But  can \nyou give us any flavor around what is the second half outlook on Med -Surg business on apples -to-apples basis \ncompared with 9% growth you had in first half?  And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d588441d772be4c00716db61d6384a5731194a88d6f3a830f8c685ddab1cd1ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e920261-aca9-4f31-a8f6-e7506a2ceabc", "node_type": "1", "metadata": {"window": "What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian. ", "original_text": "But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n "}, "hash": "059493fa43d9563909c5716205027e610b5b4ff4a91b310df365345e1fa8742c", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you for the question, and I'll let Britt respond to it. ", "start_char_idx": 1835, "end_char_idx": 1900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e920261-aca9-4f31-a8f6-e7506a2ceabc": {"__data__": {"id_": "0e920261-aca9-4f31-a8f6-e7506a2ceabc", "embedding": null, "metadata": {"window": "What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian. ", "original_text": "But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20412bbc-695a-4713-acbc-f1b25483a914", "node_type": "1", "metadata": {"window": "And same thing on International segment.  What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight. ", "original_text": "A \nThank you for the question, and I'll let Britt respond to it. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bba4b6c4ea59326ba5f15518ef398c44b3240ce29e4b6e17b29d8ac64f79e0fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eeb55b92-343a-47d5-8cd6-055b5c5384ae", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "d465ee5ca516713add3b298d3407b579f830b8b0078a1e132d442fdef6807182", "class_name": "RelatedNodeInfo"}}, "text": "But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n ", "start_char_idx": 1900, "end_char_idx": 2117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eeb55b92-343a-47d5-8cd6-055b5c5384ae": {"__data__": {"id_": "eeb55b92-343a-47d5-8cd6-055b5c5384ae", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e920261-aca9-4f31-a8f6-e7506a2ceabc", "node_type": "1", "metadata": {"window": "What is driving that \nhigh-single to low -double -digit d ecline for second half outlook versus down 3% in the first half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian. ", "original_text": "But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dec5eefe8e7e18151fe17e7b3e51ea2cdadd93f7299c067800aca1a1cb4571e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a409262-cc95-44db-9246-9aebb6ac14f7", "node_type": "1", "metadata": {"window": "A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year. ", "original_text": "A \nRight. "}, "hash": "67a30ef9a929be6baa91de6d4bc41005b793e9015a5c6a3f49917d9d1ab95ba3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2117, "end_char_idx": 2462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a409262-cc95-44db-9246-9aebb6ac14f7": {"__data__": {"id_": "5a409262-cc95-44db-9246-9aebb6ac14f7", "embedding": null, "metadata": {"window": "A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year. ", "original_text": "A \nRight. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eeb55b92-343a-47d5-8cd6-055b5c5384ae", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3a278712a83fcc1ab414ee14a173329a71bd000f68bad8e74cb5955c1201eab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b89e82e0-843e-4c15-994b-606133e1de20", "node_type": "1", "metadata": {"window": "But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n", "original_text": "Thanks , Brian. "}, "hash": "711986b9a7b6889a07056630d3dbdab9045373376d632bd2f0b74fafe03781c5", "class_name": "RelatedNodeInfo"}}, "text": "A \nRight. ", "start_char_idx": 2462, "end_char_idx": 2472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b89e82e0-843e-4c15-994b-606133e1de20": {"__data__": {"id_": "b89e82e0-843e-4c15-994b-606133e1de20", "embedding": null, "metadata": {"window": "But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n", "original_text": "Thanks , Brian. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a409262-cc95-44db-9246-9aebb6ac14f7", "node_type": "1", "metadata": {"window": "A \nThank you for the question, and I'll let Britt respond to it.  But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year. ", "original_text": "A \nRight. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a35c215231dead10d861d33ad2af3604619ed5ebcc57e7f9c7b601601430f5a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d38bb160-8e29-460c-bad0-4b261dc9ddd2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract. ", "original_text": "And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half. "}, "hash": "5ee33ab0e2e535a1adb6b4d4b8be7b0739b5120cf8905f8bee49cfcf43043752", "class_name": "RelatedNodeInfo"}}, "text": "Thanks , Brian. ", "start_char_idx": 2472, "end_char_idx": 2488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d38bb160-8e29-460c-bad0-4b261dc9ddd2": {"__data__": {"id_": "d38bb160-8e29-460c-bad0-4b261dc9ddd2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract. ", "original_text": "And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b89e82e0-843e-4c15-994b-606133e1de20", "node_type": "1", "metadata": {"window": "But just to clarify, the Medical business really is not th e \nvaccine distribution, but it's the kitting operation or the production of and storage of the kits that will support the \nadministration of the vaccine.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n", "original_text": "Thanks , Brian. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45e064bc98aecc25611469e543d4f16deaa01385dd13391edc55795008a3d64c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b7085e7-2546-4b46-8c65-8c8b57c1b2fb", "node_type": "1", "metadata": {"window": "A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out. ", "original_text": "We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year. "}, "hash": "a07ddb77aaa1119d6c6f5609b793cc90e401cdde5a35048c4d23e42f2f6ea780", "class_name": "RelatedNodeInfo"}}, "text": "And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half. ", "start_char_idx": 2488, "end_char_idx": 2607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b7085e7-2546-4b46-8c65-8c8b57c1b2fb": {"__data__": {"id_": "7b7085e7-2546-4b46-8c65-8c8b57c1b2fb", "embedding": null, "metadata": {"window": "A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out. ", "original_text": "We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d38bb160-8e29-460c-bad0-4b261dc9ddd2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract. ", "original_text": "And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e2b814680789a2cad5121bb717b54e8fdf7de6662f025f2ee6c659f55b47e8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d72ff356-f150-40db-a291-614e3a18738c", "node_type": "1", "metadata": {"window": "Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there. ", "original_text": "Our core business  continues to have very strong momentum.  \n \n"}, "hash": "ff9d83fec584b91633c4eb9e949b252c224bb2e068b2e57e7be78a05a716ab18", "class_name": "RelatedNodeInfo"}}, "text": "We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year. ", "start_char_idx": 2607, "end_char_idx": 2721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d72ff356-f150-40db-a291-614e3a18738c": {"__data__": {"id_": "d72ff356-f150-40db-a291-614e3a18738c", "embedding": null, "metadata": {"window": "Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there. ", "original_text": "Our core business  continues to have very strong momentum.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b7085e7-2546-4b46-8c65-8c8b57c1b2fb", "node_type": "1", "metadata": {"window": "A \nRight.  Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out. ", "original_text": "We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c4c616a512d24e50815a4c93c9652f72807486b5ac6dd81683a5bb5ca480d5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e12c53c7-a55f-456f-a21a-15b335caa639", "node_type": "1", "metadata": {"window": "And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n ", "original_text": "And then as Brian just clarified, we did put in guidance the kitting portion of the contract. "}, "hash": "cf58b565b464c0dac2991e03f50c6dfade92f2464e79e09aa94e127df49769cd", "class_name": "RelatedNodeInfo"}}, "text": "Our core business  continues to have very strong momentum.  \n \n", "start_char_idx": 2721, "end_char_idx": 2784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e12c53c7-a55f-456f-a21a-15b335caa639": {"__data__": {"id_": "e12c53c7-a55f-456f-a21a-15b335caa639", "embedding": null, "metadata": {"window": "And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n ", "original_text": "And then as Brian just clarified, we did put in guidance the kitting portion of the contract. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d72ff356-f150-40db-a291-614e3a18738c", "node_type": "1", "metadata": {"window": "Thanks , Brian.  And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there. ", "original_text": "Our core business  continues to have very strong momentum.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "822c88f67d7783520f56b8496e12f40728b68c20560225ee4684a7c9495104a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20e31d97-f68e-4b5f-9ce2-cc8c058204ed", "node_type": "1", "metadata": {"window": "We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out. "}, "hash": "675db003163198f66f8e0389b79827e6d0a9925b3c28a5bee7e38fc52475ad9c", "class_name": "RelatedNodeInfo"}}, "text": "And then as Brian just clarified, we did put in guidance the kitting portion of the contract. ", "start_char_idx": 2784, "end_char_idx": 2878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20e31d97-f68e-4b5f-9ce2-cc8c058204ed": {"__data__": {"id_": "20e31d97-f68e-4b5f-9ce2-cc8c058204ed", "embedding": null, "metadata": {"window": "We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e12c53c7-a55f-456f-a21a-15b335caa639", "node_type": "1", "metadata": {"window": "And so what we are seeing in our second half is a continuation of some of the momentum \nthat we saw in the first half.  We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n ", "original_text": "And then as Brian just clarified, we did put in guidance the kitting portion of the contract. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e135ec09abe026e26d41d5f95843784dcd7c66ca6dfd8dc26bb4544b58576b6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "263b706a-f418-410f-af60-272221aeb4e0", "node_type": "1", "metadata": {"window": "Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there. "}, "hash": "31c07996dfcadc5340fc5d66d91e50d7b990d52d88abcd00a0001cf15586915f", "class_name": "RelatedNodeInfo"}}, "text": "That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out. ", "start_char_idx": 2878, "end_char_idx": 2979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "263b706a-f418-410f-af60-272221aeb4e0": {"__data__": {"id_": "263b706a-f418-410f-af60-272221aeb4e0", "embedding": null, "metadata": {"window": "Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20e31d97-f68e-4b5f-9ce2-cc8c058204ed", "node_type": "1", "metadata": {"window": "We expect that COVID -19 tests will continue to be a big portion of the business in the \nsecond half of the year.  Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5bf4ad0f4a7cadb776f6dcd4d33906c6a64b4ab7d3b9c5999f8512da1faf3f7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1752a535-a875-479c-a275-644f81aed58b", "node_type": "1", "metadata": {"window": "And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America. ", "original_text": "And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n "}, "hash": "ae6eb519dcc273cbfc540d9ff97151b692ecd3d4f571582c4b76865449024cb1", "class_name": "RelatedNodeInfo"}}, "text": "So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there. ", "start_char_idx": 2979, "end_char_idx": 3166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1752a535-a875-479c-a275-644f81aed58b": {"__data__": {"id_": "1752a535-a875-479c-a275-644f81aed58b", "embedding": null, "metadata": {"window": "And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America. ", "original_text": "And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "263b706a-f418-410f-af60-272221aeb4e0", "node_type": "1", "metadata": {"window": "Our core business  continues to have very strong momentum.  \n \n And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64dd6871481f37f77ba16ddf692ec9340a8e99740e4878ac28243b01212d20dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62898a87-77eb-4f21-9539-81c5dab2ddc9", "node_type": "1", "metadata": {"window": "That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "701e5ffc42d95d8a221ed97e8c27e825f8eba69f56c90ea515e958e5c8e603f7", "class_name": "RelatedNodeInfo"}}, "text": "And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n ", "start_char_idx": 3166, "end_char_idx": 3321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62898a87-77eb-4f21-9539-81c5dab2ddc9": {"__data__": {"id_": "62898a87-77eb-4f21-9539-81c5dab2ddc9", "embedding": null, "metadata": {"window": "That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1752a535-a875-479c-a275-644f81aed58b", "node_type": "1", "metadata": {"window": "And then as Brian just clarified, we did put in guidance the kitting portion of the contract.  That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America. ", "original_text": "And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27f82e6ee930676af76488476c942d74f2f53b35e0dc21b2c2cbc957482d8423", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c2c4264-4d2e-4ed8-ba8d-0ab81cb602f9", "node_type": "1", "metadata": {"window": "So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question?  \n "}, "hash": "9d51cb605cd7d38bd9a84cb7bae6adc376cd3d18de1289fa2bfd6dbb8317b6ec", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 3321, "end_char_idx": 3651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c2c4264-4d2e-4ed8-ba8d-0ab81cb602f9": {"__data__": {"id_": "5c2c4264-4d2e-4ed8-ba8d-0ab81cb602f9", "embedding": null, "metadata": {"window": "So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question?  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62898a87-77eb-4f21-9539-81c5dab2ddc9", "node_type": "1", "metadata": {"window": "That will drive some top \nline as well as the $0.15 to $0.20 of adjusted earnings that I called out.  So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4836a31f6edf21c801de3e619eac1dfe50bde26dfa0523d336d175f7233b2660", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6d07df4-9b50-47da-a786-190855858c3f", "node_type": "1", "metadata": {"window": "And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America. "}, "hash": "7f4893479715490607a623a4b74619197e4b7f1276e6476348144828b341b458", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question?  \n ", "start_char_idx": 254, "end_char_idx": 275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6d07df4-9b50-47da-a786-190855858c3f": {"__data__": {"id_": "a6d07df4-9b50-47da-a786-190855858c3f", "embedding": null, "metadata": {"window": "And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c2c4264-4d2e-4ed8-ba8d-0ab81cb602f9", "node_type": "1", "metadata": {"window": "So what we have in o ur Medical -Surgical \nbusiness is a very broad -based business that we've talked about many times across primary care, extended care, \nand we continue to grow there.  And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question?  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f524f2b748477dea62218b58620d9d90cb83bbf5a002c190760c230e142d06c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f305ad8-251e-4dff-acd9-1628fe7fcb33", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S. ", "original_text": "Your line is now open.  \n "}, "hash": "d4663598d9c6e0f87b2b40401decaff5924f9503c5262f805e108d2103a1da82", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America. ", "start_char_idx": 3672, "end_char_idx": 3996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f305ad8-251e-4dff-acd9-1628fe7fcb33": {"__data__": {"id_": "1f305ad8-251e-4dff-acd9-1628fe7fcb33", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S. ", "original_text": "Your line is now open.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6d07df4-9b50-47da-a786-190855858c3f", "node_type": "1", "metadata": {"window": "And the opportunities that we have now through our relationships with lab \nsuppliers and others  is just providing additional momentum in the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8057f87cfe9b17e434e127c383be4ebb2869780212ac8d87179ffcc85bf465fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fa22962-8510-493c-964f-dffa34660aa8", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "e5cc17ff04c2833c4968229f9373af3575548fa832841cd6dda69199928d2c4f", "class_name": "RelatedNodeInfo"}}, "text": "Your line is now open.  \n ", "start_char_idx": 598, "end_char_idx": 624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fa22962-8510-493c-964f-dffa34660aa8": {"__data__": {"id_": "6fa22962-8510-493c-964f-dffa34660aa8", "embedding": null, "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f305ad8-251e-4dff-acd9-1628fe7fcb33", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S. ", "original_text": "Your line is now open.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7677cc3cb75d343b07abb8752ac33d8ce5298384039d00fe00d36e5849ab613a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c53ec9e9-b824-417c-a9bf-256a1e0858e2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts. ", "original_text": "Q \nGood morning and thanks for taking the question. "}, "hash": "5c1db318318b1ef1c2b15ac274c5c8cfd52e5af8b5e0036e496db28f184a9736", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 4022, "end_char_idx": 4328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c53ec9e9-b824-417c-a9bf-256a1e0858e2": {"__data__": {"id_": "c53ec9e9-b824-417c-a9bf-256a1e0858e2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts. ", "original_text": "Q \nGood morning and thanks for taking the question. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fa22962-8510-493c-964f-dffa34660aa8", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5dd396dd9f0450a60fe4f729a68cf502764822f026b90407e7338afd375dbf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16428e95-3f70-486a-ac59-804031e59d51", "node_type": "1", "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts.  This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "original_text": "I want to dive in a little bit on the U.S. "}, "hash": "9df0bb8f41820759cdb3411605d38eeb1cd988647261118262a48773fe513acd", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood morning and thanks for taking the question. ", "start_char_idx": 4328, "end_char_idx": 4380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16428e95-3f70-486a-ac59-804031e59d51": {"__data__": {"id_": "16428e95-3f70-486a-ac59-804031e59d51", "embedding": null, "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts.  This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "original_text": "I want to dive in a little bit on the U.S. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c53ec9e9-b824-417c-a9bf-256a1e0858e2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny from Bank of America.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts. ", "original_text": "Q \nGood morning and thanks for taking the question. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a06d9114d77db9a523e62d318c9ee511313dd7320573d7cddfdbeb0ab52d50f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b7ce324-9cf5-402b-a332-f88305bc06ac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts.  This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "original_text": "Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year. "}, "hash": "35773caa93a2535ff3e8fd9e351793689f869ad404a9ccb41a0a5c76631b3b85", "class_name": "RelatedNodeInfo"}}, "text": "I want to dive in a little bit on the U.S. ", "start_char_idx": 4380, "end_char_idx": 4423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b7ce324-9cf5-402b-a332-f88305bc06ac": {"__data__": {"id_": "6b7ce324-9cf5-402b-a332-f88305bc06ac", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts.  This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "original_text": "Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16428e95-3f70-486a-ac59-804031e59d51", "node_type": "1", "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts.  This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "original_text": "I want to dive in a little bit on the U.S. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "186cd0d3bd94d8bc699eb6284eb4902bd2892fe04cddb5295c3541fcd2b6bd32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26bef61e-3f39-4746-a9bf-8414de30d18b", "node_type": "1", "metadata": {"window": "Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts.  This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "original_text": "You noted some of the higher volumes from retail national accounts. "}, "hash": "d27709edb649a7a9321c70e1e381a9f8cdb2af53817418f45fdfa43875952a78", "class_name": "RelatedNodeInfo"}}, "text": "Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year. ", "start_char_idx": 4423, "end_char_idx": 4576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26bef61e-3f39-4746-a9bf-8414de30d18b": {"__data__": {"id_": "26bef61e-3f39-4746-a9bf-8414de30d18b", "embedding": null, "metadata": {"window": "Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts.  This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "original_text": "You noted some of the higher volumes from retail national accounts. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b7ce324-9cf5-402b-a332-f88305bc06ac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts.  This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "original_text": "Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d423890584ae3081de1a2d2992b17335dd0ab999e26ae7af6e65d460de5fe1d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a9657e1-dd6e-454f-9a1d-16f2a1b8e591", "node_type": "1", "metadata": {"window": "I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts.  This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "original_text": "This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n "}, "hash": "5c655d512757bf9a636b15aae59550dedd28b06afb766b4a06a0c2bf2e0876ac", "class_name": "RelatedNodeInfo"}}, "text": "You noted some of the higher volumes from retail national accounts. ", "start_char_idx": 4576, "end_char_idx": 4644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a9657e1-dd6e-454f-9a1d-16f2a1b8e591": {"__data__": {"id_": "2a9657e1-dd6e-454f-9a1d-16f2a1b8e591", "embedding": null, "metadata": {"window": "I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts.  This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "original_text": "This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5840ee703e8d2f9d1cb7fa32c7968f430916f688d40374676c1317ff321d5eb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26bef61e-3f39-4746-a9bf-8414de30d18b", "node_type": "1", "metadata": {"window": "Q \nGood morning and thanks for taking the question.  I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts.  This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "original_text": "You noted some of the higher volumes from retail national accounts. ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9661795141478e7941bfbdce73e0f849b3004461df57eb62d82510e7588524bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f83c7a0-6def-482a-9c7e-08e263a5201c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n ", "original_text": "McKesson Corp.  "}, "hash": "63f8f19f424a6d17a94dcf7e1b81b7592a7fd1a2b5be9b5ffb93610d525ddfe1", "class_name": "RelatedNodeInfo"}}, "text": "This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "start_char_idx": 4644, "end_char_idx": 4769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f83c7a0-6def-482a-9c7e-08e263a5201c": {"__data__": {"id_": "9f83c7a0-6def-482a-9c7e-08e263a5201c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a9657e1-dd6e-454f-9a1d-16f2a1b8e591", "node_type": "1", "metadata": {"window": "I want to dive in a little bit on the U.S.  Pharma side, and \nparticularly thinking about how the pacing of growth this quarter could influence or impact the growth in the bac k \nhalf of the year.  You noted some of the higher volumes from retail national accounts.  This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "original_text": "This is despite what appears \nto be market -wide softness and what you even called to in terms of the pacing of recovery.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "456a035b50bbbe7fc1f148e0a96e0f3f778153a1b43638f73defefd18ef4ce21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "382a82a6-9fc1-4e09-b54d-0bdddc7a1f00", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S. "}, "hash": "26a2b117a77d74dd5033a2b5975c4cafc01b227ef61a284658ba2cd70257ceb2", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "382a82a6-9fc1-4e09-b54d-0bdddc7a1f00": {"__data__": {"id_": "382a82a6-9fc1-4e09-b54d-0bdddc7a1f00", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f83c7a0-6def-482a-9c7e-08e263a5201c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6ae4d3f585e034a8d7ce4a6a62545b214ba523d21928fcd34546997f335d6e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e6f6582-8478-4746-a3eb-ce2ace917f0a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "Pharma revenue growth in particular? "}, "hash": "364189b257c2b59a6261909e5308daeef8033e64f38b194e7b50bf065aca69f8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S. ", "start_char_idx": 16, "end_char_idx": 327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e6f6582-8478-4746-a3eb-ce2ace917f0a": {"__data__": {"id_": "1e6f6582-8478-4746-a3eb-ce2ace917f0a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "Pharma revenue growth in particular? ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "382a82a6-9fc1-4e09-b54d-0bdddc7a1f00", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3bc735245fd21c694cfc09d29f09c88951e075c28ecaa5ad384e96d1645f0f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4471ecdc-9c2f-453b-95af-a94602186510", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate. ", "original_text": "And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n "}, "hash": "bf350affe2c0d3a9de5cb2ff5a8fc36a4f6af49dc87d0d2c81c1f74136461153", "class_name": "RelatedNodeInfo"}}, "text": "Pharma revenue growth in particular? ", "start_char_idx": 327, "end_char_idx": 364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4471ecdc-9c2f-453b-95af-a94602186510": {"__data__": {"id_": "4471ecdc-9c2f-453b-95af-a94602186510", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate. ", "original_text": "And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e6f6582-8478-4746-a3eb-ce2ace917f0a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "Pharma revenue growth in particular? ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1be0751a553f6fde623077a82f9a3c676d3c07022b9d27634612730b2a7a58ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27b8acca-1ce8-42c8-adec-ad3deece5aad", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "d0c97b0065e6baddd818fc12a76446ef98dd781af6ed55716e69eb29cf21b7d8", "class_name": "RelatedNodeInfo"}}, "text": "And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n ", "start_char_idx": 364, "end_char_idx": 469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27b8acca-1ce8-42c8-adec-ad3deece5aad": {"__data__": {"id_": "27b8acca-1ce8-42c8-adec-ad3deece5aad", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4471ecdc-9c2f-453b-95af-a94602186510", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate. ", "original_text": "And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1582219fa4818d8916524e7076bcd3c76360f77cf7df2553be283453b123612", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89b1641a-52bb-4f6b-b4a9-5e2259105d09", "node_type": "1", "metadata": {"window": "Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems. ", "original_text": "A \nYeah. "}, "hash": "60314538ca37f460a10d8bbdadab5d13e99e2ddf9f7a8e77e52fb38c66abf384", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 469, "end_char_idx": 814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89b1641a-52bb-4f6b-b4a9-5e2259105d09": {"__data__": {"id_": "89b1641a-52bb-4f6b-b4a9-5e2259105d09", "embedding": null, "metadata": {"window": "Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems. ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27b8acca-1ce8-42c8-adec-ad3deece5aad", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3460b4daa94f33a8018af41dd839d39efd298cf0cb92a697755f09b6827caf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4474c533-3735-4e03-be6f-68250069c656", "node_type": "1", "metadata": {"window": "And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n", "original_text": "I'll start, and certainly, Brian can elaborate. "}, "hash": "3d5de1a15d5c9a683bbb62889bcaabee377fec2a3da4aaef79227af25b358118", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 814, "end_char_idx": 823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4474c533-3735-4e03-be6f-68250069c656": {"__data__": {"id_": "4474c533-3735-4e03-be6f-68250069c656", "embedding": null, "metadata": {"window": "And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n", "original_text": "I'll start, and certainly, Brian can elaborate. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89b1641a-52bb-4f6b-b4a9-5e2259105d09", "node_type": "1", "metadata": {"window": "Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems. ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bbb01799b782d107efb93271debe11bc885043c5cab4126c1218525cf9863b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01402b73-3e34-4517-a43e-800a4efec9c3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth. ", "original_text": "I think what we're seeing in our U.S. "}, "hash": "30b75d400c47345d58501eeea9844491e3af7dc901ed68cc65b6d4b63c526890", "class_name": "RelatedNodeInfo"}}, "text": "I'll start, and certainly, Brian can elaborate. ", "start_char_idx": 823, "end_char_idx": 871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01402b73-3e34-4517-a43e-800a4efec9c3": {"__data__": {"id_": "01402b73-3e34-4517-a43e-800a4efec9c3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth. ", "original_text": "I think what we're seeing in our U.S. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4474c533-3735-4e03-be6f-68250069c656", "node_type": "1", "metadata": {"window": "And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n", "original_text": "I'll start, and certainly, Brian can elaborate. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e878d65bc9accf5973bf5ef9c775d8b8abe48ed9a3f2804c9944e9af07cf3ceb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7707368-8eff-444f-9f76-2d1d42794241", "node_type": "1", "metadata": {"window": "A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology. ", "original_text": "Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems. "}, "hash": "4a288bcc38393d7e6faca96a8951d2ce852699666de4a24fb9ada96aa2383a4e", "class_name": "RelatedNodeInfo"}}, "text": "I think what we're seeing in our U.S. ", "start_char_idx": 871, "end_char_idx": 909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7707368-8eff-444f-9f76-2d1d42794241": {"__data__": {"id_": "e7707368-8eff-444f-9f76-2d1d42794241", "embedding": null, "metadata": {"window": "A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology. ", "original_text": "Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01402b73-3e34-4517-a43e-800a4efec9c3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth. ", "original_text": "I think what we're seeing in our U.S. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0572651a742ab09e8d4efc2f667adb4062542635420afdc92448a65235a61984", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d704301-8170-40a7-9766-9e64fe5c6100", "node_type": "1", "metadata": {"window": "I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters. ", "original_text": "We're seeing pretty good stability in that business.  \n \n"}, "hash": "e598f4dd1ec35d39101725dcee4fcd578b9545846fe22e5a5650c5dc2a6ce862", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems. ", "start_char_idx": 909, "end_char_idx": 1066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d704301-8170-40a7-9766-9e64fe5c6100": {"__data__": {"id_": "2d704301-8170-40a7-9766-9e64fe5c6100", "embedding": null, "metadata": {"window": "I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters. ", "original_text": "We're seeing pretty good stability in that business.  \n \n", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7707368-8eff-444f-9f76-2d1d42794241", "node_type": "1", "metadata": {"window": "A \nYeah.  I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology. ", "original_text": "Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0befcdc0e3a513fdc88a502965ae4f995804c1d44930e9d93b6cfe930189ec93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18b693a4-17c5-4206-87f7-1178dd8fa271", "node_type": "1", "metadata": {"window": "I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific. ", "original_text": "Now we're seeing quarter -to-quarter stable position, stable growth. "}, "hash": "e28ec51b717af3ec0ad13bfeef2606108198030d68ae8a26859261852f066917", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing pretty good stability in that business.  \n \n", "start_char_idx": 1066, "end_char_idx": 1123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18b693a4-17c5-4206-87f7-1178dd8fa271": {"__data__": {"id_": "18b693a4-17c5-4206-87f7-1178dd8fa271", "embedding": null, "metadata": {"window": "I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific. ", "original_text": "Now we're seeing quarter -to-quarter stable position, stable growth. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d704301-8170-40a7-9766-9e64fe5c6100", "node_type": "1", "metadata": {"window": "I'll start, and certainly, Brian can elaborate.  I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters. ", "original_text": "We're seeing pretty good stability in that business.  \n \n", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0560188103c18989562146a86d28610ee06dadbe04120643d77b0376eb28df64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bd329a4-aa90-4719-8c21-eac48cb23de7", "node_type": "1", "metadata": {"window": "Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n ", "original_text": "You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology. "}, "hash": "053a06a0d434ff8cc4bb9fa1eabae7506d975373bc5709983c972217794e4c51", "class_name": "RelatedNodeInfo"}}, "text": "Now we're seeing quarter -to-quarter stable position, stable growth. ", "start_char_idx": 1123, "end_char_idx": 1192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bd329a4-aa90-4719-8c21-eac48cb23de7": {"__data__": {"id_": "8bd329a4-aa90-4719-8c21-eac48cb23de7", "embedding": null, "metadata": {"window": "Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n ", "original_text": "You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18b693a4-17c5-4206-87f7-1178dd8fa271", "node_type": "1", "metadata": {"window": "I think what we're seeing in our U.S.  Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific. ", "original_text": "Now we're seeing quarter -to-quarter stable position, stable growth. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd22263ba74575a38f3b6315f1ad85c509679ef09de1d0a57795f7d76e6eb52a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99affe29-985f-45e0-8cc3-89b2be97c981", "node_type": "1", "metadata": {"window": "We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters. "}, "hash": "f6f35d0b440c51ca41b648b559ab10c01ff445d9952ea8547cee8dd3c6fe07e6", "class_name": "RelatedNodeInfo"}}, "text": "You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology. ", "start_char_idx": 1192, "end_char_idx": 1323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99affe29-985f-45e0-8cc3-89b2be97c981": {"__data__": {"id_": "99affe29-985f-45e0-8cc3-89b2be97c981", "embedding": null, "metadata": {"window": "We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bd329a4-aa90-4719-8c21-eac48cb23de7", "node_type": "1", "metadata": {"window": "Pharmaceutical business, \njust to be clear, it's our traditional US wholesale business to indep endents, to retail national accounts in the health \nsystems.  We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n ", "original_text": "You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db3fda26d45a53de8c007cf5f53d7a025ae046383f05df1e5ef4c9c4d8adc2f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4504a48-35a8-4f31-91e1-89d26fa70e91", "node_type": "1", "metadata": {"window": "Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "So I don't think \nthere's anything specific. "}, "hash": "daa0985413b08e843a6007820f8db02f743b047ca321eaeff0310d53775e7aac", "class_name": "RelatedNodeInfo"}}, "text": "And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters. ", "start_char_idx": 1323, "end_char_idx": 1450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4504a48-35a8-4f31-91e1-89d26fa70e91": {"__data__": {"id_": "c4504a48-35a8-4f31-91e1-89d26fa70e91", "embedding": null, "metadata": {"window": "Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "So I don't think \nthere's anything specific. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99affe29-985f-45e0-8cc3-89b2be97c981", "node_type": "1", "metadata": {"window": "We're seeing pretty good stability in that business.  \n \n Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a03e60db471b2967e461f6e83f65f164afe47ae58bed83de2acd8834e7df6c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d426472f-11ee-4227-bbba-6b970cb87414", "node_type": "1", "metadata": {"window": "You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le. ", "original_text": "I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n "}, "hash": "79dbb76250665970fcd3fb9793424082840af9775b048188306ca8dff08b5679", "class_name": "RelatedNodeInfo"}}, "text": "So I don't think \nthere's anything specific. ", "start_char_idx": 1450, "end_char_idx": 1495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d426472f-11ee-4227-bbba-6b970cb87414": {"__data__": {"id_": "d426472f-11ee-4227-bbba-6b970cb87414", "embedding": null, "metadata": {"window": "You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le. ", "original_text": "I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4504a48-35a8-4f31-91e1-89d26fa70e91", "node_type": "1", "metadata": {"window": "Now we're seeing quarter -to-quarter stable position, stable growth.  You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "So I don't think \nthere's anything specific. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11d0d049712f47dc7dcd0d6c3084359d409130cb1fbcc33ee3e16040d456ec6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a234865-ef4b-4827-add9-ff42b919acaf", "node_type": "1", "metadata": {"window": "And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "931107b1fc1d9faaca5fb1b23fe94ce48bdd5d7200e1d0df4db295d0215cbd61", "class_name": "RelatedNodeInfo"}}, "text": "I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n ", "start_char_idx": 1495, "end_char_idx": 1656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a234865-ef4b-4827-add9-ff42b919acaf": {"__data__": {"id_": "4a234865-ef4b-4827-add9-ff42b919acaf", "embedding": null, "metadata": {"window": "And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d426472f-11ee-4227-bbba-6b970cb87414", "node_type": "1", "metadata": {"window": "You add to that the position that we have in \nour specialty provider busine sses, the opportunities that we're seeing in oncology.  And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le. ", "original_text": "I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1920c68a6f9c546991c94432c8055106a81b34909373196028393c0a7d354f2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29125a5c-b1fe-42fa-987f-e6fb4b7cc610", "node_type": "1", "metadata": {"window": "So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n ", "original_text": "A \nYeah. "}, "hash": "ab1de3f64fae79c0d732524efe124a101f69ccd44a71a7ffe0fe95409051c57e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1656, "end_char_idx": 1982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29125a5c-b1fe-42fa-987f-e6fb4b7cc610": {"__data__": {"id_": "29125a5c-b1fe-42fa-987f-e6fb4b7cc610", "embedding": null, "metadata": {"window": "So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a234865-ef4b-4827-add9-ff42b919acaf", "node_type": "1", "metadata": {"window": "And what you're seeing is a \nbusiness now that is growing at a stable 2% to 4% that we've seen over the last several quarters.  So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3bfa3219335d7a0d0c95fb4709663863337e9bcf5503078f452391a11853dd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f4f8438-f815-4e14-ab29-313373b4a562", "node_type": "1", "metadata": {"window": "I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "I think that the brand market has been relatively stab le. "}, "hash": "d5808b93e16e92b07b6494f598a1f9cb32280a33516f157c29cdae2c07aa95ab", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 814, "end_char_idx": 823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f4f8438-f815-4e14-ab29-313373b4a562": {"__data__": {"id_": "3f4f8438-f815-4e14-ab29-313373b4a562", "embedding": null, "metadata": {"window": "I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "I think that the brand market has been relatively stab le. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29125a5c-b1fe-42fa-987f-e6fb4b7cc610", "node_type": "1", "metadata": {"window": "So I don't think \nthere's anything specific.  I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd4a91151861780013b999186902fb4617eb412e13b9f0c7a4f879a2fdbfbf56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9741a7d3-b0bf-4a52-94f1-14663483589f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "The generic market has been relatively stable. "}, "hash": "d6ce9e8262c2ab4db310b041950f1773db4cf22d0020340a4fa309ab4f109b69", "class_name": "RelatedNodeInfo"}}, "text": "I think that the brand market has been relatively stab le. ", "start_char_idx": 1991, "end_char_idx": 2050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9741a7d3-b0bf-4a52-94f1-14663483589f": {"__data__": {"id_": "9741a7d3-b0bf-4a52-94f1-14663483589f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "The generic market has been relatively stable. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f4f8438-f815-4e14-ab29-313373b4a562", "node_type": "1", "metadata": {"window": "I think it's just the good exec ution, the stability of our customers and the stability of the \nenvironment that's really allowing us to continue to perform.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "I think that the brand market has been relatively stab le. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd0939681e83135da81f03f45170ac9854a19bbfedab10012511679b8ac9a3bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c6f7827-011d-46ae-9d81-b687a7768af9", "node_type": "1", "metadata": {"window": "A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank. ", "original_text": "And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n "}, "hash": "eb5194cb392cce169cfee8af4404ebd0cfc780db4c229ca8f5c733bd008de6c8", "class_name": "RelatedNodeInfo"}}, "text": "The generic market has been relatively stable. ", "start_char_idx": 2050, "end_char_idx": 2097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c6f7827-011d-46ae-9d81-b687a7768af9": {"__data__": {"id_": "5c6f7827-011d-46ae-9d81-b687a7768af9", "embedding": null, "metadata": {"window": "A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank. ", "original_text": "And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9741a7d3-b0bf-4a52-94f1-14663483589f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "The generic market has been relatively stable. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6739fc8d17288ee0035f0274ffd1068fcfef299739d9b5cf657ed3afd09a6d6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d82ea1b-6093-4147-b79f-2918f4a5c85a", "node_type": "1", "metadata": {"window": "I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "8441dda39f1da5b899e193a2e47ff4536d4619a8fa031184e15c4e1afde5b474", "class_name": "RelatedNodeInfo"}}, "text": "And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n ", "start_char_idx": 2097, "end_char_idx": 2204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d82ea1b-6093-4147-b79f-2918f4a5c85a": {"__data__": {"id_": "7d82ea1b-6093-4147-b79f-2918f4a5c85a", "embedding": null, "metadata": {"window": "I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c6f7827-011d-46ae-9d81-b687a7768af9", "node_type": "1", "metadata": {"window": "A \nYeah.  I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank. ", "original_text": "And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3dd5bd4e919e5827113072f9222e042fc02f3fd5413a173eadbc6ea84cb53e8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc4b2210-07db-4da3-9101-d820a5f20055", "node_type": "1", "metadata": {"window": "The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "A \nNext question?  \n "}, "hash": "fee05abb1ff21c94ab40b92756102caba540cf822422aa12347438c6e77157d7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 2204, "end_char_idx": 2534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc4b2210-07db-4da3-9101-d820a5f20055": {"__data__": {"id_": "fc4b2210-07db-4da3-9101-d820a5f20055", "embedding": null, "metadata": {"window": "The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "A \nNext question?  \n ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d82ea1b-6093-4147-b79f-2918f4a5c85a", "node_type": "1", "metadata": {"window": "I think that the brand market has been relatively stab le.  The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029081010ae384b9c1ee379a720ac5425f3599a3b3b81d06c2b18bf9dbe93b58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "011d81f6-7ce1-4c0f-b176-813a9cc1ba1b", "node_type": "1", "metadata": {"window": "And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank. "}, "hash": "fcad8a70e0c3c39e56918c427341b48219b41dfe3a0bbf10d70b4966d058f70f", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question?  \n ", "start_char_idx": 2534, "end_char_idx": 2555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "011d81f6-7ce1-4c0f-b176-813a9cc1ba1b": {"__data__": {"id_": "011d81f6-7ce1-4c0f-b176-813a9cc1ba1b", "embedding": null, "metadata": {"window": "And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc4b2210-07db-4da3-9101-d820a5f20055", "node_type": "1", "metadata": {"window": "The generic market has been relatively stable.  And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "A \nNext question?  \n ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6d1bcf0ad375ea9a34fa3ebe2caa8ea901b3ca78ea6bdbb3386cf3f9885c1bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71e4d6c5-3151-4b8a-a9e6-513c454fa036", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question. ", "original_text": "Your line is now open.  \n "}, "hash": "19cdd7ddcf07ed92b609254944a27da00c026bbed78472d4ded9a3d3a6a57417", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank. ", "start_char_idx": 2555, "end_char_idx": 2874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71e4d6c5-3151-4b8a-a9e6-513c454fa036": {"__data__": {"id_": "71e4d6c5-3151-4b8a-a9e6-513c454fa036", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question. ", "original_text": "Your line is now open.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "011d81f6-7ce1-4c0f-b176-813a9cc1ba1b", "node_type": "1", "metadata": {"window": "And \nwe've been very focused on cost and efficiency initiatives in this business to help underpin that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86b194aa4a1f414c9a3bb68bb713f106b1717922fc2aba42ae7fd605501eb205", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2fe9bec-417f-4d26-9710-c8a92c6017ae", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  "}, "hash": "64dabe89d800069a9b99c41609dd7a2197f76d51476734517f9b105fd4f0d974", "class_name": "RelatedNodeInfo"}}, "text": "Your line is now open.  \n ", "start_char_idx": 2874, "end_char_idx": 2900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2fe9bec-417f-4d26-9710-c8a92c6017ae": {"__data__": {"id_": "c2fe9bec-417f-4d26-9710-c8a92c6017ae", "embedding": null, "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71e4d6c5-3151-4b8a-a9e6-513c454fa036", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question. ", "original_text": "Your line is now open.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "119fff34bd131b6c9947e177ad9c0c24c3920736ce54358142b8fad4d8e48d26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7267ea8b-b1a3-4790-af7c-bd198da4fdfb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n ", "original_text": "Q \nHey, good morning, Britt and Brian. "}, "hash": "d3f5e44ad925077498a197fa21700b90a8c5a3843ae466824bd4c383f24fc830", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "start_char_idx": 2900, "end_char_idx": 3212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7267ea8b-b1a3-4790-af7c-bd198da4fdfb": {"__data__": {"id_": "7267ea8b-b1a3-4790-af7c-bd198da4fdfb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n ", "original_text": "Q \nHey, good morning, Britt and Brian. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2fe9bec-417f-4d26-9710-c8a92c6017ae", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5c4374cfb8f2daca482ddd4e51c36c795e758eba5729853f9571e86f73e500a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d10d99a3-7088-41c0-b29c-9bf41c385b45", "node_type": "1", "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And thanks for taking the question. "}, "hash": "19c418e603665885e1222569ff2adf5d1d66bba5a1375ab54a582fd967db4769", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHey, good morning, Britt and Brian. ", "start_char_idx": 3212, "end_char_idx": 3251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d10d99a3-7088-41c0-b29c-9bf41c385b45": {"__data__": {"id_": "d10d99a3-7088-41c0-b29c-9bf41c385b45", "embedding": null, "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And thanks for taking the question. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7267ea8b-b1a3-4790-af7c-bd198da4fdfb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be George Hill from Deutsche Bank.  Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n ", "original_text": "Q \nHey, good morning, Britt and Brian. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f71f2d095f9859b1f1b65cd506b0a82279dad22c18b3ff08e3639aa888c0f895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4efc6048-464c-4e25-81ea-d820ae9ace53", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes? "}, "hash": "59c64b980fbec03aefc5b8aa1d44d1a1ad237ada0c1d34789bd9b7b068c5426a", "class_name": "RelatedNodeInfo"}}, "text": "And thanks for taking the question. ", "start_char_idx": 3251, "end_char_idx": 3287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4efc6048-464c-4e25-81ea-d820ae9ace53": {"__data__": {"id_": "4efc6048-464c-4e25-81ea-d820ae9ace53", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes? ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d10d99a3-7088-41c0-b29c-9bf41c385b45", "node_type": "1", "metadata": {"window": "Your line is now open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And thanks for taking the question. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfb9cf922a609813ed4a36eb3c12375d906daedfdb5d570a28ef13d0f7cab6a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f42d1e67-0a93-4569-89e2-6f841d4b0dc9", "node_type": "1", "metadata": {"window": "Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question. ", "original_text": "I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n "}, "hash": "611c6f16cd4254762a591337ecd7aafd101616e26643c489e5098c6d8d55a4b3", "class_name": "RelatedNodeInfo"}}, "text": "I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes? ", "start_char_idx": 3287, "end_char_idx": 3539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f42d1e67-0a93-4569-89e2-6f841d4b0dc9": {"__data__": {"id_": "f42d1e67-0a93-4569-89e2-6f841d4b0dc9", "embedding": null, "metadata": {"window": "Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question. ", "original_text": "I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4efc6048-464c-4e25-81ea-d820ae9ace53", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes? ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66bd87143bb4096258cb34d17c8a0ace31eb2f6e9d0a3071cbc86c7052ca9db9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0727410e-fab9-455f-8b05-e8e468c323b4", "node_type": "1", "metadata": {"window": "And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "6c9dec4447ec8271a7f50a42defa7f820e554f089a4cd722ad94ceafe3f63af4", "class_name": "RelatedNodeInfo"}}, "text": "I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n ", "start_char_idx": 3539, "end_char_idx": 3716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0727410e-fab9-455f-8b05-e8e468c323b4": {"__data__": {"id_": "0727410e-fab9-455f-8b05-e8e468c323b4", "embedding": null, "metadata": {"window": "And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f42d1e67-0a93-4569-89e2-6f841d4b0dc9", "node_type": "1", "metadata": {"window": "Q \nHey, good morning, Britt and Brian.  And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question. ", "original_text": "I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b458b7d4077528588195d556549b6411fd6e539fcfa275b0d14057fe76157699", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58c4d42f-061b-4d11-ab8a-8965a72528e3", "node_type": "1", "metadata": {"window": "I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace. ", "original_text": "A \nYeah. "}, "hash": "6b3beb832016c494b30050389c782cd84b64f4a1519cbd54463d0391ad566c91", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1656, "end_char_idx": 1982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58c4d42f-061b-4d11-ab8a-8965a72528e3": {"__data__": {"id_": "58c4d42f-061b-4d11-ab8a-8965a72528e3", "embedding": null, "metadata": {"window": "I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace. ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0727410e-fab9-455f-8b05-e8e468c323b4", "node_type": "1", "metadata": {"window": "And thanks for taking the question.  I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e72604a9b4e8c72c0ada4c66a7d4a5e1f5be0af85b90294752e8e0650e5c4bf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74ec36ca-71f7-40e9-9176-4f5c2d0db9e1", "node_type": "1", "metadata": {"window": "I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n", "original_text": "Great question. "}, "hash": "51c38e470f9773b31175eb969627bf83e0da7cd1869b147f93adf7816aab1964", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 814, "end_char_idx": 823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74ec36ca-71f7-40e9-9176-4f5c2d0db9e1": {"__data__": {"id_": "74ec36ca-71f7-40e9-9176-4f5c2d0db9e1", "embedding": null, "metadata": {"window": "I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n", "original_text": "Great question. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58c4d42f-061b-4d11-ab8a-8965a72528e3", "node_type": "1", "metadata": {"window": "I was just wondering if you guys would \nquantify or de tail both from an office procedure perspective and maybe from an Rx volumes perspective, what \npercent of baseline you guys expect to achieve in the back half of the year as it relates to volumes?  I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace. ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a16f9aac59d1f3b9f3f765a4970368652f638c6ce09b6c577ffa27e6f88d814d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17a53090-2a73-49ba-9ef4-0e16b8e7b6be", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging. ", "original_text": "And always a little bit risky to prognosticate in th e current environment. "}, "hash": "a361e9d2351eb3a16ee9dba358066fbe260cfb687b5fc4e89ed229e26aedaa61", "class_name": "RelatedNodeInfo"}}, "text": "Great question. ", "start_char_idx": 4051, "end_char_idx": 4067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17a53090-2a73-49ba-9ef4-0e16b8e7b6be": {"__data__": {"id_": "17a53090-2a73-49ba-9ef4-0e16b8e7b6be", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging. ", "original_text": "And always a little bit risky to prognosticate in th e current environment. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74ec36ca-71f7-40e9-9176-4f5c2d0db9e1", "node_type": "1", "metadata": {"window": "I know in the \npress release, it says you're still not expect ing a return to baseline, but would love to know what percentage you \nguys are thinking you're getting back to?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n", "original_text": "Great question. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b41e1f59e64bc857bf6e4eb4745856255fd4e2169cf97d98b99301b21e48eaf7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "610041e0-3163-4e2b-81ee-4de62f5802a3", "node_type": "1", "metadata": {"window": "A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit. ", "original_text": "Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace. "}, "hash": "ea0bad42f7d1bb22a9ab04b883a874c160efdc18b956a18a2dcd77ea1952f9f1", "class_name": "RelatedNodeInfo"}}, "text": "And always a little bit risky to prognosticate in th e current environment. ", "start_char_idx": 4067, "end_char_idx": 4143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "610041e0-3163-4e2b-81ee-4de62f5802a3": {"__data__": {"id_": "610041e0-3163-4e2b-81ee-4de62f5802a3", "embedding": null, "metadata": {"window": "A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit. ", "original_text": "Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17a53090-2a73-49ba-9ef4-0e16b8e7b6be", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging. ", "original_text": "And always a little bit risky to prognosticate in th e current environment. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91502398b35fad12d0842e1d26c34df5fff1f18b16d54634ffdddba6b674d48d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ea7db7d-80a1-45b9-9f0c-38d8730417ba", "node_type": "1", "metadata": {"window": "Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit.  And so that 's what ", "original_text": "You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n"}, "hash": "a19c44148d84d85f6d0814d1f6391dc7da143b5e1c7f3bc04ba2f90ed80e7336", "class_name": "RelatedNodeInfo"}}, "text": "Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace. ", "start_char_idx": 4143, "end_char_idx": 4307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ea7db7d-80a1-45b9-9f0c-38d8730417ba": {"__data__": {"id_": "4ea7db7d-80a1-45b9-9f0c-38d8730417ba", "embedding": null, "metadata": {"window": "Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit.  And so that 's what ", "original_text": "You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "610041e0-3163-4e2b-81ee-4de62f5802a3", "node_type": "1", "metadata": {"window": "A \nYeah.  Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit. ", "original_text": "Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d49ad315bafe2d185392bf3249fc2865d9641af293b65cdee5de703a21bd162", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "897853c0-10d2-45e9-bb0f-7845b82564d9", "node_type": "1", "metadata": {"window": "And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit.  And so that 's what ", "original_text": "If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging. "}, "hash": "e3e79f682f43a653f5383bf89778c309a8b64efb7954cfd7357134105a0eba2f", "class_name": "RelatedNodeInfo"}}, "text": "You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n", "start_char_idx": 4307, "end_char_idx": 4550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "897853c0-10d2-45e9-bb0f-7845b82564d9": {"__data__": {"id_": "897853c0-10d2-45e9-bb0f-7845b82564d9", "embedding": null, "metadata": {"window": "And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit.  And so that 's what ", "original_text": "If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ea7db7d-80a1-45b9-9f0c-38d8730417ba", "node_type": "1", "metadata": {"window": "Great question.  And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit.  And so that 's what ", "original_text": "You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6fb66b2ec928e6228f7c10640b68b33e93a7fc5af57fec23e78868f44b543d00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15590bfa-36d8-4a5b-b10d-0172883b6f40", "node_type": "1", "metadata": {"window": "Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit.  And so that 's what ", "original_text": "I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit. "}, "hash": "06b296fc760c35f839a9d444a7c05184a19c3436189956336f8d81bb1f8d26e8", "class_name": "RelatedNodeInfo"}}, "text": "If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging. ", "start_char_idx": 4550, "end_char_idx": 4726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15590bfa-36d8-4a5b-b10d-0172883b6f40": {"__data__": {"id_": "15590bfa-36d8-4a5b-b10d-0172883b6f40", "embedding": null, "metadata": {"window": "Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit.  And so that 's what ", "original_text": "I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "897853c0-10d2-45e9-bb0f-7845b82564d9", "node_type": "1", "metadata": {"window": "And always a little bit risky to prognosticate in th e current environment.  Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit.  And so that 's what ", "original_text": "If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f26506caf0ccae0d0794dc433a7a04de59ef75e88e7b0685d1b1acaa51b5fbda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ef6ef01-3310-4c8b-b19f-e9b69569070e", "node_type": "1", "metadata": {"window": "You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit.  And so that 's what ", "original_text": "And so that 's what "}, "hash": "a5d7d24dab407699ca69355ea7a393bf4b1af964ae78c2e0242b16de522e36a1", "class_name": "RelatedNodeInfo"}}, "text": "I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit. ", "start_char_idx": 4726, "end_char_idx": 4886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ef6ef01-3310-4c8b-b19f-e9b69569070e": {"__data__": {"id_": "7ef6ef01-3310-4c8b-b19f-e9b69569070e", "embedding": null, "metadata": {"window": "You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit.  And so that 's what ", "original_text": "And so that 's what ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a615b8c5131827150da841a63a2facbc3a9a5734ae2ca671f6a8cafce998b51", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15590bfa-36d8-4a5b-b10d-0172883b6f40", "node_type": "1", "metadata": {"window": "Even given the way \nwe've seen the disease progress in Europe and the US in the last several weeks shows the volatility that's still out \nthere in the marketplace.  You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit.  And so that 's what ", "original_text": "I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit. ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eba5f2ce2f3a940d05ad30071fe1852784269d7b57f1a19bd04ea8608e3df25b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6653c9e8-2d1d-42a1-80ee-f290f0523113", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  "}, "hash": "974e4078900cda95bf5b96cfca684f70a4566c48ecbdf97300539edec22c6277", "class_name": "RelatedNodeInfo"}}, "text": "And so that 's what ", "start_char_idx": 4886, "end_char_idx": 4906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6653c9e8-2d1d-42a1-80ee-f290f0523113": {"__data__": {"id_": "6653c9e8-2d1d-42a1-80ee-f290f0523113", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ef6ef01-3310-4c8b-b19f-e9b69569070e", "node_type": "1", "metadata": {"window": "You'll recall, we \u2013 early in the year, when we gave our first guidance,  we assumed Q1 \nwas going to be the trough, that Q2 would get sequentially better, Q3 would get better and by Q4, we would be \nback to what we call pre -COVID levels.  \n \n If you think about the way the year has unfolded, we had really high volatility in the first quarter, month -to-month, \neven week -to-week, the swings were pretty challenging.  I think we saw that begin to stabilize a little bit as we got \nmidway through Q2, and the trend lines started to look like they were leveling out a little bit.  And so that 's what ", "original_text": "And so that 's what ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03ffe2678b8c8964fa37dc56d201785bb81a8551b15400adb17b652acc756184", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6763a7cb-b81f-476a-8f39-33940b76378d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021. "}, "hash": "f426eb7bd7a25de45143b7d71204621eb8c1400810dbca00e8194a1b7048bbfb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6763a7cb-b81f-476a-8f39-33940b76378d": {"__data__": {"id_": "6763a7cb-b81f-476a-8f39-33940b76378d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6653c9e8-2d1d-42a1-80ee-f290f0523113", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55a5b98539582e84829185ca435b2bcf360a30c39cef7699b05580f459a1b76c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e2acc5e-7404-4820-bb95-6966cecd433d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays. ", "original_text": "And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n "}, "hash": "a978a5814d1cce872c7d8c15ae9f55c09e706d7f98a449cb00e3f9a0037f610b", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021. ", "start_char_idx": 16, "end_char_idx": 403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e2acc5e-7404-4820-bb95-6966cecd433d": {"__data__": {"id_": "7e2acc5e-7404-4820-bb95-6966cecd433d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays. ", "original_text": "And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6763a7cb-b81f-476a-8f39-33940b76378d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32fa50d94fbd97bf2a3fe9cad4acec881c019d1445cb37cbdbc93a193ba6c813", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e93b593-5e88-45a9-be1f-d61cc95b263f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "8d9ec75f3433a4cc91af834863b03370efdb2df79040bb30ecaf8edb9a8c156f", "class_name": "RelatedNodeInfo"}}, "text": "And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n ", "start_char_idx": 403, "end_char_idx": 488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e93b593-5e88-45a9-be1f-d61cc95b263f": {"__data__": {"id_": "9e93b593-5e88-45a9-be1f-d61cc95b263f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e2acc5e-7404-4820-bb95-6966cecd433d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays. ", "original_text": "And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e4ef8dd04deb86bba5083389d7ea39fc99fd629c87c8ef433cf1ded28cce8a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32caf227-5b24-47dc-8132-68b2520c4090", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.  ", "original_text": "A \nNext question?  \n "}, "hash": "bdac955eea09dc53cf290d1001db12104737dd5199340ff59cac0b474f41a1a5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 488, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32caf227-5b24-47dc-8132-68b2520c4090": {"__data__": {"id_": "32caf227-5b24-47dc-8132-68b2520c4090", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.  ", "original_text": "A \nNext question?  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e93b593-5e88-45a9-be1f-d61cc95b263f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb25c9ca73c7e9929dab413c60492372faa817e953e8f8ef0f453c7882a2616f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8e3f6f4-00ac-4794-901c-50d5dd8ec549", "node_type": "1", "metadata": {"window": "And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays. "}, "hash": "48f0b7339ea4135d375a76a174aab81c1f7bcc2c0edbcd3476d3ff45c5651662", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question?  \n ", "start_char_idx": 818, "end_char_idx": 839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8e3f6f4-00ac-4794-901c-50d5dd8ec549": {"__data__": {"id_": "a8e3f6f4-00ac-4794-901c-50d5dd8ec549", "embedding": null, "metadata": {"window": "And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32caf227-5b24-47dc-8132-68b2520c4090", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.  ", "original_text": "A \nNext question?  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0782728c06d98e85c1f1e4d663fa0c8d7d867e317a98cf941074d990a907af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b753337-e36e-40d6-b95d-564b750fa3fc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "Your line is open.  \n "}, "hash": "b30bca5b49ae283f33b09eeafb4f4006ab13a3d05b9d8168a12959548b1acf41", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays. ", "start_char_idx": 839, "end_char_idx": 1159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b753337-e36e-40d6-b95d-564b750fa3fc": {"__data__": {"id_": "3b753337-e36e-40d6-b95d-564b750fa3fc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "Your line is open.  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8e3f6f4-00ac-4794-901c-50d5dd8ec549", "node_type": "1", "metadata": {"window": "And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f7f5b9abb4be56de2af1ae943c4b1dd2a243dc638214783a12c8b7b10c4952b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f364fea-36d8-4794-aa0e-a872b578f2a9", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, everybody. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.  "}, "hash": "abcab26ffe42d641a25a9256cc95cf05258a8a87e1da41c05f65a196bb7775a7", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 1159, "end_char_idx": 1181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f364fea-36d8-4794-aa0e-a872b578f2a9": {"__data__": {"id_": "1f364fea-36d8-4794-aa0e-a872b578f2a9", "embedding": null, "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, everybody. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.  ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b753337-e36e-40d6-b95d-564b750fa3fc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "Your line is open.  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ee68c1d118cccb1ea3dfd3a1975d8afc11766339b408b29a8dfffa550ecb1b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e03b01c-d787-4c38-be0c-c2e4ff4bb530", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago. ", "original_text": "Q \nGreat. "}, "hash": "2e7f06e5ee8157e19d4c98921542874fc92f6b74e42514fc2fb690f0e97a158b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.  ", "start_char_idx": 1181, "end_char_idx": 1498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e03b01c-d787-4c38-be0c-c2e4ff4bb530": {"__data__": {"id_": "2e03b01c-d787-4c38-be0c-c2e4ff4bb530", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago. ", "original_text": "Q \nGreat. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f364fea-36d8-4794-aa0e-a872b578f2a9", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, everybody. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.  ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e81fc9dc4e918a81f89be6110e1663af76101a7b4bafd907bfdbe5ab98fb31a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f44cdbf5-6ebb-489f-b333-bfaf5995d371", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe. ", "original_text": "Thanks. "}, "hash": "c8d7deca131b6e94703dae8b649d97be7b78d1b52c57295015182952c340a480", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGreat. ", "start_char_idx": 1498, "end_char_idx": 1508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f44cdbf5-6ebb-489f-b333-bfaf5995d371": {"__data__": {"id_": "f44cdbf5-6ebb-489f-b333-bfaf5995d371", "embedding": null, "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe. ", "original_text": "Thanks. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e03b01c-d787-4c38-be0c-c2e4ff4bb530", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Steven Valiquette from Barclays.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago. ", "original_text": "Q \nGreat. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "418dbef6460ac33e13da4d699522522229691d639397b5f2921191e2d68103e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "182942ce-9c93-4871-b1fb-e99693438cbd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode. ", "original_text": "Good morning, everybody. "}, "hash": "8b314ad6528ca23c4b5d7e99f5d0ce61905e6d431f7707a6e91e7e0d8fc9f204", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 1508, "end_char_idx": 1516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "182942ce-9c93-4871-b1fb-e99693438cbd": {"__data__": {"id_": "182942ce-9c93-4871-b1fb-e99693438cbd", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode. ", "original_text": "Good morning, everybody. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f44cdbf5-6ebb-489f-b333-bfaf5995d371", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe. ", "original_text": "Thanks. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71a3557944c02a007b9efd9072cc416afa496fc08e70d9191474dfb4bb62b4ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42469098-9d35-4f68-a2dc-fdd3c87ee8bd", "node_type": "1", "metadata": {"window": "Q \nGreat.  Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n ", "original_text": "So you touched on this for the US just a minute ago. "}, "hash": "378bfd925224b30ec6d7197f2d1e04ed62c7ec1edcdb175e06725b68977b8d81", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, everybody. ", "start_char_idx": 1516, "end_char_idx": 1541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42469098-9d35-4f68-a2dc-fdd3c87ee8bd": {"__data__": {"id_": "42469098-9d35-4f68-a2dc-fdd3c87ee8bd", "embedding": null, "metadata": {"window": "Q \nGreat.  Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n ", "original_text": "So you touched on this for the US just a minute ago. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "182942ce-9c93-4871-b1fb-e99693438cbd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteven James Valiquette  \nAnalys t, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode. ", "original_text": "Good morning, everybody. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84852ffe78fa382fe8a1aa42565713c61a602f62b9062e911c41ffb95b299a30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a3d7bf3-a375-4456-afaa-a8b4fee2a6f5", "node_type": "1", "metadata": {"window": "Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe. "}, "hash": "d59d61a2eb2e57110bf1a5cb36ea2859c55ab811a6e2fb3b332e813f1f0882eb", "class_name": "RelatedNodeInfo"}}, "text": "So you touched on this for the US just a minute ago. ", "start_char_idx": 1541, "end_char_idx": 1594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a3d7bf3-a375-4456-afaa-a8b4fee2a6f5": {"__data__": {"id_": "6a3d7bf3-a375-4456-afaa-a8b4fee2a6f5", "embedding": null, "metadata": {"window": "Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42469098-9d35-4f68-a2dc-fdd3c87ee8bd", "node_type": "1", "metadata": {"window": "Q \nGreat.  Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n ", "original_text": "So you touched on this for the US just a minute ago. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d00e00baa29f794d8382affb99d6909c15e4d4c457f821528aa5257ad431b8b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c2ca445-4f9b-4401-8498-8ba0f52273df", "node_type": "1", "metadata": {"window": "Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode. "}, "hash": "5a5e9f98981bc28e8786e8228fa64ab16504122583311a34498bbc0072b3132d", "class_name": "RelatedNodeInfo"}}, "text": "But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe. ", "start_char_idx": 1594, "end_char_idx": 1695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c2ca445-4f9b-4401-8498-8ba0f52273df": {"__data__": {"id_": "7c2ca445-4f9b-4401-8498-8ba0f52273df", "embedding": null, "metadata": {"window": "Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a3d7bf3-a375-4456-afaa-a8b4fee2a6f5", "node_type": "1", "metadata": {"window": "Thanks.  Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa465b7034e79470c1101f9d6eb129dd5a5f4019cb54ef8ac417bce4f610c35e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae0399d7-f189-4a91-8354-b84196ff6035", "node_type": "1", "metadata": {"window": "So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely. ", "original_text": "Thanks.  \n "}, "hash": "a32453d7158c6160c1c003859235a514750c451e12f165c506c7a239493e568a", "class_name": "RelatedNodeInfo"}}, "text": "Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode. ", "start_char_idx": 1695, "end_char_idx": 1842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae0399d7-f189-4a91-8354-b84196ff6035": {"__data__": {"id_": "ae0399d7-f189-4a91-8354-b84196ff6035", "embedding": null, "metadata": {"window": "So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely. ", "original_text": "Thanks.  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c2ca445-4f9b-4401-8498-8ba0f52273df", "node_type": "1", "metadata": {"window": "Good morning, everybody.  So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a48e59d73ec0960df40363c8d5e4ee7d8ee4b913ba4b0678c3e43523dcb0671", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dfe7a14-1244-488b-928d-30a372d1fd76", "node_type": "1", "metadata": {"window": "But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "f85d26a0d0fd8d27181d698f9f7fe0ead311697abc700416ea693826fc72b1ad", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 1842, "end_char_idx": 1853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1dfe7a14-1244-488b-928d-30a372d1fd76": {"__data__": {"id_": "1dfe7a14-1244-488b-928d-30a372d1fd76", "embedding": null, "metadata": {"window": "But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae0399d7-f189-4a91-8354-b84196ff6035", "node_type": "1", "metadata": {"window": "So you touched on this for the US just a minute ago.  But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely. ", "original_text": "Thanks.  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84c858800694d5db1ab64428d0df95cc60d0ec20678fe038c1a3f0cf6e85ce9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68855162-6900-4938-8a24-a148160f0b28", "node_type": "1", "metadata": {"window": "Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature. ", "original_text": "A \nYeah. "}, "hash": "9a99698bbc7d7de394d49d6edda35c89217ee649491104b62ce354a40979c76e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1853, "end_char_idx": 2179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68855162-6900-4938-8a24-a148160f0b28": {"__data__": {"id_": "68855162-6900-4938-8a24-a148160f0b28", "embedding": null, "metadata": {"window": "Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature. ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1dfe7a14-1244-488b-928d-30a372d1fd76", "node_type": "1", "metadata": {"window": "But I guess, I'm \ncurious to hear about the Rx volume progression throughout the quarter for Europe.  Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a427ae8e5d740eca5cef263b5c7930dc40bbccc0277085defce1d11635237c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71da4a22-2e82-471c-a3e4-a84e6e6ea10f", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n", "original_text": "We track these trends in Europe very closely. "}, "hash": "39ab2340de0fbf050d3189c458e46eb0ec27cb410e0f53eee4bf78d93e935a52", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2179, "end_char_idx": 2188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71da4a22-2e82-471c-a3e4-a84e6e6ea10f": {"__data__": {"id_": "71da4a22-2e82-471c-a3e4-a84e6e6ea10f", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n", "original_text": "We track these trends in Europe very closely. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68855162-6900-4938-8a24-a148160f0b28", "node_type": "1", "metadata": {"window": "Maybe any early color \naround trend s in October as well, just given that some of the regions in Europe seem to be going back into \nlockdown mode.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature. ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c939c9f774c05306db6aa1c2788031acbddf861d1c72bd55153f8c50b6a46f3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bfc12ce-c94b-4a97-85bb-439deb1123ab", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves. ", "original_text": "And frankly, what you see is it's really not a Europe trend. "}, "hash": "41d52cabee310470544f51537e3b069b85a3944a877afb249d0352cb6c383fa2", "class_name": "RelatedNodeInfo"}}, "text": "We track these trends in Europe very closely. ", "start_char_idx": 2188, "end_char_idx": 2234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bfc12ce-c94b-4a97-85bb-439deb1123ab": {"__data__": {"id_": "1bfc12ce-c94b-4a97-85bb-439deb1123ab", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves. ", "original_text": "And frankly, what you see is it's really not a Europe trend. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71da4a22-2e82-471c-a3e4-a84e6e6ea10f", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n", "original_text": "We track these trends in Europe very closely. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8df85636c73d15e2e21cb9b7f5d29cc94a304c9a4f75754872833be273e5eb16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6f911ce-402d-41a3-89e5-a2d841075f80", "node_type": "1", "metadata": {"window": "A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening. ", "original_text": "It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature. "}, "hash": "7d8826ad04dc9515eca91a3774ffeb125f80dbb3c8ba064f0f74aa786b25cc89", "class_name": "RelatedNodeInfo"}}, "text": "And frankly, what you see is it's really not a Europe trend. ", "start_char_idx": 2234, "end_char_idx": 2295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6f911ce-402d-41a3-89e5-a2d841075f80": {"__data__": {"id_": "d6f911ce-402d-41a3-89e5-a2d841075f80", "embedding": null, "metadata": {"window": "A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening. ", "original_text": "It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bfc12ce-c94b-4a97-85bb-439deb1123ab", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves. ", "original_text": "And frankly, what you see is it's really not a Europe trend. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f323bc4f97968b5c161c89493c42b4bf0e21d9a4269dae77bc8959d0498f333", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45a86a4a-daf8-401f-b332-b57dd9f909a8", "node_type": "1", "metadata": {"window": "We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there. ", "original_text": "So it really is v ery different.  \n \n"}, "hash": "f01dff5dfdf1a4b3789b1b4483e7ebc9f5edaf4305a74223d9216bb1354134d6", "class_name": "RelatedNodeInfo"}}, "text": "It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature. ", "start_char_idx": 2295, "end_char_idx": 2489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45a86a4a-daf8-401f-b332-b57dd9f909a8": {"__data__": {"id_": "45a86a4a-daf8-401f-b332-b57dd9f909a8", "embedding": null, "metadata": {"window": "We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there. ", "original_text": "So it really is v ery different.  \n \n", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6f911ce-402d-41a3-89e5-a2d841075f80", "node_type": "1", "metadata": {"window": "A \nYeah.  We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening. ", "original_text": "It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78d745309495372dfc5b5eb4d5d8f8128030773a87b8b8317e8319a81d614525", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cf77d6c-a5e8-44a2-8277-09eeaedc304e", "node_type": "1", "metadata": {"window": "And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities. ", "original_text": "We saw France, for example, tended to be ahead of the UK in the way it experienced these waves. "}, "hash": "e2d5d8aed4fe872eee6d4f2f037ef4d09ea6ca880741cee67f1f84ba3705e25a", "class_name": "RelatedNodeInfo"}}, "text": "So it really is v ery different.  \n \n", "start_char_idx": 2489, "end_char_idx": 2526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cf77d6c-a5e8-44a2-8277-09eeaedc304e": {"__data__": {"id_": "6cf77d6c-a5e8-44a2-8277-09eeaedc304e", "embedding": null, "metadata": {"window": "And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities. ", "original_text": "We saw France, for example, tended to be ahead of the UK in the way it experienced these waves. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45a86a4a-daf8-401f-b332-b57dd9f909a8", "node_type": "1", "metadata": {"window": "We track these trends in Europe very closely.  And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there. ", "original_text": "So it really is v ery different.  \n \n", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6da5c315ce0468db01160fbd9bf47ccc878cae77424861231b2a41c6e3e8e6b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0917cb20-07af-4439-ba07-357c82cc225f", "node_type": "1", "metadata": {"window": "It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care. ", "original_text": "But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening. "}, "hash": "814af4335e2d8273ac14069c470e87f195cd629a8620511b7582e5fdb6127ccf", "class_name": "RelatedNodeInfo"}}, "text": "We saw France, for example, tended to be ahead of the UK in the way it experienced these waves. ", "start_char_idx": 2526, "end_char_idx": 2622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0917cb20-07af-4439-ba07-357c82cc225f": {"__data__": {"id_": "0917cb20-07af-4439-ba07-357c82cc225f", "embedding": null, "metadata": {"window": "It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care. ", "original_text": "But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cf77d6c-a5e8-44a2-8277-09eeaedc304e", "node_type": "1", "metadata": {"window": "And frankly, what you see is it's really not a Europe trend.  It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities. ", "original_text": "We saw France, for example, tended to be ahead of the UK in the way it experienced these waves. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6894b07b458c846e1888fe6a4aea10e310f09b553e8bb46a0bae3b64e010b55c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc348259-b108-4403-9f78-790afe9a9192", "node_type": "1", "metadata": {"window": "So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n ", "original_text": "We're very proud of the  way our teams have operated there. "}, "hash": "01aa37ee74e993306d207516155d80b9237c4ae6adeffd10f71f99fc5abcc614", "class_name": "RelatedNodeInfo"}}, "text": "But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening. ", "start_char_idx": 2622, "end_char_idx": 2745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc348259-b108-4403-9f78-790afe9a9192": {"__data__": {"id_": "cc348259-b108-4403-9f78-790afe9a9192", "embedding": null, "metadata": {"window": "So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n ", "original_text": "We're very proud of the  way our teams have operated there. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0917cb20-07af-4439-ba07-357c82cc225f", "node_type": "1", "metadata": {"window": "It's \na country -by-country trend depending on how the COVID virus itself progresses and how local governments react \nwith their social policy, close down, lock down, and things of that nature.  So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care. ", "original_text": "But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0eb866e1cee504b1bc55e993d1566e878d4d294e2a1ac63bfa6e4d836ca1ab71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf1e0d29-eed4-488f-956e-f2d324b894ed", "node_type": "1", "metadata": {"window": "We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "Our pharmacies are open, they're \nservicing their communities. "}, "hash": "d7ea694d8cd87c4823a671fe9bc96becd7c8cdb1ab402845fe9a29f604934a2b", "class_name": "RelatedNodeInfo"}}, "text": "We're very proud of the  way our teams have operated there. ", "start_char_idx": 2745, "end_char_idx": 2805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf1e0d29-eed4-488f-956e-f2d324b894ed": {"__data__": {"id_": "bf1e0d29-eed4-488f-956e-f2d324b894ed", "embedding": null, "metadata": {"window": "We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "Our pharmacies are open, they're \nservicing their communities. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc348259-b108-4403-9f78-790afe9a9192", "node_type": "1", "metadata": {"window": "So it really is v ery different.  \n \n We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n ", "original_text": "We're very proud of the  way our teams have operated there. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a067772c768dd8f90617fe28208d50911ad366a6d52a58876f685f6ad7eaeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45c3f3ef-8452-48af-adca-ff9e7638e2a1", "node_type": "1", "metadata": {"window": "But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care. "}, "hash": "b0738994d0e04dc6e5516dbecc7824922632641a8c92298b184f5afa0707a4f7", "class_name": "RelatedNodeInfo"}}, "text": "Our pharmacies are open, they're \nservicing their communities. ", "start_char_idx": 2805, "end_char_idx": 2868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45c3f3ef-8452-48af-adca-ff9e7638e2a1": {"__data__": {"id_": "45c3f3ef-8452-48af-adca-ff9e7638e2a1", "embedding": null, "metadata": {"window": "But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf1e0d29-eed4-488f-956e-f2d324b894ed", "node_type": "1", "metadata": {"window": "We saw France, for example, tended to be ahead of the UK in the way it experienced these waves.  But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "Our pharmacies are open, they're \nservicing their communities. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78db174c6e35666680806a5503287693d9676430c71db6b811e2c9115a2b4054", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f1aa2e7-4d27-4efb-959c-95cfe70d872f", "node_type": "1", "metadata": {"window": "We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey. ", "original_text": "But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n "}, "hash": "e19f4c014db0316fcaaa8b2d7b6d46a71f28e5ecbe8ef902a435ad0f04cf0421", "class_name": "RelatedNodeInfo"}}, "text": "They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care. ", "start_char_idx": 2868, "end_char_idx": 2979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f1aa2e7-4d27-4efb-959c-95cfe70d872f": {"__data__": {"id_": "3f1aa2e7-4d27-4efb-959c-95cfe70d872f", "embedding": null, "metadata": {"window": "We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey. ", "original_text": "But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45c3f3ef-8452-48af-adca-ff9e7638e2a1", "node_type": "1", "metadata": {"window": "But the \ngeneral theme has been pretty consistent that we had the trough in the Q1 period, and we had slow \nstrengthening.  We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ac9cb24ca4e12a062854badd68e0c94d6609d4421ca8dd7d9abbfacfc43f91b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f48b301-5558-4d92-adc2-b3af4bc2974c", "node_type": "1", "metadata": {"window": "Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "0ea0cf62d4ddb893d27d22a353eb74d12ceb9313c5c39bd7e29354e5a69da818", "class_name": "RelatedNodeInfo"}}, "text": "But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n ", "start_char_idx": 2979, "end_char_idx": 3134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f48b301-5558-4d92-adc2-b3af4bc2974c": {"__data__": {"id_": "2f48b301-5558-4d92-adc2-b3af4bc2974c", "embedding": null, "metadata": {"window": "Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f1aa2e7-4d27-4efb-959c-95cfe70d872f", "node_type": "1", "metadata": {"window": "We're very proud of the  way our teams have operated there.  Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey. ", "original_text": "But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1de7e441fa9e8321a0060d5d08639d7ccd7cc9e82889b66b82c97d41c2066723", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "235f2210-1ad4-404b-9fd6-1045ea1322cc", "node_type": "1", "metadata": {"window": "They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "A \nNext question?  \n "}, "hash": "7185c4711cd66443147f7fabeb37dd7897bcef62808ad2fef464db503d4cba57", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 488, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "235f2210-1ad4-404b-9fd6-1045ea1322cc": {"__data__": {"id_": "235f2210-1ad4-404b-9fd6-1045ea1322cc", "embedding": null, "metadata": {"window": "They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "A \nNext question?  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f48b301-5558-4d92-adc2-b3af4bc2974c", "node_type": "1", "metadata": {"window": "Our pharmacies are open, they're \nservicing their communities.  They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d38f7a004616694450f3545dc4eb62321234e3e17a9de4c6ad16bf35b3be61f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96ea2223-6c0a-4dfa-9e7c-41ea202e4c60", "node_type": "1", "metadata": {"window": "But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey. "}, "hash": "472538bec16315fe88aff8d6d4018659ff2bedb23bcf2d2e7a30ae5d6d75888b", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question?  \n ", "start_char_idx": 818, "end_char_idx": 839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96ea2223-6c0a-4dfa-9e7c-41ea202e4c60": {"__data__": {"id_": "96ea2223-6c0a-4dfa-9e7c-41ea202e4c60", "embedding": null, "metadata": {"window": "But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "235f2210-1ad4-404b-9fd6-1045ea1322cc", "node_type": "1", "metadata": {"window": "They've adopted all the new safety protocols and standards to enable them to \nprovide that continuity of care.  But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "A \nNext question?  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b6cc1255ee1406780da16522273ad647eaca20f79acf8a04aa6312fca058b7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc109ff7-eaa4-49de-9f72-ed913a15316d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning. ", "original_text": "Your line is open.  \n "}, "hash": "4b64c8c3f0c08d46cd9e923893bc49469610b01c842c7fd907595740c13e5761", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey. ", "start_char_idx": 3485, "end_char_idx": 3811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc109ff7-eaa4-49de-9f72-ed913a15316d": {"__data__": {"id_": "bc109ff7-eaa4-49de-9f72-ed913a15316d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning. ", "original_text": "Your line is open.  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96ea2223-6c0a-4dfa-9e7c-41ea202e4c60", "node_type": "1", "metadata": {"window": "But I'd say, at a macro level, while there is de finitely difference between countries \nand the way country governments react, it's generally the same.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84487dccb8435a77710964343146984123f2885adca80fe42876e16ec9d9012a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dafab4c-2d9a-4914-87c6-fd2c7c4dab1f", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "0c84e4577c14614a9cf49f86583c63e561b44add18df2258a7abee47af6002be", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 1159, "end_char_idx": 1181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dafab4c-2d9a-4914-87c6-fd2c7c4dab1f": {"__data__": {"id_": "9dafab4c-2d9a-4914-87c6-fd2c7c4dab1f", "embedding": null, "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc109ff7-eaa4-49de-9f72-ed913a15316d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning. ", "original_text": "Your line is open.  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb037f7e3517d9f2e7d542f88b634d817018d391e2052f484d9cbec693ed063c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa18b7d1-e216-4ef4-9426-d2a81fcb0b8e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two? ", "original_text": "LLC  Q \nYes, hi. "}, "hash": "10032eb7263e9b4c5536e63e4cf13e03bf1690837a8b9b77fa438699a50db3d3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 3833, "end_char_idx": 4142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa18b7d1-e216-4ef4-9426-d2a81fcb0b8e": {"__data__": {"id_": "fa18b7d1-e216-4ef4-9426-d2a81fcb0b8e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two? ", "original_text": "LLC  Q \nYes, hi. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dafab4c-2d9a-4914-87c6-fd2c7c4dab1f", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a02a98733d813182cd3f831e2bec502dbc7b5b1e7202567a3d348c8c3df8114", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "576b8e4e-97eb-48fb-a50c-ea2703c012ef", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n ", "original_text": "Good morning. "}, "hash": "830f7bfc814ca69607db981380b1b5299ff4a272c7be0f28c0bec0412344dcf2", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYes, hi. ", "start_char_idx": 4142, "end_char_idx": 4159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "576b8e4e-97eb-48fb-a50c-ea2703c012ef": {"__data__": {"id_": "576b8e4e-97eb-48fb-a50c-ea2703c012ef", "embedding": null, "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n ", "original_text": "Good morning. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa18b7d1-e216-4ef4-9426-d2a81fcb0b8e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser from Morgan Stanl ey.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two? ", "original_text": "LLC  Q \nYes, hi. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd5e2f1c64f7f5f843011de34225267e3e4c86013ea2f2bd7c3ffae4bfc7fda1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "095e58e1-3c4a-4c14-b55e-8e1cf05d0004", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I have a quick follow -up question on the COVID vaccine benefit. "}, "hash": "44f16e1548710fa1cb648fd80f3e72103638316992713b27651a84f5e1040de7", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 4159, "end_char_idx": 4173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "095e58e1-3c4a-4c14-b55e-8e1cf05d0004": {"__data__": {"id_": "095e58e1-3c4a-4c14-b55e-8e1cf05d0004", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I have a quick follow -up question on the COVID vaccine benefit. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "576b8e4e-97eb-48fb-a50c-ea2703c012ef", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n ", "original_text": "Good morning. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0a8fda4fc1a6a2b4dee9ddd7ab6afb10b1a343ab03e78b08f8954f21b832830", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bfe3b00-6f05-43c5-bb42-27e425c32555", "node_type": "1", "metadata": {"window": "LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two? "}, "hash": "45730cff8d2200b264d4391ebc3eec4e86caa927446a7b8487faf81ba0b79db9", "class_name": "RelatedNodeInfo"}}, "text": "I have a quick follow -up question on the COVID vaccine benefit. ", "start_char_idx": 4173, "end_char_idx": 4238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bfe3b00-6f05-43c5-bb42-27e425c32555": {"__data__": {"id_": "0bfe3b00-6f05-43c5-bb42-27e425c32555", "embedding": null, "metadata": {"window": "LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two? ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "095e58e1-3c4a-4c14-b55e-8e1cf05d0004", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I have a quick follow -up question on the COVID vaccine benefit. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f276379c639f8bdc551b98ba40c2f69de1e489c5e57a8b6e8aaf9cd37618eeb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f63e1fec-060b-4df1-a86f-a82d19d7e014", "node_type": "1", "metadata": {"window": "Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n "}, "hash": "ff18baac4d42ba2303b27d2e67ae878ce8e268422a8e84b0128a6e8aa984214b", "class_name": "RelatedNodeInfo"}}, "text": "If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two? ", "start_char_idx": 4238, "end_char_idx": 4363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f63e1fec-060b-4df1-a86f-a82d19d7e014": {"__data__": {"id_": "f63e1fec-060b-4df1-a86f-a82d19d7e014", "embedding": null, "metadata": {"window": "Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bfe3b00-6f05-43c5-bb42-27e425c32555", "node_type": "1", "metadata": {"window": "LLC  Q \nYes, hi.  Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two? ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "abf2de5a8fea0edfc96929584c3d9e897106e0380559d9d63bdc2586997b42f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9243b8bd-1e03-4d02-883d-731585e2a44e", "node_type": "1", "metadata": {"window": "I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "c4a426d570bee5ccc26ab4ef15c00f52ba50af9ac24e7fa14a88b82f1f991436", "class_name": "RelatedNodeInfo"}}, "text": "Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n ", "start_char_idx": 4363, "end_char_idx": 4467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9243b8bd-1e03-4d02-883d-731585e2a44e": {"__data__": {"id_": "9243b8bd-1e03-4d02-883d-731585e2a44e", "embedding": null, "metadata": {"window": "I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f63e1fec-060b-4df1-a86f-a82d19d7e014", "node_type": "1", "metadata": {"window": "Good morning.  I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ec870bd9d9c3fffa0b5b8b6ef338e9166f09875f4a9030355dc1337b978d411", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5acaf446-e0aa-4b43-b3b6-18052da9bc07", "node_type": "1", "metadata": {"window": "If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "A \nYeah. "}, "hash": "96935fc74049c996b1242097ebca826d61d2165f0a64af1a18f7a77142430025", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1853, "end_char_idx": 2179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5acaf446-e0aa-4b43-b3b6-18052da9bc07": {"__data__": {"id_": "5acaf446-e0aa-4b43-b3b6-18052da9bc07", "embedding": null, "metadata": {"window": "If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9243b8bd-1e03-4d02-883d-731585e2a44e", "node_type": "1", "metadata": {"window": "I have a quick follow -up question on the COVID vaccine benefit.  If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a54a9f728baf0f2073ae2ea9380e1349f72093464cc0cd6f0a73bc28384d670", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ede17dc9-7391-4178-844f-abe0405e9098", "node_type": "1", "metadata": {"window": "Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "3ee94226b29faf133a1e90b98b424cf631d4c03c3f9e27d42442ee4637d8cbd3", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2179, "end_char_idx": 2188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ede17dc9-7391-4178-844f-abe0405e9098": {"__data__": {"id_": "ede17dc9-7391-4178-844f-abe0405e9098", "embedding": null, "metadata": {"window": "Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "31926609-9d2b-49e2-b1bb-39cf3b523242", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "247c2594e2865c264873f38903e71d5839e0c065203be6588f3e877db9c092c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5acaf446-e0aa-4b43-b3b6-18052da9bc07", "node_type": "1", "metadata": {"window": "If we think qualitatively \nabout the relative contribution from kitting versus vaccine, how should we think about these two?  Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8176c68dcdc96328bf5f4c30af71b1482066dc12c023a3d5619ac1bc04429460", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9513faa6-6b66-44df-93ce-1df1d2670d87", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "McKesson Corp.  "}, "hash": "5e4442b978bae5ed9e770dfa7af183daf96ee6f35efb8a6718d8048182b752e8", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 4802, "end_char_idx": 5079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9513faa6-6b66-44df-93ce-1df1d2670d87": {"__data__": {"id_": "9513faa6-6b66-44df-93ce-1df1d2670d87", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ede17dc9-7391-4178-844f-abe0405e9098", "node_type": "1", "metadata": {"window": "Is vaccine \ncontributions in general qualitatively tend to be higher than the kitting or vice versa?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Thanks for the...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "266932c6e7356c3f21dd2ef0555baedbf8634c8ba8378c6bf5b90c08c9e7dd13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65e8dcde-edc4-4038-9bf6-ba191c17ea22", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "2d03e421ded8a30aed39cc061aa521271d9db9519c1edee0032a2b3e92ff838d", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65e8dcde-edc4-4038-9bf6-ba191c17ea22": {"__data__": {"id_": "65e8dcde-edc4-4038-9bf6-ba191c17ea22", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9513faa6-6b66-44df-93ce-1df1d2670d87", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad7b6daf8556c1b924f71cdd1a9b0ba2e5282cee3a543fed796a340c39a4d24a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "624d116a-2a35-41eb-a7fe-1c20d80066f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point. ", "original_text": "LLC  Q \nI'm thinking about the broader potential opportunity.  \n "}, "hash": "48cba75590b12da714df2c02dd6d0b39d886c93ee0ba9529570b40e4677dbd58", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 16, "end_char_idx": 233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "624d116a-2a35-41eb-a7fe-1c20d80066f3": {"__data__": {"id_": "624d116a-2a35-41eb-a7fe-1c20d80066f3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point. ", "original_text": "LLC  Q \nI'm thinking about the broader potential opportunity.  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65e8dcde-edc4-4038-9bf6-ba191c17ea22", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b697e5d580ecfd80efa20f5017556d0401acc247d3e29a206bcff2c5faace84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "feaa2b71-dec6-4c26-b30a-c64a25c5d080", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "6b41d3f43dc8eb7a8a717f561191849a7db55a12e31a40fd2b28b0788ad0858d", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nI'm thinking about the broader potential opportunity.  \n ", "start_char_idx": 233, "end_char_idx": 298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "feaa2b71-dec6-4c26-b30a-c64a25c5d080": {"__data__": {"id_": "feaa2b71-dec6-4c26-b30a-c64a25c5d080", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "624d116a-2a35-41eb-a7fe-1c20d80066f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point. ", "original_text": "LLC  Q \nI'm thinking about the broader potential opportunity.  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60299ae6c33b53dd6ee75cabc3ce156af03b86c4acbada2aac3fa54561dd7441", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46430cd7-de77-4d46-87c9-1429b2294b0c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two. ", "original_text": "A \nYeah, thanks for the question, Ricky. "}, "hash": "96c0e418e1048e0aa2f51e6b12f0315e77bd78bfac2c2fb7d317e2fe8b8559c0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 298, "end_char_idx": 624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46430cd7-de77-4d46-87c9-1429b2294b0c": {"__data__": {"id_": "46430cd7-de77-4d46-87c9-1429b2294b0c", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two. ", "original_text": "A \nYeah, thanks for the question, Ricky. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "feaa2b71-dec6-4c26-b30a-c64a25c5d080", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1605f0be9877a8e737fdfdd3f2b9e4aed014f487848d35b3b951d10a512ff195", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2db1e3f-4ef9-4c2c-9c2b-12d63c00d049", "node_type": "1", "metadata": {"window": "LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n", "original_text": "Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point. "}, "hash": "6cb34ceb18ce648c1deeadba6f8b66da5f452cfb943d697715050ac0db23c0b5", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, thanks for the question, Ricky. ", "start_char_idx": 624, "end_char_idx": 665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2db1e3f-4ef9-4c2c-9c2b-12d63c00d049": {"__data__": {"id_": "e2db1e3f-4ef9-4c2c-9c2b-12d63c00d049", "embedding": null, "metadata": {"window": "LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n", "original_text": "Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46430cd7-de77-4d46-87c9-1429b2294b0c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two. ", "original_text": "A \nYeah, thanks for the question, Ricky. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d61d7a2e09cecc79603edae72e6e3b80f174ce56e47b4f1fa44a3d8c14346453", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a2002e1-832a-433c-ba45-3d5360314dc8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others. ", "original_text": "We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that. "}, "hash": "8655c8e3021ffbd1ff0e8c9cef43f5ba58a248a84d9c66a04331ad8ca4fdf7af", "class_name": "RelatedNodeInfo"}}, "text": "Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point. ", "start_char_idx": 665, "end_char_idx": 786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a2002e1-832a-433c-ba45-3d5360314dc8": {"__data__": {"id_": "7a2002e1-832a-433c-ba45-3d5360314dc8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others. ", "original_text": "We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2db1e3f-4ef9-4c2c-9c2b-12d63c00d049", "node_type": "1", "metadata": {"window": "LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n", "original_text": "Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9954825353ad65b7f3c5848030ec25fc9ac5910a8c953052ef8fa0c245a8c337", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e1094e0-2f5a-4577-a2b9-d515486de273", "node_type": "1", "metadata": {"window": "A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services. ", "original_text": "And I wouldn't try to relate the two. "}, "hash": "c7269a53df397440ba2fdccc2b0dbeef1a4636481220977e8bf8d0416bff6cea", "class_name": "RelatedNodeInfo"}}, "text": "We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that. ", "start_char_idx": 786, "end_char_idx": 890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e1094e0-2f5a-4577-a2b9-d515486de273": {"__data__": {"id_": "3e1094e0-2f5a-4577-a2b9-d515486de273", "embedding": null, "metadata": {"window": "A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services. ", "original_text": "And I wouldn't try to relate the two. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a2002e1-832a-433c-ba45-3d5360314dc8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others. ", "original_text": "We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef9a953c01250001ed8b8afcf4889b48592ef33d63b4d55a9570e27b0332fdbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f97e575e-6b17-428f-9349-42510d5608a2", "node_type": "1", "metadata": {"window": "Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight. ", "original_text": "They're very different programs.  \n \n"}, "hash": "a5db47f338b1aeb784af714d27aa4f507980e1fb564ba180f71ce3ed1212a9a5", "class_name": "RelatedNodeInfo"}}, "text": "And I wouldn't try to relate the two. ", "start_char_idx": 890, "end_char_idx": 928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f97e575e-6b17-428f-9349-42510d5608a2": {"__data__": {"id_": "f97e575e-6b17-428f-9349-42510d5608a2", "embedding": null, "metadata": {"window": "Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight. ", "original_text": "They're very different programs.  \n \n", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e1094e0-2f5a-4577-a2b9-d515486de273", "node_type": "1", "metadata": {"window": "A \nYeah, thanks for the question, Ricky.  Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services. ", "original_text": "And I wouldn't try to relate the two. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f351e91076a74d31fa56a23f5575c5882dcc15116e8ef8b5a6adffbb602531c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3dd1d8b2-0a2e-4799-997e-dabc250c59b4", "node_type": "1", "metadata": {"window": "We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n ", "original_text": "I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others. "}, "hash": "6f8e0694da52e5ac092925512e56ed24c91eeb524d95ca4bd98d40eb6ea6edb2", "class_name": "RelatedNodeInfo"}}, "text": "They're very different programs.  \n \n", "start_char_idx": 928, "end_char_idx": 965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3dd1d8b2-0a2e-4799-997e-dabc250c59b4": {"__data__": {"id_": "3dd1d8b2-0a2e-4799-997e-dabc250c59b4", "embedding": null, "metadata": {"window": "We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n ", "original_text": "I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f97e575e-6b17-428f-9349-42510d5608a2", "node_type": "1", "metadata": {"window": "Look, we've only quantified our relationship on the kitting side, that's really \nall that we can quantify at this point.  We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight. ", "original_text": "They're very different programs.  \n \n", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6343471e2c7cefd335bef2c51b0dead9a1c85ed111012f9cf795b266fbeedc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83596fac-b506-4adf-946e-163eb42d0c27", "node_type": "1", "metadata": {"window": "And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services. "}, "hash": "c13b43eff1c85dd1275abefb228eb21a7c4b605964fb0013e426b4c1adbf1901", "class_name": "RelatedNodeInfo"}}, "text": "I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others. ", "start_char_idx": 965, "end_char_idx": 1115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83596fac-b506-4adf-946e-163eb42d0c27": {"__data__": {"id_": "83596fac-b506-4adf-946e-163eb42d0c27", "embedding": null, "metadata": {"window": "And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dd1d8b2-0a2e-4799-997e-dabc250c59b4", "node_type": "1", "metadata": {"window": "We don't have a vaccine approved, so it's too early for us to really provide \nyou any guidance on that.  And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n ", "original_text": "I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c631ec3ec27780423f5e895b31f6629a6427acf58044454b35f4fd832d4974a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96f9bcb7-8f3e-4a84-86fb-179596ed7c4e", "node_type": "1", "metadata": {"window": "They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "So we're focused right now on the \nprograms that are in flight. "}, "hash": "aa9efd390d117a620f01b7ff77b406321db112b15bd4c0cd6a36375c1a144d00", "class_name": "RelatedNodeInfo"}}, "text": "We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services. ", "start_char_idx": 1115, "end_char_idx": 1253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96f9bcb7-8f3e-4a84-86fb-179596ed7c4e": {"__data__": {"id_": "96f9bcb7-8f3e-4a84-86fb-179596ed7c4e", "embedding": null, "metadata": {"window": "They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "So we're focused right now on the \nprograms that are in flight. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83596fac-b506-4adf-946e-163eb42d0c27", "node_type": "1", "metadata": {"window": "And I wouldn't try to relate the two.  They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58b83982d1afd894a844fa8d3684bc8455a67c1a02e9e1b7d3eaf748c208e004", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "501045d6-77ff-49ec-8313-77e9c24e47a7", "node_type": "1", "metadata": {"window": "I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42). ", "original_text": "But certainly, there are opportunities for us beyond that.  \n "}, "hash": "b168465a34faf4e95946b4d2b68ff2def981940640c76e07284e2182ca786b51", "class_name": "RelatedNodeInfo"}}, "text": "So we're focused right now on the \nprograms that are in flight. ", "start_char_idx": 1253, "end_char_idx": 1317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "501045d6-77ff-49ec-8313-77e9c24e47a7": {"__data__": {"id_": "501045d6-77ff-49ec-8313-77e9c24e47a7", "embedding": null, "metadata": {"window": "I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42). ", "original_text": "But certainly, there are opportunities for us beyond that.  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96f9bcb7-8f3e-4a84-86fb-179596ed7c4e", "node_type": "1", "metadata": {"window": "They're very different programs.  \n \n I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "So we're focused right now on the \nprograms that are in flight. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d21fbe6e671f26e40830d0a8e35b8de31d774c1cd15797e4a1dd5783385a987", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29203b92-1213-4bcd-823a-1635e03309cd", "node_type": "1", "metadata": {"window": "We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "f24bd1ea15e1f390661d8547de7c498f80489495391dfa5eb8151899faaa98d2", "class_name": "RelatedNodeInfo"}}, "text": "But certainly, there are opportunities for us beyond that.  \n ", "start_char_idx": 1317, "end_char_idx": 1379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29203b92-1213-4bcd-823a-1635e03309cd": {"__data__": {"id_": "29203b92-1213-4bcd-823a-1635e03309cd", "embedding": null, "metadata": {"window": "We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "501045d6-77ff-49ec-8313-77e9c24e47a7", "node_type": "1", "metadata": {"window": "I would say, though, that the kitting program does provide us the opportunity to continue to expand our \nrelationship with the government and others.  We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42). ", "original_text": "But certainly, there are opportunities for us beyond that.  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef7eaa50ab79a59e9b3c25e2aca2ea4b08372958af554d85c3b3e59356c8f7dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "299f90d7-4bac-4908-8a41-f7a3a2750177", "node_type": "1", "metadata": {"window": "So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah. ", "original_text": "A \nNext question?  \n "}, "hash": "85dcb295462a3b949799a1f5f0e22682044f2e13e5139ee93ef822c2656ae61a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 1379, "end_char_idx": 1709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "299f90d7-4bac-4908-8a41-f7a3a2750177": {"__data__": {"id_": "299f90d7-4bac-4908-8a41-f7a3a2750177", "embedding": null, "metadata": {"window": "So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah. ", "original_text": "A \nNext question?  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29203b92-1213-4bcd-823a-1635e03309cd", "node_type": "1", "metadata": {"window": "We certainly have all the capabilities, and that's why we were \nselected to be able to continue to expand our capabilitie s and services.  So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "266b9d0f45cec2713334398f88af3eb64890c7fbeba2aa388fe12c66b03946e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0619104-1553-4f64-becb-e9d5046dd5a3", "node_type": "1", "metadata": {"window": "But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42). "}, "hash": "c52f20e896fb1941981bd8c42dcb4bf6d102b0a9003ddbb2479defa3ac8b7813", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question?  \n ", "start_char_idx": 1709, "end_char_idx": 1730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0619104-1553-4f64-becb-e9d5046dd5a3": {"__data__": {"id_": "e0619104-1553-4f64-becb-e9d5046dd5a3", "embedding": null, "metadata": {"window": "But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42). ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "299f90d7-4bac-4908-8a41-f7a3a2750177", "node_type": "1", "metadata": {"window": "So we're focused right now on the \nprograms that are in flight.  But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah. ", "original_text": "A \nNext question?  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "073725bd30ae18e69f6861ebf5bac4fe917d8401db82ea65cc54047d0f4668dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8885f785-7249-4be4-95e5-254a4165ac89", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status. ", "original_text": "Your line is open.  \n "}, "hash": "e83ac00e55a4f0176817a6286eb5642b10a513292b7a62322cb66865f91f8bcf", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42). ", "start_char_idx": 1730, "end_char_idx": 2103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8885f785-7249-4be4-95e5-254a4165ac89": {"__data__": {"id_": "8885f785-7249-4be4-95e5-254a4165ac89", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status. ", "original_text": "Your line is open.  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0619104-1553-4f64-becb-e9d5046dd5a3", "node_type": "1", "metadata": {"window": "But certainly, there are opportunities for us beyond that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42). ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42e8916678ef0e2130dae1f4c1fd09e559c1317e3992c59fc9ace70d133c2d06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d7957e0-77a1-4078-bcc7-120a07d92122", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah. "}, "hash": "8b21cafad5a9168778c686bcc6ee16aa3d388ac31d135be790560727018b8c9f", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 2103, "end_char_idx": 2125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d7957e0-77a1-4078-bcc7-120a07d92122": {"__data__": {"id_": "9d7957e0-77a1-4078-bcc7-120a07d92122", "embedding": null, "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8885f785-7249-4be4-95e5-254a4165ac89", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status. ", "original_text": "Your line is open.  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5be95451ba2f264c6161121b3798bd7f0788260da8cec18dba4dafe046d46248", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d84e4b6d-3a7e-402c-8aa7-d229de081e3a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially. ", "original_text": "Thanks for taking my question. "}, "hash": "ddfc16a8dd0c36c07be76640bef22cc12e3640f432d9a773e6e980dc027cc794", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah. ", "start_char_idx": 2125, "end_char_idx": 2445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d84e4b6d-3a7e-402c-8aa7-d229de081e3a": {"__data__": {"id_": "d84e4b6d-3a7e-402c-8aa7-d229de081e3a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially. ", "original_text": "Thanks for taking my question. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d7957e0-77a1-4078-bcc7-120a07d92122", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3586eef3b3ca4944f665b899a4a4462d3f30d7feb8e37f2187e46107f471e6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11aa230a-04fb-4e38-9e4f-f1491f013cda", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here? ", "original_text": "Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status. "}, "hash": "6ee41cee13b5069a7515c647da306386fe9695787032a8d46093103a1ca9f32a", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my question. ", "start_char_idx": 2445, "end_char_idx": 2476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11aa230a-04fb-4e38-9e4f-f1491f013cda": {"__data__": {"id_": "11aa230a-04fb-4e38-9e4f-f1491f013cda", "embedding": null, "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here? ", "original_text": "Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d84e4b6d-3a7e-402c-8aa7-d229de081e3a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo from Guggenheim Investment (sic) [Guggenheim Securities] \n(01:00:42).  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially. ", "original_text": "Thanks for taking my question. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "faac582788deccd9e222434b010d0f7c1366ce6be52cc267e21bc8bbbfe90eeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "586323f2-c9f8-4d7a-925f-983506bae99e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement. ", "original_text": "It's been a while since we heard anything on this front. "}, "hash": "dbd7e339b70d91acf3e0f9318241631ed5ca9e251960efe2763df4bb0e30b45c", "class_name": "RelatedNodeInfo"}}, "text": "Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status. ", "start_char_idx": 2476, "end_char_idx": 2566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "586323f2-c9f8-4d7a-925f-983506bae99e": {"__data__": {"id_": "586323f2-c9f8-4d7a-925f-983506bae99e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement. ", "original_text": "It's been a while since we heard anything on this front. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11aa230a-04fb-4e38-9e4f-f1491f013cda", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here? ", "original_text": "Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e90df8005390dbdc80ff46a56f5e8221526f436fbf9215b73e4c27b784c2b0a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "baff1a58-58dc-4fa8-93cd-df2946e2780b", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process. ", "original_text": "And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially. "}, "hash": "91235ba7091f17299d18d225505f22f4e87aa1d2f3c53080da44665eeb6474d4", "class_name": "RelatedNodeInfo"}}, "text": "It's been a while since we heard anything on this front. ", "start_char_idx": 2566, "end_char_idx": 2623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "baff1a58-58dc-4fa8-93cd-df2946e2780b": {"__data__": {"id_": "baff1a58-58dc-4fa8-93cd-df2946e2780b", "embedding": null, "metadata": {"window": "Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process. ", "original_text": "And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "586323f2-c9f8-4d7a-925f-983506bae99e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYeah.  Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement. ", "original_text": "It's been a while since we heard anything on this front. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99e19dfeb6b43ad941d181fe10ac706a10d7ce69843971cb992ac12887db1359", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b555e5b3-c98c-4db4-a587-40c798d02091", "node_type": "1", "metadata": {"window": "Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n ", "original_text": "I was just \ncurious, has COVI D really slowed the process here? "}, "hash": "672cebc367f53beda06ab3e3a211b25efd5a487413b46064c2a0f308bc8ffc84", "class_name": "RelatedNodeInfo"}}, "text": "And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially. ", "start_char_idx": 2623, "end_char_idx": 2763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b555e5b3-c98c-4db4-a587-40c798d02091": {"__data__": {"id_": "b555e5b3-c98c-4db4-a587-40c798d02091", "embedding": null, "metadata": {"window": "Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n ", "original_text": "I was just \ncurious, has COVI D really slowed the process here? ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "baff1a58-58dc-4fa8-93cd-df2946e2780b", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process. ", "original_text": "And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6551f280facd102b41f917807632a3eb1148f37f5524d4810e99682922bff36c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e267ed57-1dae-4105-a3cc-ee5b53e6dcbe", "node_type": "1", "metadata": {"window": "It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement. "}, "hash": "1f64d7dfce5de77660117dc40c62a0dd876f6f492cc5ae9c78f833272ac75781", "class_name": "RelatedNodeInfo"}}, "text": "I was just \ncurious, has COVI D really slowed the process here? ", "start_char_idx": 2763, "end_char_idx": 2827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e267ed57-1dae-4105-a3cc-ee5b53e6dcbe": {"__data__": {"id_": "e267ed57-1dae-4105-a3cc-ee5b53e6dcbe", "embedding": null, "metadata": {"window": "It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b555e5b3-c98c-4db4-a587-40c798d02091", "node_type": "1", "metadata": {"window": "Brian, I just wanted to follow up and maybe pivot toward s the opioid \nlitigation status.  It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n ", "original_text": "I was just \ncurious, has COVI D really slowed the process here? ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bbc34c78715a2ef79a3594c43f022b16cd8406dd24d1ed7d2575202e35de688", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00cf6a7a-7c1f-42ab-8915-a3853e2078b5", "node_type": "1", "metadata": {"window": "And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up. ", "original_text": "Now it feels like there's some inertia in the process. "}, "hash": "87237d4da052deeb23381ef91de0bd56347d5a48232f6b3afc30625c06292745", "class_name": "RelatedNodeInfo"}}, "text": "It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement. ", "start_char_idx": 2827, "end_char_idx": 2941, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00cf6a7a-7c1f-42ab-8915-a3853e2078b5": {"__data__": {"id_": "00cf6a7a-7c1f-42ab-8915-a3853e2078b5", "embedding": null, "metadata": {"window": "And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up. ", "original_text": "Now it feels like there's some inertia in the process. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e267ed57-1dae-4105-a3cc-ee5b53e6dcbe", "node_type": "1", "metadata": {"window": "It's been a while since we heard anything on this front.  And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5815ea9fb062fa4f0ba682d03e7b255dd76523e5399d1dbf147da3307fb3fb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb81999d-c60e-4ce0-b0f1-d72998f4949e", "node_type": "1", "metadata": {"window": "I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018. ", "original_text": "And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n "}, "hash": "b74c15126d0a85a461df57b7bc91bdb65d37897fcc815fc5e6cf666424b233c0", "class_name": "RelatedNodeInfo"}}, "text": "Now it feels like there's some inertia in the process. ", "start_char_idx": 2941, "end_char_idx": 2996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb81999d-c60e-4ce0-b0f1-d72998f4949e": {"__data__": {"id_": "fb81999d-c60e-4ce0-b0f1-d72998f4949e", "embedding": null, "metadata": {"window": "I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018. ", "original_text": "And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00cf6a7a-7c1f-42ab-8915-a3853e2078b5", "node_type": "1", "metadata": {"window": "And in the press release, you seem to \nsuggest that you're going to reserve some money for settling with the State of New York potentially.  I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up. ", "original_text": "Now it feels like there's some inertia in the process. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "623d5e9ba43ff72ddfd1d2682603a535b71f2378b75eb76e33579839d8305cea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b26a98a-d683-4959-902e-31045c781bf2", "node_type": "1", "metadata": {"window": "It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "fe40b19eb2585e7bde6113251a5d805df64472246ef3e6130be044a41027e36a", "class_name": "RelatedNodeInfo"}}, "text": "And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n ", "start_char_idx": 2996, "end_char_idx": 3117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b26a98a-d683-4959-902e-31045c781bf2": {"__data__": {"id_": "9b26a98a-d683-4959-902e-31045c781bf2", "embedding": null, "metadata": {"window": "It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb81999d-c60e-4ce0-b0f1-d72998f4949e", "node_type": "1", "metadata": {"window": "I was just \ncurious, has COVI D really slowed the process here?  It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018. ", "original_text": "And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2c4bf62c469b226f55816034f778fc9c17e4742d0d9baab01680f11c272be08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b212d643-a520-4b1f-841b-f5c889d46590", "node_type": "1", "metadata": {"window": "Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n ", "original_text": "A \nHey Glen, just before Brian jumps in there, I just want to clear up. "}, "hash": "e74b782437aff840c48c0092475d0581ed52b0abe62992d9cc830ce758638695", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3117, "end_char_idx": 3462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b212d643-a520-4b1f-841b-f5c889d46590": {"__data__": {"id_": "b212d643-a520-4b1f-841b-f5c889d46590", "embedding": null, "metadata": {"window": "Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n ", "original_text": "A \nHey Glen, just before Brian jumps in there, I just want to clear up. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b26a98a-d683-4959-902e-31045c781bf2", "node_type": "1", "metadata": {"window": "It felt like we were making much greater progress in the \nbeginning of the year, tracking towards the settlement.  Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d7988f2e0203eb8321124e177ef06c9e220eb3fa7496a268b56f74876ebc88c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "993e6339-b9f5-4a4d-8c6c-5f01f1ffed2c", "node_type": "1", "metadata": {"window": "And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n ", "original_text": "The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018. "}, "hash": "530d5599003268eb9679394b715b714faeb465126f2ea55a70ba08959da13f4b", "class_name": "RelatedNodeInfo"}}, "text": "A \nHey Glen, just before Brian jumps in there, I just want to clear up. ", "start_char_idx": 3462, "end_char_idx": 3534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "993e6339-b9f5-4a4d-8c6c-5f01f1ffed2c": {"__data__": {"id_": "993e6339-b9f5-4a4d-8c6c-5f01f1ffed2c", "embedding": null, "metadata": {"window": "And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n ", "original_text": "The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b212d643-a520-4b1f-841b-f5c889d46590", "node_type": "1", "metadata": {"window": "Now it feels like there's some inertia in the process.  And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n ", "original_text": "A \nHey Glen, just before Brian jumps in there, I just want to clear up. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8bfb624650e482b9666ca800c08f96b951c8b19e8ebf02c74ee392fb572b8c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b66c6713-8645-4fe4-8f19-cc1d72f7a6cb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019. "}, "hash": "dc0a8da18fd07530caaa977be7fa0df1df6bc8915e34793a533ef8c155aed526", "class_name": "RelatedNodeInfo"}}, "text": "The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018. ", "start_char_idx": 3534, "end_char_idx": 3633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b66c6713-8645-4fe4-8f19-cc1d72f7a6cb": {"__data__": {"id_": "b66c6713-8645-4fe4-8f19-cc1d72f7a6cb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "993e6339-b9f5-4a4d-8c6c-5f01f1ffed2c", "node_type": "1", "metadata": {"window": "And I \nwas just curious if you can maybe give us an upd ate on any signposts that we should look out from this point?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n ", "original_text": "The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0dc5e9fa98470a9c7e251ab375d357c66cbd3801812e9de9e362bfd324bb2e2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cba23ae4-4307-49d4-9d46-2ae2f035a288", "node_type": "1", "metadata": {"window": "A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great. ", "original_text": "So it's not related to the larger opioid settlement at all.  \n "}, "hash": "0933f2c89f62c823b46f8c21b6b64c8e9adae6fda03b07d188e32ed1bd2691f9", "class_name": "RelatedNodeInfo"}}, "text": "And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019. ", "start_char_idx": 3633, "end_char_idx": 3755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cba23ae4-4307-49d4-9d46-2ae2f035a288": {"__data__": {"id_": "cba23ae4-4307-49d4-9d46-2ae2f035a288", "embedding": null, "metadata": {"window": "A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great. ", "original_text": "So it's not related to the larger opioid settlement at all.  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b66c6713-8645-4fe4-8f19-cc1d72f7a6cb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec5b8e2e9447660c3096ef77da5acdd6acc05bdf57cc4536450996246c1b7a53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6293fdae-5ef5-4bad-bc3c-863d786e221e", "node_type": "1", "metadata": {"window": "The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n "}, "hash": "4f140b8de9f534ede7ca407ef7c80eed5c69601101c20e8482260282368874b1", "class_name": "RelatedNodeInfo"}}, "text": "So it's not related to the larger opioid settlement at all.  \n ", "start_char_idx": 3755, "end_char_idx": 3818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6293fdae-5ef5-4bad-bc3c-863d786e221e": {"__data__": {"id_": "6293fdae-5ef5-4bad-bc3c-863d786e221e", "embedding": null, "metadata": {"window": "The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cba23ae4-4307-49d4-9d46-2ae2f035a288", "node_type": "1", "metadata": {"window": "A \nHey Glen, just before Brian jumps in there, I just want to clear up.  The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great. ", "original_text": "So it's not related to the larger opioid settlement at all.  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4fd57c8746d9273a9d5b7565e5f400c8434c050df9278c9192e62036cf37f03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3227db2-0b75-4c34-a192-86dd6590d83e", "node_type": "1", "metadata": {"window": "And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point.  So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "5fa39ac09e8ce53729f8ee39cbd2f8350cc3cac53e1f103e64cbab47a5a7de88", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n ", "start_char_idx": 3818, "end_char_idx": 4142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3227db2-0b75-4c34-a192-86dd6590d83e": {"__data__": {"id_": "a3227db2-0b75-4c34-a192-86dd6590d83e", "embedding": null, "metadata": {"window": "And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point.  So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6293fdae-5ef5-4bad-bc3c-863d786e221e", "node_type": "1", "metadata": {"window": "The New York charge that we took wa s related \nto the surcharge that was enacted in 2017 and 2018.  And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "612873dc73851f63261fa55b7abce10874340e332057a1cf6916d414a04bb024", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45d4df81-8d87-4599-83dc-d5276a4b3ae9", "node_type": "1", "metadata": {"window": "So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point.  So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "original_text": "A \nYes, great. "}, "hash": "e326d64faf4341d4f33ee622086300d408fc8a242a3f37d086e2a225bfd0bf41", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 298, "end_char_idx": 624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45d4df81-8d87-4599-83dc-d5276a4b3ae9": {"__data__": {"id_": "45d4df81-8d87-4599-83dc-d5276a4b3ae9", "embedding": null, "metadata": {"window": "So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point.  So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "original_text": "A \nYes, great. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3227db2-0b75-4c34-a192-86dd6590d83e", "node_type": "1", "metadata": {"window": "And so what we're doing here is just picking up the accrual \nfor the reversal of that court litigation suit back in 2019.  So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point.  So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfa0ddc53451ee44eb70763367ea61272bd6f0290b2cff76f740bfc430abc637", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0da21d3-f961-4ff4-a0fc-b52bfce51144", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point.  So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "original_text": "I was going to make that point. "}, "hash": "572ec26cf3b3641f47ea94cd23d1dcb97cea556adefbd171c51835409a87be55", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes, great. ", "start_char_idx": 4468, "end_char_idx": 4483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0da21d3-f961-4ff4-a0fc-b52bfce51144": {"__data__": {"id_": "f0da21d3-f961-4ff4-a0fc-b52bfce51144", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point.  So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "original_text": "I was going to make that point. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45d4df81-8d87-4599-83dc-d5276a4b3ae9", "node_type": "1", "metadata": {"window": "So it's not related to the larger opioid settlement at all.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point.  So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "original_text": "A \nYes, great. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d7fe68b5de1fa56326ed1a76efe5089ce60dce3cfd0b6da651b31b675fd1376", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6166384-3d3b-462b-9eff-4475c6cf0658", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point.  So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "original_text": "So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a "}, "hash": "d7f575f34b31b5eac49c8c93a1652007caabd1dbea9b747d836cba2cc5f51043", "class_name": "RelatedNodeInfo"}}, "text": "I was going to make that point. ", "start_char_idx": 4483, "end_char_idx": 4515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6166384-3d3b-462b-9eff-4475c6cf0658": {"__data__": {"id_": "e6166384-3d3b-462b-9eff-4475c6cf0658", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point.  So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "original_text": "So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7a1424f7d7f5272054d69ef4137d0f53134ef7fe5b1ed96b1c4a3e9906f150c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0da21d3-f961-4ff4-a0fc-b52bfce51144", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santan gelo  \nAnalyst, Guggenheim Securities LLC  Q \nOkay.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point.  So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "original_text": "I was going to make that point. ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d629854f8bd24bd400f0508d9f20371e4030f58bccc0525eb4083c07d383568", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b414137f-a68c-4798-bd21-bfc1b2349af0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "060feed7917d0dfc98d92a871ed68f97e0b5af783158a1aaeb5ba8c0958dc5d4", "class_name": "RelatedNodeInfo"}}, "text": "So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "start_char_idx": 4515, "end_char_idx": 4699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b414137f-a68c-4798-bd21-bfc1b2349af0": {"__data__": {"id_": "b414137f-a68c-4798-bd21-bfc1b2349af0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6166384-3d3b-462b-9eff-4475c6cf0658", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes, great.  I was going to make that point.  So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "original_text": "So as regards to the larger discussions, I think it's fair to say there was \na few -month period there where the nations and the AGs and the distributors' focus was on responding to a ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3373815731967c33b5e474e50000ae9c4ec310851262b89d29a45c9c6d7c624d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5075313f-4e72-40db-8fb0-d4b9cf384c98", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic. "}, "hash": "29516a2af71901b8b1c45b7ac3f53d40c93b475de1a64e627cf032e13e740eb0", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5075313f-4e72-40db-8fb0-d4b9cf384c98": {"__data__": {"id_": "5075313f-4e72-40db-8fb0-d4b9cf384c98", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b414137f-a68c-4798-bd21-bfc1b2349af0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f5b23855b055e7719ba32903910b2b39ced9bf7b97c6762c7f84a8b2a7a63e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae201f39-aa52-4517-983a-d74d74a10c69", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point. ", "original_text": "But we're now in the eighth month of this. "}, "hash": "a807e7aa08979a1c23ae8ce16e8db0123b1bd518f5b5b1c5782e62ed7c5f1a30", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic. ", "start_char_idx": 16, "end_char_idx": 191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae201f39-aa52-4517-983a-d74d74a10c69": {"__data__": {"id_": "ae201f39-aa52-4517-983a-d74d74a10c69", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point. ", "original_text": "But we're now in the eighth month of this. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5075313f-4e72-40db-8fb0-d4b9cf384c98", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b22b60612c7d877d1efd43ddb68b14d88df34bb246256adf04e59d68cd1a9785", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a16bc8b-54eb-4abc-bfb9-479aa1abbbbd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n ", "original_text": "And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n"}, "hash": "c5f3b893eb0008ea45d8e62d9dc76b83b14d0bdb9e4cf7ef73bc8e360ba002b7", "class_name": "RelatedNodeInfo"}}, "text": "But we're now in the eighth month of this. ", "start_char_idx": 191, "end_char_idx": 234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a16bc8b-54eb-4abc-bfb9-479aa1abbbbd": {"__data__": {"id_": "5a16bc8b-54eb-4abc-bfb9-479aa1abbbbd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n ", "original_text": "And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae201f39-aa52-4517-983a-d74d74a10c69", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point. ", "original_text": "But we're now in the eighth month of this. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea769d9be9231734a4d0192fe3d753725ef348f8c4d278c61e75e5b874ca37b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "467a11e4-e636-43ff-ae4e-9851c7a24660", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We continue to believe we're making progress in the discussions. "}, "hash": "bfce5d4095e8aed91704494fbd688045bf63dc27d956a93253e0612484cc4dad", "class_name": "RelatedNodeInfo"}}, "text": "And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n", "start_char_idx": 234, "end_char_idx": 356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "467a11e4-e636-43ff-ae4e-9851c7a24660": {"__data__": {"id_": "467a11e4-e636-43ff-ae4e-9851c7a24660", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We continue to believe we're making progress in the discussions. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a16bc8b-54eb-4abc-bfb9-479aa1abbbbd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n ", "original_text": "And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4e76a4d6535778e16b7ac4b6e1dccddd24385af6ebadf39f145fc2fe8266787", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2c9aecc-ead8-4988-9214-cf59f06e8aef", "node_type": "1", "metadata": {"window": "But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n ", "original_text": "We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point. "}, "hash": "cc811309aef475e3c15fb8d62dbfb845402d46a590465866537e425b35e8b3dc", "class_name": "RelatedNodeInfo"}}, "text": "We continue to believe we're making progress in the discussions. ", "start_char_idx": 356, "end_char_idx": 421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2c9aecc-ead8-4988-9214-cf59f06e8aef": {"__data__": {"id_": "d2c9aecc-ead8-4988-9214-cf59f06e8aef", "embedding": null, "metadata": {"window": "But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n ", "original_text": "We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "467a11e4-e636-43ff-ae4e-9851c7a24660", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "We continue to believe we're making progress in the discussions. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7468b57789045c96cff2d0e65f8efff587c5e4e5a28376995ef04448f1cfdac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0036fc3-e019-4f00-8a7e-14623618fdbd", "node_type": "1", "metadata": {"window": "And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "original_text": "So we remain very focused and hopeful.  \n "}, "hash": "d65e1dd280aa11ad3cd51a9d6f0297b1b5b3f5618f53f925adee492b27d0d5db", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point. ", "start_char_idx": 421, "end_char_idx": 635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0036fc3-e019-4f00-8a7e-14623618fdbd": {"__data__": {"id_": "c0036fc3-e019-4f00-8a7e-14623618fdbd", "embedding": null, "metadata": {"window": "And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "original_text": "So we remain very focused and hopeful.  \n ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2c9aecc-ead8-4988-9214-cf59f06e8aef", "node_type": "1", "metadata": {"window": "But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n ", "original_text": "We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9588a07d8ce231a63533a3d4c7cce0188e09204cd3fccd34c34a6fc4b86f388e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "070c498d-b52d-4ac2-a1b7-8c41e3f8f33b", "node_type": "1", "metadata": {"window": "We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "de663f158299ce3abb81f2429e1311462ee9d9e748fecb28eec712653c0412ad", "class_name": "RelatedNodeInfo"}}, "text": "So we remain very focused and hopeful.  \n ", "start_char_idx": 635, "end_char_idx": 677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "070c498d-b52d-4ac2-a1b7-8c41e3f8f33b": {"__data__": {"id_": "070c498d-b52d-4ac2-a1b7-8c41e3f8f33b", "embedding": null, "metadata": {"window": "We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0036fc3-e019-4f00-8a7e-14623618fdbd", "node_type": "1", "metadata": {"window": "And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "original_text": "So we remain very focused and hopeful.  \n ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c98c39764f2576e44b6bacc4e3684b02b591000fbaa63aa3f290a2f35949e725", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0cc3959-3e02-4bde-b385-c1dd6609f6be", "node_type": "1", "metadata": {"window": "We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n ", "original_text": "A \nOperator, we have time for one more question.  \n "}, "hash": "0fc17009bdb5c1fa66fc285ee7ad97c83085342beee4aafe7e4e749f16fd016e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 677, "end_char_idx": 1007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0cc3959-3e02-4bde-b385-c1dd6609f6be": {"__data__": {"id_": "a0cc3959-3e02-4bde-b385-c1dd6609f6be", "embedding": null, "metadata": {"window": "We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n ", "original_text": "A \nOperator, we have time for one more question.  \n ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "070c498d-b52d-4ac2-a1b7-8c41e3f8f33b", "node_type": "1", "metadata": {"window": "We continue to believe we're making progress in the discussions.  We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13ef29235318f1811b0574ad7cb9106f721a0c94e3d2fb9eac2eca455c6d0571", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83d352a7-f347-455d-8035-145532bef513", "node_type": "1", "metadata": {"window": "So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. "}, "hash": "28e233707bcb1b723f4c6fc58f5136812916c8aa45b44e838342b99ae51449b3", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, we have time for one more question.  \n ", "start_char_idx": 1007, "end_char_idx": 1059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83d352a7-f347-455d-8035-145532bef513": {"__data__": {"id_": "83d352a7-f347-455d-8035-145532bef513", "embedding": null, "metadata": {"window": "So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0cc3959-3e02-4bde-b385-c1dd6609f6be", "node_type": "1", "metadata": {"window": "We continue to be hopeful we'll reach a broad \nresolution because we think that that's the best way to accelerate relief for people and communities that have \nbeen impacted by various h ealth crises at this point.  So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n ", "original_text": "A \nOperator, we have time for one more question.  \n ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90312af344f69d869dc2b2d0011eb93d383d70c283e45243572e9484e070687c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0dabfe1c-fed8-4e84-be48-b8d928cf971e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n", "original_text": "And that question will come from Elizabeth Anderson from Evercore. "}, "hash": "12b6659694e131202823de3b1f9df2935be1940e2334d2582599c5a7ca4e5175", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "start_char_idx": 1059, "end_char_idx": 1340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0dabfe1c-fed8-4e84-be48-b8d928cf971e": {"__data__": {"id_": "0dabfe1c-fed8-4e84-be48-b8d928cf971e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n", "original_text": "And that question will come from Elizabeth Anderson from Evercore. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83d352a7-f347-455d-8035-145532bef513", "node_type": "1", "metadata": {"window": "So we remain very focused and hopeful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14b061ae8d6387f43a5ab01f4d6156fc46211e444ad88bbe7bd7cf26b4c5b950", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39b4b678-3578-4997-99f7-a5956c323b3e", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful. ", "original_text": "Your line is open.  \n "}, "hash": "7740b32d6e7c82025eefd716d3bef914665dd6c2f7fc4d19d7388d9414f800ae", "class_name": "RelatedNodeInfo"}}, "text": "And that question will come from Elizabeth Anderson from Evercore. ", "start_char_idx": 1340, "end_char_idx": 1407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39b4b678-3578-4997-99f7-a5956c323b3e": {"__data__": {"id_": "39b4b678-3578-4997-99f7-a5956c323b3e", "embedding": null, "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful. ", "original_text": "Your line is open.  \n ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0dabfe1c-fed8-4e84-be48-b8d928cf971e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n", "original_text": "And that question will come from Elizabeth Anderson from Evercore. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a0495347c1649368e59efd47ee1ab0be05bf7a7881e4f68f93721dae1514a85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd40ad81-8e74-4de2-898c-a867be1a5e1a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question. "}, "hash": "011cf3e26635833a98d6c0f98b72965d6a3160f19f9e7e0e1604412e31146310", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 1407, "end_char_idx": 1429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd40ad81-8e74-4de2-898c-a867be1a5e1a": {"__data__": {"id_": "dd40ad81-8e74-4de2-898c-a867be1a5e1a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39b4b678-3578-4997-99f7-a5956c323b3e", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful. ", "original_text": "Your line is open.  \n ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "545f10c271a7e3e973ecd3572a2e52f4206f40f8c91a9cdefe99a6ba4b5119b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48efd214-236a-4170-97c8-de5696f83fa9", "node_type": "1", "metadata": {"window": "And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "original_text": "I was wondering if you could provide a little bit more in terms of details on AMP. \n"}, "hash": "aac9c316f0f7eb84fdbedf7510835da707978be52086eb07e7f0f8887dc5aa7b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question. ", "start_char_idx": 1429, "end_char_idx": 1767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48efd214-236a-4170-97c8-de5696f83fa9": {"__data__": {"id_": "48efd214-236a-4170-97c8-de5696f83fa9", "embedding": null, "metadata": {"window": "And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "original_text": "I was wondering if you could provide a little bit more in terms of details on AMP. \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd40ad81-8e74-4de2-898c-a867be1a5e1a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81e7bcee046451a1162404bba92c22e223d6bc075a9c4a5ff21fa83ea94f66b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "385af906-c2d7-4313-ad39-466c6c6f846f", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n", "original_text": "Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful. "}, "hash": "873dc1b30751d982ddaebc984bf4c949747c66c48a241d48690239556cab1cec", "class_name": "RelatedNodeInfo"}}, "text": "I was wondering if you could provide a little bit more in terms of details on AMP. \n", "start_char_idx": 1767, "end_char_idx": 1851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "385af906-c2d7-4313-ad39-466c6c6f846f": {"__data__": {"id_": "385af906-c2d7-4313-ad39-466c6c6f846f", "embedding": null, "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n", "original_text": "Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48efd214-236a-4170-97c8-de5696f83fa9", "node_type": "1", "metadata": {"window": "And that question will come from Elizabeth Anderson from Evercore.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "original_text": "I was wondering if you could provide a little bit more in terms of details on AMP. \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da9ceef5ca1ff9225e1d185e9166dc390d2951e18ccb374eb3011f2870f2e727", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3fce861-0f18-45c6-9d52-79c4246ebbf1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time. ", "original_text": "Thanks.  \n "}, "hash": "9635d71a5967df1f2cd9825904a273671e5c9224d70ed43b28c8057e2bffca0a", "class_name": "RelatedNodeInfo"}}, "text": "Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful. ", "start_char_idx": 1851, "end_char_idx": 2098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3fce861-0f18-45c6-9d52-79c4246ebbf1": {"__data__": {"id_": "a3fce861-0f18-45c6-9d52-79c4246ebbf1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time. ", "original_text": "Thanks.  \n ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "385af906-c2d7-4313-ad39-466c6c6f846f", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n", "original_text": "Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff6f0ca70ad2c6b66af25661e4f304ba60f16b9673e5eff3656b740af4289983", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9eb6802-2fd4-41e0-b7ca-d82ad2c65949", "node_type": "1", "metadata": {"window": "I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.  "}, "hash": "02c7bfb269e88a1e2e98fa238af3319ca86cd42bd490cd875a89df37646d2ea6", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2098, "end_char_idx": 2109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9eb6802-2fd4-41e0-b7ca-d82ad2c65949": {"__data__": {"id_": "d9eb6802-2fd4-41e0-b7ca-d82ad2c65949", "embedding": null, "metadata": {"window": "I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3fce861-0f18-45c6-9d52-79c4246ebbf1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi guys, thanks for the question.  I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time. ", "original_text": "Thanks.  \n ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bf8fe2fede10808d61357897136789a761a48d2775357b5417ec399d7c1261d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b58f3e8d-cb5a-41c1-bb22-63c3b2318a05", "node_type": "1", "metadata": {"window": "Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n", "original_text": "A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n"}, "hash": "d77b5c0e113dbcbfc4f152f482b107cc9ca0e01e1f3f6842fb5a8b3a5ebab956", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "start_char_idx": 2109, "end_char_idx": 2436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b58f3e8d-cb5a-41c1-bb22-63c3b2318a05": {"__data__": {"id_": "b58f3e8d-cb5a-41c1-bb22-63c3b2318a05", "embedding": null, "metadata": {"window": "Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n", "original_text": "A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9eb6802-2fd4-41e0-b7ca-d82ad2c65949", "node_type": "1", "metadata": {"window": "I was wondering if you could provide a little bit more in terms of details on AMP. \n Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "492f659f045ca75c40103c7bf8ed696dd2864968f49b18efa69a5a208e077215", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91262010-03b0-4a86-8c34-ae4d8efcf095", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this. ", "original_text": "But really, frankly, haven't really innovated too much in a long time. "}, "hash": "8a2fb10c6933ea776738917f3a0e0370f0c979d9da7711655f1da8654fc611e0", "class_name": "RelatedNodeInfo"}}, "text": "A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n", "start_char_idx": 2436, "end_char_idx": 2555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91262010-03b0-4a86-8c34-ae4d8efcf095": {"__data__": {"id_": "91262010-03b0-4a86-8c34-ae4d8efcf095", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this. ", "original_text": "But really, frankly, haven't really innovated too much in a long time. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b58f3e8d-cb5a-41c1-bb22-63c3b2318a05", "node_type": "1", "metadata": {"window": "Just in terms of like how you see the trajectory o f that growing, the types of drugs and potentially also how you \nguys posit the value proposition to customers and sort of, if you could comment anything on margins there, that \nwould be helpful.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n", "original_text": "A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "500a2e4f721ff6c0579035706734f9474e2aa83387a6344248ab41c76c4e6e87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c20ee682-bc72-4bff-9fb7-bb8d2e5a79a7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n ", "original_text": "And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n"}, "hash": "a22716c1474f62ede0e7c36c6d32420e2205bfb374e51a2738f0809e0d2f7528", "class_name": "RelatedNodeInfo"}}, "text": "But really, frankly, haven't really innovated too much in a long time. ", "start_char_idx": 2555, "end_char_idx": 2626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c20ee682-bc72-4bff-9fb7-bb8d2e5a79a7": {"__data__": {"id_": "c20ee682-bc72-4bff-9fb7-bb8d2e5a79a7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n ", "original_text": "And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91262010-03b0-4a86-8c34-ae4d8efcf095", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this. ", "original_text": "But really, frankly, haven't really innovated too much in a long time. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6cdf3613a1a8be4f49ea457d4c00c0f344a4d34ea20cadd57eb5d9320c5d0cc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61bc2dff-fc49-4e46-96f0-ce4d553fd0cf", "node_type": "1", "metadata": {"window": "A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n"}, "hash": "43911ed39810bb14e5760b3ca447d6925b82213307fd19b0f98e05f75cf41173", "class_name": "RelatedNodeInfo"}}, "text": "And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n", "start_char_idx": 2626, "end_char_idx": 2802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61bc2dff-fc49-4e46-96f0-ce4d553fd0cf": {"__data__": {"id_": "61bc2dff-fc49-4e46-96f0-ce4d553fd0cf", "embedding": null, "metadata": {"window": "A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c20ee682-bc72-4bff-9fb7-bb8d2e5a79a7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n ", "original_text": "And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "845f534a3bc9c047be18803f66474e2fde3f8d73395056014130d74620c4ee15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18b9ff24-5dac-46c9-890b-8755f13609b0", "node_type": "1", "metadata": {"window": "But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this. "}, "hash": "9b7c3fbb69c4d0977fe8f5d55422dc2278f32e420f144bd8401d060f89ba6e98", "class_name": "RelatedNodeInfo"}}, "text": "But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n", "start_char_idx": 2802, "end_char_idx": 3083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18b9ff24-5dac-46c9-890b-8755f13609b0": {"__data__": {"id_": "18b9ff24-5dac-46c9-890b-8755f13609b0", "embedding": null, "metadata": {"window": "But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61bc2dff-fc49-4e46-96f0-ce4d553fd0cf", "node_type": "1", "metadata": {"window": "A \nSo relative to AMP, I really think about this as \u2013 there are existing models out there to do access and adherence. \n But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a3ec28d6ed2bf1867b32a83799fa9792331fe0e60407b6e0ed1092ea917855", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44593fab-f4d2-4158-8b4a-98e132846409", "node_type": "1", "metadata": {"window": "And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late. ", "original_text": "We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n "}, "hash": "8949b67cca60ae12ca031763ecc98efa06b4ba87319c65b3bd985c3b2322292c", "class_name": "RelatedNodeInfo"}}, "text": "And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this. ", "start_char_idx": 3083, "end_char_idx": 3279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44593fab-f4d2-4158-8b4a-98e132846409": {"__data__": {"id_": "44593fab-f4d2-4158-8b4a-98e132846409", "embedding": null, "metadata": {"window": "And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late. ", "original_text": "We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18b9ff24-5dac-46c9-890b-8755f13609b0", "node_type": "1", "metadata": {"window": "But really, frankly, haven't really innovated too much in a long time.  And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98bd2941823db5cc62144d645ac5f1a531e5f7f4e11bcb41bf3bf34b3f4427b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca0e5bfd-bb01-4ac2-b1ab-140e24699f5b", "node_type": "1", "metadata": {"window": "But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "22dcd64cd216eb86b8498f89e3066d074d1082a05c22e83a75afb12777b95e85", "class_name": "RelatedNodeInfo"}}, "text": "We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n ", "start_char_idx": 3279, "end_char_idx": 3470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca0e5bfd-bb01-4ac2-b1ab-140e24699f5b": {"__data__": {"id_": "ca0e5bfd-bb01-4ac2-b1ab-140e24699f5b", "embedding": null, "metadata": {"window": "But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44593fab-f4d2-4158-8b4a-98e132846409", "node_type": "1", "metadata": {"window": "And the opportunity we see here is to bring \nreally th e disease state expertise, the expertise we have over two decades supporting these access adherence -\nlike programs.  \n \n But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late. ", "original_text": "We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3774e4af962dbf1d4f52bc04f4ac23fa050cffaa9d517faf7aa9ec946be0ad91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30c084ca-abeb-477a-a61d-4719ea4e1c5e", "node_type": "1", "metadata": {"window": "And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n", "original_text": "Okay. "}, "hash": "b873864cb8dcbd53022f83046edcabc9f7b35dca64d38665db5645d6ff696846", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 3470, "end_char_idx": 3797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30c084ca-abeb-477a-a61d-4719ea4e1c5e": {"__data__": {"id_": "30c084ca-abeb-477a-a61d-4719ea4e1c5e", "embedding": null, "metadata": {"window": "And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n", "original_text": "Okay. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca0e5bfd-bb01-4ac2-b1ab-140e24699f5b", "node_type": "1", "metadata": {"window": "But then leveraging the technologies that we have in a relay or a CoverMyMeds to essentially automate and make \nthat process more efficient, get patients started on their therapies quicker, help them adhere to them longer, so \nthat ultimately, they get better health outcomes.  \n \n And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b915052d5f72223151baafa1940b38e76610dd238c1179cb28333da5b68ef807", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "332a79e5-0716-41c7-977f-6635eef73cc0", "node_type": "1", "metadata": {"window": "We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe. ", "original_text": "Well, I'd like to apologize for running a few minutes late. "}, "hash": "94508bba5cd5a5b0475409eaa85c4004a192f81d49ba75b04abaa35362d63da0", "class_name": "RelatedNodeInfo"}}, "text": "Okay. ", "start_char_idx": 3797, "end_char_idx": 3803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "332a79e5-0716-41c7-977f-6635eef73cc0": {"__data__": {"id_": "332a79e5-0716-41c7-977f-6635eef73cc0", "embedding": null, "metadata": {"window": "We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe. ", "original_text": "Well, I'd like to apologize for running a few minutes late. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30c084ca-abeb-477a-a61d-4719ea4e1c5e", "node_type": "1", "metadata": {"window": "And so it's really the combination of these things that's kind of redesigning the access and adherence model, and \nwe've been very pleased with our early partnerships and the development of this.  We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n", "original_text": "Okay. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8f04e5f892bbcce241c1a33b5df9d0903c772abb8eef3d60aad2bc623de356", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7171489-4e32-483c-9043-dfc0fd368c10", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe.  And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "original_text": "We wanted to be \u2013 provide as much insight as we \ncould on the call. "}, "hash": "c77c1a5b761065eabbe9c974fdcdf7374a8336af0c51f003ac4589f856af7b17", "class_name": "RelatedNodeInfo"}}, "text": "Well, I'd like to apologize for running a few minutes late. ", "start_char_idx": 3803, "end_char_idx": 3863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7171489-4e32-483c-9043-dfc0fd368c10": {"__data__": {"id_": "a7171489-4e32-483c-9043-dfc0fd368c10", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe.  And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "original_text": "We wanted to be \u2013 provide as much insight as we \ncould on the call. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "332a79e5-0716-41c7-977f-6635eef73cc0", "node_type": "1", "metadata": {"window": "We've been very quick to take it \nfrom concept into market, and it's been quite encouraging and nice to see the number of brands on that program \ngrow and the pipeline continue to exp and. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe. ", "original_text": "Well, I'd like to apologize for running a few minutes late. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0303adf1095d55986f8766eb362ab355b359ba95ea1f0085ec5040e0a6e89cc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2da4dd28-d907-4a56-8762-f4399872cb06", "node_type": "1", "metadata": {"window": "Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe.  And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "original_text": "I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n"}, "hash": "904514b56afec1ff2a72cae4053e25de11127c25b1a2905db5d425a4ea16d6ab", "class_name": "RelatedNodeInfo"}}, "text": "We wanted to be \u2013 provide as much insight as we \ncould on the call. ", "start_char_idx": 3863, "end_char_idx": 3931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2da4dd28-d907-4a56-8762-f4399872cb06": {"__data__": {"id_": "2da4dd28-d907-4a56-8762-f4399872cb06", "embedding": null, "metadata": {"window": "Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe.  And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "original_text": "I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7171489-4e32-483c-9043-dfc0fd368c10", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe.  And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "original_text": "We wanted to be \u2013 provide as much insight as we \ncould on the call. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1ecdc282d817746a5b9b0ca096a510e644f674d81964b5ab6f67b36b3527716", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "159861e4-492d-437b-8069-f02c94ed49b3", "node_type": "1", "metadata": {"window": "Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe.  And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "original_text": "I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe. "}, "hash": "7b5cec4dcfe70fbd3a9999aae25122f1fd690b55748b87c97ccfb3706e8a7354", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n", "start_char_idx": 3931, "end_char_idx": 4040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "159861e4-492d-437b-8069-f02c94ed49b3": {"__data__": {"id_": "159861e4-492d-437b-8069-f02c94ed49b3", "embedding": null, "metadata": {"window": "Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe.  And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "original_text": "I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2da4dd28-d907-4a56-8762-f4399872cb06", "node_type": "1", "metadata": {"window": "Okay.  Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe.  And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "original_text": "I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d0afd9d959fa518ac20d86fe61e911e8cc18acd0ea0115757ddb74670bd23ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7e187d2-0f97-4d73-9d22-8f47cb3c5b08", "node_type": "1", "metadata": {"window": "We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe.  And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "original_text": "And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency "}, "hash": "c50da4d9f1342d7762abde88177ad7754142ef598bce8eaa1fd5e621bd90beff", "class_name": "RelatedNodeInfo"}}, "text": "I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe. ", "start_char_idx": 4040, "end_char_idx": 4222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7e187d2-0f97-4d73-9d22-8f47cb3c5b08": {"__data__": {"id_": "e7e187d2-0f97-4d73-9d22-8f47cb3c5b08", "embedding": null, "metadata": {"window": "We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe.  And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "original_text": "And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f3126303c75037765435c020918a3895b24e72f067aa0396a8644243977c98", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "159861e4-492d-437b-8069-f02c94ed49b3", "node_type": "1", "metadata": {"window": "Well, I'd like to apologize for running a few minutes late.  We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe.  And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "original_text": "I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe. ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "433a3d5ee46c556f18fc0ac3dbfae6d74af5ef472a6a0f00f10caebe57ad41bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8dad0b5-a90a-41a8-8f47-f264db72b221", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day. ", "original_text": "McKesson Corp.  "}, "hash": "55f0cad94739d588892ddd734dd41b15ff937b55d26e49b9f41f5c99bd036ea0", "class_name": "RelatedNodeInfo"}}, "text": "And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "start_char_idx": 4222, "end_char_idx": 4382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8dad0b5-a90a-41a8-8f47-f264db72b221": {"__data__": {"id_": "e8dad0b5-a90a-41a8-8f47-f264db72b221", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day. ", "original_text": "McKesson Corp.  ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7e187d2-0f97-4d73-9d22-8f47cb3c5b08", "node_type": "1", "metadata": {"window": "We wanted to be \u2013 provide as much insight as we \ncould on the call.  I want to thank everybody for your great question s, and thanks, Raul, for helping facilitate this \ncall. \n \n I'm going to conclude my remarks today by once again thanking all of the frontline workers across the world, who \nare working day in and day out to keep us healthy and keep us safe.  And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "original_text": "And I want to recog nize the great work of the \nMcKesson team, all 80,000 of them, for their persistence, for their commitment, for their energy and resiliency ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4f0428eb3da41a258ff528ff91b68e9b7afeef783736a0850c62cbbfc3cca3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8861020a-e8d8-4237-a961-1e9e56739ba9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time. "}, "hash": "4b08a586fa4e24270f29e3780627ee1cb1391b4c18a3b6fbbefddf4bede000eb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8861020a-e8d8-4237-a961-1e9e56739ba9": {"__data__": {"id_": "8861020a-e8d8-4237-a961-1e9e56739ba9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8dad0b5-a90a-41a8-8f47-f264db72b221", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day. ", "original_text": "McKesson Corp.  ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d39b8ff0ac0ce08f09db74bcb8f9bddc819251c12c229b189db7fcfbb41dc3dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a074f47e-facc-4e50-a490-dc11e32ded80", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n", "original_text": "They really are playing a vital part in keeping our communities healthy as well. "}, "hash": "0f4ff4b3787acf9da477e1a9ec334a01df6128fd866075bb7f169fe55f1b0bc6", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time. ", "start_char_idx": 16, "end_char_idx": 199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a074f47e-facc-4e50-a490-dc11e32ded80": {"__data__": {"id_": "a074f47e-facc-4e50-a490-dc11e32ded80", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n", "original_text": "They really are playing a vital part in keeping our communities healthy as well. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8861020a-e8d8-4237-a961-1e9e56739ba9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted. ", "original_text": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58cad80e869f4d2250636262b9c84213ac0ab3ab814d40374dd33a79ec2ac019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ad7dfad-eff0-46e0-9d38-dbcef20478f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n ", "original_text": "So I wish you all a \nvery good day. "}, "hash": "603c3ffca9382db6ed913860c68a294b7dba22ee86bd677331c3398e47f70615", "class_name": "RelatedNodeInfo"}}, "text": "They really are playing a vital part in keeping our communities healthy as well. ", "start_char_idx": 199, "end_char_idx": 280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ad7dfad-eff0-46e0-9d38-dbcef20478f7": {"__data__": {"id_": "8ad7dfad-eff0-46e0-9d38-dbcef20478f7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n ", "original_text": "So I wish you all a \nvery good day. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a074f47e-facc-4e50-a490-dc11e32ded80", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n", "original_text": "They really are playing a vital part in keeping our communities healthy as well. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f49d398a418ace777bb3a63c1e24d89ec83c974d8c44f70171a1d3eae9676a52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41136801-b83d-462c-abae-bbde043a7dff", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I hope you voted. "}, "hash": "90b54883126a40c56dbaeee808703507efd74fe32ecdc396c2fb2fafeeb18618", "class_name": "RelatedNodeInfo"}}, "text": "So I wish you all a \nvery good day. ", "start_char_idx": 280, "end_char_idx": 316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41136801-b83d-462c-abae-bbde043a7dff": {"__data__": {"id_": "41136801-b83d-462c-abae-bbde043a7dff", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I hope you voted. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ad7dfad-eff0-46e0-9d38-dbcef20478f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n ", "original_text": "So I wish you all a \nvery good day. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0a23bcb226474856100cdad25b335cf84eb9c678787e056ed76ddabea3b28e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a092bcb-a477-496a-a5e5-d5609c31b65c", "node_type": "1", "metadata": {"window": "They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "If you haven't, please do.  \n \n"}, "hash": "5b205372eed5503e449381d7967aaff0aed514c5612c1a7a16b26463ddb82925", "class_name": "RelatedNodeInfo"}}, "text": "I hope you voted. ", "start_char_idx": 316, "end_char_idx": 334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a092bcb-a477-496a-a5e5-d5609c31b65c": {"__data__": {"id_": "6a092bcb-a477-496a-a5e5-d5609c31b65c", "embedding": null, "metadata": {"window": "They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "If you haven't, please do.  \n \n", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41136801-b83d-462c-abae-bbde043a7dff", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I hope you voted. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "632c5d7ebedfa3073e85b5f8611c5ac12a006a6ae963b7b45807ec44e31bd7df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fc85759-245d-4852-a638-990cbca048d2", "node_type": "1", "metadata": {"window": "So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n", "original_text": "And with that, we'll talk to you next quarter.  \n "}, "hash": "4ea84ff73f30ef497e9114a4d9e01db37b429743d1255982e3118e22065ddd90", "class_name": "RelatedNodeInfo"}}, "text": "If you haven't, please do.  \n \n", "start_char_idx": 334, "end_char_idx": 365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fc85759-245d-4852-a638-990cbca048d2": {"__data__": {"id_": "8fc85759-245d-4852-a638-990cbca048d2", "embedding": null, "metadata": {"window": "So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n", "original_text": "And with that, we'll talk to you next quarter.  \n ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a092bcb-a477-496a-a5e5-d5609c31b65c", "node_type": "1", "metadata": {"window": "They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "If you haven't, please do.  \n \n", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2269008a770d37ab72630401c5041c0047f4a289c9c5d7b6e2b93653b29468f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f11984e5-2127-4fe4-ae11-77677f2f0657", "node_type": "1", "metadata": {"window": "I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. "}, "hash": "e09b14ad6070cf0d1b7ccdf151bcb3f82181aaa4bd68e25581a6f8c5a8c13a7d", "class_name": "RelatedNodeInfo"}}, "text": "And with that, we'll talk to you next quarter.  \n ", "start_char_idx": 365, "end_char_idx": 415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f11984e5-2127-4fe4-ae11-77677f2f0657": {"__data__": {"id_": "f11984e5-2127-4fe4-ae11-77677f2f0657", "embedding": null, "metadata": {"window": "I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fc85759-245d-4852-a638-990cbca048d2", "node_type": "1", "metadata": {"window": "So I wish you all a \nvery good day.  I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n", "original_text": "And with that, we'll talk to you next quarter.  \n ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50ab700e779be99badd0bd922a8d3efbf365f850dfeef78e4b471b062ef9ebbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ac54769-8d83-4553-b5d1-60530d831c6f", "node_type": "1", "metadata": {"window": "If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n"}, "hash": "3ef72c166fb5752fb310b101d1ad48140071a4c6f78a9c6df0381ddd459f0d43", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 415, "end_char_idx": 732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ac54769-8d83-4553-b5d1-60530d831c6f": {"__data__": {"id_": "6ac54769-8d83-4553-b5d1-60530d831c6f", "embedding": null, "metadata": {"window": "If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f11984e5-2127-4fe4-ae11-77677f2f0657", "node_type": "1", "metadata": {"window": "I hope you voted.  If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08bb661a39655339c7fc12d1dd1d25553997ad75b93344c772d246735942d7a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8f2f31f-6906-413e-8b2e-46a02ec77196", "node_type": "1", "metadata": {"window": "And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n"}, "hash": "b48bcbea18a3753ea6452e6188c97bfb0de21b7c9a5f8d42108571bc0ec9d28f", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "start_char_idx": 732, "end_char_idx": 802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8f2f31f-6906-413e-8b2e-46a02ec77196": {"__data__": {"id_": "e8f2f31f-6906-413e-8b2e-46a02ec77196", "embedding": null, "metadata": {"window": "And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ac54769-8d83-4553-b5d1-60530d831c6f", "node_type": "1", "metadata": {"window": "If you haven't, please do.  \n \n And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "200db3a1650e9d32b990d54d6cca174b52d153a10a1ce3176c8518ac31c3743a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52aad118-b7f6-4ace-938a-daf6422be0b6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information. "}, "hash": "dc38be167b1250f4ca649130c3f6bc7620aeb01026c3ea6868b2d3e6d2b5ca34", "class_name": "RelatedNodeInfo"}}, "text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n", "start_char_idx": 802, "end_char_idx": 1010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52aad118-b7f6-4ace-938a-daf6422be0b6": {"__data__": {"id_": "52aad118-b7f6-4ace-938a-daf6422be0b6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8f2f31f-6906-413e-8b2e-46a02ec77196", "node_type": "1", "metadata": {"window": "And with that, we'll talk to you next quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "faf869dd4956a0fd68763519065176b03706707708077b36fa78068ce74731d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7560585a-a827-404d-b6d8-06145bed210a", "node_type": "1", "metadata": {"window": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "1115963a9c3eb0a470f74c44739c85f055b5045838b396c73b81f1b08d25050c", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information. ", "start_char_idx": 1010, "end_char_idx": 1133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7560585a-a827-404d-b6d8-06145bed210a": {"__data__": {"id_": "7560585a-a827-404d-b6d8-06145bed210a", "embedding": null, "metadata": {"window": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52aad118-b7f6-4ace-938a-daf6422be0b6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb63b0e57f67876c6eb99e92e08b7f1fd4a6270e6545f3db265d8ac0fbfdd6cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8a85394-9ed1-417f-afe0-50f443faa7c9", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal. "}, "hash": "b858f4620c4313d02e27a6fd5080f5e15553d6ab53919029beb1fd026a088195", "class_name": "RelatedNodeInfo"}}, "text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 1133, "end_char_idx": 1425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8a85394-9ed1-417f-afe0-50f443faa7c9": {"__data__": {"id_": "f8a85394-9ed1-417f-afe0-50f443faa7c9", "embedding": null, "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7560585a-a827-404d-b6d8-06145bed210a", "node_type": "1", "metadata": {"window": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c17a9d4ad5097ed928bfb213ce531e4ea7e1386ca7ff3b94cbdefa6829726a48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc2aa750-c0c0-488f-9593-1eeab3fc22ca", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without not ice. "}, "hash": "df20dbd4192ae72b4d978f5bdaeb495ba53b53a4389e5931ffbc5994a86585b5", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal. ", "start_char_idx": 1425, "end_char_idx": 1788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc2aa750-c0c0-488f-9593-1eeab3fc22ca": {"__data__": {"id_": "cc2aa750-c0c0-488f-9593-1eeab3fc22ca", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without not ice. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8a85394-9ed1-417f-afe0-50f443faa7c9", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or err or-free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4ee8e4139e55466fc8a04ad180e1eb495ff74bc2ea75a573f9487c22af1a9db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02642979-2f37-4b07-94f8-a360a9fb6c76", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. "}, "hash": "7abca7b2f3d1bddd1c121a1e7f53071cc4b9958d1aaeecd0ec80572f90519893", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on this date is subject to change without not ice. ", "start_char_idx": 1788, "end_char_idx": 1873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02642979-2f37-4b07-94f8-a360a9fb6c76": {"__data__": {"id_": "02642979-2f37-4b07-94f8-a360a9fb6c76", "embedding": null, "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc2aa750-c0c0-488f-9593-1eeab3fc22ca", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, in tegrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without not ice. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc00df4e0d591e5b56c66dbb0f5748ca24796ee22d7c0ce4ed9c56a4a4ff7b8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de004e9c-483a-4859-abda-a3664362144c", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n"}, "hash": "85b7703fe76476737ba8881c0360e282daa2190a27eb197a4fb89764ba4bb2db", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 1873, "end_char_idx": 2000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de004e9c-483a-4859-abda-a3664362144c": {"__data__": {"id_": "de004e9c-483a-4859-abda-a3664362144c", "embedding": null, "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02642979-2f37-4b07-94f8-a360a9fb6c76", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This informatio n is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5f47b5bef02e828ba4b54caaef176a69411aa0c1d39747f8ecfdbbfeab985c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b6885a8-5793-46e6-9d73-4f3ff7f0b906", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "76ac778ea97e8dccaa4ebac2eab1aa1cee115b93c12732d1312547e77756fc42", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "start_char_idx": 2000, "end_char_idx": 2163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b6885a8-5793-46e6-9d73-4f3ff7f0b906": {"__data__": {"id_": "2b6885a8-5793-46e6-9d73-4f3ff7f0b906", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de004e9c-483a-4859-abda-a3664362144c", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be con strued as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state w here such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68cad585167be295a3965f07378391c376bf64320a4ffce0d6eb8b163bb45ea9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05814d35-aa7a-4c7e-8d32-6eb1c8db255d", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n"}, "hash": "46581c1eaae98fd1e28c4ecb718a6f698464165236d61d729463139035fc06f3", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 2163, "end_char_idx": 2597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05814d35-aa7a-4c7e-8d32-6eb1c8db255d": {"__data__": {"id_": "05814d35-aa7a-4c7e-8d32-6eb1c8db255d", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b6885a8-5793-46e6-9d73-4f3ff7f0b906", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without not ice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd08ee6dbd4b932c510e65f29a6a239fbb6378f592ecc3e4f6c08db58ef6b4d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e628a4b6-4220-4435-9b99-f85fd1826dd0", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC. "}, "hash": "4ab295484d63201d8a389ee53d496accbcd7a216341e152fa6d015fc1a9cfe35", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "start_char_idx": 2597, "end_char_idx": 3275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e628a4b6-4220-4435-9b99-f85fd1826dd0": {"__data__": {"id_": "e628a4b6-4220-4435-9b99-f85fd1826dd0", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05814d35-aa7a-4c7e-8d32-6eb1c8db255d", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b868dd8eba4045fe536887ac84766e6f1373f6fc4e389e295889de85ed036dba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6622a67-f60e-4b37-8aef-828eeea4536a", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. "}, "hash": "5e4e7a7a7c1888798b47fe73f10d6ed86df54d75cc347bab0cdf4336815497b6", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC. ", "start_char_idx": 3275, "end_char_idx": 3465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6622a67-f60e-4b37-8aef-828eeea4536a": {"__data__": {"id_": "c6622a67-f60e-4b37-8aef-828eeea4536a", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e628a4b6-4220-4435-9b99-f85fd1826dd0", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c318c095fa933d91d550f9be2613856b2db336123aba8f11379c3e0accd053dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8620a51-29e1-4d4b-9a37-d3a56bed0c1f", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "6777d3dfdaab0884d8ba4bcdbd194b69336f0523912bc2d74c37899a56f22da9", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 3465, "end_char_idx": 3543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8620a51-29e1-4d4b-9a37-d3a56bed0c1f": {"__data__": {"id_": "d8620a51-29e1-4d4b-9a37-d3a56bed0c1f", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17910a97d794a73e472922fc27c5a3eb70ac5cd96cc53f229ee708929eb24849", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6622a67-f60e-4b37-8aef-828eeea4536a", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WIT H RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW , NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES , ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and ser vice marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76ac7c1f24e2ffdb9df759e0e3edc63d48286b4815413c71bf08790fc4df9c69", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 3543, "end_char_idx": 3565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"eff7e52a-08db-4ac3-b46e-6cc21f3adffd": {"doc_hash": "bdc79c4c913235839802b027888f15a0eec2827c2fd83459c43a4015a91a2320", "ref_doc_id": "8b9e5ddb-7151-4cb2-836a-8f1bdc98fb5c"}, "1da1dc66-7f50-43b3-91f0-293b59bf0317": {"doc_hash": "cd161097cdb1ae44418cef3d6f961db15fe03ec922b76976cf0a7af1e9f160b6", "ref_doc_id": "8b9e5ddb-7151-4cb2-836a-8f1bdc98fb5c"}, "5da07ecc-ff80-4239-aabc-a892eb1e1f53": {"doc_hash": "98747909f7feeea0752842ce33042a6d035d47fb55eac7fd4c90cd8efa7c3cfe", "ref_doc_id": "f9364e07-dc15-47ba-96b5-75de90875e02"}, "2b0f0910-2b13-4dbb-b754-de48679ad7f8": {"doc_hash": "cf0f5260780093edfc351363fd3b10c82c9bbcdd38a2efb6cc19343a4fa4d9da", "ref_doc_id": "f9364e07-dc15-47ba-96b5-75de90875e02"}, "e42cb57f-4904-47c5-9d22-abab9171a7e2": {"doc_hash": "8f133b5a3474682912101ec934b5b6c17520d7028ec35236dd3f19d279735cfc", "ref_doc_id": "f9364e07-dc15-47ba-96b5-75de90875e02"}, "3e26c4f5-f14a-44d6-9b6c-b80aecbd24b4": {"doc_hash": "cdaad2d8ccb54d854df8f59fbd2c47f8b50e26c992b17aa9e6c1958e0ea99f5c", "ref_doc_id": "f9364e07-dc15-47ba-96b5-75de90875e02"}, "8315f097-a3e9-4286-ae03-4ad1d4a71029": {"doc_hash": "68aca5b23c7ceb53144e013bbfef456df4cc244942e8bc2011a0d36886fa77c4", "ref_doc_id": "f9364e07-dc15-47ba-96b5-75de90875e02"}, "65d5b5b0-3eee-4144-9fc2-f8a843da5e7c": {"doc_hash": "57bfbc17f7c357d55fe09ff07b6cce6530dac1abb79ab2eee4c03af6b2902624", "ref_doc_id": "f9364e07-dc15-47ba-96b5-75de90875e02"}, "d9ccbd9a-0451-4657-a0ca-cbdbeeb7f237": {"doc_hash": "f355298b81d84fd78bcbe8ca4a036876d146011bfd953434c6b0025a6ddbf5dc", "ref_doc_id": "f9364e07-dc15-47ba-96b5-75de90875e02"}, "211cf7c3-43bd-4d98-a63a-6e0328470c20": {"doc_hash": "e9abad8ea7de59c2e7b78400f2470c45bc241a5344db63d14d283d756c0eb6cf", "ref_doc_id": "f9364e07-dc15-47ba-96b5-75de90875e02"}, "0d83bee9-ee1d-496e-b84b-3ec76839accf": {"doc_hash": "c539af8208f8a885b39358fdc112df0d26193b238c4e81f45d8e5057fedfab96", "ref_doc_id": "f9364e07-dc15-47ba-96b5-75de90875e02"}, "d7615220-df24-4af1-9c35-c796fc90ff10": {"doc_hash": "4f18aae036f7f5ad04cbcfc08f216bd03a3fce8bc4dc938126cb608bb237756e", "ref_doc_id": "f9364e07-dc15-47ba-96b5-75de90875e02"}, "978d241e-ce10-4784-8a77-788120fedd81": {"doc_hash": "e0588a15a738c4d4c0f4509040b9e4e5b10ff2ad060b637ef7ec063b9470ce4c", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "8f3313d5-334e-4295-8362-f271498801e8": {"doc_hash": "d68082404d3ecf9c250207745a7167dd655a9e9b63d55ae70b5842b025d98074", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "c2128b17-6472-449e-8939-f240d981ccec": {"doc_hash": "c1c1011421e3c0b4ef5f8b3026efe89af05dc066faca223ba390f87d3f3d2068", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "1e0912d4-d061-4b02-977c-ce1479c11588": {"doc_hash": "ced9e3e153ceedca34cd68853cfe88577789d14c60fb4b5f031bfa909dfa8e58", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "90c1e3bc-f9d1-4919-ab2b-51fea9441b59": {"doc_hash": "327b3bf8e06b3f1b634778f9ce4fe50ddc6fca161bd69442fc92fac8b9bacab9", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "e2559ea3-b524-4586-a74a-0acd02d5bfab": {"doc_hash": "5b074a34a87c0a1713f1336c5f4ad3cd14df4cccfc94cdb6bcece4147de7cb2b", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "d11f05a2-24ed-4095-a543-046c29916d40": {"doc_hash": "afd894446191428c8d7b2b47333cdaec47fa33a441ac67551355d075073f153c", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "d11269d0-a319-420a-8c69-6894073cdefd": {"doc_hash": "3ed9c473bab687d01d86afd798fb9d6f5e52607d4d9593a148df4dfc9f85aa56", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "96997316-b758-4bc7-955f-dae5b426a931": {"doc_hash": "cf817b0d85432693ef39db6fbe3b1c1bfba399cda526077672bff2fcd79e6623", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "b65b8129-12d1-4816-b8a4-0a2ed5d4067a": {"doc_hash": "77a76e8ad31b5d6a3d7534f7e7ca5dfcf5a8e41097a71990183c042489b8b11e", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "1c17328d-94b2-4108-9d4c-7b5dd9b7232f": {"doc_hash": "3c2e6866ecd76036b3d295c5f85e4142f6483c1643ba26c011201d374893c0ee", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "78274872-e763-4d78-80d0-253106120cd2": {"doc_hash": "fdea1aa9287c9451a119ef8b73faa84b17f47399abd07dfa407c32a7e491c23a", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "dd72bdd7-4b99-4119-9c6c-a97f3416b3ee": {"doc_hash": "06338d4ead37c1798f5b7958ff915c1590010970f415a2f272f5a74114e11b92", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "a36632fb-658e-4f94-9d8b-9f6b6c6cd1eb": {"doc_hash": "a44762205bb34633baa6193857114af21f2c7394e5b7538804c47d050473929c", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "52879760-07ff-4c74-b5d7-e79e7a119d96": {"doc_hash": "4e3fc840571f4896ae467d1c1f733ab2057839c00c91b47de3f1013cade53b12", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "453ff5dd-392d-4a61-baf0-bfb34e965d26": {"doc_hash": "384ea9ea9c601dc94a358e7b3204f67feaea500426befdcfa9922c20b88e0667", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "7966551d-66fe-4893-9eff-9953f5093e6a": {"doc_hash": "d0a99c33a3a2eeb8366877f84615c399dabf29bbcc1c681c9e93e8b05c0f585a", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "b8ff732e-8c44-440d-bebd-61981b6a6928": {"doc_hash": "592f59beab07215ed43e4accea9c6656ae0b73b114dab0bf7a57e0b896e9b850", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "ec7c15a1-5c47-49b5-aed3-9608c56c9f45": {"doc_hash": "fcf6ab2afa26a28872e6c2f384428323ecb3d5b802f6674f4be73e74fecdf2c5", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "b929044c-248b-42b1-9011-c44b6b980842": {"doc_hash": "6de3a88e513e84db8fbb854c563eda599430fedb85f40f51a5ea37fbf3a6a9dd", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "fa78d77c-d5ec-419a-9b69-0a5f178c745e": {"doc_hash": "ea0aa8dda3a59c8acf41594714c43854aaf8f34c0a1bbd10e4fffc54253334bb", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "d524128a-bbae-4ef7-86f8-35759f762b21": {"doc_hash": "cbbe159744eae432b8b8d42d2de534a42059dccd973d1e1d8917d460ba0431f0", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "90b08ef3-2288-47e1-9773-7e80bbe19cb5": {"doc_hash": "d3e1f5072e0100b0020a345fe9ab77be00a60852e6cdfa23d0223a50b93309f3", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "4faaa692-c4ed-4ebf-a292-7be17cba0201": {"doc_hash": "267335d62d172ed5d38daa2814d5b43a29737e5b0c1b1316bd0c846720212516", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "e5653ee3-f0c2-45fa-9d1f-981577a2f96c": {"doc_hash": "77386416cb5e5d7b4216479f74a56d441c2ba1d5793825f92f3caaf9f010e8ee", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "ec34d79b-527b-43c8-a94f-f7839eb38867": {"doc_hash": "bd68bcdd5d746fe3ee3ca413663e8186b69a85f75b82b27db9b1630c11781ab1", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "92ba47b9-f66f-4c56-9ba7-727f3c428fdf": {"doc_hash": "5aa97fe98990def7cdfb2cce939a0bb91225dcce491e4708520edb1227d363ed", "ref_doc_id": "4918134e-30b2-42ef-aabf-32bbcb34951a"}, "01403a4f-c183-4d6a-957d-0af9a86c9df3": {"doc_hash": "81f37e401700258fb6539a313357d8b750b06144b8e11ccd4b5e2565b006765f", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "75907d43-1f18-4a40-a47d-2292fb907a32": {"doc_hash": "10c630da2dca2f7e9912b96ae615c86807ce772beabd3cd3143ccceb276ee7fe", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "792349b9-fb36-4663-a7d0-c8b104f4639c": {"doc_hash": "0a31f22e3f8ce384ac78f19ac644312292711208fb01560aa191a6795a0782e0", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "e8b9a543-ceff-4d5d-8252-5d5aa6a1955b": {"doc_hash": "ac10ff38f89375078c4cfcf12bc0b5dbb9e796f491432d1955f49f66a0f11959", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "13a1e639-68cc-45a9-9e7a-34e6e5957ee6": {"doc_hash": "96db6735ff3485fdd278aaddad79e445a106dc29abb392b367bd5a8a6da49841", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "01667e9b-d436-464d-83da-eda4b1086442": {"doc_hash": "7cffdff80a87f28bc70142fed83ce8cbbbaa43c40f8c96f447d60edbfbe37fca", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "0eb1dc3f-2306-495a-8067-8f6a6cdd0810": {"doc_hash": "79e35fd312a6b4de9750a241a029e4479d114aabbd50e20e51bb079103a308f4", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "89eb22f4-99f4-4e42-a0a7-117674472fe2": {"doc_hash": "9f76759364d161b5a0879b65ee2005c717c9409200432b3263d1ac64b26b2237", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "217ec653-a35d-4e80-b4a4-b237aeb7ceac": {"doc_hash": "360df2371c069349583a52e743554439bd47cf469d573069fe5cddd996d82313", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "159be188-4a87-46e0-b33e-e86c68822a30": {"doc_hash": "1dcb00e6055d941689787579235a2fc249d659e0fbcc209fcd7b01fda71da1ea", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "b89c3c52-4f18-4e8d-846e-85e855133ab4": {"doc_hash": "903a92a5caddc233b7e17085279287f98e93d180f9ef1aad87f18770680099cb", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "b5b8adbd-bb09-4186-a243-9904aab15541": {"doc_hash": "a3e8108c7c2bbf1b1577dc871f547723630033729b6035c7dbe669e0f928c7df", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "eec6d4f3-1e1d-490e-97f4-e3b26eecd029": {"doc_hash": "894d681a49496f7f093cec8fd804c907c2a96c6b2bc9b5f1cd64058d585b7db5", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "be85fbee-c97e-49bc-abf6-bc508cb41225": {"doc_hash": "2abb120db8bc105d8f1d2eaf1e57caa167869c06ff0234085e090feb0eef1094", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "fb8f314e-1034-4bcd-ab18-ae5c5c13c040": {"doc_hash": "914a27a87ad8e826166e4b3b06e2e636dae796e1fbe037a39102b930133ac88d", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "f421750d-025c-432c-9af2-59730b621e0b": {"doc_hash": "204611ca689c4ac5398e5dec0968480a030cdb52b1d5283453f746190ad2a0b9", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "a59173e5-8dcf-48a0-9662-05ff58f0dc65": {"doc_hash": "b401fed427662077495af4378a7ae838181996f824adf3b659a7c0439c9d89a4", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "beda16bd-81fe-4517-9f4e-1d24e6c33aeb": {"doc_hash": "593f64c5ada68e5dd20d8bb05e2685665d0d97607e33849a1165739218c89aa4", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "a0eced27-752c-4b58-83f4-fda3dfe4dbd4": {"doc_hash": "364c2813920e20a63b464ac1ea2cf0539c9e18dc437fb4101ff2406bc1ac95c4", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "fa96991a-ebf0-4e68-8e80-2c8095c4ea1f": {"doc_hash": "b94069fb4cd9c042d85f34459d9d2e42df4bdffb0793c0ae97c86541c9cd84fb", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "d68c2e67-142d-46f1-8819-dec121e7da03": {"doc_hash": "8b94e819923866543a4a73fa50e65192aea57621ab0eb752f04048521d2148f3", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "a3dd03da-299d-4c58-b893-5b59f49373c0": {"doc_hash": "943ee3f020eb224726fe2f80ce2446dae7d06ea88e921f37771abc82a8ac019c", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "94ee9b4f-3cff-4d56-8bac-7c39a6c93693": {"doc_hash": "b1c99cb6077ff4be27659a839a0d7b78d18a427d6933aff0726e38217ad97d6d", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "c51f5b47-d4ba-41ce-b6a3-dcfea731212c": {"doc_hash": "e49533f8cc9e4c6514f92bfc58e6e72f8e732fae00b39c7c1ec4e43f69f30b21", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "fa768a22-2ae8-4edf-bd74-840e83a47126": {"doc_hash": "58630eff43f5b41808c745b4207f818c2fd39540638401306941d8816af302e9", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "46555894-7e9b-4c08-a6e2-67bdb18edbdd": {"doc_hash": "b35c83381ea8e601467d31a3bb41a73e3db79a1a3b81455dd556f8d6edd9f2dd", "ref_doc_id": "c0dd24eb-9281-4069-82c1-5a5021fec3ed"}, "9b58f1b9-2469-4d1f-b4fa-2e6582e98a61": {"doc_hash": "ddce76f43c98e7d1c9cd01ffd7ce11afdbf729e3ee82bfae94635f0a0a5dd478", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "1beb06c2-80c0-4bce-8c7f-1a71bb151bd3": {"doc_hash": "1d362f96cbe788b1785be9f08131d30bc12481ee9b12ea4bba3c06389f799b6a", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "c8a45a34-3b28-447e-b13e-a02512b32278": {"doc_hash": "3d19c70a21f6ad949fc53d4960c2bd46559399f50aa36c59047053376d7df380", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "a2e78921-fa04-46d8-9ba8-1fa0cdc21e3a": {"doc_hash": "9e7dc481a8622091ebec8fb4571f632416635aacc4876ae8eaab4a0ae725969d", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "b89867ca-346f-45d4-97fa-597aa7276bee": {"doc_hash": "d0b38f9b5fad5a6308b567b437ba7a847008c9b10e86236a02a3379aa1dbf95a", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "7b71177c-939c-4cd9-bdc4-4fd8bf4a5c76": {"doc_hash": "8247f3a07099cd1ffdc361b2f3bfb1279d63751c716b245d8bc48deab908690d", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "3d06f08d-51cc-4928-bbb4-25a1f3d5ad29": {"doc_hash": "9008b95b3fef2e87275b9892f9291944a56b4999b220ce18ecb37ad0add79c8a", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "2dda7f2b-d0ee-4b05-83bf-2bf7c6267252": {"doc_hash": "9b1b0d41deb0b8b3779bde8487b945925d6db4bd9258471c707ebd1483c54bbd", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "39ba1757-a428-4e8a-9cbd-e55d9db2c942": {"doc_hash": "73968054e81860b033bb06ff3364a1e2d974c4554166ac54a33d0c69a414ded5", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "6fd6e858-d5a7-4817-b6b8-9440be130d30": {"doc_hash": "276fd4defa0e1b74204e8ae453fa9c0958ee37453941745166127e1b2fa99cb0", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "2e8e6fb3-fb47-4cb6-b85e-23fe6ac13fc0": {"doc_hash": "5e552db84023de9ea119d666cdfc9f449f446e83608cf7573f68966ec477a692", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "0bf27108-e6b5-477c-bbfe-e7753cd3014e": {"doc_hash": "5a7c9dc9ba54cdd1931ab621d2d4c45a00bfc5408a41fa76c30351493acd92ee", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "09f89967-f6f1-4c2a-8248-178af3867765": {"doc_hash": "c82dd4a077d9fcb145333570993c84e6c3b8c7485ccd6f688462ca630ff1e9c4", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "a6d17bf4-a02a-4313-aa2d-c2ce7cab50f1": {"doc_hash": "4b1263f88fb18a3e33cb3b97312933cadf1d966f5245f8397f2b8be01e1307bd", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "b915ce9c-0b46-469f-8dbf-9b6c37f03419": {"doc_hash": "b373aa08e77bbb858d3165808d29d8ea880f3449c0dbc31f742ff5a920660a7a", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "91b88300-59dc-450a-8b4b-1276f89c348a": {"doc_hash": "aa3cd7aa0481498af46e45535558c5f79084be6fdec36ed6c81f4e8ef7a2f507", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "12d51299-4caf-41b3-80a3-61284fbc85d7": {"doc_hash": "78a3d08bfaf7020ea7700679cbbdea1a27065f1c948ce781dbe127a23f3d956d", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "68828cb9-6c0a-4d48-b3d7-eb97b6f32041": {"doc_hash": "a65703790a58540911c19de97717da30fd5b845ddfc6689596ea69629df742a6", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "9d342053-5756-4a9a-a83a-bfbe2891d354": {"doc_hash": "3b5e947259f3e043cf858c93f4f3a5ef980f1747c82d4b29a4993e04a1067fee", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "f8032eb5-67ef-44dd-b72c-43339a9118fd": {"doc_hash": "8fe15cb8ee7c3f38e62d813534b41d29944c31f3f25d64e7f83cabffe35ec6c6", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "10c11773-a09c-4f04-9003-275abfa23c4f": {"doc_hash": "1d350c537bdda814d4a6653d57456d58e9781c354419f0c736a0a17170fe1e39", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "557abd74-169a-4351-ac5e-3ed6af2f6af4": {"doc_hash": "3fe4d421a93f0ccbd6e524f966bce1126c5aa5d425acb34bab7367e3b09241c5", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "e0c49e85-2a11-4780-b182-9cedf32e81d3": {"doc_hash": "2197ca56d0238e631324ef4edad33a72e3dd988a037f713a42745a7a512a2cc6", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "cf574893-bc69-4742-86db-cde785edf694": {"doc_hash": "54cbda947ad28deda4531e0e02efbe2156cd69f6ccebe0529ca28e364964666f", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "9da630ce-fe3a-44b4-99c4-3ed774519aa4": {"doc_hash": "e7aafee9b35866fff9dd0b0a3bb9b26ebaf7248424fbc7417f751a455c8326f8", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "37ad1863-9ac5-4598-adb9-831f0eb682d3": {"doc_hash": "05e811da28557db92bbf78f800f29475edbe65262705596aef46d3faba292c11", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "03ce59c9-fdcd-4cd6-bc46-fc848b8131cc": {"doc_hash": "f45aed163079f95fc15c44af71a63b8b2accfe9e5dd9db28c6644ec981012bad", "ref_doc_id": "5cac0380-8059-4b84-9a94-8c07041ebaf5"}, "bb122474-0272-4582-8d26-aef23e492659": {"doc_hash": "64da17606fcd7f4404489b10f47986a6a93c937ddd0d4f7741c072c7fc0d1a9e", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "447fd27a-400c-453b-968e-5860d0dd737e": {"doc_hash": "096435a1d4f22bd2c9301afd89a7964084da3d4574ddc15892c646d587a7a3bf", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "01d00602-0657-43aa-a299-966c45055e39": {"doc_hash": "02c59de987ad7e5f8409b781dd178e9a0db08e5c487031a72118fad911869d8c", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "484b6787-a8bf-4266-bc4b-b864e4ffbc45": {"doc_hash": "0f2187c81551e9f4c03fcff55a24be32325d8a9b21469f26d48964c037453721", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "98b954ae-5c78-4c57-ba85-81375fa8f1e0": {"doc_hash": "210346c51bf491cca86a4097c75f1c518520d964327d936a2d97a00a29513fe9", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "f922f7c8-1b59-4ba0-908a-5812f27efce5": {"doc_hash": "de6bd3427344c013177c98c8bd48f55a5e52038387e692febac0486826e1e12f", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "0b0c9310-8d76-4c8a-a60b-0151e6befd71": {"doc_hash": "dc9ae9fe25a8f21c1b1e7f89436fe3d560c80882e4d43c933e491a6e39cd5db7", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "fef7e26a-ed63-4480-acdc-c904f24988e5": {"doc_hash": "e50a9e74cd9aec9d55a3e63adbd322b4ccf4c0265a0ab57d83bcae5d370e7050", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "7e0e04a8-14f1-4110-a089-8439922003d5": {"doc_hash": "e485a404a2fa70f1f77610fe0a7ebeec09930869e79b3450f306812175b4f765", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "dd4b8e71-0f7a-4e9f-982e-da653868d40d": {"doc_hash": "41126c1bb86cc70a099613ad6f7dd5583ce56316ca942e261405e737b24c358b", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "4041fb0c-ae9e-412e-8fb5-02e2ced8a06b": {"doc_hash": "0e349d9f5ec304b9ce6823c1c0e69474ae26f04bb8d9fa5f15420b4b217d7f73", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "8cc1e46b-a2b9-4bb8-b152-c12427c89d1a": {"doc_hash": "dff56f2b0d322bfbb9de8dbb7baa3ff1dda720780282afeec14b2058403193d4", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "85470ae1-ab08-4bd0-904d-8ced01c5e327": {"doc_hash": "d24e1c1948992dbc462939219ded42b5a1dfdedf0ec994b7d453ea2ca260bd0d", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "20996a86-179c-4124-b4c5-ad53616661b4": {"doc_hash": "5123744408d869169803b51b51de402cd9e6e246585e30e2016c2f3eaff9dfe4", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "5648997c-0402-4542-a16c-ed89921e828a": {"doc_hash": "d95c22619a8707c6763fb79dd2a0294683b2ae45d1a4a6cee54e00527c05f90f", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "0bf5634e-29d9-46a1-a2b8-79002497850a": {"doc_hash": "6309461f5bdcf509ca30233a50184a94f239014a1ccef29215de1f884e1c8300", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "59d5af51-1c5d-4fb2-adc3-1f49da83e9cf": {"doc_hash": "86005b2151cc12d487df14ccbfe01a289e58db48a70bc46a913b12447b407976", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "b1113f56-34dc-4a30-a210-62ef4adc371c": {"doc_hash": "8169eac50c11902aacc3a5e276b2985986c6682fed19d957688d6972d655f199", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "ec05ca3e-b3a0-47aa-9767-01f9b8f618b0": {"doc_hash": "b82af118c1389e47de49cf7b11f9bc23886202081ae83643b3cb55bcde9f1606", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "6ded22ea-6e44-4929-9c1d-3c972fe46057": {"doc_hash": "7d1b69cd1d12b3d74c2325c9bdb4b37467b5387b863243c14abbedd7ef756705", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "c89da44e-4797-431d-9dc6-ce28e181f175": {"doc_hash": "9f993be5a6ae3b2f90cba644a0735103849360f575c4902380ad4cb350a43c06", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "40314b4d-a7bf-4b4c-a183-2deca2b36d40": {"doc_hash": "5a286612d9918d6cd8454b8b8cab6ceff6848e118fc93806534557242b01e4a3", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "0ec2d565-505a-46f8-96a6-22ffe810147b": {"doc_hash": "46441c36fa44c961bbde584a6518a8d2442b474cc5f423887442b193b4b6ca14", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "e0881548-b614-49ec-bcba-da5ea76b438d": {"doc_hash": "05e1b0f041311914b85d38395eec90c5d656911f1c6f254496224fc06adb0fc4", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "13d2e301-7e95-40b6-b297-0474ead6597f": {"doc_hash": "4f5d6b021d01c45589d407c232fc0e3e75d902e17a893671ae377bcbb5b3c5a2", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "67860bd9-b1c2-4dc8-a059-dd2aab87878f": {"doc_hash": "31b16bfabd40fbe65594bbcfdadeab8c75e6166c37ad9feae36f184bc62f287f", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "ab0e6971-8356-4952-bf60-4c2bf8d0953c": {"doc_hash": "31da02b78780295d6128612dcb800d1a67fb71dc3822f467236e78e58d7cde40", "ref_doc_id": "19550c90-5f96-4757-8fc8-b4b3ba17e7ff"}, "06be7699-8424-4c9c-8d81-95bc5eeb3ea5": {"doc_hash": "3896dd5ee6393ff1cafeb3ab51b165133a911a89d324aa128a28d0930dcc6d35", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "7d5b48d7-85d7-4c00-88d5-8292c610eabd": {"doc_hash": "deca38182fb9adda7c062631f87030009167899fa585789427105d5f3b96bb41", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "d00b4317-f51e-461b-911a-4998c0cb96da": {"doc_hash": "d3230397de58519a599f9c490501ce179c13bc1ab1e394e572e06dc6db90858d", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "17fb00bd-fdcd-4bed-ac0a-918088bdcb70": {"doc_hash": "34f54dbb87ea35615d41e2b5869d022de2d86420d85eb0f50d610c8045f16552", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "59ecd9de-9b3b-418d-a58e-2a16c4b78758": {"doc_hash": "3687c30bc3cae1cb39518c375f4efbcd8d51b914dea92e1ba8c06ae8a586c6fe", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "3cc95782-b51b-4a2a-81b1-71b0f2588da0": {"doc_hash": "63f30e1c05593572601192e3f2af716b1ea1509272f4942d6c02bbd4cd26afc9", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "3f458862-b0ce-4d3f-8133-378c890ec6e7": {"doc_hash": "d4c7b1d1ea525102d954149904cd38a381439255666c8272ad65ce77784ec78f", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "fe3677ff-d66a-423d-a4f2-bcb1c547ac17": {"doc_hash": "2ae867a845e5c61ae43b5517bb49f1b7f147cce8f97f431be6431d85c0d8efa8", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "213a8d01-729b-4925-b707-1aa53b45b4fa": {"doc_hash": "20e936c3c1d779d8d04319d0c5e3c0e449716c32a7784c536d4a7991414efa2d", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "f0c0c23f-a3f4-441d-8767-6b67883d0c32": {"doc_hash": "d27f3fd6c792a38d058e8d9fa016552e357fa4e93d9eec3589cafc6e46485794", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "85e5f92f-9765-4151-b8d0-02dca00ff98c": {"doc_hash": "97a9d1aa699aec9b13f0f04ad5fb5a22666ce1a7ec5aff89d171ae3182e90e5c", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "08f13952-574e-46d8-8109-a064f88ac190": {"doc_hash": "d7a31aba2f85501a5dc66d3497c5da1867f972046d3a0ab3c4958ed37a66eaff", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "2ce100bc-d58f-49ed-8abe-1fe597321a51": {"doc_hash": "260604736ae1def2691ee97434989236e19e7e446702ab7873665f22140fe16c", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "bdc1a40d-9ade-4649-acba-e41d676fce7a": {"doc_hash": "b3f7a31125721938466eb1eb2b11b374cb45f432961139d1c03de36054bb7b9f", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "bb13e090-ea4c-4ac7-a5a9-926dea001897": {"doc_hash": "4426dcab980ec31f4500004701598668c981d41dfbd6c1ea2685e70fe34fc3a4", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "58342e23-d19c-4ca9-bb29-5b5f3cdff859": {"doc_hash": "2f5cb1ef7839fdcab5f1d8c5c695f484273c76721f00ea9d4ed88ae18a825c2a", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "881180c5-48f6-4db6-9eee-b8de937ea9df": {"doc_hash": "ae6bbfc8a92319464ba12d98e059a7a8904dc3f345e5ce1ae74187522993cabe", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "7bfce775-91e8-4c38-a42d-12fdcf8abd0c": {"doc_hash": "52f3c34dd144f753e8ea238c562f88c5d52bc2b592a0181f8153a44ab76eb947", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "d72e59a3-95ad-41c5-b0e1-c721a4a1f6ca": {"doc_hash": "845d04a4e8a40dd7147d921c7d0310430c144f815cb5860e42e165b09c9bae3c", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "8e057b55-0490-4d22-96bc-c6a1cf51f22e": {"doc_hash": "b33268e0e75ee4de8c14fa967f9d142b678f641c4b8dcf7f3fc4d6a8d6ce428a", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "d2ce4fa3-4b86-44f8-a336-bc751b03378a": {"doc_hash": "5e678dc72e5dc0d84767cbf3ac7d1e036e4d005afc31c85a9f6b6f87abb03930", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "b1ec3cb6-983f-4b5b-ad81-f22ef4992f26": {"doc_hash": "d2ceeed4d108a10efc31d0616d35ec02d96c79af3b6351f5e07718fa26ef27ad", "ref_doc_id": "d964d354-bff0-40f6-acef-781e7ddcbda3"}, "81b6dcf9-bf71-40ee-8605-e21a996b6a85": {"doc_hash": "940abecdc19fbd8101816fafdd363fba8f37d3bb2680089ffdee67c191dad79d", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "d23e1f3c-3377-45e8-b3b3-16ae8e7dde41": {"doc_hash": "7beec56001e0a844f39482e3ff0772013b872fadafc876685d405707d64a6dcc", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "368d2ae2-c328-4df3-a230-c766bcde3eff": {"doc_hash": "ef4b2e660f7c5cf1b11497a8569ae73ae986cc748a357b12571371931c9641be", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "5b2f5128-c7cf-4abf-8b89-779f0150e03a": {"doc_hash": "4e479b2a269ed16bc919d9df7f78cb1bcb84cb51ca0f52955a59df654f967a2a", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "85d687c9-672b-46e6-a53f-f809b5910d45": {"doc_hash": "dc02d4cf90233833d30c920e19e0d553c731edca84173178955603742317f733", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "f510d8bf-f809-4956-97e9-ae5ee81437b6": {"doc_hash": "d174ce399838c8b731be3f54b15879a09ab12a0c0273b7080a0ccd7297749384", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "89591fc1-cb60-4c14-9d8c-60b500014281": {"doc_hash": "2c86fde2a5a9b4bb7ba477a1cf73fe000bb4d491ca9faaba3c8a4c4e2a3779c0", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "acabfbd0-24f1-481c-8241-3cb712b65744": {"doc_hash": "cce9f9457424b03eb6f5bee98eae90a1496eb4d31e0ba47b967612496f1c8d07", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "bfa7f71a-f92b-4357-b8e7-c6ab71de066e": {"doc_hash": "326aa5f03c29cfb29a02a9f0d0be2b1915b4231161c9b8ed2d37094beef24b81", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "c4da77f1-638c-45be-89b6-361004092b80": {"doc_hash": "a5a6be75c9acfd21a326253155fed9744cf803906bc42275d9a7742864598507", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "e27299bd-8f40-4c12-af8b-492a392f4e98": {"doc_hash": "062343bd3206bf848dc404c5254699ad15c08925597c5b5bc42353b1f100c350", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "31d50cda-1b18-4b92-9e91-66b42613d643": {"doc_hash": "958e1b3e778bdf35bdf5ab4f1a20ea34853b4714f13b9a43eaf5a87395a7dbeb", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "56ca2338-383c-4156-b536-2aaf11ff5858": {"doc_hash": "9f1abdd8526529a09f5383e3ddc072c34714040491426ee871a326bce1d64703", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "71333dd6-1421-4fad-bcd5-167c766fbf11": {"doc_hash": "ded5de4cc33fac336b3995855610e345a3ecfaf125d96f580ff1916480706bc1", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "4ab2dedf-397b-4326-84e8-7d7243f04192": {"doc_hash": "a12998bbf5f126e6cbfab18cd7f0f6d4d80a902ac18c1b38b934f2395df6f15f", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "4db34b4b-0351-4ec0-bf6b-54045210c891": {"doc_hash": "45f436689382a36e8e72ce074705697f1ed8e3a10b3055d6bbe64949cabcbbc0", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "5d8f78ec-08a1-4eca-a2fa-0e283370d169": {"doc_hash": "08022a312f03ad9dd2143b2b590bc4ba4ff2d0651f0e9056fbd0e1d1a01ad245", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "9200f140-9cc6-40c7-b1a7-c0fa9769bca5": {"doc_hash": "5549bcd6842a1f48582c27b365833c61b394ca24ccd6dc9fbb748c568219471f", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "109f2840-c7ae-43f6-87d2-5a01b500b366": {"doc_hash": "2be030d1636aa0de4e5245c5648e2c8d103c6f66bdf0f73f27ead272abdec599", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "13377c9d-cd52-4502-a15d-254cbb9094e9": {"doc_hash": "f90bd7cffc993ccb919c3510734cff5d31ab040e2ef0b332d301972bd372c272", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "7da5e19e-5d32-4bef-999b-140bafbcb6dc": {"doc_hash": "ec421c662b47d52f40359336c36dcf01955aefeb86709a9216b99fec293a5722", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "4d6a699e-d61c-4087-8ce1-5b0067369d2b": {"doc_hash": "208484f6369daf08d82f26b36a89991216d52c7cfcebba4d7233df7f5afa2ac4", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "643fbba6-b279-412e-85c1-d96b9d917964": {"doc_hash": "a0a68c15e2603c5209540e5f09c71dce731194fee812cf1e3496941fc22a0b1a", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "48f80638-24c5-460a-8172-800ef8ec4f2f": {"doc_hash": "b9c80d53f2c410ac0e605253d70c56322c09111cbbf794a7b7bd4f18c94d56d4", "ref_doc_id": "13d23129-4960-4cc7-af95-389a0c0d6697"}, "99817f68-c552-4db8-8234-886f8fc6246c": {"doc_hash": "8558044f76cf326e801d860456bff82acf946ff923cd0e27408c8121288aac74", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "a66c3684-5e79-43a1-9690-d30d39c12d70": {"doc_hash": "93c690eb2c6ddb85b4fcbf19ddebc63e8fd3dfa8f7a3e96f6778eda3dcf409b6", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "04d626f7-cf85-4b49-b389-5c21ee79fe9e": {"doc_hash": "a2303e04be8dee71891d02282a195625b5277631037961594773b1077ee4aeac", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "79653d9b-dbb4-4b0b-b761-80b82f0ec569": {"doc_hash": "7318af18263d87c3252eb96a90d039bd22253f52ee9e3e9d8dbd8bd0a039db8a", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "5080262e-06d0-4596-a7b6-accbce816414": {"doc_hash": "44d414d6521a6333ce94818c61e2a0ef1503dcc63cca38da5408d17c4ac170ad", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "9351f254-eeca-4f5a-bb8c-1622e3de85bd": {"doc_hash": "fe59d0513a588decdabbee47bb4c16216d60286cc16cdb5c6d4cdd39a5807d1d", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "41344b54-a2e9-4e16-ab59-d47b15685456": {"doc_hash": "f3f65409c2e87228043c8d398efac146cbd1422db22af545abe15a3f555bc084", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "cad915c4-9036-4588-879d-27ea909e64f2": {"doc_hash": "9179f742dd2fc007408c08721b7645e083e1d4965fcafb7f6b65b10144f6ac57", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "284badfd-c1f3-4e57-9994-826a3f911a83": {"doc_hash": "080bf2c2dbe2428e5fbd46a2b629632d7cc25244683bd11e9a88b77f1b74e459", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "f3c43a67-0d71-4e7b-bb85-5c4ac96f81e4": {"doc_hash": "24c40ff58abf5add25cb68e2b6f1b513043f34799e4b354568b60371fa2dd0ea", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "70aee11f-6346-4dce-9418-45ee0c57889a": {"doc_hash": "9da77818d4cb92b18ddc4e55fdc39996dcb6c7bf84c8aa29860d862644f01c27", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "b11f41b0-ba70-41c0-9854-d77fdaeb7a1d": {"doc_hash": "11b4c6915dd59dc83d2266cf1306bd6bca2c11e8dd79906e6129ed446f9fa059", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "ec55db0e-b7ee-4fc7-b49f-f091d34ec653": {"doc_hash": "1c5ca0c99d3470755c66918d54d4a02cd828c895bfa4aa2c0feaa45d6fef01a5", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "747068e3-cf15-436d-a008-ccdc2c0d6a29": {"doc_hash": "b5fd3b50ced73711cb496040d257c1590e68050b37cc5f130d9cd7cabf17bb80", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "fe853fa1-eafa-4b3e-a2cb-c719ffddde0c": {"doc_hash": "be25cd2d8c92313eb97768f3a9dcaeaeda4077425774a1657cbc33fb303b1f60", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "ada048cf-2705-4ff6-92a9-a04d82a13d79": {"doc_hash": "4b0bd97a78dc9dac88877f8e3e06a05f2fc9fc81862c71411b1d6bb876c3d6c9", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "1dc37204-f1a1-48e4-ba66-750c16b41da7": {"doc_hash": "37b152f82f3c4e6843e0a2918b3935b97aa94f3ebe1baf296aaba1fc5e5f5a5b", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "0ac813a9-65a9-49b0-bbfd-48b1968c8d78": {"doc_hash": "df2ca8ee38a8898c59f4b233bda8e26b8a7cb7a940729ece994346d15a3c14ea", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "acff1dbf-0995-492d-9efb-76c3340225b7": {"doc_hash": "ca5e8e346b5523ce57366c6cd7d83f9773b820120f646b152af8a5e67007c353", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "a7098573-2d39-4f8d-8f0e-1b0b80e519d9": {"doc_hash": "a4292ddd1cf73521219779bdf1b46da26e0b0ffad79abcda8ff4caeacaa48a7a", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "cd52d963-2443-432a-b2da-935c79b52bd8": {"doc_hash": "2b1063eb997e096ee817ec97a5ff1539b7ba9094a78e85e1dfdcd5f69398778a", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "d18ef9c3-5379-4c05-8d95-af610a441cbd": {"doc_hash": "147e3eec579b6809f5ba3fb7819c1fe89dac62792715ee87cc7c89a66581224b", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "11583a9d-d48c-4db2-9a1b-fd99cae37e40": {"doc_hash": "0e367be75ae0bb2b6e32e6522b891f4303b834218af72619a39b5f6a56efa8ba", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "29c9cf25-4f6b-46fb-aaaf-5960870387d8": {"doc_hash": "945d55d1e28511f1e6d708f61ed3ccac4e85415f3ff8b5ded7988bd0a8babb5a", "ref_doc_id": "2989bb78-334d-425a-9ec3-3e667aa42e51"}, "cb452796-1e02-4c2e-96ef-a1a47e4a66be": {"doc_hash": "684e3fd89164f10d49e04e7fe42a8603b0825724fe90589103df69426a288802", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "cf683daa-014e-48b4-aeef-f5d291c1a8d4": {"doc_hash": "ba3c4fa9974d764a83c5c8e0dcebcc682fc0e9a6358632e8522f4f6ab904a3d8", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "0e686490-6e76-4e59-805a-845f9cd23c9f": {"doc_hash": "475faba66650d0654f59353684d4004d051f660af98cfd484f6918c71f2fe74c", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "ca99d896-b0e4-4f85-8952-16425e808a94": {"doc_hash": "c244c067a502f0159fe1ad0ee88c11e144650f73b0055780bcb877630a0bb4b2", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "fc333dbc-39c7-4e4c-9f8f-3dafc3f6283a": {"doc_hash": "c091c107ce28e0fb10b173509de7f3c4745e65ae541808598bed6ff22bee9747", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "44509b68-5be1-4883-9501-91f6817d8950": {"doc_hash": "88df865cb1f725d77ce4d2f56c08c9294a37e025ae43a009a6d69cf3138744ea", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "97e1b638-1ec4-43bf-b6e7-5dab6631dd54": {"doc_hash": "e086fb4376a94b09ccfe9a85add29bfde13d459b3e48c45f6c7b8b8d249274ff", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "628c309b-fd15-499d-a52a-8a1a39769bfb": {"doc_hash": "285fe6bae113917cef550349c724be9d926467df9bcbead4d53877a2134dd355", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "36f383c0-9425-49c4-a407-ced748b5eaaa": {"doc_hash": "3466468db9d14d810cf3fc5cc3f76f6535255eec3afe6546df9c4d4f38e0ec8b", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "1c5716e1-01ad-4ae7-942c-26fd27d46f23": {"doc_hash": "b81ff8f4d5b598bcdb38e02dcb6b4da2fb2fdb4b88fddc372ef23a8b9e516481", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "2ae56136-fb7b-4aca-9b31-2e10ebeb198a": {"doc_hash": "db6331745aab7f7099641b0145fd13a12b68c5e08558a825f02604cde978218b", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "19e4bad6-1ee8-47ed-add4-b296aed2722a": {"doc_hash": "0871cb574b6e84c66162b4bc5a75de35d093101c201c66a7897ce20672450ee0", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "83de34a6-a573-4ef4-b851-44715005d905": {"doc_hash": "cff223eb127cc6dec3f742ee8a2f3003dd250d132ed919c74e768c1ff3a93cdd", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "207d11e0-7b96-44c8-9089-30b630e9aee5": {"doc_hash": "7a0f6b36c8aa1d271139ff93ad14344c753ba5e7b87a22c68c60b8d0a96e1145", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "38926973-85ea-4c85-ab65-f2558b1263d1": {"doc_hash": "5f70fb0a7588a90689272e59fc446b766bf2eace76ed9a98496f48994c3e517e", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "9f78c7d7-f9ad-4d06-96e3-25eacf310247": {"doc_hash": "652b6a36b0eb68574613c5d3df775fe3ccbd3a71163906d200a7ba7fec4da09a", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "3785c2f2-5351-4f11-bb22-f01099072f3a": {"doc_hash": "fb8e9dab6f19dea864a7154089003e4ab7128347a0016c41e35be7fb52b31840", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "e78f5308-0232-455c-938a-084dc27583f4": {"doc_hash": "d2b0e01dbea2ff64deec96e6640777e90ff1ccd8c67a027bc346bf22c1a03600", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "f8dd868b-653d-4501-9419-f090c2b45494": {"doc_hash": "e1d6b79195080075ae14fb471d36e902e00962234330a970354da04e45a54fca", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "24332a6a-5bf3-487a-bf35-d4268fc80e1e": {"doc_hash": "0f509809404a58a4efffe92cdec9f18a1d4fbc6b7b6e4b65f11d823cba6d9d5a", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "235109be-f4db-4c06-b934-3a34f05656a6": {"doc_hash": "5f0dcf951237c17d8b5da7e8c0e8ce58a599440b76ed8d467821c83583d7275d", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "358d0956-7a0c-4cb8-a410-18de14ba5e1e": {"doc_hash": "d8d5aa48a68c5cf6aee0cffda756b06e34e308f7f03940d453337b8908901a10", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "fcff213f-5433-4515-a35f-f7317fb49cf2": {"doc_hash": "c85f5aec22b561452381194a16e695a1aeb131cd2de1208fcbd63932407f3bf2", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "35552375-67ac-4520-aff3-5dbfd621ba28": {"doc_hash": "ae54e03b9ba78d15bd13995d88e5a752ac87eba59bfec4dc3ed18c14d81b30cd", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "5f86cfa2-2645-49e9-8cd9-bafd6795adce": {"doc_hash": "a67e8fc736f6b1b97ee74b58cf191ff4905520e1aaeefc6e217dc350f33ac585", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "385e4aee-1f66-4237-afa2-2e8194fe24e2": {"doc_hash": "6693302426f327eddfe6d20e3f5c7ec8941cb700c0ec1b425cd1961dbe3ed0b2", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "af591777-70f0-43e7-8ce7-93bbcc37218b": {"doc_hash": "646d0dfaa5c98271401f0263356247201d92e04f44502b33ab1952f2b38731f6", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "8714f82c-f055-473a-864f-73be59998030": {"doc_hash": "c9785291bc4658d4c20139e76055ba01eacaeb7e4c56ea543e0f6b704d8bda5d", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "afee8698-a687-42da-8a9a-5a67060b6ec8": {"doc_hash": "c42d9ece743ec54ac374b7b73d122bd60e81c47c306c57caea98a5f033817f26", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "004f8e69-16b9-41f3-adad-47b7b657a1cb": {"doc_hash": "00b07954b26cfe52e41bd06fe400c4c54df5f98ad1cea7a98d88144d6fb67633", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "9cc7f4eb-9a05-4043-930c-da1977280c55": {"doc_hash": "3f4cd88956b228053c5a4b0173fc119500d68d5565ca739a03e69d58bc1a8a19", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "0d0eb489-fd65-4005-a43a-2b68cf4e6f91": {"doc_hash": "42d7958456cc7543ef124b2e3990f08ad0d8cc87d4c0b044e984d045460444b4", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "71dbbf7c-f364-4d5a-9477-59fc1ade8521": {"doc_hash": "1a154d2c35948bc41ae95db0ebee80d4b3b295a573bc1152b3f2c8b30c546726", "ref_doc_id": "0b1fd7f7-0544-48fc-a193-41e5ab87342d"}, "34497735-d302-4efd-a43d-29b3886ce3b6": {"doc_hash": "2c8d900257b69c90d3c473d1fb686d4f8596d63563f9c10db81d8c8da7f70fcd", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "d6ea87a8-d9fb-4648-a4aa-681eda4d4da1": {"doc_hash": "bbff555d00d8766c673d0681ef94fc532f1d75ac42127a8bb3ad961db2b6937a", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "4737085b-5ee4-49ce-b203-056e77e3fa18": {"doc_hash": "0d73d3f06c75e9dc31581ad7f26e21735973d77dda3de6af8a4492e0e1893673", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "79292547-fd87-43b9-9426-4403d6687deb": {"doc_hash": "3608c1fff0dbd2df66cb15949ac9536da766411f0c30499ade3f9e97d6b5e63b", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "bf7fd448-8a96-4c37-81cf-1e9b5686a15b": {"doc_hash": "785301dccff07f52d437f68a68c4362a1e95282212d9b8d18c0089ece7066e00", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "cfc199ae-e89c-4ee4-9510-506e85967d84": {"doc_hash": "247aef636f845de207e772bc97e339d593d28ab215650ba39d8c80d1cb262647", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "f0d59686-f80b-42b8-93bc-f9af021287be": {"doc_hash": "730a38a5d21871e853e942da36f649fdc3b64a083970fd20fd0da1569d969629", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "82d75c38-fa59-416f-81ea-b1c1249fe97e": {"doc_hash": "2f8ec769a2d1143dd66f66a9622b85b84abe61e9550a0443bccb83ac906448c8", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "304ed8b9-9b6d-42c4-9b55-86d780ac1351": {"doc_hash": "1caa2fc9d6e1d7cbcdb6012887ea25f56b0c78d12060b931add89382aae90695", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "4f95db83-e739-40fb-9f0d-ce8888a1331c": {"doc_hash": "f38918b3e4dffb80ffe84b1557ce64469d298000ffb07882679880f86d0572b4", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "469849f5-3d85-4edb-ba11-15cbded7c081": {"doc_hash": "ffa75b27df53ae41bb8b494989f556625bfa227b914f420fbb89a732772c838a", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "6b41b73c-4ac6-4d0f-af01-fa1dbf1f1331": {"doc_hash": "7194922bdae51c5dc88df2e23164e6b03644eaa633baac5019e605e965ae54ee", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "d24c778f-3266-4d84-8941-b31595241abc": {"doc_hash": "464dfe749b76ad070de40069a39f5e7234a1983e2bdd21a418560a4fa8eafd54", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "fbc48e75-b81f-403e-ba5d-8c9199f8dc94": {"doc_hash": "6e5d805fd23fba4860d25ccf25f9fab1191e2323b2095651a8d6972feda18616", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "ad589ec3-105f-404b-971e-3b8f381b311c": {"doc_hash": "a93536dec2cdc52e04014e66566ee1d94c641ba3657722bdcec44c05856b6486", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "b72c5771-c5ba-489d-a2e1-8b9a2895839c": {"doc_hash": "9fd43623a343e88bc81c4f5986e2afdf3322696cd3e8cbe61cbeac5677696418", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "1e734949-51d9-4955-9c77-0e7f02cfc427": {"doc_hash": "a5d1dd171e970fc5e8b34b3f4a35a2ace10ee36b2b2c52653f0666da7c2e2d90", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "9375b3dc-e28c-478f-9b27-7238535e1dae": {"doc_hash": "9de473130668d5862fd32ac66ffb37d451fe6c09e225bd949c50814e89f25389", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "03b563c3-e182-4507-80b2-be8c301e8c00": {"doc_hash": "9e9be29d800268d34ed94092b20f987b5bf286ea73c08864c94385ac7713810f", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "e1cea6d1-9186-4f69-b981-59217e0ce3e1": {"doc_hash": "89f1c634854abf75e273225f9298dd8bdf9644ff709de1f3a5cd1d07a180d18d", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "e4f877dc-4cef-4c00-91cc-e6d76982494a": {"doc_hash": "024afb2a64a091f8b5a5045aa2b028432bc12cc88dc3c6d49e2c21af2497f015", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "697ed088-6026-46dc-9879-6ab3487fb66c": {"doc_hash": "c5ab773f4e0b9f7f06b41bafa7987a916591a994dfd5532ea230ae269b84f98b", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "107ad55c-a6b4-46fe-a50f-58d4b0318d80": {"doc_hash": "694c7a15ff86a5f993e61f9874391ffee70adc953bc744a0a7843bcb1945c2e9", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "f4dfc77f-3058-4c8e-b96d-a513dafefb84": {"doc_hash": "af334bd9e9bb938861bd480d6437a325edc131994df9e5f4a1278fcc8113283d", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "c3efceb1-ef42-4dcb-a662-cbcdbbc80547": {"doc_hash": "3a821628f787c887051b305db327c4b5b83c258e222bab4b0a72af33b7295b6f", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "d3662475-0c68-4d97-853f-c15e6ea2901c": {"doc_hash": "b791b47acf3281dff404e02c2c72d3427a45464042f59f176e04424d307088b7", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "bcc94ab3-2d4b-46c2-822a-d30d2efd300e": {"doc_hash": "8e9457717fa11d9123291913310e2cd6c0428fc91393a9878ea2a0e3f66cf8a5", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "3ae10751-f739-46ba-b288-d626f4b472a9": {"doc_hash": "e479ef32ec0f9f14e399180f0fba48389d1f3539ebc0f763e09d8866f692aa7f", "ref_doc_id": "9626c25a-11b2-47e0-b378-5811bb4653a6"}, "2b69d287-7fa4-4682-89ba-fbc935be6917": {"doc_hash": "221cf22827f087623e2a14d8d3d29b72735f5c6d241a5fa38b3a150371312fe0", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "7e99d861-5dd0-432d-a064-ee9cb69a4ed9": {"doc_hash": "bd642730ae3e7b57e72665951b586e8a89b105d9b5cd3787f1b88e12587f69b0", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "8db7d773-1cde-4087-8c2f-78d55e867c60": {"doc_hash": "0b681b153fe82d02ee1b70b03776c5da141b84188a3a7e2e1a52eeb9f24b5644", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "be7f5bfb-1606-4da9-94f4-34315c9451fc": {"doc_hash": "1863bc118830d4830c85de6c505a64e3309da33041ffbd3cbc742f751a544cf1", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "883d0e3f-9b00-4ba5-b5b2-d6a3df2afc36": {"doc_hash": "5b32da01020766a467d6d98e78d468ecb6ba1b657575556a7487b25afaa1d160", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "104a1641-04bf-4d1a-bcb2-d2252e4502ea": {"doc_hash": "bc0c16db5bc8143330dfe2954d5e90b2f33531741ef35829132a5397692f9358", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "76c2234a-2fab-446c-aa82-1a88569fea67": {"doc_hash": "50f755ff2f7143800aa0f762d1a5440177a0fe6b86b03c6679f12e26d901a44b", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "ca030fd1-c851-4234-bc2a-f77a8ae36586": {"doc_hash": "8b17622c5360c4fb365f52333abef19dbfd89bf8a6cda3a0b4a8fe578c32617c", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "d9751d62-ebff-471c-954f-271abd1b5410": {"doc_hash": "3b7a84783031c6c82258342eb8514f6085160269f16556fe4160ae13079c36df", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "492e82bd-5524-494e-8393-207e178452f7": {"doc_hash": "afdf255fd341e40d68650f5f016b6ef96fffcd9bfd197d6fe3b75a11c181de40", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "430f2993-01bd-412a-a81c-e447b9375336": {"doc_hash": "161cb3b1697587e276a9dcdb006d28d615895a0d3f40b02b30a499a301d10a4c", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "9732e4ec-c16b-4328-9478-d68b089f64fb": {"doc_hash": "4dbc7e88e906659ad8ae2429f9cba82a539d97632581713ecbf65eb5f6897861", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "f83493c3-d368-4a19-a4f4-4130be60582e": {"doc_hash": "e69e11130b580974b5fe251964ab8d524c6ce3bc80e1dfa899a0e30f13ba9a9e", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "0fd5e168-256e-4a30-8964-412f523a2b5c": {"doc_hash": "ffb35552e69b079c26b6d4bdf34211d47e4d363ccfcca224140267c09d0c8800", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "689be454-3a77-484b-93f2-37206fb3f37d": {"doc_hash": "3afeee2e5fd902608b3bbd70c763e5ca4d1cc9276253a496d73fd522c22902f6", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "6f21ca65-5aac-4589-8be3-a5216fc15afb": {"doc_hash": "b2490713bbe887140b1c30dcbea52d649340167a0a8bed0788ecd89995a8c86a", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "24eee756-b4f3-4a11-8c06-d7ab10e8c00c": {"doc_hash": "233235cb5601ca95419caecb0bfd81981684944a249996f180f3871749c3a8ee", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "8d406279-487c-4264-9cbf-50a89ca7544f": {"doc_hash": "48d988b41e0abf67be75a3a19a7c566185536b86314a871d1f133e8eb6424961", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "34ddf94a-9bec-414f-8085-0033df113baf": {"doc_hash": "656c5f0f64b114091a4a609fc56928875990edf6b6cfcbeb9d06ae292f7747c5", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "d9fd8132-0535-454d-9d0f-9351da7909ff": {"doc_hash": "a19142d04259ff6a4df403cdf5a55ad49eb1109a7dd8cf918a9d54c7492d3498", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "0e4f8e28-b118-4587-876a-436fd4cfe440": {"doc_hash": "3cdafce466b1d07c367f9ae158f1f637850626dddf0ec91619227d64c1934f1d", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "22073531-06c5-48bc-8cf5-cc133bf1c945": {"doc_hash": "08087b016f4ebe1517ebd402bf49e90e1d5e1ed1a122bc45a201d154110bfb37", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "e3694065-ccbe-4066-8c4c-ae88effa2f69": {"doc_hash": "8e6bbdeef4c770daadfee9155a7bde2e478a9c5e30e186bf3b02f2188cea70a2", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "4a3cab22-b2fb-42a1-b3d3-37eb902b9b2a": {"doc_hash": "4de1b6895a32066c6cf18cd5f8ff79f8f584786f65021432862da3012b942a9c", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "65038fc3-505a-4c36-a921-46e6d62d0047": {"doc_hash": "391c3d9feed1fe0dc68b5c4b5e88254c36041bedde92f2970f1cce44f7ebe225", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "5c759395-b778-4b80-855c-37852cededb2": {"doc_hash": "cc345108065c8f55eeee8727f0d0fcd7a77097cbac424d7fcd7213e5e118443e", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "a208060f-ce6f-4573-b55d-30c9efbdcf16": {"doc_hash": "783cafe0c8281b107a8141d2de02b0cc7d0b4721a2ef8b22bc001db70af48cfa", "ref_doc_id": "81b0d965-d238-487e-a107-7fe09d3f7fcf"}, "bce708e3-7103-4f4c-a87a-5e89b7005199": {"doc_hash": "9fcdd2356408735e712b570b07e7425d85a0ff1f83356c1d36de2dc86f3466f4", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "0fbd4b4f-7c30-4d15-858f-adfd8078e25f": {"doc_hash": "000ae1bd68098c849e40bfae5438b029edf7f5a8edb6b7a3e868bd1c3a9bfa86", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "525c1d4a-4f43-41d3-8004-2f52267f8378": {"doc_hash": "27112a5c55a429f887318d0186cf5c3dd0c5f5972cadec12ae0fb34895a07abf", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "cbac8b95-974f-47e4-8c53-b0a882dba469": {"doc_hash": "20f3d54742c1bc4083c5be9b70e5851c2c55763ace696005b173dfc8a0e6389f", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "c311d376-9ee9-49ab-ba79-9c18cc34cb50": {"doc_hash": "346c6cc5a0c91c3598314f81d2f7a62c37436ed47c42dba58fe93147533cf53f", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "b133e3e5-95bf-4a8d-8bda-7edd9a37b013": {"doc_hash": "8f078f40d8c87b9550fae5b130888932fce62ce32ef335ef7af4ccdb0a2b13ca", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "ef33d0f6-5f22-4dc7-8c93-d5717d839aaf": {"doc_hash": "7aec040872d402cfad84a84c4413c9832a7fee42e2f28d6ebe0ad05550d7b499", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "7f3867f1-0076-4c8a-b852-d89d639b3be5": {"doc_hash": "a3fa1c53650f8635979fa881abdc489fc09fa4c625b18a4410c85805fe4a8a6c", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "1644836e-3914-41dc-bc40-79d7eb82dac3": {"doc_hash": "420452e7ae2313432a2631f0b4ad43469808ec0339964609c0e19904a9b1ebe5", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "f297ce9a-27a7-455b-a56c-ca9d6a9e0b18": {"doc_hash": "d04dce5f6c94b010b235d2c159411154f11f371dd6191a96ab608e1c0afa7005", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "d4dae317-6674-46cc-a0ad-ceb22b74526d": {"doc_hash": "6af9d6a10628766e296b63cb9a8b9363c90c3615a4189dbdc8d567592edf843d", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "e7466c40-eff8-4514-8ab0-a05e3000cded": {"doc_hash": "c6740e5469a647fa13d0d14406187a0ff20f6ecff3a7b4eda5b6c78b00c7444a", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "6d82a48d-3bc1-46c6-972e-21262b0821cc": {"doc_hash": "9975d8d362e8bd332b8cc7e5df9e45d2df8e816ee989a94cf45161ef7fdd9dc2", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "251f4a41-6beb-4b54-b368-c7a1bd9808ce": {"doc_hash": "b75f738073c6f52dcd793a87b9864ac54a9bcd24f15c4217ea8f0340e0735691", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "d86f7aab-b552-4bbe-91a3-415d25aef9bb": {"doc_hash": "f1fb92f36c689a673b125a59fd46a6f530f6b815b3adf62b39aaf08c6a1ca499", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "b23e89c7-3707-4c86-a935-b774e3baa6c2": {"doc_hash": "0475b454103c59ca750833ff486f402033acd13fccb1f9c229e0577b0f410d75", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "80438911-4b64-402a-b16d-a6b822eebb49": {"doc_hash": "28043faaf4046fa48d17b3b0c60c1ce59eaa02bdc4bc660b993fead4228190b3", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "dcba99af-1ca1-4db5-a588-7b0b2a924684": {"doc_hash": "52da4e3676596cc1478dd29b28a22c8e15c2eec57c1a113900c834e5f333304f", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "3a96cfa5-c5c7-4a3b-9f18-f0bb67cd4989": {"doc_hash": "a9e15ff55fa82bad947dc00f710d505f9014cfd6e81a4e4db452907b4ae70b78", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "2c3db873-b00d-4c53-8fb9-c2413c448c9a": {"doc_hash": "7e258ce161ea61fcf5d7f11daf29cf73def8cbc4d3864fadfbab21b4a0624239", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "454a9c20-ba63-4c50-af45-1edaa9e936d8": {"doc_hash": "34c91039baa0ae13e088a34f51d7d7be12fe51e70a4f94cf1c189505aec03ab7", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "b7a746b9-7698-4cce-a2d3-d546bd47059f": {"doc_hash": "79754b2856b8d84eb61cafc6aa991e9c411f8127ade5f3d46fd35b6a220b594c", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "86cb85c8-02f1-4bc8-b8fb-8b50aade4aff": {"doc_hash": "37f28e6bc1437731071edd6cfdd4053d0a7a5f1f3b3a9a719a9820626ba4e501", "ref_doc_id": "e4e006ee-96d7-4435-b226-99b78a3d5b1e"}, "d198b7ae-1903-4fd0-adad-c80e1df97d9b": {"doc_hash": "aff5bb35873b654a536d359013043581d1c1ce6340e4d84ecefa27bb7670ed8b", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "08919262-c666-4298-9f5f-deadd6d00ee9": {"doc_hash": "03dd1dfb066e7f46b1a155cc89542c42462b98f64932c1512959a3bc79d3109c", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "a68c8f72-47d8-4538-a4ab-3fd1416fb421": {"doc_hash": "7d7e4e2b08495d8ece50e1cc3298cba2f1ba3da6ce3d705afd31c35c7c406e71", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "30d609df-dfd5-4e95-98f6-53b24813fdf6": {"doc_hash": "974faf66e0924494965eec4b5500a336270a764622dd9c0314ae63ee3b3490be", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "74304ce1-f520-40d4-8cb3-794b2be40f37": {"doc_hash": "7cb618cfc4f0cfccf3511c7fc717923886f00e72a35145d1da0ca7e79030ef01", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "b4a4fd84-176e-4cd0-b243-69c5c5cb5c31": {"doc_hash": "8b1760ce8d3881c699fa773e872ec5bff870356cdc87a33033539447dc1dc912", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "9da12cae-b6bb-4318-aed6-b6b18860a4a6": {"doc_hash": "945bb266c8d75530c8942abf6ffa0f5bde3535b788feae02b464233e5f23f7ad", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "b9433b1c-d7fc-40db-b94b-1440859b4ff7": {"doc_hash": "9914a47c85cf322e9cf4b2cb0a062486db936e9ae528a463d78c72632e8c0532", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "9603f71d-5a51-4198-bae9-c44de78c5a08": {"doc_hash": "76cbefb029064d26222164a32f53dadaeb86edb5b768531d48ff65ef97a28799", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "ed767a5e-e2e0-4b74-b95c-abb091755063": {"doc_hash": "466dae1e16f807f22386b6a0cbdef38f9d1691a633b13fd0687d570ff96e2aa6", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "73246742-8cea-4ba5-8805-b4c3a458d355": {"doc_hash": "ebcd6ffb6637684ada37e266ac0200bfd74ce5a011d887f5b6279418fd0e23be", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "ad2c18a0-d210-4478-bed9-f5373d63d586": {"doc_hash": "fd9a72f00b7e93f9ffd42799d627fe6706d567fc3f41260c6c09e2dc5770ad42", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "a068e472-1b21-4466-80ab-8c41105b38ba": {"doc_hash": "57acc63755f42a37c88c6cb7ac9217b12d0a6e143caf428829ca6204ddc4a33a", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "970ded1d-eb35-4306-8fb5-3e07ab0ca50e": {"doc_hash": "c8cf0606d27b41c6d459c1961949ccc53d514b159fa4cc97c70b5c883727bcfc", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "569fdabb-4cca-4cd2-8fd7-98111ca55de4": {"doc_hash": "79a47024b2a32781a89da6af46029bcb9a3c874f4b30437000d46ea51d6f6916", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "c250e829-a07f-4203-b08c-fc167bde1375": {"doc_hash": "226da995ed428f0efcd1ab3d408f26d0850e6f989c6f33b25c48e40dc86ec491", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "ecbf4371-65bd-4d00-a71c-cb004cb3b5b3": {"doc_hash": "f8f1d19125416877a8f9c3b9ef27bd0fa2a8939f9cccb17f43a85d6f7524c149", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "1a7eb11b-938e-42bb-bbc5-7f81fb645db0": {"doc_hash": "94407438f4227a8cf8206718bc0bbe4ab9d3a42182ac1e9ac441096e775ff616", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "adb983bf-fc80-4a3d-8f85-816393097273": {"doc_hash": "fa657f634a83ae3d7206582ea4b7d2cbffe6dd555d563330c51e6d5cd19198a8", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "f071b475-2dfa-4b72-8386-d4696468bde3": {"doc_hash": "f62305ee482d8072100abd9eaca3e8a5aa3403e5d0b1899b2b85a4260dc0b379", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "81f3b4d3-6ac3-416c-b961-9ef04ef19fab": {"doc_hash": "ad2f1b78faa2b959659c309e5864a76fc4895d9da030ec6a5596761fb7b295f5", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "3c696ca8-0be5-43a8-9886-85182f864bee": {"doc_hash": "d7f02ff68eb2abcda1baed9b7d3916f8248c961af100ac84ef35f4eb81e9973a", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "067716d8-691c-48d5-b9b3-5efb06e4d26b": {"doc_hash": "ccb041a6f880d859fdd4f41b550b468b21114b980982ca3e03d16221ac013e35", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "f231061c-2542-4519-b0ec-77c822c172fb": {"doc_hash": "65f0fa096ee88b9976e68bb383142564d729dc7a24464839927b578cb53f0f3f", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "9b8d3836-7571-45c7-85d9-8bdc7a651e77": {"doc_hash": "a62f30fa7bdb5d482ce11fa5fd193e718d03be3b0cb56cb5dc999a78991d2a14", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "c06fb672-a916-4321-bcf3-f7ef000f8862": {"doc_hash": "bc414b87370d62f1f6b1073e5ec05a3c92a4cb930c74a039588186a422f0186a", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "b46de158-df7f-488d-a164-44f031858c9f": {"doc_hash": "a8b05e3d389d1326947230b751d8737bf0edf12c00fc16a3979d46ac436a128a", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "269b903f-d595-482b-875b-f8d4979dbb30": {"doc_hash": "475af3221e678e8284c2348432e022ad5f347c6bf29e4fbe0dba022120e33635", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "91899606-e6e1-4bd3-8047-221bf6322263": {"doc_hash": "06295f54d29be7acebb456cb8cee41bfcf84fa0394db1264d94a085a9b93301c", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "660a32db-9859-46af-9b58-f719324a3981": {"doc_hash": "8aced22ffd2db00b8bc7c9ccfd3d8b47f9b675ca379a5a1e8e9fdd76d24f8b56", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "e62903ca-1cde-4899-a770-0d7fdf3c0999": {"doc_hash": "70221dc3421b98f60909589ebdcbd934e29a3c6227bedb77d376b28eafdc9e4a", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "72e02a3b-0d91-442c-ab7f-456edb67ca2d": {"doc_hash": "b9f9b5e354e4a1c63883e8f851a627456bcd2ce34af5873d95ed28e4f2314a20", "ref_doc_id": "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5"}, "28ac2ad2-2ded-40da-b03e-31bf0181ded8": {"doc_hash": "d9d609f92b3c5e01f657aa4f3a03bfd396f0fdd28d293d52cf84de1391f45be0", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "9f8706ac-902a-4bf2-9d05-93025a7b0702": {"doc_hash": "8ed368e355fb717bf9d285030afcedbc29e9b76317ef347f75a0097b2f31d258", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "e0967196-a6e7-45bc-bf55-2b7d25cd52d3": {"doc_hash": "930a529185e214ef2051868da3421c4abaa9ed0762cc5867a542437e6bac8f50", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "27256c29-4245-4bc3-9370-f0ad86d8f7f7": {"doc_hash": "7c36e3193faa9568741ed6c098bb2b68d33dc46516d0e89c73332862059968c5", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "c498d0ed-8234-4c09-adfe-b759638d6d60": {"doc_hash": "c655f6a1b19671dcc748c928e662838c265e57ccd5901d1c790b620ca40d0cfd", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "6d635ec5-4a12-45bb-819d-0956a72f8560": {"doc_hash": "112204b4a4d975a844f87b550dabcae771aaaedcab3323a98c1dc411e258dcb8", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "ee4137e9-6a1c-4f4f-9b77-c3a1dde4d264": {"doc_hash": "7b0ab760479cdf0d49182b2f2ce457947f1016394924bd651a2bb7f855ef2b44", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "7c5a93cc-a44b-4977-abb3-0c2e7ab30c7e": {"doc_hash": "0400c26fadbcaca687ce2ccd761e9823438e18aadfed8824f303709355c8b502", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "94884a65-f0ea-49c7-83f0-1cb7ffdc278f": {"doc_hash": "8c765442813c2fbb018f72da331596b1008bda411e4f129b03b8e6a68f7e9cd2", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "d5ecaa08-f479-474e-92af-f8b7d22eb988": {"doc_hash": "4b0a0ff31469c3e125613a35c337e815944f6811155b906ad4d237219fde9182", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "748a7a2d-f33b-4fca-995c-b53c6d5880d7": {"doc_hash": "7b781f193fbfb703d5f60a9a2f1bd55c572fb35339a2e4aeb5c5999026ea045d", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "e5e788c4-f952-4cd6-8cc0-d6f335d0d961": {"doc_hash": "c5244bb4669bab4505f40b9ca57eb300cb1ca874858577c144f7d3e9de202c9a", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "be5b1b35-253a-404f-a333-442874d7e4a3": {"doc_hash": "00579004e9405f14375b1c300df4736e1c75b9913a5161dd1a3f09e992cbcf9b", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "c7a95356-4b98-4daf-a03d-171201c33f80": {"doc_hash": "9e533a5d2a1b1215b0ab07cf417af4fbca21c6cde94bc0f948ee8bd7e6be7359", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "8ab9153c-62a4-4a1b-8f8a-6cd4a7a48aa6": {"doc_hash": "7fcf2ceb1a6474c7588321601567f1067b385a7bc226dee46e8bbc70260a4fd7", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "5e3daa55-de69-46aa-b25c-2b53b2ccdd24": {"doc_hash": "043975070e1e05c2d102acd6eaa92e545c72450bd0c5e0d97eba6c255a67fe2f", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "267df6a6-2283-4aa5-9a15-de18bdf91455": {"doc_hash": "601862d2839bf31015d3967c3f8a0d1d8da2f974f5d91dab3ea14ed20262d926", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "f407262d-7c13-4949-8849-a6103972a6e2": {"doc_hash": "909b444627791769cd288ed65b42e1f47ade9ea9c01ab497e7255565fd301972", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "cc6011b1-2b3d-40b9-9755-62ce3c32ec01": {"doc_hash": "2ca975fc0cdc90f105df658f4bc18cd84348001836f1d358459834a5cc1c325e", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "c54c4ff7-3dc2-4071-8c47-aa2b7c34a707": {"doc_hash": "b3779fd65f08864b588a85b7653d9f6ae7f80b6086488e1453de3f1dc9d29fc4", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "37c8a389-7d51-4686-889e-82473d148328": {"doc_hash": "b3cabe0359fba8d1d4ebfaddf0171ece092166abfb8765dd61efc8dbe4f425a2", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "c6329dde-1100-410e-8c63-28b4653eb53a": {"doc_hash": "a06b066b3ca5bcd681aa70e72345adc07fc21373a268dc05e24892831aa11332", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "9a8194a4-04a7-495a-b502-3ecfa1c1df71": {"doc_hash": "3e9d3124b9c5d502f5a8402d1babd61ae4dcd320ff019adc3f0121a0520f3c34", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "75c48052-a4e2-4869-9696-f8bf4edf5622": {"doc_hash": "e76b35ede87e0e12f56d25ce19b55784f37134b2ab2fd2a514bcfab27c402a15", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "0220677f-e0f6-4885-978f-08f2f811043b": {"doc_hash": "91a158b40b4f1bb33c80e6d25bf27bc3d9a40bcc24b0f3e4a639183bbc7fba74", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "e0c7caba-81a6-477a-b66d-224da74a8bc0": {"doc_hash": "c8c8f83ac05d051b09fe87b58cd06422690bc7f0f7085273cccc61ae37be0bec", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "2f8e253a-b7a5-46ab-a4e8-bf2c30724176": {"doc_hash": "f81cec4cc7ffc6985e9ab70f963cf2371c39e075bf201ec729b2e4788f5688b0", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "6c694b8a-edc5-401a-83ff-59050c4a8eeb": {"doc_hash": "5e2a5936adbe46e41a93dc4ec10de84ac048d766218dfce02886f888b971b4c7", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "fe0ddabc-fd4b-4091-bac8-c057e2184b56": {"doc_hash": "7617d427d8359a51b1950ca611b0cd466087e3645f6569b198ae2da94de5741a", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "26747cc6-7dc3-4f10-8418-5b1c18df0b31": {"doc_hash": "6c34a640a05e15f2423e4612e841ddbbfcf7d39f2f993a2b02d4bddc0abac5fa", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "5e697210-982a-46b9-bb30-2d11ea1a3fd6": {"doc_hash": "f90dad722fe957b4d26e30a8f4aa6f1f0f1ada31c4dbc075752eeb3a2426d678", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "78e8b9b0-f173-4d85-93ff-b7207e4e7462": {"doc_hash": "741b3ea58c352296a92a6fdac90aec3566ef76bacd1e923fe979598485f1c9c3", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "1e4cfc30-5871-4b3d-9ccf-6dc34cb29542": {"doc_hash": "2445e25b0e666c27b1dab610996e1e22dd8cae018eb06b5f6941a03bb512ab31", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "acc53dbe-4107-4c48-997b-8495124eac69": {"doc_hash": "b027de2047449fa7ea26477c544c106cd3619060d8b753a4d87bf87837b22ef0", "ref_doc_id": "e0272ebc-50c0-4c16-af25-22cbfd264179"}, "9c5c6056-d497-45a1-9572-bcbec6b7d294": {"doc_hash": "825a507544eedc39306a4f64b778a7190583d611c0702655e36ae94aab87fb9e", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "2fb789ab-a4a2-423c-b15c-cfc1dd40aabb": {"doc_hash": "8f3447f0b94a9dec1213afc8904e9c87e42a497b7e3ae2e107da62ad4f0eda55", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "fdbd590d-fe5d-4eb5-8ee6-ca7dc5c008aa": {"doc_hash": "c9db356af55b025eabe4a6e06d73adf96e9cce44066c652203b9dc0cc8eae5ff", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "db9d0db2-0d30-4a58-9e99-a7bb01cb25a9": {"doc_hash": "4a0fe68065a63b2c90597fb906608758888147dc09bbd2a38bbb36d08cf1074d", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "a898b39a-b6fa-47ab-8fe1-bf800c18026d": {"doc_hash": "c5504d00f6014ac2cebb4d6f098892f4569a4cc132f4f40bccf7f2a0d01db203", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "ddb6d2b7-2e14-47ec-b299-769ddc716015": {"doc_hash": "428b1ea29be2dc920f52d958e558cf42e9ff1bf69e38fc765666623bd7a4353e", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "80a3d7e0-1b13-429c-b36e-c086739f2dac": {"doc_hash": "4ecdbb9170afdcb0ee8cc72cf83ed557464e0cdcd4c8c2e64a5883abb582c050", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "f4634cdd-4dca-41c3-8e48-8b343ca8ff5a": {"doc_hash": "05cc1c9bd2792fb12941c50f87a7c20a5b078235350f5d30fb3b54f2db58270f", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "553b5d83-2cf9-446a-8878-05bad1bcff00": {"doc_hash": "d67be44b1964cae54f40ad11063d5086f8aec6d85bfbf1ea37b7ef3fd6cfb79f", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "965218ce-8521-41ad-9852-58140423a408": {"doc_hash": "98a41f7a24862572c930ebd0d68e035b19fe3d01ce8cb07ffff413879dddc28e", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "5512b3da-092b-463d-a3a2-b8001c27492a": {"doc_hash": "d7e6bbdcf391fdf5a0ac661a1db9f73ee68221fdb13fe2f9edb93a591d341de2", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "532c4d51-400d-411f-aea2-c17f8c127fd2": {"doc_hash": "cb02513e7c481911a53c4d1576216e184c705f318d7e3e1972d0775295256199", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "5b63520f-7cdf-4206-81eb-fa2a2d48fe9d": {"doc_hash": "815e9606deaddd91b382389a15045738d380999ec6a3ca97cf2ae622e3646cc3", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "39647126-04c2-4c96-a634-0360f35e7692": {"doc_hash": "b1770d603882c9c17f7137bda2ead83a27f7cf2a3db72b859d2c4b6722c44334", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "effab34a-b17c-42f7-b8bc-36e4dc71a1e2": {"doc_hash": "211335f121f34a0ee80037af727dc54858e9f7659105123202bb43a1cc0b3074", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "ad864e59-9c5d-40fa-af99-5410bfcb3878": {"doc_hash": "be57fb66f02223f60302522037f3c7f5e5fe28dc0fcf7053044b02e22cba1d06", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "e5c67827-89f4-40f0-b747-ec080e541fed": {"doc_hash": "3ba7c2bc8ff55d069d5a1836e4fb66b850e53af4b1955536970be7f2248e8f6c", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "2b928ce8-7d26-4947-8f93-8af90acada3d": {"doc_hash": "be6494f8d60e7553bddf4c05e5f32e4ff1467f8b0c54310e4e672053e8451142", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "423edd0c-89c7-4172-8947-0cf406b4a587": {"doc_hash": "8da050e656c15658a2ee6f108a75fee5f8d66d9115e1b0a8e9d1edb4c9772289", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "860ea337-c813-4922-9578-b3f557b2d079": {"doc_hash": "be45398890f9c4314b19fb27bb6b4d92abf041092f29337ffdfc39d97e545962", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "d72f4b2c-2318-407f-9875-fbdb38e81a2c": {"doc_hash": "19aa2b7f61557fd716633c123323f7c8b348df28cd616c666263ce78797917c1", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "4832c9de-a31c-4675-936c-009d8a2e2907": {"doc_hash": "a282f2be51635f9f2f54af13a80e9dfa6c1530bb12410bc9f401141668ab4a62", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "3f392a4a-bec7-4817-b88a-87626b6654d6": {"doc_hash": "253d15c041bb191032b0b5697b6da589fc56aed7db4e741ff15f6fc8e4fbf4e4", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "ca9c7b12-8f3f-4740-882e-f3f369b45330": {"doc_hash": "8ea424ff172c706cde04982261e45df84ae8b948ca03ecc20be5825f72c5e406", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "908b6883-3f55-403b-b00c-928f25738a9f": {"doc_hash": "a3d9c86f7867ab6a6c0e5c42202ee9aa898d4c78e72971557b9535a3e53b3277", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "4b530ef0-319f-41f6-8113-36b68ca9e953": {"doc_hash": "2f524b5e5845810a640f7346f3e90c96c92f948459ff028e788e5db975a24f6e", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "e4ceed05-6a00-4e0a-a57c-1bf5104d6baa": {"doc_hash": "3ce54aad2b6d2f2ca3074e324c7abd16624beb27c1f4ce0d1b717aed1999e426", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "45932477-dfc5-4998-bf63-ec15a1c0d406": {"doc_hash": "b73d72a468352dadb0ddaa139b7ae5c5be0466bbd85b4b056988156fb577dc6c", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "5d869fe8-27e4-4a9e-bb54-dc7976adb53c": {"doc_hash": "0e5dafd22bafd90874f4463485ed75e1de2cc370217936e3892f7b3ebed85a83", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "2ba6b5e2-be2c-4628-9d99-174bd7677bb4": {"doc_hash": "06413d1f3cb44778ed23ffaf3fc625fbaaa9a1c756546ce70e62124e53767159", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "1fe567d8-c335-42c5-bfae-27cb9253b607": {"doc_hash": "d2f733087441f1be7b0e075b615a63420ba27c5ec8796bbb3464b34f270b6b5d", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "19be509d-6b26-4501-93d5-33e03855d76e": {"doc_hash": "ef1c0308714ba15a10bdd19fa68ce9f0b8969d0776a51e4e21a333aa36dffc21", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "ccf3f1dd-f01d-4a78-ba39-b4c3f0425393": {"doc_hash": "9a7d9b58519f7423545f33ddf902b0164a3de20fba9f2ce6c2fe3c003a6de9fb", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "10a56380-0ca5-4303-8248-2de4647e32c5": {"doc_hash": "8d5312e854dd929cfbee5b993f8309c9667ee24925e396f2c241282ade253125", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "1441197e-591f-46db-9315-e1ae12772806": {"doc_hash": "506258fdbb2a531425191dc8487092bba14de16cf2ee3cdb3017b51732d36324", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "ab116df6-e7cd-42bc-90ff-0ba38088c40f": {"doc_hash": "05cd28e4e195e08d7898b43c7a5dff7b137de3b6b7faca91ac760d032c3c044f", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "02fd1170-7c2f-4943-a9a3-09438c0218b1": {"doc_hash": "412e6aa31ea26f4ca4d1e4d9b1f15abcff1aec94bdfff9e49f2ebfc5776aa0f1", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "6a8129d7-017b-4e31-a7ae-70b914957b2b": {"doc_hash": "dd76f4f71ef5f35c31ac5854bc5384d09aac088c8d2a7196ac336736359e2e12", "ref_doc_id": "47336f7e-6a2b-4e92-8b2d-13253b5b1f65"}, "2aaeb0a5-589d-4de7-81b5-2114961eb165": {"doc_hash": "ec1727a3b048ef98120f7004e21fd3554701b5562a66a7838eb345bf0f45945f", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "c5db4b3e-2635-4913-a011-b1e6b0233e92": {"doc_hash": "4c001671124c6f0a1e9286d27f57c1e8d387774e6051f254844c71a556141317", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "2d88e2a7-efcf-4c1d-ac84-4de2125fe996": {"doc_hash": "6d23f624b056b051a2e2efa8e436ade681ab2275b96ed3c8c23c8506dd3a12bf", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "216af6f7-8578-42da-9068-171d3cef9877": {"doc_hash": "178f3e440693a9b1d29bb47374d00c8492e3bff963e343d4a18fced2ee13774f", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "ff22aa49-5557-4d52-b4e2-9cb5d057dd9f": {"doc_hash": "93c5c59acf8238984a3f1c0fba28d505640160a9c1825ccdbcc44729a1e43e85", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "2d7fbdf6-4fd1-4f6d-bfbe-36ccb665f8fd": {"doc_hash": "278232520acb4d9a9d3efa47b94a6e11b950c77582c3a68a7736c80cbd2cc0a1", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "95cdc8ee-24d6-486e-8a3b-9dc8440911ac": {"doc_hash": "7a83322521c8937624dc7f7b490d713b804692c95b8f613656589c9e1af00d07", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "c43c63a8-ac50-49f8-8615-d31a8c310236": {"doc_hash": "2bbf4602ea37cb00a721ed32f5e011986da7167ac851e9ad893c5ea37e9c48f6", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "9e76c317-276e-4f2e-9382-f2c24caa51a3": {"doc_hash": "ce63d244cf036cf45372260d6d0a32d0ed241b4c2d13b3fbd9975d7cb557c9c4", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "093a216e-b8a6-4d0b-ace3-20716a5c1167": {"doc_hash": "8ad076a594f4313b3cb039ff3e1f327b05cddf01307ae7a5b4c6204f3688b56f", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "20010948-eafb-4867-bd6a-91499c7f582f": {"doc_hash": "eb5743f0fcd1498d7cccaf18f6aae911c9d51b6d242d99daa770589c1d5ce36a", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "d1054f49-879f-41cf-869d-5839345048f4": {"doc_hash": "153d04715bc6a937403bb888131c66fe5b1e9bd80cb3a234c9158ce0bbd79efe", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "a5dc21fa-3031-47d5-8f59-e462ba5ec667": {"doc_hash": "f456bbbfec4d7b3acce89e073da6c777b429a44d23b500e2da620bb4583604b1", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "60bffb39-a7e5-4797-a394-cd5846f0cfd7": {"doc_hash": "33f8464e078cf1f21280e855a33725eb01c32abc7df4282d58839fcac99f5cb3", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "ddb99fdf-8637-43c1-8316-53cd70f356e9": {"doc_hash": "c3394b74c70d07811d6052371848adcd7a269fd75c800a7bc1475720f2c6249d", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "7eb400b7-77a0-4805-9e0e-2c9ee4da08c3": {"doc_hash": "fd15cf03375699aee297881b3a6f6d13f90b9a1cc64b3e269e6d981dd976a286", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "8d5ce72e-5d04-41c5-a0a6-ffcffc8858a1": {"doc_hash": "09dfdb6436346a3f644401afbe9eb72b01c1edf4253f696e02c756c04b4b8858", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "215ad2a5-4aba-4df3-88e7-94a01ef29edc": {"doc_hash": "e476726eeba05bffd4584637a6b64bd2c651fc9749d5d3de3534d3344f107254", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "282d9598-72da-4796-8184-e578cbabc78f": {"doc_hash": "34f63c2d0a2bc06c069f04f10d12e42af7b4789bc5545b091feedf838609b90a", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "e4f56e62-e43a-4671-bcd8-1650e43ebaf3": {"doc_hash": "5d14a1ba73222d2a7f94027e366e8ab17e64d040f2f77a06c427c6fa20fc942f", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "60b2b852-ceb5-4ee9-80a4-59ca073b37d7": {"doc_hash": "2c7c007d3f6f6b8e656188eae81a8e7a26c365a87ce838044a6d8d115e5995ac", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "dbf30737-0edc-47df-abc6-364f5e400d23": {"doc_hash": "30cbc32dead22264f5e7b075eaaa7cf6e4014661f82154fc9049389caa48ec0b", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "916ff713-4525-4385-88e4-c95058045699": {"doc_hash": "d09bedc6cb732720ba85631067399a6de1fa6d99671c7f3c7d38d52d66cd5155", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "1afdc28f-e8c6-4471-800c-55ab929b6701": {"doc_hash": "3f5a95e34dcfd85529c3af3ad9da0bd5187de57babe6791526eb30dfccf660b3", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "d165e6e6-d04a-47c6-9a49-1ef46b641609": {"doc_hash": "00415e643b6ea7752d4fc963ac89f51e422ec1e65e87fb2e9874043ec6ef2b3c", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "53046e13-95d7-470e-bea0-29676f629017": {"doc_hash": "0c3d248702daea6b40a6386a2889a26250d93cfdf518fabcf81b1f4f15c49a9e", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "26e3c629-25ee-4806-8d6f-cb1a6fc3ffdf": {"doc_hash": "7b9e1362dbbadc5cddf8b9d0c8f7f1677c248ecf080630d4b3cbae3e01de5315", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "50a6efb0-0129-4c41-abf1-f618b7b5145b": {"doc_hash": "edd9af0ade4620b734017a903bfb5fad45061b38f78333241b13b5da4732307d", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "527847f0-57c9-403a-9af8-0af8e6619a54": {"doc_hash": "410153faebbbd0f46601f31a3a4fce61394f0a937f5364ba6e3ad626f3fe91be", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "064cb640-629e-4b9e-9486-1d2154f584c9": {"doc_hash": "c04a6e8e60125ad0479090fdec3e7c1f3894c189c4e162540a88459f6c99eb36", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "765b38b6-e349-4732-be4e-4c6d5fb0d03f": {"doc_hash": "3ccc38cec675584818b6c7162690e1fa9458c230dcb3e36e505d54ae062dbcce", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "f84a80b6-9dda-4e02-9a8d-2ebfb859e47e": {"doc_hash": "f515fbaf20056a9a7172e5ff197ccf57afcf039d7f2aeb949b40cfeb96303520", "ref_doc_id": "2ea47e19-e47d-4fb6-a71b-6888dfce66ba"}, "5d548e97-62fc-494d-860a-619720b66b06": {"doc_hash": "dc5bee8c60aae59601b79cde7c1a786f7dbe59bf32cd79bfada5f4e748ad1774", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "79843188-dea1-4c74-a1a4-bfcdfc0ae45c": {"doc_hash": "f88a2922c1ca31966f27fc43246ff9ed192bbe42c37414c0c506c9441c2094bc", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "7f4bda3f-0512-4f7d-905c-d11767c01716": {"doc_hash": "b1cefa57b6947cd71215c57a46fb59fe807316876c002f3bd461b392c4bd02ef", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "422c30fa-431f-470d-94a3-8d4f656ca883": {"doc_hash": "1e7df1458ed5d3521301bc0aa90101f9bd4c15049eddd9ccb7578f501b33281d", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "d56f18b1-0908-45c4-adef-b683db9aa321": {"doc_hash": "c2a85be0ec4def6908aeb0262cc67c1de3b04578d4d7f23e75769f917b8e8b81", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "a998a922-4d35-48c7-8d9d-7f2e9c8b686b": {"doc_hash": "dc32f2146132eb46f984a6da0da7770ba546b80066c61a1b78867107ab7151e1", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "c50dbf64-b2dc-494e-b5d0-ac72ae1272b5": {"doc_hash": "0b81ecc1c8bdc0be9912ed753ab9f78e7304f9b3299a11400f7d363b90401d66", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "3a8dfa99-e104-4a27-a914-99814bf75d5f": {"doc_hash": "e97a592297ebb4e868ac6ccac307dcd1d7b033f4a0efdad9b63bd0ece7a4490d", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "54e4c0b2-371e-43ee-9f1e-c9388dbb0aa4": {"doc_hash": "dbf76d319006c4972e42bd367c4516efb5e5698035e6b8cd519ed1ba9919d942", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "ce340f7a-8aea-4b08-88da-76ca24101d65": {"doc_hash": "56687f161f728032fcd457aa68ff7e7355580e395bbec3e5ca999304766e3cff", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "dbe17c5a-d057-4f31-87d2-cbc0838c8df7": {"doc_hash": "64ee0416cd3e9d9ed1dcf158d726d340c40a6466d864e3f3e878e70c1e95b2b5", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "715ddbc9-5b9a-404c-85b3-1a8230b24851": {"doc_hash": "d588441d772be4c00716db61d6384a5731194a88d6f3a830f8c685ddab1cd1ac", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "20412bbc-695a-4713-acbc-f1b25483a914": {"doc_hash": "bba4b6c4ea59326ba5f15518ef398c44b3240ce29e4b6e17b29d8ac64f79e0fa", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "0e920261-aca9-4f31-a8f6-e7506a2ceabc": {"doc_hash": "dec5eefe8e7e18151fe17e7b3e51ea2cdadd93f7299c067800aca1a1cb4571e7", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "eeb55b92-343a-47d5-8cd6-055b5c5384ae": {"doc_hash": "f3a278712a83fcc1ab414ee14a173329a71bd000f68bad8e74cb5955c1201eab", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "5a409262-cc95-44db-9246-9aebb6ac14f7": {"doc_hash": "a35c215231dead10d861d33ad2af3604619ed5ebcc57e7f9c7b601601430f5a5", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "b89e82e0-843e-4c15-994b-606133e1de20": {"doc_hash": "45e064bc98aecc25611469e543d4f16deaa01385dd13391edc55795008a3d64c", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "d38bb160-8e29-460c-bad0-4b261dc9ddd2": {"doc_hash": "2e2b814680789a2cad5121bb717b54e8fdf7de6662f025f2ee6c659f55b47e8a", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "7b7085e7-2546-4b46-8c65-8c8b57c1b2fb": {"doc_hash": "9c4c616a512d24e50815a4c93c9652f72807486b5ac6dd81683a5bb5ca480d5f", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "d72ff356-f150-40db-a291-614e3a18738c": {"doc_hash": "822c88f67d7783520f56b8496e12f40728b68c20560225ee4684a7c9495104a0", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "e12c53c7-a55f-456f-a21a-15b335caa639": {"doc_hash": "e135ec09abe026e26d41d5f95843784dcd7c66ca6dfd8dc26bb4544b58576b6d", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "20e31d97-f68e-4b5f-9ce2-cc8c058204ed": {"doc_hash": "5bf4ad0f4a7cadb776f6dcd4d33906c6a64b4ab7d3b9c5999f8512da1faf3f7a", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "263b706a-f418-410f-af60-272221aeb4e0": {"doc_hash": "64dd6871481f37f77ba16ddf692ec9340a8e99740e4878ac28243b01212d20dd", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "1752a535-a875-479c-a275-644f81aed58b": {"doc_hash": "27f82e6ee930676af76488476c942d74f2f53b35e0dc21b2c2cbc957482d8423", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "62898a87-77eb-4f21-9539-81c5dab2ddc9": {"doc_hash": "4836a31f6edf21c801de3e619eac1dfe50bde26dfa0523d336d175f7233b2660", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "5c2c4264-4d2e-4ed8-ba8d-0ab81cb602f9": {"doc_hash": "f524f2b748477dea62218b58620d9d90cb83bbf5a002c190760c230e142d06c1", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "a6d07df4-9b50-47da-a786-190855858c3f": {"doc_hash": "8057f87cfe9b17e434e127c383be4ebb2869780212ac8d87179ffcc85bf465fc", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "1f305ad8-251e-4dff-acd9-1628fe7fcb33": {"doc_hash": "7677cc3cb75d343b07abb8752ac33d8ce5298384039d00fe00d36e5849ab613a", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "6fa22962-8510-493c-964f-dffa34660aa8": {"doc_hash": "c5dd396dd9f0450a60fe4f729a68cf502764822f026b90407e7338afd375dbf8", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "c53ec9e9-b824-417c-a9bf-256a1e0858e2": {"doc_hash": "5a06d9114d77db9a523e62d318c9ee511313dd7320573d7cddfdbeb0ab52d50f", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "16428e95-3f70-486a-ac59-804031e59d51": {"doc_hash": "186cd0d3bd94d8bc699eb6284eb4902bd2892fe04cddb5295c3541fcd2b6bd32", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "6b7ce324-9cf5-402b-a332-f88305bc06ac": {"doc_hash": "d423890584ae3081de1a2d2992b17335dd0ab999e26ae7af6e65d460de5fe1d4", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "26bef61e-3f39-4746-a9bf-8414de30d18b": {"doc_hash": "9661795141478e7941bfbdce73e0f849b3004461df57eb62d82510e7588524bb", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "2a9657e1-dd6e-454f-9a1d-16f2a1b8e591": {"doc_hash": "456a035b50bbbe7fc1f148e0a96e0f3f778153a1b43638f73defefd18ef4ce21", "ref_doc_id": "e8252d69-2f41-4589-b620-a9d3a9e021b5"}, "9f83c7a0-6def-482a-9c7e-08e263a5201c": {"doc_hash": "b6ae4d3f585e034a8d7ce4a6a62545b214ba523d21928fcd34546997f335d6e0", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "382a82a6-9fc1-4e09-b54d-0bdddc7a1f00": {"doc_hash": "f3bc735245fd21c694cfc09d29f09c88951e075c28ecaa5ad384e96d1645f0f4", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "1e6f6582-8478-4746-a3eb-ce2ace917f0a": {"doc_hash": "1be0751a553f6fde623077a82f9a3c676d3c07022b9d27634612730b2a7a58ac", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "4471ecdc-9c2f-453b-95af-a94602186510": {"doc_hash": "f1582219fa4818d8916524e7076bcd3c76360f77cf7df2553be283453b123612", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "27b8acca-1ce8-42c8-adec-ad3deece5aad": {"doc_hash": "f3460b4daa94f33a8018af41dd839d39efd298cf0cb92a697755f09b6827caf8", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "89b1641a-52bb-4f6b-b4a9-5e2259105d09": {"doc_hash": "9bbb01799b782d107efb93271debe11bc885043c5cab4126c1218525cf9863b2", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "4474c533-3735-4e03-be6f-68250069c656": {"doc_hash": "e878d65bc9accf5973bf5ef9c775d8b8abe48ed9a3f2804c9944e9af07cf3ceb", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "01402b73-3e34-4517-a43e-800a4efec9c3": {"doc_hash": "0572651a742ab09e8d4efc2f667adb4062542635420afdc92448a65235a61984", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "e7707368-8eff-444f-9f76-2d1d42794241": {"doc_hash": "0befcdc0e3a513fdc88a502965ae4f995804c1d44930e9d93b6cfe930189ec93", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "2d704301-8170-40a7-9766-9e64fe5c6100": {"doc_hash": "0560188103c18989562146a86d28610ee06dadbe04120643d77b0376eb28df64", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "18b693a4-17c5-4206-87f7-1178dd8fa271": {"doc_hash": "dd22263ba74575a38f3b6315f1ad85c509679ef09de1d0a57795f7d76e6eb52a", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "8bd329a4-aa90-4719-8c21-eac48cb23de7": {"doc_hash": "db3fda26d45a53de8c007cf5f53d7a025ae046383f05df1e5ef4c9c4d8adc2f3", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "99affe29-985f-45e0-8cc3-89b2be97c981": {"doc_hash": "5a03e60db471b2967e461f6e83f65f164afe47ae58bed83de2acd8834e7df6c2", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "c4504a48-35a8-4f31-91e1-89d26fa70e91": {"doc_hash": "11d0d049712f47dc7dcd0d6c3084359d409130cb1fbcc33ee3e16040d456ec6a", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "d426472f-11ee-4227-bbba-6b970cb87414": {"doc_hash": "1920c68a6f9c546991c94432c8055106a81b34909373196028393c0a7d354f2e", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "4a234865-ef4b-4827-add9-ff42b919acaf": {"doc_hash": "a3bfa3219335d7a0d0c95fb4709663863337e9bcf5503078f452391a11853dd9", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "29125a5c-b1fe-42fa-987f-e6fb4b7cc610": {"doc_hash": "dd4a91151861780013b999186902fb4617eb412e13b9f0c7a4f879a2fdbfbf56", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "3f4f8438-f815-4e14-ab29-313373b4a562": {"doc_hash": "cd0939681e83135da81f03f45170ac9854a19bbfedab10012511679b8ac9a3bd", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "9741a7d3-b0bf-4a52-94f1-14663483589f": {"doc_hash": "6739fc8d17288ee0035f0274ffd1068fcfef299739d9b5cf657ed3afd09a6d6a", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "5c6f7827-011d-46ae-9d81-b687a7768af9": {"doc_hash": "3dd5bd4e919e5827113072f9222e042fc02f3fd5413a173eadbc6ea84cb53e8a", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "7d82ea1b-6093-4147-b79f-2918f4a5c85a": {"doc_hash": "029081010ae384b9c1ee379a720ac5425f3599a3b3b81d06c2b18bf9dbe93b58", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "fc4b2210-07db-4da3-9101-d820a5f20055": {"doc_hash": "b6d1bcf0ad375ea9a34fa3ebe2caa8ea901b3ca78ea6bdbb3386cf3f9885c1bd", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "011d81f6-7ce1-4c0f-b176-813a9cc1ba1b": {"doc_hash": "86b194aa4a1f414c9a3bb68bb713f106b1717922fc2aba42ae7fd605501eb205", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "71e4d6c5-3151-4b8a-a9e6-513c454fa036": {"doc_hash": "119fff34bd131b6c9947e177ad9c0c24c3920736ce54358142b8fad4d8e48d26", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "c2fe9bec-417f-4d26-9710-c8a92c6017ae": {"doc_hash": "a5c4374cfb8f2daca482ddd4e51c36c795e758eba5729853f9571e86f73e500a", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "7267ea8b-b1a3-4790-af7c-bd198da4fdfb": {"doc_hash": "f71f2d095f9859b1f1b65cd506b0a82279dad22c18b3ff08e3639aa888c0f895", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "d10d99a3-7088-41c0-b29c-9bf41c385b45": {"doc_hash": "cfb9cf922a609813ed4a36eb3c12375d906daedfdb5d570a28ef13d0f7cab6a5", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "4efc6048-464c-4e25-81ea-d820ae9ace53": {"doc_hash": "66bd87143bb4096258cb34d17c8a0ace31eb2f6e9d0a3071cbc86c7052ca9db9", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "f42d1e67-0a93-4569-89e2-6f841d4b0dc9": {"doc_hash": "b458b7d4077528588195d556549b6411fd6e539fcfa275b0d14057fe76157699", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "0727410e-fab9-455f-8b05-e8e468c323b4": {"doc_hash": "e72604a9b4e8c72c0ada4c66a7d4a5e1f5be0af85b90294752e8e0650e5c4bf0", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "58c4d42f-061b-4d11-ab8a-8965a72528e3": {"doc_hash": "a16f9aac59d1f3b9f3f765a4970368652f638c6ce09b6c577ffa27e6f88d814d", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "74ec36ca-71f7-40e9-9176-4f5c2d0db9e1": {"doc_hash": "b41e1f59e64bc857bf6e4eb4745856255fd4e2169cf97d98b99301b21e48eaf7", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "17a53090-2a73-49ba-9ef4-0e16b8e7b6be": {"doc_hash": "91502398b35fad12d0842e1d26c34df5fff1f18b16d54634ffdddba6b674d48d", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "610041e0-3163-4e2b-81ee-4de62f5802a3": {"doc_hash": "3d49ad315bafe2d185392bf3249fc2865d9641af293b65cdee5de703a21bd162", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "4ea7db7d-80a1-45b9-9f0c-38d8730417ba": {"doc_hash": "6fb66b2ec928e6228f7c10640b68b33e93a7fc5af57fec23e78868f44b543d00", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "897853c0-10d2-45e9-bb0f-7845b82564d9": {"doc_hash": "f26506caf0ccae0d0794dc433a7a04de59ef75e88e7b0685d1b1acaa51b5fbda", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "15590bfa-36d8-4a5b-b10d-0172883b6f40": {"doc_hash": "eba5f2ce2f3a940d05ad30071fe1852784269d7b57f1a19bd04ea8608e3df25b", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "7ef6ef01-3310-4c8b-b19f-e9b69569070e": {"doc_hash": "03ffe2678b8c8964fa37dc56d201785bb81a8551b15400adb17b652acc756184", "ref_doc_id": "ebbe3133-02cb-466e-b644-dc3fe310cf85"}, "6653c9e8-2d1d-42a1-80ee-f290f0523113": {"doc_hash": "55a5b98539582e84829185ca435b2bcf360a30c39cef7699b05580f459a1b76c", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "6763a7cb-b81f-476a-8f39-33940b76378d": {"doc_hash": "32fa50d94fbd97bf2a3fe9cad4acec881c019d1445cb37cbdbc93a193ba6c813", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "7e2acc5e-7404-4820-bb95-6966cecd433d": {"doc_hash": "6e4ef8dd04deb86bba5083389d7ea39fc99fd629c87c8ef433cf1ded28cce8a4", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "9e93b593-5e88-45a9-be1f-d61cc95b263f": {"doc_hash": "cb25c9ca73c7e9929dab413c60492372faa817e953e8f8ef0f453c7882a2616f", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "32caf227-5b24-47dc-8132-68b2520c4090": {"doc_hash": "5e0782728c06d98e85c1f1e4d663fa0c8d7d867e317a98cf941074d990a907af", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "a8e3f6f4-00ac-4794-901c-50d5dd8ec549": {"doc_hash": "5f7f5b9abb4be56de2af1ae943c4b1dd2a243dc638214783a12c8b7b10c4952b", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "3b753337-e36e-40d6-b95d-564b750fa3fc": {"doc_hash": "0ee68c1d118cccb1ea3dfd3a1975d8afc11766339b408b29a8dfffa550ecb1b0", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "1f364fea-36d8-4794-aa0e-a872b578f2a9": {"doc_hash": "4e81fc9dc4e918a81f89be6110e1663af76101a7b4bafd907bfdbe5ab98fb31a", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "2e03b01c-d787-4c38-be0c-c2e4ff4bb530": {"doc_hash": "418dbef6460ac33e13da4d699522522229691d639397b5f2921191e2d68103e9", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "f44cdbf5-6ebb-489f-b333-bfaf5995d371": {"doc_hash": "71a3557944c02a007b9efd9072cc416afa496fc08e70d9191474dfb4bb62b4ec", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "182942ce-9c93-4871-b1fb-e99693438cbd": {"doc_hash": "84852ffe78fa382fe8a1aa42565713c61a602f62b9062e911c41ffb95b299a30", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "42469098-9d35-4f68-a2dc-fdd3c87ee8bd": {"doc_hash": "d00e00baa29f794d8382affb99d6909c15e4d4c457f821528aa5257ad431b8b8", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "6a3d7bf3-a375-4456-afaa-a8b4fee2a6f5": {"doc_hash": "aa465b7034e79470c1101f9d6eb129dd5a5f4019cb54ef8ac417bce4f610c35e", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "7c2ca445-4f9b-4401-8498-8ba0f52273df": {"doc_hash": "2a48e59d73ec0960df40363c8d5e4ee7d8ee4b913ba4b0678c3e43523dcb0671", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "ae0399d7-f189-4a91-8354-b84196ff6035": {"doc_hash": "84c858800694d5db1ab64428d0df95cc60d0ec20678fe038c1a3f0cf6e85ce9d", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "1dfe7a14-1244-488b-928d-30a372d1fd76": {"doc_hash": "4a427ae8e5d740eca5cef263b5c7930dc40bbccc0277085defce1d11635237c7", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "68855162-6900-4938-8a24-a148160f0b28": {"doc_hash": "c939c9f774c05306db6aa1c2788031acbddf861d1c72bd55153f8c50b6a46f3a", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "71da4a22-2e82-471c-a3e4-a84e6e6ea10f": {"doc_hash": "8df85636c73d15e2e21cb9b7f5d29cc94a304c9a4f75754872833be273e5eb16", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "1bfc12ce-c94b-4a97-85bb-439deb1123ab": {"doc_hash": "9f323bc4f97968b5c161c89493c42b4bf0e21d9a4269dae77bc8959d0498f333", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "d6f911ce-402d-41a3-89e5-a2d841075f80": {"doc_hash": "78d745309495372dfc5b5eb4d5d8f8128030773a87b8b8317e8319a81d614525", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "45a86a4a-daf8-401f-b332-b57dd9f909a8": {"doc_hash": "6da5c315ce0468db01160fbd9bf47ccc878cae77424861231b2a41c6e3e8e6b2", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "6cf77d6c-a5e8-44a2-8277-09eeaedc304e": {"doc_hash": "6894b07b458c846e1888fe6a4aea10e310f09b553e8bb46a0bae3b64e010b55c", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "0917cb20-07af-4439-ba07-357c82cc225f": {"doc_hash": "0eb866e1cee504b1bc55e993d1566e878d4d294e2a1ac63bfa6e4d836ca1ab71", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "cc348259-b108-4403-9f78-790afe9a9192": {"doc_hash": "a7a067772c768dd8f90617fe28208d50911ad366a6d52a58876f685f6ad7eaeb", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "bf1e0d29-eed4-488f-956e-f2d324b894ed": {"doc_hash": "78db174c6e35666680806a5503287693d9676430c71db6b811e2c9115a2b4054", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "45c3f3ef-8452-48af-adca-ff9e7638e2a1": {"doc_hash": "2ac9cb24ca4e12a062854badd68e0c94d6609d4421ca8dd7d9abbfacfc43f91b", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "3f1aa2e7-4d27-4efb-959c-95cfe70d872f": {"doc_hash": "1de7e441fa9e8321a0060d5d08639d7ccd7cc9e82889b66b82c97d41c2066723", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "2f48b301-5558-4d92-adc2-b3af4bc2974c": {"doc_hash": "6d38f7a004616694450f3545dc4eb62321234e3e17a9de4c6ad16bf35b3be61f", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "235f2210-1ad4-404b-9fd6-1045ea1322cc": {"doc_hash": "3b6cc1255ee1406780da16522273ad647eaca20f79acf8a04aa6312fca058b7a", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "96ea2223-6c0a-4dfa-9e7c-41ea202e4c60": {"doc_hash": "84487dccb8435a77710964343146984123f2885adca80fe42876e16ec9d9012a", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "bc109ff7-eaa4-49de-9f72-ed913a15316d": {"doc_hash": "bb037f7e3517d9f2e7d542f88b634d817018d391e2052f484d9cbec693ed063c", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "9dafab4c-2d9a-4914-87c6-fd2c7c4dab1f": {"doc_hash": "6a02a98733d813182cd3f831e2bec502dbc7b5b1e7202567a3d348c8c3df8114", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "fa18b7d1-e216-4ef4-9426-d2a81fcb0b8e": {"doc_hash": "dd5e2f1c64f7f5f843011de34225267e3e4c86013ea2f2bd7c3ffae4bfc7fda1", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "576b8e4e-97eb-48fb-a50c-ea2703c012ef": {"doc_hash": "e0a8fda4fc1a6a2b4dee9ddd7ab6afb10b1a343ab03e78b08f8954f21b832830", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "095e58e1-3c4a-4c14-b55e-8e1cf05d0004": {"doc_hash": "f276379c639f8bdc551b98ba40c2f69de1e489c5e57a8b6e8aaf9cd37618eeb4", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "0bfe3b00-6f05-43c5-bb42-27e425c32555": {"doc_hash": "abf2de5a8fea0edfc96929584c3d9e897106e0380559d9d63bdc2586997b42f0", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "f63e1fec-060b-4df1-a86f-a82d19d7e014": {"doc_hash": "3ec870bd9d9c3fffa0b5b8b6ef338e9166f09875f4a9030355dc1337b978d411", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "9243b8bd-1e03-4d02-883d-731585e2a44e": {"doc_hash": "1a54a9f728baf0f2073ae2ea9380e1349f72093464cc0cd6f0a73bc28384d670", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "5acaf446-e0aa-4b43-b3b6-18052da9bc07": {"doc_hash": "8176c68dcdc96328bf5f4c30af71b1482066dc12c023a3d5619ac1bc04429460", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "ede17dc9-7391-4178-844f-abe0405e9098": {"doc_hash": "266932c6e7356c3f21dd2ef0555baedbf8634c8ba8378c6bf5b90c08c9e7dd13", "ref_doc_id": "31926609-9d2b-49e2-b1bb-39cf3b523242"}, "9513faa6-6b66-44df-93ce-1df1d2670d87": {"doc_hash": "ad7b6daf8556c1b924f71cdd1a9b0ba2e5282cee3a543fed796a340c39a4d24a", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "65e8dcde-edc4-4038-9bf6-ba191c17ea22": {"doc_hash": "8b697e5d580ecfd80efa20f5017556d0401acc247d3e29a206bcff2c5faace84", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "624d116a-2a35-41eb-a7fe-1c20d80066f3": {"doc_hash": "60299ae6c33b53dd6ee75cabc3ce156af03b86c4acbada2aac3fa54561dd7441", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "feaa2b71-dec6-4c26-b30a-c64a25c5d080": {"doc_hash": "1605f0be9877a8e737fdfdd3f2b9e4aed014f487848d35b3b951d10a512ff195", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "46430cd7-de77-4d46-87c9-1429b2294b0c": {"doc_hash": "d61d7a2e09cecc79603edae72e6e3b80f174ce56e47b4f1fa44a3d8c14346453", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "e2db1e3f-4ef9-4c2c-9c2b-12d63c00d049": {"doc_hash": "9954825353ad65b7f3c5848030ec25fc9ac5910a8c953052ef8fa0c245a8c337", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "7a2002e1-832a-433c-ba45-3d5360314dc8": {"doc_hash": "ef9a953c01250001ed8b8afcf4889b48592ef33d63b4d55a9570e27b0332fdbc", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "3e1094e0-2f5a-4577-a2b9-d515486de273": {"doc_hash": "4f351e91076a74d31fa56a23f5575c5882dcc15116e8ef8b5a6adffbb602531c", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "f97e575e-6b17-428f-9349-42510d5608a2": {"doc_hash": "e6343471e2c7cefd335bef2c51b0dead9a1c85ed111012f9cf795b266fbeedc9", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "3dd1d8b2-0a2e-4799-997e-dabc250c59b4": {"doc_hash": "2c631ec3ec27780423f5e895b31f6629a6427acf58044454b35f4fd832d4974a", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "83596fac-b506-4adf-946e-163eb42d0c27": {"doc_hash": "58b83982d1afd894a844fa8d3684bc8455a67c1a02e9e1b7d3eaf748c208e004", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "96f9bcb7-8f3e-4a84-86fb-179596ed7c4e": {"doc_hash": "8d21fbe6e671f26e40830d0a8e35b8de31d774c1cd15797e4a1dd5783385a987", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "501045d6-77ff-49ec-8313-77e9c24e47a7": {"doc_hash": "ef7eaa50ab79a59e9b3c25e2aca2ea4b08372958af554d85c3b3e59356c8f7dc", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "29203b92-1213-4bcd-823a-1635e03309cd": {"doc_hash": "266b9d0f45cec2713334398f88af3eb64890c7fbeba2aa388fe12c66b03946e4", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "299f90d7-4bac-4908-8a41-f7a3a2750177": {"doc_hash": "073725bd30ae18e69f6861ebf5bac4fe917d8401db82ea65cc54047d0f4668dd", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "e0619104-1553-4f64-becb-e9d5046dd5a3": {"doc_hash": "42e8916678ef0e2130dae1f4c1fd09e559c1317e3992c59fc9ace70d133c2d06", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "8885f785-7249-4be4-95e5-254a4165ac89": {"doc_hash": "5be95451ba2f264c6161121b3798bd7f0788260da8cec18dba4dafe046d46248", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "9d7957e0-77a1-4078-bcc7-120a07d92122": {"doc_hash": "e3586eef3b3ca4944f665b899a4a4462d3f30d7feb8e37f2187e46107f471e6d", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "d84e4b6d-3a7e-402c-8aa7-d229de081e3a": {"doc_hash": "faac582788deccd9e222434b010d0f7c1366ce6be52cc267e21bc8bbbfe90eeb", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "11aa230a-04fb-4e38-9e4f-f1491f013cda": {"doc_hash": "e90df8005390dbdc80ff46a56f5e8221526f436fbf9215b73e4c27b784c2b0a5", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "586323f2-c9f8-4d7a-925f-983506bae99e": {"doc_hash": "99e19dfeb6b43ad941d181fe10ac706a10d7ce69843971cb992ac12887db1359", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "baff1a58-58dc-4fa8-93cd-df2946e2780b": {"doc_hash": "6551f280facd102b41f917807632a3eb1148f37f5524d4810e99682922bff36c", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "b555e5b3-c98c-4db4-a587-40c798d02091": {"doc_hash": "3bbc34c78715a2ef79a3594c43f022b16cd8406dd24d1ed7d2575202e35de688", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "e267ed57-1dae-4105-a3cc-ee5b53e6dcbe": {"doc_hash": "d5815ea9fb062fa4f0ba682d03e7b255dd76523e5399d1dbf147da3307fb3fb9", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "00cf6a7a-7c1f-42ab-8915-a3853e2078b5": {"doc_hash": "623d5e9ba43ff72ddfd1d2682603a535b71f2378b75eb76e33579839d8305cea", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "fb81999d-c60e-4ce0-b0f1-d72998f4949e": {"doc_hash": "c2c4bf62c469b226f55816034f778fc9c17e4742d0d9baab01680f11c272be08", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "9b26a98a-d683-4959-902e-31045c781bf2": {"doc_hash": "7d7988f2e0203eb8321124e177ef06c9e220eb3fa7496a268b56f74876ebc88c", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "b212d643-a520-4b1f-841b-f5c889d46590": {"doc_hash": "f8bfb624650e482b9666ca800c08f96b951c8b19e8ebf02c74ee392fb572b8c5", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "993e6339-b9f5-4a4d-8c6c-5f01f1ffed2c": {"doc_hash": "0dc5e9fa98470a9c7e251ab375d357c66cbd3801812e9de9e362bfd324bb2e2a", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "b66c6713-8645-4fe4-8f19-cc1d72f7a6cb": {"doc_hash": "ec5b8e2e9447660c3096ef77da5acdd6acc05bdf57cc4536450996246c1b7a53", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "cba23ae4-4307-49d4-9d46-2ae2f035a288": {"doc_hash": "e4fd57c8746d9273a9d5b7565e5f400c8434c050df9278c9192e62036cf37f03", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "6293fdae-5ef5-4bad-bc3c-863d786e221e": {"doc_hash": "612873dc73851f63261fa55b7abce10874340e332057a1cf6916d414a04bb024", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "a3227db2-0b75-4c34-a192-86dd6590d83e": {"doc_hash": "dfa0ddc53451ee44eb70763367ea61272bd6f0290b2cff76f740bfc430abc637", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "45d4df81-8d87-4599-83dc-d5276a4b3ae9": {"doc_hash": "1d7fe68b5de1fa56326ed1a76efe5089ce60dce3cfd0b6da651b31b675fd1376", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "f0da21d3-f961-4ff4-a0fc-b52bfce51144": {"doc_hash": "3d629854f8bd24bd400f0508d9f20371e4030f58bccc0525eb4083c07d383568", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "e6166384-3d3b-462b-9eff-4475c6cf0658": {"doc_hash": "3373815731967c33b5e474e50000ae9c4ec310851262b89d29a45c9c6d7c624d", "ref_doc_id": "6a602aad-f114-47a4-9aa6-caf07a332c0d"}, "b414137f-a68c-4798-bd21-bfc1b2349af0": {"doc_hash": "8f5b23855b055e7719ba32903910b2b39ced9bf7b97c6762c7f84a8b2a7a63e7", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "5075313f-4e72-40db-8fb0-d4b9cf384c98": {"doc_hash": "b22b60612c7d877d1efd43ddb68b14d88df34bb246256adf04e59d68cd1a9785", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "ae201f39-aa52-4517-983a-d74d74a10c69": {"doc_hash": "ea769d9be9231734a4d0192fe3d753725ef348f8c4d278c61e75e5b874ca37b4", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "5a16bc8b-54eb-4abc-bfb9-479aa1abbbbd": {"doc_hash": "d4e76a4d6535778e16b7ac4b6e1dccddd24385af6ebadf39f145fc2fe8266787", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "467a11e4-e636-43ff-ae4e-9851c7a24660": {"doc_hash": "c7468b57789045c96cff2d0e65f8efff587c5e4e5a28376995ef04448f1cfdac", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "d2c9aecc-ead8-4988-9214-cf59f06e8aef": {"doc_hash": "9588a07d8ce231a63533a3d4c7cce0188e09204cd3fccd34c34a6fc4b86f388e", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "c0036fc3-e019-4f00-8a7e-14623618fdbd": {"doc_hash": "c98c39764f2576e44b6bacc4e3684b02b591000fbaa63aa3f290a2f35949e725", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "070c498d-b52d-4ac2-a1b7-8c41e3f8f33b": {"doc_hash": "13ef29235318f1811b0574ad7cb9106f721a0c94e3d2fb9eac2eca455c6d0571", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "a0cc3959-3e02-4bde-b385-c1dd6609f6be": {"doc_hash": "90312af344f69d869dc2b2d0011eb93d383d70c283e45243572e9484e070687c", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "83d352a7-f347-455d-8035-145532bef513": {"doc_hash": "14b061ae8d6387f43a5ab01f4d6156fc46211e444ad88bbe7bd7cf26b4c5b950", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "0dabfe1c-fed8-4e84-be48-b8d928cf971e": {"doc_hash": "9a0495347c1649368e59efd47ee1ab0be05bf7a7881e4f68f93721dae1514a85", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "39b4b678-3578-4997-99f7-a5956c323b3e": {"doc_hash": "545f10c271a7e3e973ecd3572a2e52f4206f40f8c91a9cdefe99a6ba4b5119b9", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "dd40ad81-8e74-4de2-898c-a867be1a5e1a": {"doc_hash": "81e7bcee046451a1162404bba92c22e223d6bc075a9c4a5ff21fa83ea94f66b6", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "48efd214-236a-4170-97c8-de5696f83fa9": {"doc_hash": "da9ceef5ca1ff9225e1d185e9166dc390d2951e18ccb374eb3011f2870f2e727", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "385af906-c2d7-4313-ad39-466c6c6f846f": {"doc_hash": "ff6f0ca70ad2c6b66af25661e4f304ba60f16b9673e5eff3656b740af4289983", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "a3fce861-0f18-45c6-9d52-79c4246ebbf1": {"doc_hash": "9bf8fe2fede10808d61357897136789a761a48d2775357b5417ec399d7c1261d", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "d9eb6802-2fd4-41e0-b7ca-d82ad2c65949": {"doc_hash": "492f659f045ca75c40103c7bf8ed696dd2864968f49b18efa69a5a208e077215", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "b58f3e8d-cb5a-41c1-bb22-63c3b2318a05": {"doc_hash": "500a2e4f721ff6c0579035706734f9474e2aa83387a6344248ab41c76c4e6e87", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "91262010-03b0-4a86-8c34-ae4d8efcf095": {"doc_hash": "6cdf3613a1a8be4f49ea457d4c00c0f344a4d34ea20cadd57eb5d9320c5d0cc6", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "c20ee682-bc72-4bff-9fb7-bb8d2e5a79a7": {"doc_hash": "845f534a3bc9c047be18803f66474e2fde3f8d73395056014130d74620c4ee15", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "61bc2dff-fc49-4e46-96f0-ce4d553fd0cf": {"doc_hash": "f8a3ec28d6ed2bf1867b32a83799fa9792331fe0e60407b6e0ed1092ea917855", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "18b9ff24-5dac-46c9-890b-8755f13609b0": {"doc_hash": "98bd2941823db5cc62144d645ac5f1a531e5f7f4e11bcb41bf3bf34b3f4427b7", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "44593fab-f4d2-4158-8b4a-98e132846409": {"doc_hash": "3774e4af962dbf1d4f52bc04f4ac23fa050cffaa9d517faf7aa9ec946be0ad91", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "ca0e5bfd-bb01-4ac2-b1ab-140e24699f5b": {"doc_hash": "b915052d5f72223151baafa1940b38e76610dd238c1179cb28333da5b68ef807", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "30c084ca-abeb-477a-a61d-4719ea4e1c5e": {"doc_hash": "6f8f04e5f892bbcce241c1a33b5df9d0903c772abb8eef3d60aad2bc623de356", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "332a79e5-0716-41c7-977f-6635eef73cc0": {"doc_hash": "0303adf1095d55986f8766eb362ab355b359ba95ea1f0085ec5040e0a6e89cc0", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "a7171489-4e32-483c-9043-dfc0fd368c10": {"doc_hash": "a1ecdc282d817746a5b9b0ca096a510e644f674d81964b5ab6f67b36b3527716", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "2da4dd28-d907-4a56-8762-f4399872cb06": {"doc_hash": "7d0afd9d959fa518ac20d86fe61e911e8cc18acd0ea0115757ddb74670bd23ea", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "159861e4-492d-437b-8069-f02c94ed49b3": {"doc_hash": "433a3d5ee46c556f18fc0ac3dbfae6d74af5ef472a6a0f00f10caebe57ad41bd", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "e7e187d2-0f97-4d73-9d22-8f47cb3c5b08": {"doc_hash": "f4f0428eb3da41a258ff528ff91b68e9b7afeef783736a0850c62cbbfc3cca3b", "ref_doc_id": "9dea9387-b5af-4434-b4c0-7be2cc973ae9"}, "e8dad0b5-a90a-41a8-8f47-f264db72b221": {"doc_hash": "d39b8ff0ac0ce08f09db74bcb8f9bddc819251c12c229b189db7fcfbb41dc3dc", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "8861020a-e8d8-4237-a961-1e9e56739ba9": {"doc_hash": "58cad80e869f4d2250636262b9c84213ac0ab3ab814d40374dd33a79ec2ac019", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "a074f47e-facc-4e50-a490-dc11e32ded80": {"doc_hash": "f49d398a418ace777bb3a63c1e24d89ec83c974d8c44f70171a1d3eae9676a52", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "8ad7dfad-eff0-46e0-9d38-dbcef20478f7": {"doc_hash": "5e0a23bcb226474856100cdad25b335cf84eb9c678787e056ed76ddabea3b28e", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "41136801-b83d-462c-abae-bbde043a7dff": {"doc_hash": "632c5d7ebedfa3073e85b5f8611c5ac12a006a6ae963b7b45807ec44e31bd7df", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "6a092bcb-a477-496a-a5e5-d5609c31b65c": {"doc_hash": "d2269008a770d37ab72630401c5041c0047f4a289c9c5d7b6e2b93653b29468f", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "8fc85759-245d-4852-a638-990cbca048d2": {"doc_hash": "50ab700e779be99badd0bd922a8d3efbf365f850dfeef78e4b471b062ef9ebbd", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "f11984e5-2127-4fe4-ae11-77677f2f0657": {"doc_hash": "08bb661a39655339c7fc12d1dd1d25553997ad75b93344c772d246735942d7a6", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "6ac54769-8d83-4553-b5d1-60530d831c6f": {"doc_hash": "200db3a1650e9d32b990d54d6cca174b52d153a10a1ce3176c8518ac31c3743a", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "e8f2f31f-6906-413e-8b2e-46a02ec77196": {"doc_hash": "faf869dd4956a0fd68763519065176b03706707708077b36fa78068ce74731d7", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "52aad118-b7f6-4ace-938a-daf6422be0b6": {"doc_hash": "fb63b0e57f67876c6eb99e92e08b7f1fd4a6270e6545f3db265d8ac0fbfdd6cf", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "7560585a-a827-404d-b6d8-06145bed210a": {"doc_hash": "c17a9d4ad5097ed928bfb213ce531e4ea7e1386ca7ff3b94cbdefa6829726a48", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "f8a85394-9ed1-417f-afe0-50f443faa7c9": {"doc_hash": "c4ee8e4139e55466fc8a04ad180e1eb495ff74bc2ea75a573f9487c22af1a9db", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "cc2aa750-c0c0-488f-9593-1eeab3fc22ca": {"doc_hash": "bc00df4e0d591e5b56c66dbb0f5748ca24796ee22d7c0ce4ed9c56a4a4ff7b8d", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "02642979-2f37-4b07-94f8-a360a9fb6c76": {"doc_hash": "d5f47b5bef02e828ba4b54caaef176a69411aa0c1d39747f8ecfdbbfeab985c8", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "de004e9c-483a-4859-abda-a3664362144c": {"doc_hash": "68cad585167be295a3965f07378391c376bf64320a4ffce0d6eb8b163bb45ea9", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "2b6885a8-5793-46e6-9d73-4f3ff7f0b906": {"doc_hash": "dd08ee6dbd4b932c510e65f29a6a239fbb6378f592ecc3e4f6c08db58ef6b4d4", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "05814d35-aa7a-4c7e-8d32-6eb1c8db255d": {"doc_hash": "b868dd8eba4045fe536887ac84766e6f1373f6fc4e389e295889de85ed036dba", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "e628a4b6-4220-4435-9b99-f85fd1826dd0": {"doc_hash": "c318c095fa933d91d550f9be2613856b2db336123aba8f11379c3e0accd053dd", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "c6622a67-f60e-4b37-8aef-828eeea4536a": {"doc_hash": "76ac7c1f24e2ffdb9df759e0e3edc63d48286b4815413c71bf08790fc4df9c69", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}, "d8620a51-29e1-4d4b-9a37-d3a56bed0c1f": {"doc_hash": "153265c2d9d2f21d3441b9e0e0b0ca4e764066a5e5fb09ab6253b1eee0cbb85a", "ref_doc_id": "0e914f33-8b8d-476c-b1d2-afc53dd32bf3"}}, "docstore/ref_doc_info": {"8b9e5ddb-7151-4cb2-836a-8f1bdc98fb5c": {"node_ids": ["eff7e52a-08db-4ac3-b46e-6cc21f3adffd", "1da1dc66-7f50-43b3-91f0-293b59bf0317"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Nov-2020  \nMcKesson Corp.   (MCK ) \nQ2 2021 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n03-Nov-2020  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f9364e07-dc15-47ba-96b5-75de90875e02": {"node_ids": ["5da07ecc-ff80-4239-aabc-a892eb1e1f53", "2b0f0910-2b13-4dbb-b754-de48679ad7f8", "e42cb57f-4904-47c5-9d22-abab9171a7e2", "3e26c4f5-f14a-44d6-9b6c-b80aecbd24b4", "8315f097-a3e9-4286-ae03-4ad1d4a71029", "65d5b5b0-3eee-4144-9fc2-f8a843da5e7c", "d9ccbd9a-0451-4657-a0ca-cbdbeeb7f237", "211cf7c3-43bd-4d98-a63a-6e0328470c20", "0d83bee9-ee1d-496e-b84b-3ec76839accf", "d7615220-df24-4af1-9c35-c796fc90ff10"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4918134e-30b2-42ef-aabf-32bbcb34951a": {"node_ids": ["978d241e-ce10-4784-8a77-788120fedd81", "8f3313d5-334e-4295-8362-f271498801e8", "c2128b17-6472-449e-8939-f240d981ccec", "1e0912d4-d061-4b02-977c-ce1479c11588", "90c1e3bc-f9d1-4919-ab2b-51fea9441b59", "e2559ea3-b524-4586-a74a-0acd02d5bfab", "d11f05a2-24ed-4095-a543-046c29916d40", "d11269d0-a319-420a-8c69-6894073cdefd", "96997316-b758-4bc7-955f-dae5b426a931", "b65b8129-12d1-4816-b8a4-0a2ed5d4067a", "1c17328d-94b2-4108-9d4c-7b5dd9b7232f", "78274872-e763-4d78-80d0-253106120cd2", "dd72bdd7-4b99-4119-9c6c-a97f3416b3ee", "a36632fb-658e-4f94-9d8b-9f6b6c6cd1eb", "52879760-07ff-4c74-b5d7-e79e7a119d96", "453ff5dd-392d-4a61-baf0-bfb34e965d26", "7966551d-66fe-4893-9eff-9953f5093e6a", "b8ff732e-8c44-440d-bebd-61981b6a6928", "ec7c15a1-5c47-49b5-aed3-9608c56c9f45", "b929044c-248b-42b1-9011-c44b6b980842", "fa78d77c-d5ec-419a-9b69-0a5f178c745e", "d524128a-bbae-4ef7-86f8-35759f762b21", "90b08ef3-2288-47e1-9773-7e80bbe19cb5", "4faaa692-c4ed-4ebf-a292-7be17cba0201", "e5653ee3-f0c2-45fa-9d1f-981577a2f96c", "ec34d79b-527b-43c8-a94f-f7839eb38867", "92ba47b9-f66f-4c56-9ba7-727f3c428fdf"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q2 Earnings Call.  This conference is being recorded.  \n \n At this time, I'd like to turn over the call to Ms. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c0dd24eb-9281-4069-82c1-5a5021fec3ed": {"node_ids": ["01403a4f-c183-4d6a-957d-0af9a86c9df3", "75907d43-1f18-4a40-a47d-2292fb907a32", "792349b9-fb36-4663-a7d0-c8b104f4639c", "e8b9a543-ceff-4d5d-8252-5d5aa6a1955b", "13a1e639-68cc-45a9-9e7a-34e6e5957ee6", "01667e9b-d436-464d-83da-eda4b1086442", "0eb1dc3f-2306-495a-8067-8f6a6cdd0810", "89eb22f4-99f4-4e42-a0a7-117674472fe2", "217ec653-a35d-4e80-b4a4-b237aeb7ceac", "159be188-4a87-46e0-b33e-e86c68822a30", "b89c3c52-4f18-4e8d-846e-85e855133ab4", "b5b8adbd-bb09-4186-a243-9904aab15541", "eec6d4f3-1e1d-490e-97f4-e3b26eecd029", "be85fbee-c97e-49bc-abf6-bc508cb41225", "fb8f314e-1034-4bcd-ab18-ae5c5c13c040", "f421750d-025c-432c-9af2-59730b621e0b", "a59173e5-8dcf-48a0-9662-05ff58f0dc65", "beda16bd-81fe-4517-9f4e-1d24e6c33aeb", "a0eced27-752c-4b58-83f4-fda3dfe4dbd4", "fa96991a-ebf0-4e68-8e80-2c8095c4ea1f", "d68c2e67-142d-46f1-8819-dec121e7da03", "a3dd03da-299d-4c58-b893-5b59f49373c0", "94ee9b4f-3cff-4d56-8bac-7c39a6c93693", "c51f5b47-d4ba-41ce-b6a3-dcfea731212c", "fa768a22-2ae8-4edf-bd74-840e83a47126", "46555894-7e9b-4c08-a6e2-67bdb18edbdd"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nnonlinear is the word we've adopted.  And our second quarter results are a good e xample of the unpredictability of \nthe pace and the trajectory of the recovery.  \n \n In addition, the pandemic has caused customer needs to evolve, and we've pivoted quickly to meet the \nincremental demands and needs. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5cac0380-8059-4b84-9a94-8c07041ebaf5": {"node_ids": ["9b58f1b9-2469-4d1f-b4fa-2e6582e98a61", "1beb06c2-80c0-4bce-8c7f-1a71bb151bd3", "c8a45a34-3b28-447e-b13e-a02512b32278", "a2e78921-fa04-46d8-9ba8-1fa0cdc21e3a", "b89867ca-346f-45d4-97fa-597aa7276bee", "7b71177c-939c-4cd9-bdc4-4fd8bf4a5c76", "3d06f08d-51cc-4928-bbb4-25a1f3d5ad29", "2dda7f2b-d0ee-4b05-83bf-2bf7c6267252", "39ba1757-a428-4e8a-9cbd-e55d9db2c942", "6fd6e858-d5a7-4817-b6b8-9440be130d30", "2e8e6fb3-fb47-4cb6-b85e-23fe6ac13fc0", "0bf27108-e6b5-477c-bbfe-e7753cd3014e", "09f89967-f6f1-4c2a-8248-178af3867765", "a6d17bf4-a02a-4313-aa2d-c2ce7cab50f1", "b915ce9c-0b46-469f-8dbf-9b6c37f03419", "91b88300-59dc-450a-8b4b-1276f89c348a", "12d51299-4caf-41b3-80a3-61284fbc85d7", "68828cb9-6c0a-4d48-b3d7-eb97b6f32041", "9d342053-5756-4a9a-a83a-bfbe2891d354", "f8032eb5-67ef-44dd-b72c-43339a9118fd", "10c11773-a09c-4f04-9003-275abfa23c4f", "557abd74-169a-4351-ac5e-3ed6af2f6af4", "e0c49e85-2a11-4780-b182-9cedf32e81d3", "cf574893-bc69-4742-86db-cde785edf694", "9da630ce-fe3a-44b4-99c4-3ed774519aa4", "37ad1863-9ac5-4598-adb9-831f0eb682d3", "03ce59c9-fdcd-4cd6-bc46-fc848b8131cc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nprocess and a vaccine has not yet been approved for distribution, our role in Operation Warp Speed has been \nand will continue to be our company's top priority since we were selected by the CDC in August.  \n \n We've been working to scale up the  infrastructure necessary to be ready to distribute approved vaccines as soon \nas they are available.  Given the uncertainty around the timing and volume of vaccines that may become available, \nfuture earnings tied to the distribution of COVID -19 vaccines as a centralized distributor for the US government \nare not reflected in our current outlook. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "19550c90-5f96-4757-8fc8-b4b3ba17e7ff": {"node_ids": ["bb122474-0272-4582-8d26-aef23e492659", "447fd27a-400c-453b-968e-5860d0dd737e", "01d00602-0657-43aa-a299-966c45055e39", "484b6787-a8bf-4266-bc4b-b864e4ffbc45", "98b954ae-5c78-4c57-ba85-81375fa8f1e0", "f922f7c8-1b59-4ba0-908a-5812f27efce5", "0b0c9310-8d76-4c8a-a60b-0151e6befd71", "fef7e26a-ed63-4480-acdc-c904f24988e5", "7e0e04a8-14f1-4110-a089-8439922003d5", "dd4b8e71-0f7a-4e9f-982e-da653868d40d", "4041fb0c-ae9e-412e-8fb5-02e2ced8a06b", "8cc1e46b-a2b9-4bb8-b152-c12427c89d1a", "85470ae1-ab08-4bd0-904d-8ced01c5e327", "20996a86-179c-4124-b4c5-ad53616661b4", "5648997c-0402-4542-a16c-ed89921e828a", "0bf5634e-29d9-46a1-a2b8-79002497850a", "59d5af51-1c5d-4fb2-adc3-1f49da83e9cf", "b1113f56-34dc-4a30-a210-62ef4adc371c", "ec05ca3e-b3a0-47aa-9767-01f9b8f618b0", "6ded22ea-6e44-4929-9c1d-3c972fe46057", "c89da44e-4797-431d-9dc6-ce28e181f175", "40314b4d-a7bf-4b4c-a183-2deca2b36d40", "0ec2d565-505a-46f8-96a6-22ffe810147b", "e0881548-b614-49ec-bcba-da5ea76b438d", "13d2e301-7e95-40b6-b297-0474ead6597f", "67860bd9-b1c2-4dc8-a059-dd2aab87878f", "ab0e6971-8356-4952-bf60-4c2bf8d0953c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur Health M art franchises continue to play a vital role in community healthcare, as they roll out COVID -19 testing \nefforts and expand immunization capabilities ahead of this year's influenza season.  \n \n Transitioning to our International segment, as part of our segment realignment, we brought together our strong \npresence in non -US-based drug distribution and retail operations in Canada and Europe.  Together, these \nbusinesses are positioned to further leverage the company's global footprint to drive value across key \ndiffer entiators like the company's owned retail pharmacy assets.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "d964d354-bff0-40f6-acef-781e7ddcbda3": {"node_ids": ["06be7699-8424-4c9c-8d81-95bc5eeb3ea5", "7d5b48d7-85d7-4c00-88d5-8292c610eabd", "d00b4317-f51e-461b-911a-4998c0cb96da", "17fb00bd-fdcd-4bed-ac0a-918088bdcb70", "59ecd9de-9b3b-418d-a58e-2a16c4b78758", "3cc95782-b51b-4a2a-81b1-71b0f2588da0", "3f458862-b0ce-4d3f-8133-378c890ec6e7", "fe3677ff-d66a-423d-a4f2-bcb1c547ac17", "213a8d01-729b-4925-b707-1aa53b45b4fa", "f0c0c23f-a3f4-441d-8767-6b67883d0c32", "85e5f92f-9765-4151-b8d0-02dca00ff98c", "08f13952-574e-46d8-8109-a064f88ac190", "2ce100bc-d58f-49ed-8abe-1fe597321a51", "bdc1a40d-9ade-4649-acba-e41d676fce7a", "bb13e090-ea4c-4ac7-a5a9-926dea001897", "58342e23-d19c-4ca9-bb29-5b5f3cdff859", "881180c5-48f6-4db6-9eee-b8de937ea9df", "7bfce775-91e8-4c38-a42d-12fdcf8abd0c", "d72e59a3-95ad-41c5-b0e1-c721a4a1f6ca", "8e057b55-0490-4d22-96bc-c6a1cf51f22e", "d2ce4fa3-4b86-44f8-a336-bc751b03378a", "b1ec3cb6-983f-4b5b-ad81-f22ef4992f26"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOver time, we have acquired capabilities that together create a broad set of commercial serv ices businesses. \n RelayHealth is an asset that's been in the McKesson family dating back to 2006.  This business processes over 19 \nbillion transactions a year and connects us to over 50,000 US pharmacies, giving us access to the workflow of the \nvast majority  of pharmacies in the US, with the goal of delivering value -added services directly into this pharmacy \nworkflow.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "13d23129-4960-4cc7-af95-389a0c0d6697": {"node_ids": ["81b6dcf9-bf71-40ee-8605-e21a996b6a85", "d23e1f3c-3377-45e8-b3b3-16ae8e7dde41", "368d2ae2-c328-4df3-a230-c766bcde3eff", "5b2f5128-c7cf-4abf-8b89-779f0150e03a", "85d687c9-672b-46e6-a53f-f809b5910d45", "f510d8bf-f809-4956-97e9-ae5ee81437b6", "89591fc1-cb60-4c14-9d8c-60b500014281", "acabfbd0-24f1-481c-8241-3cb712b65744", "bfa7f71a-f92b-4357-b8e7-c6ab71de066e", "c4da77f1-638c-45be-89b6-361004092b80", "e27299bd-8f40-4c12-af8b-492a392f4e98", "31d50cda-1b18-4b92-9e91-66b42613d643", "56ca2338-383c-4156-b536-2aaf11ff5858", "71333dd6-1421-4fad-bcd5-167c766fbf11", "4ab2dedf-397b-4326-84e8-7d7243f04192", "4db34b4b-0351-4ec0-bf6b-54045210c891", "5d8f78ec-08a1-4eca-a2fa-0e283370d169", "9200f140-9cc6-40c7-b1a7-c0fa9769bca5", "109f2840-c7ae-43f6-87d2-5a01b500b366", "13377c9d-cd52-4502-a15d-254cbb9094e9", "7da5e19e-5d32-4bef-999b-140bafbcb6dc", "4d6a699e-d61c-4087-8ce1-5b0067369d2b", "643fbba6-b279-412e-85c1-d96b9d917964", "48f80638-24c5-460a-8172-800ef8ec4f2f"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOn our first quarter call, I talked about the biggest theme through the pandemic would be change, and that I \nthought McKesson was well -positioned to respond and react to that change.  And I belie ve the second quarter was \na clear example of how McKesson shines when faced with challenges and new opportunities.  Despite an evolving \nmarket landscape, we've remained focused on executing against our priorities, which now proudly includes \nplaying an even larger role in the fight against the COVID -19 pandemic, leveraging our deep expertise as we \npartner with the US government on future COVID -19 vaccine efforts.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2989bb78-334d-425a-9ec3-3e667aa42e51": {"node_ids": ["99817f68-c552-4db8-8234-886f8fc6246c", "a66c3684-5e79-43a1-9690-d30d39c12d70", "04d626f7-cf85-4b49-b389-5c21ee79fe9e", "79653d9b-dbb4-4b0b-b761-80b82f0ec569", "5080262e-06d0-4596-a7b6-accbce816414", "9351f254-eeca-4f5a-bb8c-1622e3de85bd", "41344b54-a2e9-4e16-ab59-d47b15685456", "cad915c4-9036-4588-879d-27ea909e64f2", "284badfd-c1f3-4e57-9994-826a3f911a83", "f3c43a67-0d71-4e7b-bb85-5c4ac96f81e4", "70aee11f-6346-4dce-9418-45ee0c57889a", "b11f41b0-ba70-41c0-9854-d77fdaeb7a1d", "ec55db0e-b7ee-4fc7-b49f-f091d34ec653", "747068e3-cf15-436d-a008-ccdc2c0d6a29", "fe853fa1-eafa-4b3e-a2cb-c719ffddde0c", "ada048cf-2705-4ff6-92a9-a04d82a13d79", "1dc37204-f1a1-48e4-ba66-750c16b41da7", "0ac813a9-65a9-49b0-bbfd-48b1968c8d78", "acff1dbf-0995-492d-9efb-76c3340225b7", "a7098573-2d39-4f8d-8f0e-1b0b80e519d9", "cd52d963-2443-432a-b2da-935c79b52bd8", "d18ef9c3-5379-4c05-8d95-af610a441cbd", "11583a9d-d48c-4db2-9a1b-fd99cae37e40", "29c9cf25-4f6b-46fb-aaaf-5960870387d8"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nFirst, within U.S.  Pharmaceutical, we recorded a pre -tax charge of $50 million for an estimated liability related to \nthe New York State Opioid Stewardship Act or OSA.  The charge is the estimated share of the New York OSA \nsurcharge for calendar years 2017 and 2018.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0b1fd7f7-0544-48fc-a193-41e5ab87342d": {"node_ids": ["cb452796-1e02-4c2e-96ef-a1a47e4a66be", "cf683daa-014e-48b4-aeef-f5d291c1a8d4", "0e686490-6e76-4e59-805a-845f9cd23c9f", "ca99d896-b0e4-4f85-8952-16425e808a94", "fc333dbc-39c7-4e4c-9f8f-3dafc3f6283a", "44509b68-5be1-4883-9501-91f6817d8950", "97e1b638-1ec4-43bf-b6e7-5dab6631dd54", "628c309b-fd15-499d-a52a-8a1a39769bfb", "36f383c0-9425-49c4-a407-ced748b5eaaa", "1c5716e1-01ad-4ae7-942c-26fd27d46f23", "2ae56136-fb7b-4aca-9b31-2e10ebeb198a", "19e4bad6-1ee8-47ed-add4-b296aed2722a", "83de34a6-a573-4ef4-b851-44715005d905", "207d11e0-7b96-44c8-9089-30b630e9aee5", "38926973-85ea-4c85-ab65-f2558b1263d1", "9f78c7d7-f9ad-4d06-96e3-25eacf310247", "3785c2f2-5351-4f11-bb22-f01099072f3a", "e78f5308-0232-455c-938a-084dc27583f4", "f8dd868b-653d-4501-9419-f090c2b45494", "24332a6a-5bf3-487a-bf35-d4268fc80e1e", "235109be-f4db-4c06-b934-3a34f05656a6", "358d0956-7a0c-4cb8-a410-18de14ba5e1e", "fcff213f-5433-4515-a35f-f7317fb49cf2", "35552375-67ac-4520-aff3-5dbfd621ba28", "5f86cfa2-2645-49e9-8cd9-bafd6795adce", "385e4aee-1f66-4237-afa2-2e8194fe24e2", "af591777-70f0-43e7-8ce7-93bbcc37218b", "8714f82c-f055-473a-864f-73be59998030", "afee8698-a687-42da-8a9a-5a67060b6ec8", "004f8e69-16b9-41f3-adad-47b7b657a1cb", "9cc7f4eb-9a05-4043-930c-da1977280c55", "0d0eb489-fd65-4005-a43a-2b68cf4e6f91", "71dbbf7c-f364-4d5a-9477-59fc1ade8521"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nNext, I'll review our second quarter segment results, which can be found on slides 5 through 9.  As a reminder, \neffective with the second quarter of fiscal 2021, McKesson revised its segment reporting structure.  We now report \nresults in four reportable seg ments, which include U.S. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "9626c25a-11b2-47e0-b378-5811bb4653a6": {"node_ids": ["34497735-d302-4efd-a43d-29b3886ce3b6", "d6ea87a8-d9fb-4648-a4aa-681eda4d4da1", "4737085b-5ee4-49ce-b203-056e77e3fa18", "79292547-fd87-43b9-9426-4403d6687deb", "bf7fd448-8a96-4c37-81cf-1e9b5686a15b", "cfc199ae-e89c-4ee4-9510-506e85967d84", "f0d59686-f80b-42b8-93bc-f9af021287be", "82d75c38-fa59-416f-81ea-b1c1249fe97e", "304ed8b9-9b6d-42c4-9b55-86d780ac1351", "4f95db83-e739-40fb-9f0d-ce8888a1331c", "469849f5-3d85-4edb-ba11-15cbded7c081", "6b41b73c-4ac6-4d0f-af01-fa1dbf1f1331", "d24c778f-3266-4d84-8941-b31595241abc", "fbc48e75-b81f-403e-ba5d-8c9199f8dc94", "ad589ec3-105f-404b-971e-3b8f381b311c", "b72c5771-c5ba-489d-a2e1-8b9a2895839c", "1e734949-51d9-4955-9c77-0e7f02cfc427", "9375b3dc-e28c-478f-9b27-7238535e1dae", "03b563c3-e182-4507-80b2-be8c301e8c00", "e1cea6d1-9186-4f69-b981-59217e0ce3e1", "e4f877dc-4cef-4c00-91cc-e6d76982494a", "697ed088-6026-46dc-9879-6ab3487fb66c", "107ad55c-a6b4-46fe-a50f-58d4b0318d80", "f4dfc77f-3058-4c8e-b96d-a513dafefb84", "c3efceb1-ef42-4dcb-a662-cbcdbbc80547", "d3662475-0c68-4d97-853f-c15e6ea2901c", "bcc94ab3-2d4b-46c2-822a-d30d2efd300e", "3ae10751-f739-46ba-b288-d626f4b472a9"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nof our technology offerings for our retail and biopharma customers to support the future operating profit growth of \nthis segment.  The segment adjusted operating margin for the second quarter was 15.57%, down from 18.37% in \nthe prior year.  \n \n And moving on to corporate. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "81b0d965-d238-487e-a107-7fe09d3f7fcf": {"node_ids": ["2b69d287-7fa4-4682-89ba-fbc935be6917", "7e99d861-5dd0-432d-a064-ee9cb69a4ed9", "8db7d773-1cde-4087-8c2f-78d55e867c60", "be7f5bfb-1606-4da9-94f4-34315c9451fc", "883d0e3f-9b00-4ba5-b5b2-d6a3df2afc36", "104a1641-04bf-4d1a-bcb2-d2252e4502ea", "76c2234a-2fab-446c-aa82-1a88569fea67", "ca030fd1-c851-4234-bc2a-f77a8ae36586", "d9751d62-ebff-471c-954f-271abd1b5410", "492e82bd-5524-494e-8393-207e178452f7", "430f2993-01bd-412a-a81c-e447b9375336", "9732e4ec-c16b-4328-9478-d68b089f64fb", "f83493c3-d368-4a19-a4f4-4130be60582e", "0fd5e168-256e-4a30-8964-412f523a2b5c", "689be454-3a77-484b-93f2-37206fb3f37d", "6f21ca65-5aac-4589-8be3-a5216fc15afb", "24eee756-b4f3-4a11-8c06-d7ab10e8c00c", "8d406279-487c-4264-9cbf-50a89ca7544f", "34ddf94a-9bec-414f-8085-0033df113baf", "d9fd8132-0535-454d-9d0f-9351da7909ff", "0e4f8e28-b118-4587-876a-436fd4cfe440", "22073531-06c5-48bc-8cf5-cc133bf1c945", "e3694065-ccbe-4066-8c4c-ae88effa2f69", "4a3cab22-b2fb-42a1-b3d3-37eb902b9b2a", "65038fc3-505a-4c36-a921-46e6d62d0047", "5c759395-b778-4b80-855c-37852cededb2", "a208060f-ce6f-4573-b55d-30c9efbdcf16"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nThe no nlinear nature of the recovery continued in our second quarter.  As a result of our second quarter \nperformance and outlook for the remainder of the year, including near -term opportunities related to COVID -19 \ndemand, we're increasing our adjusted earnings gu idance range to $16 to $16.50 from our previous range of \n$14.70 to $15.50.  \n \n While our guidance does not take into account any revenues or earnings related to future COVID -19 vaccine \ndistribution, it does include volumes from our kitting program in our Medical -Surgical segment, which I'll provide \nmore details on shortly. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e4e006ee-96d7-4435-b226-99b78a3d5b1e": {"node_ids": ["bce708e3-7103-4f4c-a87a-5e89b7005199", "0fbd4b4f-7c30-4d15-858f-adfd8078e25f", "525c1d4a-4f43-41d3-8004-2f52267f8378", "cbac8b95-974f-47e4-8c53-b0a882dba469", "c311d376-9ee9-49ab-ba79-9c18cc34cb50", "b133e3e5-95bf-4a8d-8bda-7edd9a37b013", "ef33d0f6-5f22-4dc7-8c93-d5717d839aaf", "7f3867f1-0076-4c8a-b852-d89d639b3be5", "1644836e-3914-41dc-bc40-79d7eb82dac3", "f297ce9a-27a7-455b-a56c-ca9d6a9e0b18", "d4dae317-6674-46cc-a0ad-ceb22b74526d", "e7466c40-eff8-4514-8ab0-a05e3000cded", "6d82a48d-3bc1-46c6-972e-21262b0821cc", "251f4a41-6beb-4b54-b368-c7a1bd9808ce", "d86f7aab-b552-4bbe-91a3-415d25aef9bb", "b23e89c7-3707-4c86-a935-b774e3baa6c2", "80438911-4b64-402a-b16d-a6b822eebb49", "dcba99af-1ca1-4db5-a588-7b0b2a924684", "3a96cfa5-c5c7-4a3b-9f18-f0bb67cd4989", "2c3db873-b00d-4c53-8fb9-c2413c448c9a", "454a9c20-ba63-4c50-af45-1edaa9e936d8", "b7a746b9-7698-4cce-a2d3-d546bd47059f", "86cb85c8-02f1-4bc8-b8fb-8b50aade4aff"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nMoving on to corporate.  We now expect corporate expenses i n the range of $625 million to $675 million.  Our \ncorporate guidance takes into account increased technology investments and the impact of our second quarter \nequity investment gains in our McKesson Ventures portfolio as previously discussed.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "1e1d74ea-3e0f-405c-bd23-a7fbbc5158e5": {"node_ids": ["d198b7ae-1903-4fd0-adad-c80e1df97d9b", "08919262-c666-4298-9f5f-deadd6d00ee9", "a68c8f72-47d8-4538-a4ab-3fd1416fb421", "30d609df-dfd5-4e95-98f6-53b24813fdf6", "74304ce1-f520-40d4-8cb3-794b2be40f37", "b4a4fd84-176e-4cd0-b243-69c5c5cb5c31", "9da12cae-b6bb-4318-aed6-b6b18860a4a6", "b9433b1c-d7fc-40db-b94b-1440859b4ff7", "9603f71d-5a51-4198-bae9-c44de78c5a08", "ed767a5e-e2e0-4b74-b95c-abb091755063", "73246742-8cea-4ba5-8805-b4c3a458d355", "ad2c18a0-d210-4478-bed9-f5373d63d586", "a068e472-1b21-4466-80ab-8c41105b38ba", "970ded1d-eb35-4306-8fb5-3e07ab0ca50e", "569fdabb-4cca-4cd2-8fd7-98111ca55de4", "c250e829-a07f-4203-b08c-fc167bde1375", "ecbf4371-65bd-4d00-a71c-cb004cb3b5b3", "1a7eb11b-938e-42bb-bbc5-7f81fb645db0", "adb983bf-fc80-4a3d-8f85-816393097273", "f071b475-2dfa-4b72-8386-d4696468bde3", "81f3b4d3-6ac3-416c-b961-9ef04ef19fab", "3c696ca8-0be5-43a8-9886-85182f864bee", "067716d8-691c-48d5-b9b3-5efb06e4d26b", "f231061c-2542-4519-b0ec-77c822c172fb", "9b8d3836-7571-45c7-85d9-8bdc7a651e77", "c06fb672-a916-4321-bcf3-f7ef000f8862", "b46de158-df7f-488d-a164-44f031858c9f", "269b903f-d595-482b-875b-f8d4979dbb30", "91899606-e6e1-4bd3-8047-221bf6322263", "660a32db-9859-46af-9b58-f719324a3981", "e62903ca-1cde-4899-a770-0d7fdf3c0999", "72e02a3b-0d91-442c-ab7f-456edb67ca2d"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n \n \n \nThank you.  [Operator Instructions] Our first question will come from Eric Percher from Nephron Research.  Your \nline is now open.  \n ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e0272ebc-50c0-4c16-af25-22cbfd264179": {"node_ids": ["28ac2ad2-2ded-40da-b03e-31bf0181ded8", "9f8706ac-902a-4bf2-9d05-93025a7b0702", "e0967196-a6e7-45bc-bf55-2b7d25cd52d3", "27256c29-4245-4bc3-9370-f0ad86d8f7f7", "c498d0ed-8234-4c09-adfe-b759638d6d60", "6d635ec5-4a12-45bb-819d-0956a72f8560", "ee4137e9-6a1c-4f4f-9b77-c3a1dde4d264", "7c5a93cc-a44b-4977-abb3-0c2e7ab30c7e", "94884a65-f0ea-49c7-83f0-1cb7ffdc278f", "d5ecaa08-f479-474e-92af-f8b7d22eb988", "748a7a2d-f33b-4fca-995c-b53c6d5880d7", "e5e788c4-f952-4cd6-8cc0-d6f335d0d961", "be5b1b35-253a-404f-a333-442874d7e4a3", "c7a95356-4b98-4daf-a03d-171201c33f80", "8ab9153c-62a4-4a1b-8f8a-6cd4a7a48aa6", "5e3daa55-de69-46aa-b25c-2b53b2ccdd24", "267df6a6-2283-4aa5-9a15-de18bdf91455", "f407262d-7c13-4949-8849-a6103972a6e2", "cc6011b1-2b3d-40b9-9755-62ce3c32ec01", "c54c4ff7-3dc2-4071-8c47-aa2b7c34a707", "37c8a389-7d51-4686-889e-82473d148328", "c6329dde-1100-410e-8c63-28b4653eb53a", "9a8194a4-04a7-495a-b502-3ecfa1c1df71", "75c48052-a4e2-4869-9696-f8bf4edf5622", "0220677f-e0f6-4885-978f-08f2f811043b", "e0c7caba-81a6-477a-b66d-224da74a8bc0", "2f8e253a-b7a5-46ab-a4e8-bf2c30724176", "6c694b8a-edc5-401a-83ff-59050c4a8eeb", "fe0ddabc-fd4b-4091-bac8-c057e2184b56", "26747cc6-7dc3-4f10-8418-5b1c18df0b31", "5e697210-982a-46b9-bb30-2d11ea1a3fd6", "78e8b9b0-f173-4d85-93ff-b7207e4e7462", "1e4cfc30-5871-4b3d-9ccf-6dc34cb29542", "acc53dbe-4107-4c48-997b-8495124eac69"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "47336f7e-6a2b-4e92-8b2d-13253b5b1f65": {"node_ids": ["9c5c6056-d497-45a1-9572-bcbec6b7d294", "2fb789ab-a4a2-423c-b15c-cfc1dd40aabb", "fdbd590d-fe5d-4eb5-8ee6-ca7dc5c008aa", "db9d0db2-0d30-4a58-9e99-a7bb01cb25a9", "a898b39a-b6fa-47ab-8fe1-bf800c18026d", "ddb6d2b7-2e14-47ec-b299-769ddc716015", "80a3d7e0-1b13-429c-b36e-c086739f2dac", "f4634cdd-4dca-41c3-8e48-8b343ca8ff5a", "553b5d83-2cf9-446a-8878-05bad1bcff00", "965218ce-8521-41ad-9852-58140423a408", "5512b3da-092b-463d-a3a2-b8001c27492a", "532c4d51-400d-411f-aea2-c17f8c127fd2", "5b63520f-7cdf-4206-81eb-fa2a2d48fe9d", "39647126-04c2-4c96-a634-0360f35e7692", "effab34a-b17c-42f7-b8bc-36e4dc71a1e2", "ad864e59-9c5d-40fa-af99-5410bfcb3878", "e5c67827-89f4-40f0-b747-ec080e541fed", "2b928ce8-7d26-4947-8f93-8af90acada3d", "423edd0c-89c7-4172-8947-0cf406b4a587", "860ea337-c813-4922-9578-b3f557b2d079", "d72f4b2c-2318-407f-9875-fbdb38e81a2c", "4832c9de-a31c-4675-936c-009d8a2e2907", "3f392a4a-bec7-4817-b88a-87626b6654d6", "ca9c7b12-8f3f-4740-882e-f3f369b45330", "908b6883-3f55-403b-b00c-928f25738a9f", "4b530ef0-319f-41f6-8113-36b68ca9e953", "e4ceed05-6a00-4e0a-a57c-1bf5104d6baa", "45932477-dfc5-4998-bf63-ec15a1c0d406", "5d869fe8-27e4-4a9e-bb54-dc7976adb53c", "2ba6b5e2-be2c-4628-9d99-174bd7677bb4", "1fe567d8-c335-42c5-bfae-27cb9253b607", "19be509d-6b26-4501-93d5-33e03855d76e", "ccf3f1dd-f01d-4a78-ba39-b4c3f0425393", "10a56380-0ca5-4303-8248-2de4647e32c5", "1441197e-591f-46db-9315-e1ae12772806", "ab116df6-e7cd-42bc-90ff-0ba38088c40f", "02fd1170-7c2f-4943-a9a3-09438c0218b1", "6a8129d7-017b-4e31-a7ae-70b914957b2b"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nYeah, appreciate that question.  I'll start and then Brian can certainly elaborate.  We have been making \ninvestments into this business. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2ea47e19-e47d-4fb6-a71b-6888dfce66ba": {"node_ids": ["2aaeb0a5-589d-4de7-81b5-2114961eb165", "c5db4b3e-2635-4913-a011-b1e6b0233e92", "2d88e2a7-efcf-4c1d-ac84-4de2125fe996", "216af6f7-8578-42da-9068-171d3cef9877", "ff22aa49-5557-4d52-b4e2-9cb5d057dd9f", "2d7fbdf6-4fd1-4f6d-bfbe-36ccb665f8fd", "95cdc8ee-24d6-486e-8a3b-9dc8440911ac", "c43c63a8-ac50-49f8-8615-d31a8c310236", "9e76c317-276e-4f2e-9382-f2c24caa51a3", "093a216e-b8a6-4d0b-ace3-20716a5c1167", "20010948-eafb-4867-bd6a-91499c7f582f", "d1054f49-879f-41cf-869d-5839345048f4", "a5dc21fa-3031-47d5-8f59-e462ba5ec667", "60bffb39-a7e5-4797-a394-cd5846f0cfd7", "ddb99fdf-8637-43c1-8316-53cd70f356e9", "7eb400b7-77a0-4805-9e0e-2c9ee4da08c3", "8d5ce72e-5d04-41c5-a0a6-ffcffc8858a1", "215ad2a5-4aba-4df3-88e7-94a01ef29edc", "282d9598-72da-4796-8184-e578cbabc78f", "e4f56e62-e43a-4671-bcd8-1650e43ebaf3", "60b2b852-ceb5-4ee9-80a4-59ca073b37d7", "dbf30737-0edc-47df-abc6-364f5e400d23", "916ff713-4525-4385-88e4-c95058045699", "1afdc28f-e8c6-4471-800c-55ab929b6701", "d165e6e6-d04a-47c6-9a49-1ef46b641609", "53046e13-95d7-470e-bea0-29676f629017", "26e3c629-25ee-4806-8d6f-cb1a6fc3ffdf", "50a6efb0-0129-4c41-abf1-f618b7b5145b", "527847f0-57c9-403a-9af8-0af8e6619a54", "064cb640-629e-4b9e-9486-1d2154f584c9", "765b38b6-e349-4732-be4e-4c6d5fb0d03f", "f84a80b6-9dda-4e02-9a8d-2ebfb859e47e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThere's a lot of \u2013 the demand is changing as the year goes on, and our sourcing will adjust to that.  And so what \nwe're really trying to call out here is that we've seen a lot of demand in the first half of the year .  It's been kind of \nvolatile, and we would expect that we'll see good demand in the second half of the year, but certainly not in a \nstraight line, but we feel that the relationships that we have with our suppliers put us in a good position to meet \nthe cust omer demand.  \n ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e8252d69-2f41-4589-b620-a9d3a9e021b5": {"node_ids": ["5d548e97-62fc-494d-860a-619720b66b06", "79843188-dea1-4c74-a1a4-bfcdfc0ae45c", "7f4bda3f-0512-4f7d-905c-d11767c01716", "422c30fa-431f-470d-94a3-8d4f656ca883", "d56f18b1-0908-45c4-adef-b683db9aa321", "a998a922-4d35-48c7-8d9d-7f2e9c8b686b", "c50dbf64-b2dc-494e-b5d0-ac72ae1272b5", "3a8dfa99-e104-4a27-a914-99814bf75d5f", "54e4c0b2-371e-43ee-9f1e-c9388dbb0aa4", "ce340f7a-8aea-4b08-88da-76ca24101d65", "dbe17c5a-d057-4f31-87d2-cbc0838c8df7", "715ddbc9-5b9a-404c-85b3-1a8230b24851", "20412bbc-695a-4713-acbc-f1b25483a914", "0e920261-aca9-4f31-a8f6-e7506a2ceabc", "eeb55b92-343a-47d5-8cd6-055b5c5384ae", "5a409262-cc95-44db-9246-9aebb6ac14f7", "b89e82e0-843e-4c15-994b-606133e1de20", "d38bb160-8e29-460c-bad0-4b261dc9ddd2", "7b7085e7-2546-4b46-8c65-8c8b57c1b2fb", "d72ff356-f150-40db-a291-614e3a18738c", "e12c53c7-a55f-456f-a21a-15b335caa639", "20e31d97-f68e-4b5f-9ce2-cc8c058204ed", "263b706a-f418-410f-af60-272221aeb4e0", "1752a535-a875-479c-a275-644f81aed58b", "62898a87-77eb-4f21-9539-81c5dab2ddc9", "5c2c4264-4d2e-4ed8-ba8d-0ab81cb602f9", "a6d07df4-9b50-47da-a786-190855858c3f", "1f305ad8-251e-4dff-acd9-1628fe7fcb33", "6fa22962-8510-493c-964f-dffa34660aa8", "c53ec9e9-b824-417c-a9bf-256a1e0858e2", "16428e95-3f70-486a-ac59-804031e59d51", "6b7ce324-9cf5-402b-a332-f88305bc06ac", "26bef61e-3f39-4746-a9bf-8414de30d18b", "2a9657e1-dd6e-454f-9a1d-16f2a1b8e591"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh from Credit Suisse. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ebbe3133-02cb-466e-b644-dc3fe310cf85": {"node_ids": ["9f83c7a0-6def-482a-9c7e-08e263a5201c", "382a82a6-9fc1-4e09-b54d-0bdddc7a1f00", "1e6f6582-8478-4746-a3eb-ce2ace917f0a", "4471ecdc-9c2f-453b-95af-a94602186510", "27b8acca-1ce8-42c8-adec-ad3deece5aad", "89b1641a-52bb-4f6b-b4a9-5e2259105d09", "4474c533-3735-4e03-be6f-68250069c656", "01402b73-3e34-4517-a43e-800a4efec9c3", "e7707368-8eff-444f-9f76-2d1d42794241", "2d704301-8170-40a7-9766-9e64fe5c6100", "18b693a4-17c5-4206-87f7-1178dd8fa271", "8bd329a4-aa90-4719-8c21-eac48cb23de7", "99affe29-985f-45e0-8cc3-89b2be97c981", "c4504a48-35a8-4f31-91e1-89d26fa70e91", "d426472f-11ee-4227-bbba-6b970cb87414", "4a234865-ef4b-4827-add9-ff42b919acaf", "29125a5c-b1fe-42fa-987f-e6fb4b7cc610", "3f4f8438-f815-4e14-ab29-313373b4a562", "9741a7d3-b0bf-4a52-94f1-14663483589f", "5c6f7827-011d-46ae-9d81-b687a7768af9", "7d82ea1b-6093-4147-b79f-2918f4a5c85a", "fc4b2210-07db-4da3-9101-d820a5f20055", "011d81f6-7ce1-4c0f-b176-813a9cc1ba1b", "71e4d6c5-3151-4b8a-a9e6-513c454fa036", "c2fe9bec-417f-4d26-9710-c8a92c6017ae", "7267ea8b-b1a3-4790-af7c-bd198da4fdfb", "d10d99a3-7088-41c0-b29c-9bf41c385b45", "4efc6048-464c-4e25-81ea-d820ae9ace53", "f42d1e67-0a93-4569-89e2-6f841d4b0dc9", "0727410e-fab9-455f-8b05-e8e468c323b4", "58c4d42f-061b-4d11-ab8a-8965a72528e3", "74ec36ca-71f7-40e9-9176-4f5c2d0db9e1", "17a53090-2a73-49ba-9ef4-0e16b8e7b6be", "610041e0-3163-4e2b-81ee-4de62f5802a3", "4ea7db7d-80a1-45b9-9f0c-38d8730417ba", "897853c0-10d2-45e9-bb0f-7845b82564d9", "15590bfa-36d8-4a5b-b10d-0172883b6f40", "7ef6ef01-3310-4c8b-b19f-e9b69569070e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nSo heading into the second half of the year, ou tside of specialty, which I know you already addressed, what are \nthe key drivers to support U.S.  Pharma revenue growth in particular?  And how should we think about how those \nshould drop down to the bottom line and incremental margins?  \n ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "31926609-9d2b-49e2-b1bb-39cf3b523242": {"node_ids": ["6653c9e8-2d1d-42a1-80ee-f290f0523113", "6763a7cb-b81f-476a-8f39-33940b76378d", "7e2acc5e-7404-4820-bb95-6966cecd433d", "9e93b593-5e88-45a9-be1f-d61cc95b263f", "32caf227-5b24-47dc-8132-68b2520c4090", "a8e3f6f4-00ac-4794-901c-50d5dd8ec549", "3b753337-e36e-40d6-b95d-564b750fa3fc", "1f364fea-36d8-4794-aa0e-a872b578f2a9", "2e03b01c-d787-4c38-be0c-c2e4ff4bb530", "f44cdbf5-6ebb-489f-b333-bfaf5995d371", "182942ce-9c93-4871-b1fb-e99693438cbd", "42469098-9d35-4f68-a2dc-fdd3c87ee8bd", "6a3d7bf3-a375-4456-afaa-a8b4fee2a6f5", "7c2ca445-4f9b-4401-8498-8ba0f52273df", "ae0399d7-f189-4a91-8354-b84196ff6035", "1dfe7a14-1244-488b-928d-30a372d1fd76", "68855162-6900-4938-8a24-a148160f0b28", "71da4a22-2e82-471c-a3e4-a84e6e6ea10f", "1bfc12ce-c94b-4a97-85bb-439deb1123ab", "d6f911ce-402d-41a3-89e5-a2d841075f80", "45a86a4a-daf8-401f-b332-b57dd9f909a8", "6cf77d6c-a5e8-44a2-8277-09eeaedc304e", "0917cb20-07af-4439-ba07-357c82cc225f", "cc348259-b108-4403-9f78-790afe9a9192", "bf1e0d29-eed4-488f-956e-f2d324b894ed", "45c3f3ef-8452-48af-adca-ff9e7638e2a1", "3f1aa2e7-4d27-4efb-959c-95cfe70d872f", "2f48b301-5558-4d92-adc2-b3af4bc2974c", "235f2210-1ad4-404b-9fd6-1045ea1322cc", "96ea2223-6c0a-4dfa-9e7c-41ea202e4c60", "bc109ff7-eaa4-49de-9f72-ed913a15316d", "9dafab4c-2d9a-4914-87c6-fd2c7c4dab1f", "fa18b7d1-e216-4ef4-9426-d2a81fcb0b8e", "576b8e4e-97eb-48fb-a50c-ea2703c012ef", "095e58e1-3c4a-4c14-b55e-8e1cf05d0004", "0bfe3b00-6f05-43c5-bb42-27e425c32555", "f63e1fec-060b-4df1-a86f-a82d19d7e014", "9243b8bd-1e03-4d02-883d-731585e2a44e", "5acaf446-e0aa-4b43-b3b6-18052da9bc07", "ede17dc9-7391-4178-844f-abe0405e9098"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \ngives us the pause or the revised view, I guess, that we won't get back to full pre -COVID elective procedures, \nphysician office visits and scripts by Q4, but the recovery is likely to extend well into the calendar 2021.  And so \nthat's our current vi ew, and that's what we've worked into our guidance.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "6a602aad-f114-47a4-9aa6-caf07a332c0d": {"node_ids": ["9513faa6-6b66-44df-93ce-1df1d2670d87", "65e8dcde-edc4-4038-9bf6-ba191c17ea22", "624d116a-2a35-41eb-a7fe-1c20d80066f3", "feaa2b71-dec6-4c26-b30a-c64a25c5d080", "46430cd7-de77-4d46-87c9-1429b2294b0c", "e2db1e3f-4ef9-4c2c-9c2b-12d63c00d049", "7a2002e1-832a-433c-ba45-3d5360314dc8", "3e1094e0-2f5a-4577-a2b9-d515486de273", "f97e575e-6b17-428f-9349-42510d5608a2", "3dd1d8b2-0a2e-4799-997e-dabc250c59b4", "83596fac-b506-4adf-946e-163eb42d0c27", "96f9bcb7-8f3e-4a84-86fb-179596ed7c4e", "501045d6-77ff-49ec-8313-77e9c24e47a7", "29203b92-1213-4bcd-823a-1635e03309cd", "299f90d7-4bac-4908-8a41-f7a3a2750177", "e0619104-1553-4f64-becb-e9d5046dd5a3", "8885f785-7249-4be4-95e5-254a4165ac89", "9d7957e0-77a1-4078-bcc7-120a07d92122", "d84e4b6d-3a7e-402c-8aa7-d229de081e3a", "11aa230a-04fb-4e38-9e4f-f1491f013cda", "586323f2-c9f8-4d7a-925f-983506bae99e", "baff1a58-58dc-4fa8-93cd-df2946e2780b", "b555e5b3-c98c-4db4-a587-40c798d02091", "e267ed57-1dae-4105-a3cc-ee5b53e6dcbe", "00cf6a7a-7c1f-42ab-8915-a3853e2078b5", "fb81999d-c60e-4ce0-b0f1-d72998f4949e", "9b26a98a-d683-4959-902e-31045c781bf2", "b212d643-a520-4b1f-841b-f5c889d46590", "993e6339-b9f5-4a4d-8c6c-5f01f1ffed2c", "b66c6713-8645-4fe4-8f19-cc1d72f7a6cb", "cba23ae4-4307-49d4-9d46-2ae2f035a288", "6293fdae-5ef5-4bad-bc3c-863d786e221e", "a3227db2-0b75-4c34-a192-86dd6590d83e", "45d4df81-8d87-4599-83dc-d5276a4b3ae9", "f0da21d3-f961-4ff4-a0fc-b52bfce51144", "e6166384-3d3b-462b-9eff-4475c6cf0658"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nI'm thinking about the broader potential opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "9dea9387-b5af-4434-b4c0-7be2cc973ae9": {"node_ids": ["b414137f-a68c-4798-bd21-bfc1b2349af0", "5075313f-4e72-40db-8fb0-d4b9cf384c98", "ae201f39-aa52-4517-983a-d74d74a10c69", "5a16bc8b-54eb-4abc-bfb9-479aa1abbbbd", "467a11e4-e636-43ff-ae4e-9851c7a24660", "d2c9aecc-ead8-4988-9214-cf59f06e8aef", "c0036fc3-e019-4f00-8a7e-14623618fdbd", "070c498d-b52d-4ac2-a1b7-8c41e3f8f33b", "a0cc3959-3e02-4bde-b385-c1dd6609f6be", "83d352a7-f347-455d-8035-145532bef513", "0dabfe1c-fed8-4e84-be48-b8d928cf971e", "39b4b678-3578-4997-99f7-a5956c323b3e", "dd40ad81-8e74-4de2-898c-a867be1a5e1a", "48efd214-236a-4170-97c8-de5696f83fa9", "385af906-c2d7-4313-ad39-466c6c6f846f", "a3fce861-0f18-45c6-9d52-79c4246ebbf1", "d9eb6802-2fd4-41e0-b7ca-d82ad2c65949", "b58f3e8d-cb5a-41c1-bb22-63c3b2318a05", "91262010-03b0-4a86-8c34-ae4d8efcf095", "c20ee682-bc72-4bff-9fb7-bb8d2e5a79a7", "61bc2dff-fc49-4e46-96f0-ce4d553fd0cf", "18b9ff24-5dac-46c9-890b-8755f13609b0", "44593fab-f4d2-4158-8b4a-98e132846409", "ca0e5bfd-bb01-4ac2-b1ab-140e24699f5b", "30c084ca-abeb-477a-a61d-4719ea4e1c5e", "332a79e5-0716-41c7-977f-6635eef73cc0", "a7171489-4e32-483c-9043-dfc0fd368c10", "2da4dd28-d907-4a56-8762-f4399872cb06", "159861e4-492d-437b-8069-f02c94ed49b3", "e7e187d2-0f97-4d73-9d22-8f47cb3c5b08"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \npandemic.  But we're now in the eighth month of this.  And just like all of us have had to find ways to return to \nnormal business, we continue to be engaged with th e AGs.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0e914f33-8b8d-476c-b1d2-afc53dd32bf3": {"node_ids": ["e8dad0b5-a90a-41a8-8f47-f264db72b221", "8861020a-e8d8-4237-a961-1e9e56739ba9", "a074f47e-facc-4e50-a490-dc11e32ded80", "8ad7dfad-eff0-46e0-9d38-dbcef20478f7", "41136801-b83d-462c-abae-bbde043a7dff", "6a092bcb-a477-496a-a5e5-d5609c31b65c", "8fc85759-245d-4852-a638-990cbca048d2", "f11984e5-2127-4fe4-ae11-77677f2f0657", "6ac54769-8d83-4553-b5d1-60530d831c6f", "e8f2f31f-6906-413e-8b2e-46a02ec77196", "52aad118-b7f6-4ace-938a-daf6422be0b6", "7560585a-a827-404d-b6d8-06145bed210a", "f8a85394-9ed1-417f-afe0-50f443faa7c9", "cc2aa750-c0c0-488f-9593-1eeab3fc22ca", "02642979-2f37-4b07-94f8-a360a9fb6c76", "de004e9c-483a-4859-abda-a3664362144c", "2b6885a8-5793-46e6-9d73-4f3ff7f0b906", "05814d35-aa7a-4c7e-8d32-6eb1c8db255d", "e628a4b6-4220-4435-9b99-f85fd1826dd0", "c6622a67-f60e-4b37-8aef-828eeea4536a", "d8620a51-29e1-4d4b-9a37-d3a56bed0c1f"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2021 Earnings Call  Corrected Transcript  \n03-Nov-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring this time.  They really are playing a vital part in keeping our communities healthy as well.  So I wish you all a \nvery good day. ", "original_text": "McKesson Corp.  ", "page_label": "23", "file_name": "MCK-Q2-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 411565, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}